1	Under	O
2	these	O
3	schedules	O
4	,	O
5	a	O
6	reinforced	O
7	response	O
8	run	O
9	consisted	O
10	of	O
11	responding	O
12	between	O
13	eight	O
14	and	O
15	12	O
16	times	O
17	on	O
18	one	O
19	response	O
20	key	O
21	(	O
22	work	O
23	key	O
24	)	O
25	and	O
26	then	O
27	responding	O
28	once	O
29	on	O
30	a	O
31	second	O
32	response	O
33	key	O
34	(	O
35	reinforced	O
36	key	O
37	).	O

1	The	O
2	majority	O
3	of	O
4	the	O
5	cases	O
6	with	O
7	0	O
8	-	O
9	I	O
10	or	O
11	0	O
12	-	O
13	III	O
14	components	O
15	were	O
16	sm	O
17	.	O
18	cancer	O
19	.	O

1	Serum	O
2	induction	O
3	of	O
4	a	B
5	MEF2	I
6	reporter	I
7	gene	O
8	was	O
9	not	O
10	observed	O
11	in	O
12	a	O
13	line	O
14	of	O
15	NIH	O
16	3T3	O
17	cells	O
18	which	O
19	contain	O
20	low	B
21	MEF2	I
22	site	I
23	binding	O
24	activity	O
25	.	O

1	The	O
2	subunit	O
3	-	O
4	a	O
5	gene	O
6	is	O
7	preceded	O
8	by	O
9	a	O
10	gene	O
11	coding	O
12	for	O
13	a	O
14	small	O
15	hydrophobic	O
16	protein	O
17	,	O
18	as	O
19	has	O
20	been	O
21	observed	O
22	previously	O
23	in	O
24	the	O
25	atp	O
26	operons	O
27	in	O
28	E	O
29	.	O
30	coli	O
31	,	O
32	bacterium	O
33	PS3	O
34	and	O
35	cyanobacteria	O
36	.	O

1	To	O
2	study	O
3	the	O
4	retinal	O
5	surface	O
6	in	O
7	the	O
8	human	O
9	eye	O
10	in	O
11	normal	O
12	and	O
13	diseased	O
14	states	O
15	we	O
16	used	O
17	laser	O
18	scanning	O
19	tomography	O
20	.	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	various	O
6	repeats	O
7	suggests	O
8	its	O
9	organization	O
10	is	O
11	similar	O
12	to	O
13	the	O
14	beta	O
15	-	O
16	heterochromatic	O
17	regions	O
18	near	O
19	the	O
20	base	O
21	of	O
22	the	O
23	major	O
24	chromosome	O
25	arms	O
26	.	O

1	Consciousness	O
2	is	O
3	connected	O
4	with	O
5	attention	O
6	,	O
7	working	O
8	memory	O
9	and	O
10	perception	O
11	.	O

1	Analysis	O
2	of	O
3	clearance	O
4	curve	O
5	of	O
6	rose	O
7	bengal	I
8	-	I
9	I	I
10	-	I
11	131	I

1	HFA	O
2	134a	O
3	had	O
4	a	O
5	greater	O
6	tendency	O
7	to	O
8	take	O
9	up	O
10	moisture	O
11	from	O
12	the	O
13	environment	O
14	than	O
15	did	O
16	HFA	O
17	227	O
18	.	O

1	According	O
2	to	O
3	pilot	O
4	experiments	O
5	which	O
6	considered	O
7	various	O
8	durations	O
9	of	O
10	global	O
11	no	O
12	-	O
13	flow	O
14	ischemia	O
15	ranging	O
16	from	O
17	10	O
18	to	O
19	20	O
20	minutes	O
21	,	O
22	two	O
23	durations	O
24	were	O
25	chosen	O
26	for	O
27	the	O
28	present	O
29	study	O
30	:	O
31	20	O
32	minutes	O
33	(	O
34	group	O
35	20	O
36	)	O
37	in	O
38	which	O
39	ventricular	O
40	fibrillation	O
41	(	O
42	VF	O
43	)	O
44	was	O
45	the	O
46	predominant	O
47	form	O
48	of	O
49	arrhythmias	O
50	,	O
51	and	O
52	18	O
53	minutes	O
54	(	O
55	group	O
56	18	O
57	)	O
58	in	O
59	which	O
60	the	O
61	prevalence	O
62	of	O
63	VF	O
64	was	O
65	markedly	O
66	lower	O
67	despite	O
68	the	O
69	small	O
70	difference	O
71	in	O
72	the	O
73	duration	O
74	of	O
75	ischemia	O
76	.	O

1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	a	O
7	vitamin	O
8	D	O
9	response	O
10	element	O
11	(	O
12	VDRE	O
13	)	O
14	in	O
15	the	O
16	promoter	O
17	of	B
18	c	I
19	-	I
20	fos	I
21	.	I

1	An	O
2	explanation	O
3	explored	O
4	for	O
5	this	O
6	lack	O
7	of	O
8	gene	O
9	expression	O
10	was	O
11	that	O
12	increased	O
13	levels	O
14	of	B
15	RAR	I
16	alpha	O
17	or	O
18	PML	O
19	might	O
20	suppress	O
21	APL	O
22	cell	O
23	growth	O
24	.	O

1	Antibodies	O
2	directed	O
3	against	O
4	the	B
5	SNM1	I
6	protein	O
7	immunoprecipitated	B
8	RNase	B
9	MRP	B
10	RNA	O
11	from	O
12	whole	O
13	-	O
14	cell	O
15	extracts	O
16	without	O
17	precipitating	O
18	the	O
19	structurally	O
20	and	O
21	functionally	O
22	related	B
23	RNase	B
24	P	I
25	RNA	I
26	.	I

1	In	O
2	order	O
3	to	O
4	infer	O
5	shape	O
6	from	O
7	contour	O
8	,	O
9	the	O
10	human	O
11	visual	O
12	system	O
13	must	O
14	selectively	O
15	integrate	O
16	fragments	O
17	projecting	O
18	from	O
19	a	O
20	common	O
21	object	O
22	while	O
23	keeping	O
24	fragments	O
25	from	O
26	different	O
27	objects	O
28	separate	O
29	.	O

1	The	O
2	human	O
3	papillomavirus	I
4	type	I
5	16	I
6	E7	I
7	protein	I
8	complements	I
9	adenovirus	I
10	type	I
11	5	I
12	E1A	I
13	amino	I
14	-	I
15	terminus	I
16	-	I
17	dependent	O
18	transactivation	O
19	of	O
20	adenovirus	O
21	type	O
22	5	O
23	early	O
24	genes	O
25	and	O
26	increases	O
27	ATF	O
28	and	B
29	Oct	I
30	-	I
31	1	I
32	DNA	I
33	binding	O
34	activity	O
35	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	demonstrate	O
7	that	O
8	CAP1	O
9	is	O
10	involved	O
11	in	O
12	multidrug	O
13	resistance	O
14	and	O
15	oxidative	O
16	stress	O
17	response	O
18	in	O
19	C	O
20	.	O
21	albicans	O
22	.	O

1	Identification	O
2	of	O
3	a	O
4	cis	O
5	-	O
6	acting	O
7	element	O
8	in	O
9	the	B
10	class	I
11	I	I
12	major	I
13	histocompatibility	I
14	complex	I
15	gene	I
16	promoter	I
17	responsive	O
18	to	O
19	activation	O
20	by	O
21	retroviral	O
22	sequences	O
23	.	O

1	Immunolocalization	O
2	of	B
3	Sop1p	O
4	revealed	O
5	a	O
6	cytoplasmic	O
7	distribution	O
8	and	O
9	cell	O
10	fractionation	O
11	studies	O
12	showed	O
13	that	O
14	a	O
15	significant	O
16	fraction	O
17	of	B
18	Sop1p	O
19	was	O
20	recovered	O
21	in	O
22	a	O
23	sedimentable	O
24	fraction	O
25	of	O
26	the	O
27	cytosolic	O
28	material	O
29	.	O

1	GCR1	I
2	gene	O
3	function	O
4	is	O
5	required	O
6	for	O
7	high	O
8	-	O
9	level	O
10	glycolytic	O
11	gene	O
12	expression	O
13	in	O
14	Saccharomyces	O
15	cerevisiae	O
16	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	increased	O
6	pulmonary	O
7	blood	O
8	flow	O
9	and	O
10	decreased	O
11	pulmonary	O
12	vascular	O
13	resistance	O
14	with	O
15	advancing	O
16	gestation	O
17	are	O
18	due	O
19	to	O
20	an	O
21	increase	O
22	in	O
23	the	O
24	total	O
25	number	O
26	of	O
27	vessels	O
28	and	O
29	increased	O
30	vasomotor	O
31	reactivity	O
32	is	O
33	related	O
34	to	O
35	an	O
36	increase	O
37	in	O
38	the	O
39	total	O
40	amount	O
41	of	O
42	smooth	O
43	muscle	O
44	while	O
45	the	O
46	thickness	O
47	of	O
48	muscle	O
49	in	O
50	individual	O
51	vessels	O
52	remains	O
53	constant	O
54	.	O

1	This	O
2	resulted	O
3	in	O
4	a	O
5	complete	O
6	inhibition	O
7	of	O
8	Site	O
9	-	O
10	1	O
11	cleavage	O
12	that	O
13	was	O
14	restored	O
15	by	O
16	concomitant	O
17	overexpression	O
18	of	O
19	full	O
20	-	O
21	length	O
22	SCAP	O
23	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	a	O
7	transfected	O
8	Chinese	O
9	hamster	O
10	ovary	O
11	(	O
12	CHO	O
13	)	O
14	cell	O
15	line	O
16	expressing	O
17	a	B
18	murine	B
19	CD4	I
20	fragment	O
21	containing	O
22	the	O
23	first	O
24	two	O
25	N	O
26	-	O
27	terminal	O
28	domains	O
29	secretes	O
30	both	O
31	monomeric	O
32	molecules	O
33	and	O
34	disulfide	O
35	-	O
36	linked	O
37	multimers	O
38	.	O

1	Transgenic	O
2	mice	O
3	harboring	O
4	the	B
5	rat	B
6	TnI	I
7	-	I
8	CAT	I
9	fusion	I
10	gene	O
11	expressed	O
12	the	O
13	reporter	O
14	specifically	O
15	in	O
16	the	O
17	skeletal	O
18	muscle	O
19	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	interaction	O
7	of	B
8	eIF4A	O
9	with	O
10	the	O
11	middle	O
12	region	O
13	of	B
14	eIF4GI	O
15	is	O
16	necessary	O
17	for	O
18	translation	O
19	,	O
20	whereas	O
21	the	O
22	interaction	O
23	of	B
24	eIF4A	O
25	with	O
26	the	O
27	C	O
28	-	O
29	terminal	O
30	region	O
31	plays	O
32	a	O
33	modulatory	O
34	role	O
35	.	O

1	However	O
2	,	O
3	the	O
4	a1	O
5	isoform	O
6	is	O
7	expressed	O
8	most	O
9	heavily	O
10	in	O
11	brain	O
12	and	O
13	heart	O
14	,	O
15	a2	O
16	in	O
17	liver	O
18	and	O
19	kidney	O
20	,	O
21	and	O
22	a3	O
23	in	O
24	liver	O
25	,	O
26	lung	O
27	,	O
28	heart	O
29	,	O
30	brain	O
31	,	O
32	spleen	O
33	,	O
34	and	O
35	kidney	O
36	.	O

1	Obesity	O
2	was	O
3	strongly	O
4	associated	O
5	with	O
6	the	O
7	proportions	O
8	of	O
9	nonprotein	O
10	-	O
11	bound	O
12	and	O
13	albumin	O
14	-	O
15	bound	O
16	estradiol	O
17	,	O
18	and	O
19	inversely	O
20	associated	O
21	with	B
22	sex	I
23	hormone	I
24	binding	I
25	globulin	I
26	(	I
27	SHBG	O
28	)	O
29	levels	O
30	and	O
31	the	O
32	proportion	O
33	of	B
34	SHBG	I
35	-	O
36	bound	O
37	estradiol	O
38	.	O

1	NF	O
2	-	O
3	kappaB	O
4	,	O
5	which	O
6	is	O
7	probably	O
8	important	O
9	for	O
10	basal	O
11	activity	O
12	of	O
13	the	B
14	human	B
15	NOS	I
16	II	I
17	promoter	O
18	,	O
19	is	O
20	unlikely	O
21	to	O
22	function	O
23	as	O
24	a	O
25	major	O
26	effector	O
27	of	O
28	CM	O
29	in	O
30	DLD	O
31	-	O
32	1	O
33	cells	O
34	.	O

1	They	O
2	were	O
3	checked	O
4	for	B
5	anti	I
6	-	I
7	HCV	I
8	(	I
9	anti	I
10	-	I
11	C100	I
12	-	I
13	3	O
14	)	O
15	with	O
16	HCV	O
17	EIA	O
18	kit	O
19	(	O
20	Abbott	O
21	Lab	O
22	.,	O
23	North	O
24	Chicago	O
25	,	O
26	IL	O
27	).	O

1	Protein	B
2	tyrosine	B
3	phosphatases	I
4	(	I
5	PTPs	O
6	),	O
7	together	O
8	with	O
9	protein	O
10	tyrosine	O
11	kinases	O
12	(	O
13	PTKs	O
14	),	O
15	are	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	cell	O
22	activation	O
23	,	O
24	growth	O
25	,	O
26	and	O
27	differentiation	O
28	.	O

1	Chronic	O
2	E	O
3	-	O
4	B	O
5	virus	O
6	infection	O
7	terminated	O
8	in	O
9	malignant	O
10	lymphoma	O
11	:	O
12	a	O
13	case	O
14	report	O

1	The	O
2	mean	O
3	percentage	O
4	of	O
5	linoleic	O
6	acid	O
7	in	O
8	the	O
9	triglycerides	O
10	of	O
11	the	O
12	subcutaneous	O
13	adipose	O
14	tissue	O
15	(	O
16	PLASAT	O
17	)	O
18	of	O
19	these	O
20	subjects	O
21	was	O
22	substantially	O
23	higher	O
24	than	O
25	that	O
26	in	O
27	a	O
28	similar	O
29	group	O
30	examined	O
31	in	O
32	1975	O
33	-	O
34	1976	O
35	.	O

1	However	O
2	,	O
3	serial	O
4	passages	O
5	of	O
6	fetal	O
7	lamb	O
8	kidney	O
9	(	O
10	FLK	O
11	)	O
12	cells	O
13	,	O
14	which	O
15	are	O
16	sensitive	O
17	to	O
18	infection	O
19	with	O
20	BLV	O
21	,	O
22	after	O
23	transient	O
24	transfection	O
25	revealed	O
26	that	O
27	mutation	O
28	of	O
29	a	O
30	second	O
31	tyrosine	O
32	residue	O
33	in	O
34	the	O
35	N	O
36	-	O
37	terminal	O
38	motif	O
39	completely	O
40	prevented	O
41	the	O
42	propagation	O
43	of	O
44	the	O
45	virus	O
46	.	O

1	Mutagenesis	O
2	of	O
3	each	B
4	NRF	I
5	-	I
6	1	I
7	motif	O
8	in	O
9	the	O
10	ALAS	O
11	promoter	O
12	gave	O
13	substantially	O
14	lowered	O
15	levels	O
16	of	B
17	chloramphenicol	I
18	acetyltransferase	O
19	expression	O
20	,	O
21	whereas	O
22	mutagenesis	O
23	of	O
24	both	B
25	NRF	I
26	-	I
27	1	O
28	motifs	O
29	resulted	O
30	in	O
31	the	O
32	almost	O
33	complete	O
34	loss	O
35	of	O
36	expression	O
37	.	O

1	Pneumothorax	O
2	complicated	O
3	by	O
4	chronic	O
5	steroid	O
6	treatment	O
7	.	O

1	We	O
2	detected	O
3	mos	O
4	transcripts	O
5	by	O
6	Northern	O
7	(	O
8	RNA	O
9	)	O
10	analyses	O
11	in	O
12	RNA	O
13	prepared	O
14	from	O
15	chicken	O
16	and	O
17	quail	O
18	ovaries	O
19	and	O
20	testes	O
21	.	O

1	CMV	O
2	hyperimmunoglobulin	O
3	treatment	O
4	(	O
5	Cytotect	O
6	,	O
7	Biotest	O
8	)	O
9	was	O
10	started	O
11	(	O
12	2	O
13	ml	O
14	/	O
15	kg	O
16	bw	O
17	on	O
18	day	O
19	1	O
20	and	O
21	3	O
22	,	O
23	and	O
24	1	O
25	ml	O
26	/	O
27	kg	O
28	on	O
29	days	O
30	5	O
31	,	O
32	7	O
33	and	O
34	9	O
35	),	O
36	which	O
37	led	O
38	to	O
39	the	O
40	eradication	O
41	of	O
42	the	O
43	residual	O
44	infiltrate	O
45	and	O
46	CMV	O
47	-	O
48	DNA	O
49	in	O
50	the	O
51	myocardium	O
52	.	O

1	A	O
2	pharmacokinetic	O
3	study	O
4	of	O
5	apalcillin	O
6	was	O
7	performed	O
8	in	O
9	12	O
10	patients	O
11	in	O
12	an	O
13	intensive	O
14	-	O
15	care	O
16	unit	O
17	.	O

1	A	O
2	preliminary	O
3	study	O
4	of	O
5	vincristine	O
6	,	O
7	methotrexate	O
8	,	O
9	and	O
10	prednisolone	O
11	(	O
12	VM	O
13	*	O
14	P	O
15	)	O
16	combination	O
17	chemotherapy	O
18	for	O
19	advanced	O
20	adult	O
21	non	O
22	-	O
23	Hodgkin	O
24	'	O
25	s	O
26	lymphoma	O

1	At	O
2	some	O
3	sites	O
4	,	O
5	%	O
6	T	O
7	is	O
8	greatly	O
9	increased	O
10	by	O
11	Cl	O
12	-	O
13	concentrations	O
14	up	O
15	to	O
16	1	O
17	M	O
18	,	O
19	while	O
20	at	O
21	other	O
22	sites	O
23	%	O
24	T	O
25	is	O
26	reduced	O
27	or	O
28	unaffected	O
29	by	O
30	these	O
31	conditions	O
32	.	O

1	Effects	O
2	of	O
3	ionizing	O
4	radiation	O
5	in	O
6	the	O
7	human	O
8	oral	O
9	cavity	O
10	and	O
11	oropharynx	O
12	:	O
13	results	O
14	of	O
15	a	O
16	survey	O
17	.	O

1	We	O
2	report	O
3	the	O
4	construction	O
5	of	O
6	an	O
7	approximately	O
8	1	O
9	.	O
10	7	O
11	-	O
12	Mb	O
13	sequence	O
14	-	O
15	ready	O
16	YAC	O
17	/	O
18	BAC	O
19	clone	O
20	contig	O
21	of	O
22	8p22	I
23	-	I
24	p23	I
25	.	I

1	The	O
2	genomic	O
3	structure	O
4	of	O
5	four	O
6	members	O
7	of	O
8	the	B
9	SRC	I
10	-	I
11	family	O
12	revealed	O
13	nearly	O
14	identical	O
15	exon	O
16	/	O
17	intron	O
18	boundaries	O
19	within	O
20	the	O
21	catalytic	O
22	domain	O
23	of	O
24	this	O
25	family	O
26	.	O

1	Total	O
2	cholesterol	O
3	was	O
4	measured	O
5	in	O
6	amniotic	O
7	fluids	O
8	collected	O
9	at	O
10	different	O
11	stages	O
12	of	O
13	gestation	O
14	.	O

1	Intracranial	O
2	arachnoid	O
3	cyst	O
4	of	O
5	the	O
6	middle	O
7	fossa	O
8	demonstrated	O
9	by	O
10	positive	O
11	99mTc	O
12	brainscintigraphy	O
13	.	O

1	We	O
2	failed	O
3	to	O
4	find	O
5	these	O
6	data	O
7	to	O
8	be	O
9	useful	O
10	in	O
11	predicting	O
12	the	O
13	time	O
14	of	O
15	onset	O
16	of	O
17	initial	O
18	seizures	O
19	after	O
20	acute	O
21	ischemic	O
22	stroke	O
23	and	O
24	recurrence	O
25	.	O

1	A	O
2	computed	O
3	tomographic	O
4	scan	O
5	obtained	O
6	after	O
7	EOE	O
8	-	O
9	13	O
10	infusion	O
11	accurately	O
12	showed	O
13	the	O
14	perfusion	O
15	pattern	O
16	of	O
17	the	O
18	implanted	O
19	catheter	O
20	.	O

1	The	B
2	Oct	I
3	-	I
4	2	I
5	glutamine	I
6	-	O
7	rich	O
8	and	O
9	proline	O
10	-	O
11	rich	O
12	activation	O
13	domains	O
14	can	O
15	synergize	O
16	with	O
17	each	O
18	other	O
19	or	O
20	duplicates	O
21	of	O
22	themselves	O
23	to	O
24	activate	O
25	transcription	O
26	.	O

1	One	O
2	of	O
3	its	O
4	lysine	O
5	residues	O
6	is	O
7	modified	O
8	by	O
9	spermidine	O
10	to	O
11	form	O
12	hypusine	O
13	,	O
14	a	O
15	posttranslational	O
16	modification	O
17	unique	O
18	to	B
19	eIF	I
20	-	O
21	5A	O
22	.	O

1	DNase	O
2	I	O
3	footprint	O
4	analysis	O
5	identified	O
6	a	O
7	protected	O
8	region	O
9	from	O
10	-	O
11	37	O
12	to	O
13	-	O
14	53	O
15	.	O

1	Two	O
2	patients	O
3	had	O
4	immediate	O
5	adverse	O
6	effects	O
7	from	O
8	NMF	O
9	;	O
10	one	O
11	had	O
12	a	O
13	grand	O
14	mal	O
15	seizure	O
16	and	O
17	the	O
18	other	O
19	developed	O
20	severe	O
21	abdominal	O
22	pain	O
23	.	O

1	On	O
2	the	O
3	third	O
4	occasion	O
5	water	O
6	(	O
7	W	O
8	)	O
9	was	O
10	ingested	O
11	throughout	O
12	the	O
13	run	O
14	.	O

1	The	O
2	identification	O
3	of	O
4	the	O
5	hepatitis	O
6	C	O
7	virus	O
8	as	O
9	the	O
10	major	O
11	cause	O
12	of	O
13	liver	O
14	disease	O
15	both	O
16	in	O
17	dialysis	O
18	patients	O
19	and	O
20	in	O
21	transplant	O
22	patients	O
23	has	O
24	focused	O
25	attention	O
26	on	O
27	the	O
28	epidemiology	O
29	and	O
30	the	O
31	impact	O
32	of	O
33	continuing	O
34	infection	O
35	in	O
36	these	O
37	patient	O
38	groups	O
39	.	O

1	Moreover	O
2	,	O
3	the	O
4	observation	O
5	of	O
6	enhanced	O
7	luteal	B
8	HSP	I
9	-	O
10	27	O
11	phosphorylation	O
12	in	O
13	vivo	O
14	,	O
15	in	O
16	late	O
17	pregnancy	O
18	,	O
19	when	B
20	PKC	I
21	-	I
22	delta	O
23	is	O
24	abundant	O
25	and	O
26	active	O
27	,	O
28	suggests	O
29	that	O
30	select	B
31	PKC	I
32	family	O
33	members	O
34	contribute	O
35	to	O
36	sHSP	O
37	phosphorylation	O
38	events	O
39	in	O
40	vivo	O
41	.	O

1	Basal	O
2	midexpiratory	O
3	lower	O
4	esophageal	O
5	sphincter	O
6	pressure	O
7	was	O
8	similar	O
9	in	O
10	the	O
11	study	O
12	group	O
13	(	O
14	mean	O
15	[	O
16	SD	O
17	]	O
18	20	O
19	.	O
20	1	O
21	[	O
22	9	O
23	.	O
24	1	O
25	]	O
26	mmHg	O
27	)	O
28	and	O
29	controls	O
30	(	O
31	17	O
32	.	O
33	6	O
34	[	O
35	6	O
36	.	O
37	0	O
38	]	O
39	mmHg	O
40	);	O
41	the	O
42	pressure	O
43	did	O
44	not	O
45	change	O
46	following	O
47	EVS	O
48	or	O
49	EVL	O
50	.	O

1	Inducible	O
2	VT	O
3	was	O
4	suppressed	O
5	entirely	O
6	in	O
7	one	O
8	patient	O
9	.	O

1	Furthermore	O
2	,	O
3	deletion	O
4	and	O
5	mutation	O
6	analyses	O
7	of	O
8	the	B
9	VCAM	I
10	-	I
11	1	I
12	promoter	O
13	performed	O
14	with	B
15	chloramphenicol	I
16	acetyltransferase	I
17	constructs	O
18	revealed	O
19	that	O
20	Tax	O
21	was	O
22	trans	O
23	activating	O
24	the	B
25	VCAM	I
26	-	I
27	1	I
28	promoter	O
29	via	O
30	two	B
31	NF	I
32	-	I
33	kappaB	I
34	sites	O
35	present	O
36	at	O
37	bp	O
38	-	O
39	72	O
40	and	O
41	-	O
42	57	O
43	in	O
44	the	B
45	VCAM	I
46	-	I
47	1	I
48	gene	I
49	promoter	O
50	,	O
51	with	O
52	both	O
53	of	O
54	them	O
55	being	O
56	required	O
57	for	O
58	the	O
59	Tax	O
60	-	O
61	induced	O
62	expression	O
63	of	O
64	this	O
65	adhesion	O
66	molecule	O
67	.	O

1	Regulation	O
2	of	O
3	embryonic	O
4	growth	O
5	and	O
6	lysosomal	O
7	targeting	O
8	by	O
9	the	O
10	imprinted	B
11	Igf2	I
12	/	I
13	Mpr	I
14	gene	I
15	.	I

1	By	B
2	creating	B
3	Pax	I
4	-	I
5	6	I
6	-	I
7	BSAP	I
8	fusion	I
9	proteins	O
10	,	O
11	we	O
12	were	O
13	able	O
14	to	O
15	identify	O
16	a	O
17	short	O
18	amino	O
19	acid	O
20	stretch	O
21	in	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	part	O
27	of	O
28	the	O
29	paired	O
30	domain	O
31	which	O
32	is	O
33	responsible	O
34	for	O
35	these	O
36	differences	O
37	in	O
38	DNA	O
39	-	O
40	binding	O
41	specificity	O
42	.	O

1	Re	O
2	-	O
3	evaluation	O
4	of	O
5	the	O
6	biopsy	O
7	specimen	O
8	from	O
9	the	O
10	right	O
11	hip	O
12	taken	O
13	at	O
14	the	O
15	time	O
16	of	O
17	the	O
18	initial	O
19	operation	O
20	showed	O
21	areas	O
22	of	O
23	chondrosarcoma	O
24	arising	O
25	in	O
26	the	O
27	background	O
28	of	O
29	synovial	O
30	chondromatosis	O
31	.	O

1	Identical	O
2	results	O
3	were	O
4	obtained	O
5	when	O
6	transfections	O
7	and	O
8	mobility	O
9	shift	O
10	assays	O
11	were	O
12	performed	O
13	in	O
14	primary	O
15	rat	O
16	hepatocytes	O
17	in	O
18	which	O
19	the	O
20	endogenous	O
21	ALS	O
22	gene	O
23	is	O
24	expressed	O
25	.	O

1	The	B
2	TCF	I
3	-	I
4	1	I
5	alpha	I
6	binding	I
7	site	O
8	was	O
9	also	O
10	required	O
11	for	B
12	TCR	I
13	alpha	I
14	enhancer	O
15	activity	O
16	in	O
17	transcriptionally	O
18	active	O
19	extracts	O
20	from	O
21	Jurkat	O
22	but	O
23	not	O
24	HeLa	O
25	cells	O
26	,	O
27	confirming	O
28	that	B
29	TCF	I
30	-	I
31	1	I
32	alpha	O
33	is	O
34	a	B
35	T	I
36	-	I
37	cell	I
38	-	I
39	specific	I
40	transcription	I
41	factor	I
42	.	I

1	Three	O
2	classes	O
3	of	O
4	test	O
5	objects	O
6	were	O
7	considered	O
8	:	O
9	(	O
10	1	O
11	)	O
12	a	O
13	multicompartment	O
14	test	O
15	object	O
16	for	O
17	31P	O
18	MRS	O
19	measurements	O
20	performed	O
21	with	O
22	slice	O
23	-	O
24	selective	O
25	sequences	O
26	;	O
27	(	O
28	2	O
29	)	O
30	a	O
31	two	O
32	-	O
33	compartment	O
34	test	O
35	object	O
36	for	O
37	volume	O
38	-	O
39	selection	O
40	1H	O
41	MRS	O
42	;	O
43	and	O
44	(	O
45	3	O
46	)	O
47	two	O
48	-	O
49	compartment	O
50	test	O
51	objects	O
52	for	O
53	assessing	O
54	the	O
55	performance	O
56	of	O
57	experimental	O
58	systems	O
59	using	O
60	ISIS	O
61	as	O
62	volume	O
63	localization	O
64	sequence	O
65	in	O
66	31P	O
67	MRS	O
68	.	O

1	Phenazone	O
2	potentiates	O
3	the	O
4	local	O
5	anaesthetic	O
6	effect	O
7	of	O
8	lidocaine	O
9	in	O
10	mice	O
11	.	O

1	The	O
2	effect	O
3	of	O
4	water	O
5	deprivation	O
6	for	O
7	19	O
8	h	O
9	on	O
10	renal	O
11	Na	O
12	excretion	O
13	of	O
14	conscious	O
15	adrenalectomized	O
16	(	O
17	ADX	O
18	)	O
19	sheep	O
20	maintained	O
21	on	O
22	a	O
23	constant	O
24	intravenous	O
25	infusion	O
26	of	O
27	aldosterone	O
28	and	O
29	cortisol	O
30	(	O
31	ADX	O
32	-	O
33	constant	O
34	steroid	O
35	sheep	O
36	)	O
37	was	O
38	investigated	O
39	.	O

1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	HRT	O
7	on	O
8	those	O
9	factors	O
10	in	O
11	end	O
12	-	O
13	stage	O
14	renal	O
15	disease	O
16	(	O
17	ESRD	O
18	)	O
19	patients	O
20	,	O
21	we	O
22	evaluated	O
23	the	O
24	changes	O
25	of	O
26	lipid	O
27	profile	O
28	,	O
29	coagulation	O
30	and	O
31	fibrinolysis	O
32	markers	O
33	,	O
34	and	O
35	plasma	O
36	homocysteine	O
37	levels	O
38	after	O
39	treatment	O
40	.	O

1	To	O
2	identify	O
3	cis	O
4	-	O
5	acting	O
6	elements	O
7	that	O
8	target	B
9	c	I
10	-	I
11	myc	I
12	mRNA	O
13	for	O
14	downregulation	O
15	during	O
16	myogenesis	O
17	,	O
18	we	O
19	stably	O
20	transfected	B
21	C2C12	O
22	cells	O
23	with	O
24	mutant	O
25	myc	O
26	genes	O
27	or	O
28	chimeric	O
29	genes	O
30	in	O
31	which	O
32	various	O
33	myc	O
34	sequences	O
35	were	O
36	fused	O
37	to	O
38	the	B
39	human	I
40	beta	I
41	-	I
42	globin	I
43	gene	O
44	or	O
45	to	O
46	the	B
47	bacterial	B
48	chloramphenicol	I
49	acetyltransferase	I
50	(	I
51	CAT	I
52	)	I
53	gene	I
54	.	I

1	Because	O
2	the	O
3	number	O
4	of	O
5	parameters	O
6	required	O
7	by	O
8	a	O
9	Volterra	O
10	series	O
11	grows	O
12	rapidly	O
13	with	O
14	both	O
15	the	O
16	length	O
17	of	O
18	its	O
19	memory	O
20	and	O
21	the	O
22	order	O
23	of	O
24	its	O
25	nonlinearity	O
26	,	O
27	methods	O
28	for	O
29	identifying	O
30	these	O
31	models	O
32	from	O
33	measurements	O
34	of	O
35	input	O
36	/	O
37	output	O
38	data	O
39	are	O
40	limited	O
41	to	O
42	low	O
43	-	O
44	order	O
45	systems	O
46	with	O
47	relatively	O
48	short	O
49	memories	O
50	.	O

1	In	O
2	addition	O
3	,	O
4	negatively	O
5	regulatory	O
6	region	O
7	may	O
8	exist	O
9	from	O
10	-	O
11	1782	O
12	to	O
13	-	O
14	1295	O
15	bp	O
16	.	O

1	However	O
2	,	O
3	the	O
4	ratio	O
5	M	O
6	/	O
7	Pc	O
8	provides	O
9	a	O
10	useful	O
11	index	O
12	that	O
13	seems	O
14	to	O
15	be	O
16	independent	O
17	of	O
18	the	O
19	metabolic	O
20	demand	O
21	.	O

1	On	O
2	the	O
3	basis	O
4	of	B
5	serum	I
6	alpha1AT	O
7	quantitation	O
8	,	O
9	newborn	O
10	infants	O
11	may	O
12	be	O
13	separated	O
14	into	O
15	two	O
16	groups	O
17	,	O
18	characterized	O
19	respectively	O
20	by	O
21	concentrations	O
22	above	O
23	or	O
24	below	O
25	150	O
26	mg	O
27	%.	O

1	Paracrine	O
2	activation	O
3	of	O
4	the	B
5	HIV	I
6	-	I
7	1	I
8	LTR	I
9	promoter	O
10	by	O
11	the	B
12	viral	B
13	Tat	I
14	protein	O
15	is	O
16	mechanistically	O
17	similar	O
18	to	O
19	trans	O
20	-	O
21	activation	O
22	within	O
23	a	O
24	cell	O
25	.	O

1	Over	O
2	-	O
3	expression	O
4	of	O
5	Azf1p	O
6	in	O
7	the	O
8	yeast	O
9	cell	O
10	does	O
11	not	O
12	influence	O
13	the	O
14	expression	O
15	level	O
16	of	O
17	the	O
18	mitochondrial	O
19	transcription	O
20	factor	B
21	Mtf1p	O
22	,	O
23	indicating	O
24	that	O
25	the	O
26	influence	O
27	of	O
28	Azf1p	O
29	on	O
30	the	O
31	suppression	O
32	of	O
33	the	O
34	special	B
35	mitochondrial	I
36	RNA	I
37	polymerase	I
38	mutant	O
39	is	O
40	an	O
41	indirect	O
42	one	O
43	.	O

1	A	O
2	set	O
3	of	O
4	peptides	O
5	corresponding	O
6	to	O
7	the	O
8	individual	O
9	elements	O
10	of	O
11	secondary	O
12	structure	O
13	derived	O
14	from	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	domain	O
20	of	O
21	the	O
22	ribosomal	O
23	protein	O
24	L9	O
25	have	O
26	been	O
27	synthesized	O
28	.	O

1	They	O
2	contrast	O
3	trends	O
4	in	O
5	fertility	O
6	,	O
7	life	O
8	expectancy	O
9	ratios	O
10	,	O
11	and	O
12	gender	O
13	differences	O
14	in	O
15	these	O
16	countries	O
17	with	O
18	the	O
19	Hispanic	O
20	population	O
21	of	O
22	the	O
23	United	O
24	States	O
25	.	O

1	In	O
2	light	O
3	of	O
4	the	O
5	importance	O
6	of	B
7	GnRHR	O
8	,	O
9	the	O
10	molecular	O
11	mechanisms	O
12	underlying	O
13	the	O
14	transcriptional	O
15	regulation	O
16	of	O
17	the	B
18	human	B
19	GnRHR	O
20	(	B
21	hGnRHR	I
22	)	I
23	gene	O
24	become	O
25	a	O
26	key	O
27	issue	O
28	in	O
29	understanding	O
30	human	O
31	reproduction	O
32	.	O

1	Selection	O
2	was	O
3	based	O
4	on	O
5	expression	O
6	of	O
7	an	O
8	integrated	O
9	DNA	O
10	fragment	O
11	containing	O
12	the	O
13	con	O
14	-	O
15	10	O
16	promoter	O
17	-	O
18	regulatory	O
19	region	O
20	followed	O
21	by	O
22	the	O
23	initial	O
24	segment	O
25	of	O
26	the	O
27	con	O
28	-	O
29	10	O
30	open	O
31	reading	O
32	frame	O
33	fused	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	bacterial	O
39	hygromycin	B
40	B	I
41	phosphotransferase	I
42	structural	I
43	gene	O
44	(	O
45	con10	O
46	'-'	O
47	hph	O
48	).	O

1	Hypersplenism	B

1	Insertional	O
2	inactivation	O
3	of	O
4	sms	O
5	led	O
6	to	O
7	increased	O
8	sensitivity	O
9	to	O
10	the	O
11	alkylating	O
12	agent	O
13	methylmethane	O
14	sulfonate	O
15	,	O
16	but	O
17	not	O
18	to	O
19	a	O
20	requirement	O
21	for	O
22	serine	O
23	or	O
24	other	O
25	metabolites	O
26	.	O

1	An	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	was	O
7	performed	O
8	to	O
9	characterize	O
10	the	O
11	binding	O
12	property	O
13	of	B
14	TR2	O
15	and	O
16	its	O
17	truncated	O
18	isoform	O
19	.	O

1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	select	O
10	strong	O
11	enhancer	O
12	-	O
13	type	O
14	activation	O
15	domains	O
16	from	O
17	the	O
18	immediate	O
19	early	O
20	regions	O
21	of	O
22	two	O
23	herpesviruses	O
24	,	O
25	namely	O
26	pseudorabies	O
27	virus	O
28	and	O
29	bovine	O
30	herpesvirus	O
31	1	O
32	.	O

1	Azygos	O
2	vein	O
3	abutting	O
4	the	O
5	posterior	O
6	wall	O
7	of	O
8	the	O
9	right	O
10	main	O
11	and	O
12	upper	O
13	lobe	O
14	bronchi	O
15	:	O
16	a	O
17	normal	O
18	CT	O
19	variant	O
20	.	O

1	The	O
2	results	O
3	confirm	O
4	and	O
5	extend	O
6	previous	O
7	work	O
8	by	O
9	other	O
10	researchers	O
11	.	O

1	Lysosomal	O
2	enzymes	O
3	that	O
4	degrade	O
5	cartilage	O
6	are	O
7	released	O
8	.	O

1	Ras	O
2	-	O
3	and	O
4	ultra	O
5	-	O
6	violet	I
7	-	I
8	responsive	I
9	protein	I
10	kinases	O
11	that	O
12	phosphorylate	B
13	c	I
14	-	I
15	Jun	O
16	on	O
17	serine	O
18	residues	O
19	at	O
20	positions	O
21	63	O
22	and	O
23	73	O
24	and	O
25	stimulate	O
26	its	O
27	transcriptional	O
28	activity	O
29	have	O
30	been	O
31	identified	O
32	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	other	O
6	Ras	O
7	effectors	O
8	can	O
9	collaborate	O
10	with	B
11	PI	I
12	3	I
13	-	I
14	kinase	O
15	and	O
16	with	O
17	each	O
18	other	O
19	to	O
20	activate	O
21	Pak	O
22	.	O

1	The	O
2	96	O
3	-	O
4	bp	O
5	insert	O
6	contained	O
7	a	O
8	termination	O
9	signal	O
10	which	O
11	caused	O
12	the	O
13	premature	O
14	termination	O
15	of	O
16	the	O
17	protein	O
18	,	O
19	leading	O
20	to	O
21	the	O
22	generation	O
23	of	O
24	a	B
25	p53	I
26	product	O
27	9	O
28	amino	O
29	acids	O
30	shorter	O
31	than	O
32	usual	O
33	.	O

1	The	O
2	95	O
3	%	O
4	confidence	O
5	values	O
6	(	O
7	2SD	O
8	)	O
9	for	O
10	the	O
11	change	O
12	in	O
13	Ros	O
14	required	O
15	to	O
16	exclude	O
17	natural	O
18	variability	O
19	were	O
20	0	O
21	.	O
22	39	O
23	,	O
24	0	O
25	.	O
26	50	O
27	and	O
28	0	O
29	.	O
30	53	O
31	cmH2O	O
32	l	O
33	-	O
34	1	O
35	s	O
36	,	O
37	respectively	O
38	.	O

1	Determination	O
2	of	O
3	potassium	O
4	iodide	O
5	in	O
6	Polish	O
7	edible	O
8	salt	O

1	The	O
2	FCMS	O
3	conditions	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	2	O
9	kW	O
10	maximum	O
11	electrical	O
12	power	O
13	consumption	O
14	,	O
15	800	O
16	V	O
17	maximum	O
18	capacitor	O
19	voltage	O
20	,	O
21	720	O
22	microseconds	O
23	pulsewidth	O
24	(	O
25	180	O
26	microseconds	O
27	rise	O
28	time	O
29	),	O
30	and	O
31	5	O
32	-	O
33	30	O
34	Hz	O
35	frequency	O
36	.	O

1	However	O
2	,	O
3	we	O
4	could	O
5	not	O
6	find	O
7	the	O
8	homologous	O
9	regions	O
10	with	B
11	guanine	I
12	nucleotide	I
13	exchange	I
14	factors	I
15	or	I
16	GTPase	I
17	-	I
18	activating	I
19	proteins	O
20	in	O
21	the	B
22	c	I
23	-	I
24	cbl	I
25	gene	I
26	.	I

1	Expression	O
2	in	O
3	early	O
4	postnatal	O
5	pituitary	O
6	and	O
7	in	O
8	pre	O
9	-	O
10	somatotrophic	O
11	cells	O
12	suggests	O
13	that	O
14	Zn	O
15	-	O
16	16	O
17	could	O
18	play	O
19	a	O
20	role	O
21	in	O
22	pituitary	O
23	development	O
24	prior	O
25	to	O
26	somatotroph	O
27	differentiation	O
28	.	O

1	Fourth	O
2	,	O
3	the	O
4	3	O
5	'-	O
6	region	O
7	splice	O
8	junctions	O
9	of	O
10	the	O
11	MSRs	O
12	during	O
13	latent	O
14	and	O
15	productive	O
16	infection	O
17	were	O
18	determined	O
19	by	O
20	sequencing	O
21	RNA	O
22	-	O
23	PCR	O
24	products	O
25	generated	O
26	with	O
27	primers	O
28	that	O
29	flank	O
30	the	O
31	3	O
32	'	O
33	splice	O
34	region	O
35	.	O

1	Bacillus	O
2	cereus	O
3	cross	O
4	-	O
5	infection	O
6	in	O
7	a	O
8	maternity	O
9	-	O
10	unit	O
11	.	O

1	CONTEXT	O
2	:	O
3	ThinPrep	O
4	,	O
5	AutoPap	O
6	,	O
7	and	O
8	Papnet	O
9	are	O
10	3	O
11	new	O
12	technologies	O
13	that	O
14	increase	O
15	the	O
16	sensitivity	O
17	and	O
18	cost	O
19	of	O
20	cervical	O
21	cancer	O
22	screening	O
23	.	O

1	Transcriptional	O
2	analysis	O
3	of	O
4	a	O
5	series	O
6	of	O
7	deletion	O
8	mutants	O
9	of	O
10	the	O
11	gene	O
12	in	O
13	the	O
14	nuclear	O
15	extracts	O
16	prepared	O
17	from	O
18	the	O
19	middle	O
20	silk	O
21	gland	O
22	of	O
23	2	O
24	-	O
25	day	O
26	-	O
27	old	O
28	fifth	O
29	instar	O
30	larvae	O
31	revealed	O
32	the	O
33	presence	O
34	of	O
35	multiple	O
36	cis	O
37	-	O
38	regulatory	O
39	elements	O
40	located	O
41	both	O
42	upstream	O
43	and	O
44	downstream	O
45	of	O
46	the	O
47	initiation	O
48	site	O
49	.	O

1	Statement	O
2	of	O
3	the	O
4	American	O
5	Academy	O
6	of	O
7	Implant	O
8	Dentistry	O
9	.	O

1	The	O
2	deduced	O
3	protein	O
4	sequence	O
5	is	O
6	characterized	O
7	by	O
8	a	O
9	putative	O
10	16	O
11	-	O
12	residue	O
13	amino	O
14	-	O
15	terminal	O
16	signal	O
17	peptide	O
18	that	O
19	is	O
20	cleaved	O
21	,	O
22	resulting	O
23	in	O
24	a	O
25	239	O
26	-	O
27	residue	O
28	polypeptide	O
29	.	O

1	In	O
2	vivo	O
3	,	O
4	MyoD	O
5	requires	O
6	this	O
7	tryptophan	O
8	motif	O
9	to	O
10	evoke	O
11	chromatin	O
12	remodeling	O
13	in	O
14	the	B
15	Myogenin	I
16	promoter	O
17	and	O
18	to	O
19	activate	B
20	Myogenin	I
21	transcription	I
22	.	I

1	A	O
2	quantitative	O
3	analysis	O
4	of	O
5	the	O
6	diffraction	O
7	intensity	O
8	as	O
9	function	O
10	of	O
11	the	O
12	accumulated	O
13	electron	O
14	dose	O
15	suggests	O
16	the	O
17	possibility	O
18	of	O
19	recording	O
20	up	O
21	to	O
22	250	O
23	diffraction	O
24	patterns	O
25	with	O
26	3	O
27	.	O
28	5	O
29	A	O
30	resolution	O
31	from	O
32	a	O
33	single	O
34	crotoxin	O
35	complex	O
36	crystal	O
37	128	O
38	A	O
39	thick	O
40	.	O

1	Promoter	O
2	region	O
3	of	O
4	the	O
5	transcriptional	O
6	unit	O
7	for	B
8	human	I
9	alpha	I
10	1	I
11	-	I
12	chimaerin	O
13	,	O
14	a	B
15	neuron	I
16	-	I
17	specific	I
18	GTPase	I
19	-	I
20	activating	I
21	protein	O
22	for	B
23	p21rac	I
24	.	I
25	alpha	I
26	1	I
27	-	I
28	chimaerin	O
29	is	O
30	a	B
31	neuron	I
32	-	I
33	specific	I
34	GTPase	I
35	-	I
36	activating	I
37	protein	O
38	for	B
39	p21rac	O
40	,	O
41	a	O
42	protein	O
43	involved	O
44	in	O
45	morphological	O
46	events	O
47	.	O

1	At	O
2	4	O
3	wk	O
4	however	O
5	,	O
6	tumor	O
7	relapse	O
8	was	O
9	noted	O
10	in	O
11	6	O
12	of	O
13	7	O
14	group	O
15	4	O
16	responders	O
17	,	O
18	10	O
19	of	O
20	12	O
21	in	O
22	group	O
23	5	O
24	,	O
25	13	O
26	of	O
27	16	O
28	in	O
29	group	O
30	7	O
31	,	O
32	but	O
33	only	O
34	4	O
35	of	O
36	19	O
37	group	O
38	8	O
39	responders	O
40	(	O
41	p	O
42	less	O
43	than	O
44	.	O
45	001	O
46	group	O
47	8	O
48	versus	O
49	4	O
50	,	O
51	5	O
52	,	O
53	7	O
54	).	O

1	Based	O
2	on	O
3	the	O
4	occurrence	O
5	of	O
6	several	O
7	transcription	O
8	signals	O
9	in	O
10	the	O
11	Thermus	O
12	pyr	O
13	promoter	O
14	region	O
15	and	O
16	strong	O
17	amino	O
18	acid	O
19	sequence	O
20	identities	O
21	(	O
22	about	O
23	60	O
24	%)	O
25	between	O
26	Thermus	O
27	PyrR	O
28	and	O
29	the	O
30	PyrR	O
31	attenuation	O
32	proteins	O
33	of	O
34	two	O
35	Bacillus	O
36	sp	O
37	.,	O
38	we	O
39	propose	O
40	a	O
41	regulatory	O
42	mechanism	O
43	involving	O
44	transcriptional	O
45	attenuation	O
46	to	O
47	control	O
48	pyr	O
49	gene	O
50	expression	O
51	in	O
52	Thermus	O
53	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterised	O
6	a	O
7	differentially	O
8	-	O
9	regulated	O
10	gene	O
11	family	O
12	in	O
13	the	O
14	protozoan	O
15	parasite	O
16	Leishmania	O
17	major	O
18	.	O

1	Sensitization	O
2	to	O
3	hyperlactatemia	O
4	induced	O
5	by	O
6	phenformin	O
7	after	O
8	subtotal	O
9	ablation	O
10	of	O
11	the	O
12	pancreas	O
13	.	O

1	Routine	O
2	psychometric	O
3	screening	O
4	of	O
5	IHD	O
6	patients	O
7	may	O
8	provide	O
9	a	O
10	cost	O
11	-	O
12	effective	O
13	means	O
14	of	O
15	alerting	O
16	cardiologists	O
17	and	O
18	internists	O
19	to	O
20	the	O
21	relatively	O
22	high	O
23	levels	O
24	of	O
25	distress	O
26	among	O
27	their	O
28	patients	O
29	.	O

1	Basing	O
2	on	O
3	experimental	O
4	toxicity	O
5	research	O
6	it	O
7	was	O
8	established	O
9	that	O
10	,	O
11	out	O
12	of	O
13	50	O
14	atmosphere	O
15	metal	O
16	corrosion	O
17	inhibitors	O
18	,	O
19	some	O
20	14	O
21	per	O
22	cent	O
23	were	O
24	found	O
25	extremely	O
26	hazardous	O
27	,	O
28	42	O
29	per	O
30	cent	O
31	--	O
32	of	O
33	high	O
34	level	O
35	hazardous	O
36	,	O
37	33	O
38	percent	O
39	--	O
40	of	O
41	moderate	O
42	and	O
43	11	O
44	per	O
45	cent	O
46	--	O
47	of	O
48	low	O
49	hazardous	O
50	.	O

1	Stroop	O
2	interference	O
3	:	O
4	aging	O
5	effects	O
6	assessed	O
7	with	O
8	the	O
9	Stroop	O
10	Color	O
11	-	O
12	Word	O
13	Test	O
14	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	view	O
6	that	O
7	clonidine	O
8	and	O
9	6	O
10	-	O
11	OHDA	O
12	,	O
13	but	O
14	not	O
15	alpha	O
16	-	O
17	MD	O
18	,	O
19	have	O
20	central	O
21	pressor	O
22	actions	O
23	in	O
24	the	O
25	rat	O
26	that	O
27	oppose	O
28	their	O
29	antihypertensive	O
30	action	O
31	.	O

1	Serum	O
2	antibody	O
3	titre	O
4	was	O
5	not	O
6	significantly	O
7	associated	O
8	with	O
9	the	O
10	recurrence	O
11	rate	O
12	or	O
13	the	O
14	duration	O
15	of	O
16	infection	O
17	.	O

1	Significant	O
2	alterations	O
3	in	O
4	CBC	O
5	results	O
6	and	B
7	serum	B
8	CRP	O
9	concentration	O
10	,	O
11	compared	O
12	with	O
13	baseline	O
14	values	O
15	,	O
16	were	O
17	lacking	O
18	in	O
19	dogs	O
20	of	O
21	the	O
22	control	O
23	group	O
24	.	O

1	A	O
2	five	O
3	-	O
4	phase	O
5	experiment	O
6	was	O
7	designed	O
8	to	O
9	investigate	O
10	(	O
11	a	O
12	)	O
13	whether	O
14	contingent	O
15	music	O
16	-	O
17	listening	O
18	would	O
19	act	O
20	as	O
21	a	O
22	reinforcer	O
23	to	O
24	increase	O
25	arithmetic	O
26	performance	O
27	of	O
28	EMR	O
29	children	O
30	and	O
31	(	O
32	b	O
33	)	O
34	whether	O
35	this	O
36	contingent	O
37	reinforcement	O
38	would	O
39	affect	O
40	preference	O
41	for	O
42	that	O
43	reinforcer	O
44	.	O

1	To	O
2	define	O
3	the	O
4	mechanism	O
5	responsible	O
6	for	O
7	the	O
8	loss	O
9	of	O
10	transcription	O
11	elongation	O
12	blockage	O
13	and	O
14	resulting	B
15	c	I
16	-	I
17	myc	O
18	deregulation	O
19	in	O
20	Burkitt	O
21	'	O
22	s	O
23	lymphoma	O
24	,	O
25	we	O
26	analyzed	O
27	transcription	O
28	patterns	O
29	after	O
30	transfer	O
31	of	O
32	normal	O
33	and	O
34	Burkitt	O
35	'	O
36	s	O
37	lymphoma	B
38	c	I
39	-	I
40	myc	I
41	alleles	O
42	into	O
43	murine	O
44	cells	O
45	and	O
46	Xenopus	O
47	oocyte	O
48	germinal	O
49	vesicles	O
50	.	O

1	In	O
2	Wnt	O
3	signaling	O
4	,	B
5	beta	I
6	-	I
7	catenin	I
8	and	I
9	plakoglobin	O
10	transduce	O
11	signals	O
12	to	O
13	the	O
14	nucleus	O
15	through	O
16	interactions	O
17	with	B
18	TCF	I
19	-	I
20	type	I
21	transcription	I
22	factors	I
23	.	I

1	Giant	O
2	pilomatrix	O
3	carcinoma	O
4	:	O
5	report	O
6	and	O
7	review	O
8	of	O
9	the	O
10	literature	O
11	.	O

1	Mutational	O
2	analyses	O
3	have	O
4	demonstrated	O
5	the	O
6	importance	O
7	of	O
8	sequences	O
9	within	O
10	the	O
11	327	O
12	bp	O
13	segment	O
14	that	O
15	contain	O
16	a	O
17	putative	B
18	cyclic	I
19	AMP	I
20	responsive	I
21	element	I
22	binding	I
23	protein	I
24	(	I
25	CREB	I
26	)	I
27	binding	I
28	site	O
29	for	B
30	TGF	I
31	-	I
32	beta	I
33	1	O
34	and	O
35	PMA	O
36	responsiveness	O
37	and	O
38	putative	O
39	PU	O
40	-	O
41	1	O
42	and	B
43	Sp1	I
44	binding	I
45	sites	O
46	for	O
47	basal	O
48	promoter	O
49	activity	O
50	.	O

1	Lack	O
2	of	B
3	cyclin	B
4	D	I
5	-	I
6	Cdk	I
7	complexes	O
8	in	O
9	Rb	O
10	-	O
11	negative	O
12	cells	O
13	correlates	O
14	with	O
15	high	O
16	levels	O
17	of	B
18	p16INK4	I
19	/	I
20	MTS1	I
21	tumour	I
22	suppressor	I
23	gene	I
24	product	I
25	.	I

1	We	O
2	report	O
3	here	O
4	the	O
5	identification	O
6	of	O
7	a	O
8	cDNA	O
9	that	O
10	encodes	O
11	a	O
12	new	O
13	member	O
14	of	O
15	the	B
16	GTPase	I
17	-	I
18	activating	I
19	protein	I
20	(	I
21	GAP	I
22	)	I
23	family	I
24	of	I
25	GTPase	I
26	regulators	I
27	.	I

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	depletion	O
7	of	O
8	protein	O
9	kinase	O
10	C	O
11	by	O
12	long	O
13	-	O
14	term	O
15	treatment	O
16	of	O
17	B16	O
18	mouse	O
19	melanoma	O
20	cells	O
21	with	O
22	phorbol	O
23	dibutyrate	O
24	(	O
25	PDBu	O
26	)	O
27	prevented	O
28	cell	O
29	density	O
30	-	O
31	dependent	O
32	melanogenesis	O
33	.	O

1	Infectious	O
2	mutant	O
3	virus	O
4	progeny	O
5	was	O
6	obtained	O
7	only	O
8	on	O
9	complementing	O
10	gK	O
11	-	O
12	expressing	O
13	cells	O
14	,	O
15	suggesting	O
16	that	O
17	gK	O
18	has	O
19	an	O
20	important	O
21	function	O
22	in	O
23	the	O
24	replication	O
25	cycle	O
26	.	O

1	The	O
2	inferred	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	cyanobacterial	O
9	HemB	O
10	protein	O
11	indicates	O
12	a	O
13	significant	O
14	difference	O
15	in	O
16	the	O
17	metal	O
18	cofactor	O
19	requirement	O
20	from	O
21	the	O
22	higher	O
23	-	O
24	plant	O
25	enzymes	O
26	,	O
27	which	O
28	was	O
29	confirmed	O
30	by	O
31	overexpression	O
32	and	O
33	biochemical	O
34	analysis	O
35	.	O

1	To	O
2	achieve	O
3	complete	O
4	dissection	O
5	of	O
6	the	O
7	anterior	O
8	vitreous	O
9	,	O
10	we	O
11	remove	O
12	even	O
13	a	O
14	clear	O
15	lens	O
16	during	O
17	the	O
18	first	O
19	surgical	O
20	intervention	O
21	in	O
22	selected	O
23	cases	O
24	.	O

1	The	O
2	grandfather	O
3	and	O
4	the	O
5	granddaughter	O
6	both	O
7	had	O
8	microtia	O
9	and	O
10	meatal	O
11	atresia	O
12	,	O
13	whereas	O
14	the	O
15	daughter	O
16	had	O
17	a	O
18	normal	O
19	outer	O
20	ear	O
21	except	O
22	for	O
23	a	O
24	narrow	O
25	meatus	O
26	and	O
27	auricular	O
28	appendages	O
29	.	O

1	Moreover	O
2	,	O
3	an	O
4	in	O
5	vitro	O
6	pull	O
7	-	O
8	down	O
9	assay	O
10	showed	O
11	that	O
12	Os	O
13	;	B
14	CycH	O
15	;	O
16	1	O
17	specifically	O
18	bound	O
19	to	O
20	R2	O
21	but	O
22	not	O
23	to	O
24	other	O
25	rice	B
26	CDKs	O
27	.	O

1	Intron	O
2	8	O
3	harbored	O
4	a	O
5	strong	O
6	erythroid	O
7	-	O
8	specific	O
9	enhancer	O
10	activity	O
11	which	O
12	was	O
13	orientation	O
14	-	O
15	dependent	O
16	.	O

1	There	O
2	is	O
3	general	O
4	agreement	O
5	that	O
6	the	O
7	hepatitis	O
8	C	O
9	virus	O
10	is	O
11	efficiently	O
12	transmitted	O
13	parenterally	O
14	,	O
15	while	O
16	data	O
17	on	O
18	viral	O
19	transmission	O
20	from	O
21	mothers	O
22	to	O
23	babies	O
24	or	O
25	by	O
26	sexual	O
27	or	O
28	non	O
29	-	O
30	sexual	O
31	household	O
32	contact	O
33	are	O
34	conflicting	O
35	.	O

1	The	O
2	significance	O
3	of	O
4	the	O
5	phenolphthalein	B
6	sulphatase	O
7	test	O
8	for	O
9	the	O
10	differentiation	O
11	and	O
12	identification	O
13	of	O
14	Nocardia	O
15	species	O
16	.	O

1	NiCl	O
2	(	O
3	2	O
4	)-	O
5	induced	B
6	MCP	I
7	-	I
8	1	O
9	synthesis	O
10	required	O
11	activation	O
12	of	B
13	NF	I
14	-	I
15	kappaB	O
16	since	O
17	mutation	O
18	of	B
19	NF	I
20	-	I
21	kappaB	I
22	-	I
23	binding	I
24	sites	O
25	in	O
26	the	O
27	promoter	O
28	resulted	O
29	in	O
30	complete	O
31	loss	O
32	of	O
33	inducible	O
34	promoter	O
35	activity	O
36	.	O

1	The	O
2	encoded	O
3	protein	O
4	has	O
5	a	O
6	leader	O
7	sequence	O
8	of	O
9	27	O
10	amino	O
11	acids	O
12	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	comparison	O
6	of	O
7	the	B
8	hCHLR	I
9	gene	I
10	sequences	O
11	with	O
12	available	O
13	databases	O
14	indicates	O
15	that	O
16	a	O
17	large	O
18	portion	O
19	of	O
20	these	O
21	genes	O
22	,	O
23	including	O
24	exons	O
25	encoding	O
26	two	O
27	functional	O
28	domains	O
29	of	O
30	the	O
31	carboxyl	O
32	-	O
33	terminal	O
34	region	O
35	of	O
36	these	O
37	proteins	O
38	,	O
39	has	O
40	been	O
41	duplicated	O
42	as	O
43	part	O
44	of	O
45	a	O
46	larger	O
47	human	O
48	telomeric	O
49	repeat	O
50	sequence	O
51	found	O
52	on	O
53	many	O
54	human	O
55	chromosomes	O
56	.	O

1	The	O
2	second	O
3	method	O
4	,	O
5	the	O
6	"	O
7	macro	O
8	"	O
9	assay	O
10	,	O
11	has	O
12	a	O
13	sensitivity	O
14	range	O
15	of	O
16	0	O
17	.	O
18	03	O
19	-	O
20	5	O
21	.	O
22	0	O
23	micrograms	O
24	phosphorus	O
25	with	O
26	100	O
27	-	O
28	500	O
29	microliters	O
30	HClO4	O
31	.	O

1	Specific	O
2	requirements	O
3	for	O
4	branched	O
5	-	O
6	chain	O
7	amino	O
8	acids	O
9	,	O
10	glutamine	O
11	,	O
12	and	O
13	arginine	O
14	are	O
15	evaluated	O
16	.	O

1	The	O
2	BAL	O
3	concentrations	O
4	of	O
5	the	O
6	nine	O
7	cytokines	O
8	evaluated	O
9	for	O
10	the	O
11	more	O
12	and	O
13	less	O
14	affected	O
15	lungs	O
16	were	O
17	compared	O
18	:	B
19	interleukin	I
20	-	I
21	6	I
22	(	I
23	IL	I
24	-	I
25	6	O
26	),	B
27	IL	I
28	-	I
29	8	I
30	,	I
31	IL	I
32	-	I
33	12	I
34	,	I
35	tumor	I
36	necrosis	I
37	factor	I
38	-	I
39	alpha	I
40	(	I
41	TNF	I
42	-	I
43	alpha	O
44	),	O
45	and	B
46	interferon	I
47	gamma	I
48	(	I
49	IFN	I
50	-	I
51	gamma	O
52	)	O
53	showed	O
54	significant	O
55	differences	O
56	(	O
57	p	O
58	ranged	O
59	between	O
60	0	O
61	.	O

1	Neither	O
2	clone	O
3	encoded	O
4	the	O
5	cognate	O
6	endonuclease	O
7	.	O

1	Atorvastatin	O
2	was	O
3	the	O
4	most	O
5	cost	O
6	-	O
7	effective	B
8	HMG	I
9	-	I
10	CoA	I
11	reductase	I
12	inhibitor	I
13	.	I

1	An	O
2	open	O
3	-	O
4	label	O
5	,	O
6	placebo	O
7	-	O
8	controlled	O
9	,	O
10	randomized	O
11	,	O
12	two	O
13	-	O
14	way	O
15	crossover	O
16	study	O
17	was	O
18	performed	O
19	in	O
20	12	O
21	healthy	O
22	volunteers	O
23	(	O
24	between	O
25	20	O
26	and	O
27	44	O
28	years	O
29	of	O
30	age	O
31	)	O
32	to	O
33	assess	O
34	the	O
35	effect	O
36	of	O
37	orlistat	O
38	,	O
39	a	O
40	gastrointestinal	B
41	lipase	I
42	inhibitor	O
43	that	O
44	reduces	O
45	dietary	O
46	fat	O
47	absorption	O
48	and	O
49	is	O
50	being	O
51	developed	O
52	for	O
53	weight	O
54	control	O
55	in	O
56	obesity	O
57	,	O
58	on	O
59	the	O
60	absorption	O
61	of	O
62	vitamins	O
63	A	O
64	and	O
65	E	O
66	.	O

1	Despite	O
2	its	O
3	requirement	O
4	for	O
5	enhancer	O
6	-	O
7	dependent	O
8	splicing	O
9	activity	O
10	in	O
11	vitro	O
12	,	O
13	the	O
14	dU2AF38	B
15	RS	I
16	domain	O
17	was	O
18	also	O
19	inessential	O
20	in	O
21	vivo	O
22	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	largest	O
5	value	O
6	of	O
7	the	O
8	joint	O
9	space	O
10	may	O
11	be	O
12	used	O
13	when	O
14	evaluating	O
15	rheumatoid	O
16	AC	O
17	joint	O
18	space	O
19	.	O

1	Gng3lg	O
2	transcripts	O
3	are	O
4	expressed	O
5	in	O
6	a	O
7	variety	O
8	of	O
9	tissues	O
10	including	O
11	both	O
12	brain	O
13	and	O
14	testes	O
15	.	O

1	Serum	O
2	lipids	O
3	and	O
4	lipoproteins	O
5	of	O
6	29	B
7	insulin	I
8	dependent	O
9	diabetic	O
10	children	O
11	have	O
12	been	O
13	determined	O
14	and	O
15	related	O
16	to	O
17	the	O
18	metabolic	O
19	status	O
20	of	O
21	the	O
22	patients	O
23	.	O

1	The	O
2	E1	O
3	replication	O
4	protein	O
5	of	O
6	bovine	O
7	papillomavirus	O
8	type	O
9	1	O
10	contains	O
11	an	O
12	extended	O
13	nuclear	O
14	localization	O
15	signal	O
16	that	O
17	includes	O
18	a	B
19	p34cdc2	O
20	phosphorylation	O
21	site	O
22	.	O

1	These	O
2	results	O
3	continue	O
4	to	O
5	support	O
6	the	O
7	hypothesis	O
8	that	O
9	HS2	O
10	,	O
11	HS3	O
12	,	O
13	and	O
14	HS4	O
15	act	O
16	as	O
17	a	O
18	single	O
19	,	O
20	integral	O
21	unit	O
22	to	O
23	regulate	B
24	human	I
25	globin	I
26	gene	I
27	transcription	O
28	as	O
29	a	O
30	holocomplex	O
31	,	O
32	but	O
33	they	O
34	can	O
35	also	O
36	be	O
37	interpreted	O
38	to	O
39	say	O
40	that	O
41	formation	O
42	of	O
43	a	O
44	DNase	O
45	I	O
46	hypersensitive	O
47	holocomplex	O
48	alone	O
49	is	O
50	not	O
51	sufficient	O
52	for	O
53	mediating	O
54	high	O
55	-	O
56	level	B
57	globin	I
58	gene	I
59	transcription	I
60	.	I

1	The	B
2	tryptase	I
3	locus	O
4	also	O
5	contains	O
6	at	O
7	least	O
8	four	B
9	tryptase	I
10	-	I
11	like	I
12	pseudogenes	O
13	,	O
14	including	O
15	mastin	O
16	,	O
17	a	O
18	gene	O
19	expressed	O
20	in	O
21	dogs	O
22	but	O
23	not	O
24	in	O
25	humans	O
26	.	O

1	The	O
2	pyramidal	O
3	tract	O
4	and	O
5	Mesencephalic	O
6	Reticular	O
7	Formation	O
8	(	O
9	MRF	O
10	)	O
11	were	O
12	stimulated	O
13	before	O
14	and	O
15	after	O
16	the	O
17	transection	O
18	.	O

1	The	O
2	present	O
3	study	O
4	describes	O
5	the	O
6	cell	O
7	volume	O
8	dynamics	O
9	in	O
10	intact	O
11	rat	O
12	hearts	O
13	,	O
14	during	O
15	ischemia	O
16	and	O
17	after	O
18	reperfusion	O
19	.	O

1	Stable	O
2	transfection	O
3	of	O
4	the	O
5	BL	O
6	cell	O
7	line	O
8	Raji	O
9	with	O
10	constructs	O
11	containing	O
12	core	O
13	promoter	O
14	mutations	O
15	confirmed	O
16	that	O
17	the	O
18	proximal	B
19	Sp1	I
20	site	O
21	and	O
22	the	O
23	TATA	O
24	box	O
25	are	O
26	essential	O
27	for	O
28	the	O
29	activation	O
30	of	O
31	promoter	O
32	P1	O
33	by	O
34	the	B
35	Ig	I
36	kappa	I
37	enhancers	I
38	.	I

1	The	O
2	delta	B
3	srb10	O
4	mutation	O
5	also	O
6	influenced	O
7	on	O
8	the	O
9	transcript	O
10	levels	O
11	of	O
12	meiosis	O
13	-	O
14	inducing	O
15	genes	O
16	called	B
17	IME1	I
18	and	I
19	IME2	O
20	:	O
21	the	O
22	mutation	O
23	elevated	O
24	the	O
25	transcript	O
26	level	O
27	of	B
28	IME1	O
29	but	O
30	reduced	O
31	that	O
32	of	O
33	IME2	O
34	,	O
35	resulting	O
36	in	O
37	partial	O
38	defects	O
39	in	O
40	premeiotic	O
41	DNA	O
42	synthesis	O
43	and	O
44	meiosis	O
45	.	O

1	Specifically	O
2	,	O
3	by	O
4	oligonucleotide	O
5	-	O
6	directed	O
7	site	O
8	-	O
9	specific	O
10	mutagenesis	O
11	,	O
12	we	O
13	demonstrate	O
14	that	O
15	of	O
16	10	O
17	cysteine	O
18	residues	O
19	in	O
20	the	O
21	ORF4	O
22	polypeptide	O
23	,	O
24	only	O
25	C	O
26	-	O
27	421	O
28	and	O
29	C	O
30	-	O
31	426	O
32	are	O
33	essential	O
34	for	O
35	transactivator	O
36	function	O
37	and	O
38	suggest	O
39	that	O
40	these	O
41	cysteine	O
42	residues	O
43	may	O
44	participate	O
45	in	O
46	critical	O
47	protein	O
48	-	O
49	protein	O
50	interactions	O
51	rather	O
52	than	O
53	protein	O
54	-	O
55	nucleic	O
56	acid	O
57	interactions	O
58	to	O
59	mediate	O
60	ORF4	O
61	inducibility	O
62	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	115	O
6	amino	O
7	acids	O
8	correspond	O
9	to	O
10	a	O
11	putative	O
12	DNA	O
13	-	O
14	binding	O
15	domain	O
16	and	O
17	show	O
18	significant	O
19	sequence	O
20	similarity	O
21	with	O
22	other	O
23	cloned	B
24	IFN	I
25	response	I
26	factors	I
27	(	I
28	IRF	I
29	-	I
30	1	O
31	and	B
32	IRF	I
33	-	I
34	2	O
35	).	O

1	In	O
2	these	O
3	experiments	O
4	we	O
5	begin	O
6	to	O
7	study	O
8	the	O
9	potential	O
10	functions	O
11	of	O
12	the	O
13	alpha	O
14	7	O
15	cytoplasmic	O
16	domain	O
17	by	O
18	analyzing	O
19	homologies	O
20	between	O
21	the	O
22	rat	O
23	and	O
24	human	O
25	sequences	O
26	,	O
27	by	O
28	immunologic	O
29	studies	O
30	using	O
31	an	O
32	anti	O
33	-	O
34	cytoplasmic	O
35	domain	O
36	antiserum	O
37	,	O
38	and	O
39	by	O
40	identifying	O
41	two	O
42	alternate	O
43	forms	O
44	.	O

1	This	O
2	brief	O
3	hypercapnic	O
4	challenge	O
5	induced	O
6	a	O
7	rapid	O
8	increase	O
9	in	O
10	CBF	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	any	O
16	change	O
17	in	O
18	MABP	O
19	.	O

1	The	O
2	concentrations	O
3	of	O
4	plasma	O
5	ACTH	O
6	and	O
7	cortisol	O
8	increased	O
9	by	O
10	40	O
11	%	O
12	and	O
13	60	O
14	%	O
15	after	O
16	MPTP	O
17	treatment	O
18	,	O
19	respectively	O
20	.	O

1	Furthermore	O
2	,	O
3	upstream	O
4	insertion	O
5	of	O
6	the	O
7	GSTP1	O
8	silencer	O
9	element	O
10	failed	O
11	to	O
12	inhibit	O
13	activity	O
14	of	O
15	a	O
16	heterologous	O
17	promoter	O
18	in	O
19	MCF7	O
20	cells	O
21	.	O

1	Four	O
2	transcription	O
3	initiation	O
4	sites	O
5	have	O
6	been	O
7	identified	O
8	by	B
9	full	I
10	-	I
11	length	I
12	RNA	I
13	ligase	I
14	-	O
15	mediated	O
16	rapid	O
17	amplification	O
18	of	O
19	cDNA	O
20	ends	O
21	(	O
22	RLM	O
23	-	O
24	RACE	O
25	)	O
26	between	O
27	-	O
28	61	O
29	and	O
30	-	O
31	32	O
32	bp	O
33	from	O
34	the	O
35	translation	O
36	initiation	O
37	codon	O
38	.	O
39	Reverse	O
40	transcription	O
41	-	O
42	PCR	O
43	analysis	O
44	revealed	O
45	that	O
46	PFK	O
47	-	O
48	A	O
49	,	B
50	PFK	I
51	-	I
52	B	I
53	and	I
54	PFK	I
55	-	I
56	C	I
57	genes	O
58	were	O
59	expressed	O
60	,	O
61	in	O
62	all	O
63	mouse	O
64	tissues	O
65	tested	O
66	,	O
67	at	O
68	varying	O
69	levels	O
70	.	O

1	Studied	O
2	groups	O
3	were	O
4	(	O
5	1	O
6	)	O
7	untreated	O
8	control	O
9	,	O
10	n	O
11	=	O
12	12	O
13	;	O
14	(	O
15	2	O
16	)	B
17	FK	I
18	-	I
19	1	O
20	,	O
21	n	O
22	=	O
23	8	O
24	;	O
25	(	O
26	3	O
27	)	B
28	FK	I
29	-	I
30	3	O
31	,	O
32	n	O
33	=	O
34	8	O
35	.	O

1	These	O
2	results	O
3	indicate	O
4	that	B
5	HIV	I
6	-	I
7	1	I
8	Gag	I
9	sequences	O
10	can	O
11	influence	O
12	the	O
13	viral	O
14	PR	O
15	-	O
16	mediated	O
17	processing	O
18	of	O
19	the	O
20	MuLV	I
21	TM	I
22	Env	I
23	protein	I
24	p15	O
25	(	O
26	E	O
27	).	O

1	When	O
2	both	O
3	lesions	O
4	were	O
5	complete	O
6	lateral	O
7	hemisections	O
8	in	O
9	weanling	O
10	operates	O
11	,	O
12	little	O
13	behavioral	O
14	recovery	O
15	was	O
16	observed	O
17	,	O
18	similar	O
19	to	O
20	complete	O
21	spinal	O
22	cord	O
23	transection	O
24	(	O
25	N	O
26	=	O
27	3	O
28	).	O

1	The	O
2	highest	O
3	prevalence	O
4	of	O
5	reported	O
6	pet	O
7	allergy	O
8	,	O
9	chronic	O
10	cough	O
11	,	O
12	wheeze	O
13	,	O
14	attacks	O
15	of	O
16	shortness	O
17	of	O
18	breath	O
19	with	O
20	wheezing	O
21	,	O
22	and	O
23	doctor	O
24	-	O
25	diagnosed	O
26	asthma	O
27	was	O
28	found	O
29	in	O
30	children	O
31	who	O
32	had	O
33	pets	O
34	in	O
35	the	O
36	past	O
37	but	O
38	not	O
39	anymore	O
40	.	O

1	The	O
2	transcription	O
3	and	O
4	alternative	O
5	splicing	O
6	of	O
7	human	O
8	ORL1	O
9	and	O
10	GAIP	O
11	are	O
12	cell	O
13	-	O
14	type	O
15	specific	O
16	.	O

1	Theories	O
2	proffered	O
3	to	O
4	account	O
5	for	O
6	the	O
7	modality	O
8	shift	O
9	effect	O
10	are	O
11	critically	O
12	evaluated	O
13	.	O

1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	propranolol	O
7	on	O
8	myocardial	O
9	metabolism	O
10	after	O
11	coronary	O
12	reperfusion	O
13	,	O
14	serial	O
15	measurements	O
16	of	O
17	myocardial	B
18	creatine	I
19	kinase	O
20	(	O
21	CK	O
22	)	O
23	and	O
24	calcium	O
25	(	O
26	Ca	O
27	)	O
28	contents	O
29	and	O
30	CK	O
31	and	O
32	lactic	O
33	acid	O
34	(	O
35	LA	O
36	)	O
37	concentrations	O
38	in	O
39	coronary	O
40	sinus	O
41	blood	O
42	were	O
43	carried	O
44	out	O
45	in	O
46	33	O
47	open	O
48	-	O
49	chest	O
50	dogs	O
51	.	O

1	Possibilities	O
2	and	O
3	outlook	O
4	for	O
5	wrist	O
6	joint	O
7	endoprosthesis	<s>

1	Adhesion	O
2	,	O
3	phagocytosis	O
4	,	O
5	chemotactic	O
6	and	O
7	random	O
8	migration	O
9	,	O
10	nitroblue	O
11	tetrazolium	O
12	dye	O
13	reduction	O
14	of	O
15	peritoneal	O
16	exudate	O
17	neutrophils	O
18	and	O
19	macrophages	O
20	,	B
21	fibrinogen	O
22	level	O
23	,	O
24	gelation	O
25	of	O
26	soluble	O
27	fibrin	O
28	and	O
29	serial	O
30	dilution	O
31	protamine	O
32	sulfate	O
33	test	O
34	were	O
35	investigated	O
36	in	O
37	115	O
38	New	O
39	Zealand	O
40	white	O
41	rabbits	O
42	with	O
43	experimentally	O
44	induced	O
45	Shwartzman	O
46	phenomenon	O
47	in	O
48	the	O
49	colon	O
50	,	O
51	and	O
52	in	O
53	control	O
54	animals	O
55	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	protein	O
7	kinase	B
8	MEKK1	O
9	can	O
10	induce	O
11	reporter	O
12	gene	O
13	expression	O
14	from	O
15	the	O
16	atrial	O
17	natriuretic	O
18	factor	O
19	(	O
20	ANF	O
21	)	O
22	promoter	O
23	,	O
24	a	O
25	genetic	O
26	marker	O
27	that	O
28	is	O
29	activated	O
30	during	O
31	in	O
32	vivo	O
33	hypertrophy	O
34	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	relationship	O
7	between	O
8	blood	O
9	flow	O
10	in	O
11	the	O
12	tumor	O
13	assessed	O
14	by	O
15	color	O
16	Doppler	O
17	ultrasound	O
18	,	O
19	microvessel	O
20	density	O
21	,	O
22	and	O
23	vascular	O
24	endothelial	O
25	growth	O
26	factor	O
27	levels	O
28	in	O
29	endometrial	O
30	carcinoma	O
31	.	O

1	Androgens	O
2	and	O
3	growth	O
4	.	O

1	Practical	O
2	use	O
3	and	O
4	interpretation	O
5	of	O
6	viral	O
7	hepatitis	O
8	B	O
9	markers	O
10	and	O
11	hepatic	O
12	biopsy	O
13	in	O
14	HBs	O
15	Ag	O
16	carriers	O
17	and	O
18	at	O
19	the	O
20	chronic	O
21	hepatitis	O
22	stage	O

1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	B
9	p53	I
10	-	O
11	induced	O
12	Waf1	I
13	/	I
14	Cip1	I
15	-	O
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	B
26	myb	I
27	oncogene	I
28	family	I
29	.	I

1	The	O
2	Y	O
3	-	O
4	type	O
5	structural	O
6	motif	O
7	is	O
8	also	O
9	conserved	O
10	among	O
11	a	O
12	number	O
13	of	O
14	divergent	O
15	BiP	O
16	mRNAs	O
17	.	O

1	Cytogenetic	O
2	analysis	O
3	of	O
4	LOH	O
5	mutants	O
6	by	O
7	chromosome	O
8	painting	O
9	indicated	O
10	a	O
11	mosaic	O
12	of	O
13	chromosomal	O
14	aberrations	O
15	involving	O
16	chromosome	O
17	17	O
18	,	O
19	in	O
20	which	O
21	partial	O
22	chromosome	O
23	deletions	O
24	,	O
25	amplifications	O
26	,	O
27	and	O
28	multiple	O
29	translocations	O
30	appeared	O
31	heterogeneously	O
32	in	O
33	a	O
34	single	O
35	mutant	O
36	.	O

1	Acute	O
2	pancreatitis	O
3	is	O
4	a	O
5	rather	O
6	common	O
7	abdominal	O
8	disorder	O
9	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	total	O
7	pinealectomy	O
8	in	O
9	these	O
10	already	O
11	sympathectomized	O
12	blinded	O
13	rabbits	O
14	always	O
15	resulted	O
16	in	O
17	a	O
18	substantial	O
19	deceleration	O
20	of	O
21	the	O
22	rhythms	O
23	(	O
24	mean	O
25	delta	O
26	tau	O
27	=	O
28	+	O
29	0	O
30	.	O
31	23	O
32	h	O
33	).	O

1	Postnatal	O
2	volumetric	O
3	development	O
4	of	O
5	the	O
6	prefrontal	O
7	cortex	O
8	in	O
9	the	O
10	rat	O
11	.	O

1	Handgrip	B
2	dynamometry	O
3	was	O
4	also	O
5	carried	O
6	out	O
7	in	O
8	249	O
9	of	O
10	the	O
11	patients	O
12	.	O

1	We	O
2	investigated	O
3	the	O
4	diagnostic	O
5	value	O
6	of	O
7	a	O
8	new	O
9	in	O
10	vitro	O
11	test	O
12	,	O
13	Pharmacia	O
14	CAP	O
15	System	O
16	(	O
17	Pharmacia	O
18	Diagnostics	O
19	AB	O
20	,	O
21	Uppsala	O
22	,	O
23	Sweden	O
24	),	O
25	for	O
26	the	O
27	quantitative	O
28	measurement	O
29	of	O
30	allergen	I
31	-	I
32	specific	I
33	IgE	I
34	antibodies	O
35	by	O
36	comparison	O
37	with	O
38	RAST	O
39	in	O
40	2	O
41	groups	O
42	of	O
43	patients	O
44	,	O
45	71	O
46	atopic	O
47	and	O
48	48	O
49	non	O
50	-	O
51	atopic	O
52	.	O

1	We	O
2	have	O
3	subcloned	O
4	into	O
5	pBR322	O
6	deoxyribonucleic	O
7	acid	O
8	(	O
9	DNA	O
10	)	O
11	sequences	O
12	mapping	O
13	either	O
14	in	O
15	the	O
16	coding	O
17	region	O
18	,	O
19	the	O
20	5	O
21	'	O
22	spacer	O
23	,	O
24	or	O
25	the	O
26	3	O
27	'	O
28	spacer	O
29	of	O
30	the	B
31	H2B	I
32	histone	I
33	gene	I
34	.	I

1	Kss1	O
2	binds	O
3	specifically	O
4	to	O
5	a	O
6	GST	O
7	-	O
8	Dig1	O
9	fusion	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	other	O
16	yeast	O
17	protein	O
18	.	O

1	The	O
2	high	O
3	conservation	O
4	of	O
5	the	O
6	3	O
7	'	O
8	terminus	O
9	suggests	O
10	that	O
11	this	O
12	region	O
13	directs	O
14	the	O
15	assembly	O
16	of	O
17	proteins	O
18	required	O
19	for	O
20	the	O
21	initiation	O
22	of	O
23	RNA	O
24	replication	O
25	.	O

1	3	O
2	.	O

1	The	O
2	addition	O
3	of	O
4	an	O
5	equimolar	O
6	complex	O
7	of	O
8	the	O
9	fourth	O
10	and	O
11	seventh	O
12	largest	O
13	subunits	O
14	,	O
15	purified	O
16	from	O
17	pol	O
18	II	O
19	holoenzyme	O
20	by	O
21	ion	O
22	-	O
23	exchange	O
24	chromatography	O
25	in	O
26	the	O
27	presence	O
28	of	O
29	urea	O
30	,	O
31	restored	O
32	promoter	O
33	-	O
34	directed	O
35	initiation	O
36	activity	O
37	to	B
38	pol	I
39	II	I
40	delta	I
41	4	I
42	/	I
43	7	I
44	.	I

1	More	O
2	recently	O
3	,	O
4	however	O
5	,	O
6	a	O
7	number	O
8	of	O
9	developments	O
10	such	O
11	as	O
12	the	O
13	successful	O
14	use	O
15	of	O
16	the	O
17	inhaled	O
18	steroid	O
19	budesonide	O
20	and	O
21	oral	O
22	dexamethasone	O
23	have	O
24	reinforced	O
25	the	O
26	argument	O
27	for	O
28	using	O
29	steroids	O
30	.	O

1	In	O
2	the	O
3	PMR	O
4	target	O
5	area	O
6	but	O
7	not	O
8	in	O
9	the	O
10	nontreated	O
11	area	O
12	an	O
13	improvement	O
14	in	O
15	regional	O
16	myocardial	O
17	flow	O
18	reserve	O
19	occurs	O
20	in	O
21	wall	O
22	segments	O
23	with	O
24	initially	O
25	severely	O
26	or	O
27	moderately	O
28	reduced	O
29	stress	O
30	perfusion	O
31	.	O

1	Furthermore	O
2	,	O
3	both	B
4	rhHR23	I
5	proteins	O
6	function	O
7	in	O
8	a	O
9	defined	O
10	NER	O
11	system	O
12	reconstituted	O
13	with	O
14	purified	O
15	proteins	O
16	,	O
17	indicating	O
18	direct	O
19	involvement	O
20	of	O
21	hHR23	O
22	proteins	O
23	in	O
24	the	O
25	DNA	O
26	repair	O
27	reaction	O
28	via	O
29	interaction	O
30	with	O
31	XPC	O
32	.	O

1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	B
8	extracellular	B
9	matrix	I
10	glycoprotein	I
11	undulin	I
12	.	I

1	Determination	O
2	of	O
3	an	O
4	RNA	O
5	structure	O
6	involved	O
7	in	O
8	splicing	O
9	inhibition	O
10	of	O
11	a	O
12	muscle	O
13	-	O
14	specific	O
15	exon	O
16	.	O

1	We	O
2	describe	O
3	here	O
4	17	O
5	dominant	O
6	GCN2	O
7	mutations	O
8	that	O
9	lead	O
10	to	O
11	derepression	O
12	of	O
13	GCN4	O
14	expression	O
15	in	O
16	the	O
17	absence	O
18	of	O
19	amino	O
20	acid	O
21	starvation	O
22	.	O

1	Multiple	O
2	dosing	O
3	four	O
4	times	O
5	daily	O
6	for	O
7	7	O
8	days	O
9	of	O
10	indoprofen	O
11	200	O
12	mg	O
13	,	O
14	a	O
15	non	O
16	-	O
17	steroidal	O
18	anti	O
19	-	O
20	inflammatory	O
21	drug	O
22	with	O
23	a	O
24	short	O
25	half	O
26	-	O
27	life	O
28	(	O
29	t1	O
30	/	O
31	2	O
32	),	O
33	revealed	O
34	drug	O
35	accumulation	O
36	in	O
37	eight	O
38	elderly	O
39	subjects	O
40	.	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	alternative	B
7	sigma	I
8	factor	O
9	,	O
10	RpoN	O
11	,	O
12	in	O
13	Rhodobacter	O
14	capsulatus	O
15	;	O
16	physiological	O
17	relevance	O
18	of	O
19	an	O
20	autoactivated	B
21	nifU2	I
22	-	I
23	rpoN	I
24	superoperon	I
25	.	I

1	Multivariate	O
2	logistic	O
3	regression	O
4	analysis	O
5	indicated	O
6	that	O
7	seropositivity	O
8	was	O
9	strongly	O
10	associated	O
11	with	O
12	the	O
13	prevalence	O
14	of	O
15	hepatitis	O
16	B	O
17	in	O
18	an	O
19	employee	O
20	'	O
21	s	O
22	country	O
23	of	O
24	birth	O
25	and	O
26	with	O
27	age	O
28	.	O

1	Northern	O
2	blot	O
3	and	O
4	reverse	O
5	transcription	O
6	-	O
7	PCR	O
8	analyses	O
9	of	O
10	human	O
11	mRNA	O
12	samples	O
13	demonstrate	O
14	that	O
15	RNR	O
16	is	O
17	expressed	O
18	exclusively	O
19	in	O
20	the	O
21	retina	O
22	,	O
23	with	O
24	transcripts	O
25	of	O
26	approximately	O
27	7	O
28	.	O
29	5	O
30	kb	O
31	,	O
32	approximately	O
33	3	O
34	.	O
35	0	O
36	kb	O
37	,	O
38	and	O
39	approximately	O
40	2	O
41	.	O
42	3	O
43	kb	O
44	by	O
45	Northern	O
46	blot	O
47	analysis	O
48	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	cumulative	O
6	behavioral	O
7	toxicity	O
8	after	O
9	chronic	O
10	oral	O
11	administration	O
12	of	B
13	l	I
14	-	I
15	alpha	I
16	-	I
17	acetylmethadol	O
18	to	O
19	female	O
20	rats	O
21	.	O

1	Issues	O
2	of	O
3	distribution	O
4	of	O
5	kinetic	O
6	energy	O
7	of	O
8	traumatizing	O
9	object	O
10	in	O
11	direct	O
12	contact	O
13	interaction	O
14	with	O
15	head	O
16	during	O
17	impact	O
18	are	O
19	discussed	O
20	from	O
21	position	O
22	of	O
23	biomechanics	O
24	.	O

1	Mutations	O
2	of	O
3	the	B
4	RET	I
5	gene	I
6	,	I
7	encoding	I
8	a	I
9	receptor	I
10	tyrosine	I
11	kinase	O
12	,	O
13	have	O
14	been	O
15	associated	O
16	with	O
17	the	O
18	inherited	O
19	cancer	O
20	syndromes	O
21	MEN	O
22	2A	O
23	and	O
24	MEN	O
25	2B	O
26	.	O

1	Three	O
2	chromosomal	O
3	crsA	O
4	mutations	O
5	,	O
6	crsA1	O
7	,	O
8	crsA4	O
9	,	O
10	and	O
11	crsA47	O
12	,	O
13	were	O
14	transferred	O
15	by	O
16	the	O
17	"	O
18	gene	O
19	conversion	O
20	"	O
21	process	O
22	to	O
23	B	O
24	.	O
25	subtilis	O
26	plasmid	B
27	pRPD11	O
28	,	O
29	which	O
30	consists	O
31	of	O
32	the	O
33	entire	O
34	wild	O
35	-	O
36	type	O
37	rpoD	O
38	coding	O
39	sequence	O
40	,	O
41	encoding	O
42	the	O
43	major	B
44	sigma	B
45	43	I
46	factor	I
47	of	I
48	B	I
49	.	I
50	subtilis	I
51	RNA	I
52	polymerase	O
53	,	O
54	and	O
55	pUB110	O
56	.	O

1	A	O
2	critical	O
3	heart	O
4	rate	O
5	and	O
6	/	O
7	or	O
8	appropriate	O
9	sympathetic	O
10	state	O
11	was	O
12	found	O
13	to	O
14	provoke	O
15	all	O
16	instances	O
17	of	O
18	reentrant	O
19	or	O
20	automatic	O
21	atrial	O
22	tachycardia	O
23	and	O
24	atypical	O
25	junctional	O
26	tachycardia	O
27	.	O

1	267	O
2	,	O
3	4870	O
4	-	O
5	4877	O
6	))	O
7	indicates	O
8	an	O
9	overall	O
10	identity	O
11	of	O
12	58	O
13	and	O
14	56	O
15	%,	O
16	respectively	O
17	,	O
18	with	O
19	a	O
20	91	O
21	and	O
22	92	O
23	%	O
24	identity	O
25	in	O
26	the	O
27	highly	O
28	conserved	O
29	transmembrane	O
30	and	O
31	cytoplasmic	O
32	domains	O
33	.	O

1	A	O
2	contiguous	O
3	and	O
4	sequentially	O
5	occupied	O
6	secondary	O
7	Fur	O
8	-	O
9	binding	O
10	site	O
11	in	O
12	entC	O
13	was	O
14	protected	O
15	at	O
16	higher	O
17	Fur	O
18	concentrations	O
19	,	O
20	extending	O
21	the	O
22	protected	O
23	region	O
24	to	O
25	+	O
26	49	O
27	,	O
28	and	O
29	sequestering	O
30	the	O
31	putative	O
32	Shine	O
33	-	O
34	Dalgarno	O
35	sequence	O
36	.	O

1	CONCLUSION	O
2	:	O
3	Sonographic	O
4	angiography	O
5	has	O
6	a	O
7	possible	O
8	role	O
9	in	O
10	the	O
11	detection	O
12	of	O
13	small	O
14	nodules	O
15	in	O
16	patients	O
17	with	B
18	CRF	I
19	.	I

1	The	O
2	Thr161Val	O
3	mutation	O
4	causes	O
5	a	O
6	lethal	O
7	phenotype	O
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	,	O
15	while	O
16	replacement	O
17	of	O
18	Thr161	O
19	with	O
20	glutamic	O
21	acid	O
22	,	O
23	potentially	O
24	mimicking	O
25	phosphorylation	O
26	,	O
27	causes	O
28	uncoordination	O
29	of	O
30	mitosis	O
31	and	O
32	multiple	O
33	cytokinesis	O
34	.	O

1	Strontium	O
2	-	O
3	90	O
4	was	O
5	inject	O
6	i	O
7	.	O
8	v	O
9	.	O
10	into	O
11	pregnant	O
12	rats	O
13	on	O
14	day	O
15	18	O
16	post	O
17	conception	O
18	(	O
19	p	O
20	.	O
21	c	O
22	.).	O

1	16	O
2	subjects	O
3	were	O
4	repatch	O
5	tested	O
6	to	O
7	ethylmercury	O
8	chloride	O
9	(	O
10	EtHgCl	O
11	)	O
12	and	O
13	to	O
14	solutions	O
15	containing	O
16	EtHgCl	O
17	mixed	O
18	with	O
19	L	O
20	-	O
21	cysteine	O
22	and	B
23	glutathione	O
24	,	O
25	respectively	O
26	.	O

1	Expression	O
2	of	B
3	lacZ	O
4	from	O
5	the	O
6	promoter	O
7	of	O
8	the	O
9	Escherichia	O
10	coli	B
11	spc	I
12	operon	O
13	cloned	O
14	into	O
15	vectors	O
16	carrying	O
17	the	O
18	W205	B
19	trp	I
20	-	I
21	lac	I
22	fusion	I
23	.	I

1	The	O
2	analysis	O
3	of	O
4	two	O
5	distinct	B
6	mitogen	I
7	-	I
8	activated	I
9	protein	I
10	kinase	O
11	pathways	O
12	shows	O
13	that	B
14	stress	I
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	-	I
20	Jun	I
21	N	I
22	-	I
23	terminal	I
24	kinase	O
25	activation	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	phosphorylation	O
31	of	O
32	ATF	I
33	-	I
34	2	I
35	,	I
36	c	I
37	-	I
38	Jun	O
39	,	O
40	and	O
41	JunD	O
42	,	O
43	is	O
44	required	O
45	not	O
46	only	O
47	for	O
48	the	B
49	IL	I
50	-	I
51	1	I
52	-	O
53	but	O
54	also	O
55	for	O
56	the	O
57	TPA	O
58	-	O
59	dependent	O
60	induction	O
61	,	O
62	while	O
63	the	B
64	extracellular	I
65	signal	I
66	-	I
67	related	I
68	kinase	I
69	1	I
70	(	I
71	ERK	I
72	-	I
73	1	O
74	)	O
75	and	B
76	ERK	I
77	-	I
78	2	O
79	activation	O
80	is	O
81	involved	O
82	in	O
83	the	O
84	TPA	O
85	-	O
86	but	O
87	not	O
88	in	O
89	the	B
90	IL	I
91	-	I
92	1	I
93	-	I
94	dependent	O
95	stimulation	O
96	of	O
97	the	O
98	uPA	O
99	enhancer	O
100	.	O

1	One	O
2	chimpanzee	O
3	reliably	O
4	selected	O
5	the	O
6	larger	O
7	numeral	O
8	4	O
9	during	O
10	testing	O
11	with	O
12	a	O
13	nonadjacent	O
14	pair	O
15	(	O
16	2	O
17	-	O
18	4	O
19	),	O
20	and	O
21	2	O
22	chimps	O
23	showed	O
24	no	O
25	preference	O
26	.	O

1	The	O
2	recombinant	O
3	contains	O
4	the	O
5	normal	B
6	beta	I
7	A	I
8	-	I
9	globin	I
10	gene	O
11	,	O
12	the	O
13	mutant	O
14	gene	O
15	and	O
16	Ylp	O
17	vector	O
18	sequences	O
19	between	O
20	the	O
21	two	O
22	copies	O
23	.	O

1	All	O
2	8	O
3	(	O
4	100	O
5	%)	O
6	patients	O
7	with	O
8	fulminant	O
9	hepatic	O
10	failure	O
11	who	O
12	received	O
13	grafts	O
14	survived	O
15	,	O
16	including	O
17	3	O
18	who	O
19	received	O
20	ABO	O
21	-	O
22	incompatible	O
23	grafts	O
24	,	O
25	though	O
26	2	O
27	of	O
28	these	O
29	subsequently	O
30	required	O
31	retransplantation	O
32	.	O

1	I	O
2	.	O

1	Each	O
2	half	O
3	molecule	O
4	contains	O
5	four	O
6	disulfide	O
7	linkages	O
8	and	O
9	four	O
10	cis	O
11	peptides	O
12	.	O

1	In	O
2	addition	O
3	,	O
4	npm3	O
5	,	O
6	which	O
7	is	O
8	usually	O
9	coactivated	O
10	with	B
11	fgf8	O
12	by	O
13	MMTV	O
14	insertion	O
15	,	O
16	was	O
17	not	O
18	up	O
19	-	O
20	regulated	O
21	by	O
22	androgens	O
23	in	O
24	SC	O
25	-	O
26	3	O
27	cells	O
28	.	O

1	Analysis	O
2	of	O
3	the	O
4	protein	O
5	sequences	O
6	of	O
7	these	O
8	two	O
9	replicases	O
10	,	O
11	together	O
12	with	O
13	previously	O
14	characterized	O
15	H	O
16	.	O
17	pylori	O
18	plasmid	O
19	replication	O
20	proteins	O
21	,	O
22	supports	O
23	the	O
24	formation	O
25	of	O
26	a	O
27	distinct	O
28	class	O
29	of	O
30	H	O
31	.	O
32	pylori	O
33	plasmid	O
34	proteins	O
35	.	O

1	In	O
2	H4IIE	O
3	rat	O
4	hepatoma	O
5	cells	O
6	,	O
7	glucocorticoids	O
8	,	O
9	retinoic	O
10	acid	O
11	and	O
12	cyclic	O
13	AMP	O
14	(	O
15	cAMP	O
16	)	O
17	increase	B
18	PEPCK	I
19	gene	I
20	transcription	O
21	whereas	B
22	insulin	O
23	and	O
24	phorbol	O
25	esters	O
26	have	O
27	the	O
28	opposite	O
29	effect	O
30	.	O

1	These	O
2	results	O
3	lead	O
4	us	O
5	to	O
6	hypothesize	O
7	that	O
8	a	O
9	single	O
10	multisubunit	B
11	TFIID	I
12	protein	O
13	supports	O
14	transcriptional	O
15	stimulation	O
16	by	O
17	diverse	O
18	activation	O
19	domains	O
20	and	O
21	from	O
22	a	O
23	TATA	O
24	-	O
25	less	O
26	promoter	O
27	.	O

1	Defects	O
2	of	O
3	fibrillin	O
4	(	O
5	FBN1	O
6	),	O
7	a	O
8	glycoprotein	O
9	component	O
10	of	O
11	the	O
12	extracellular	O
13	microfibril	O
14	,	O
15	cause	O
16	Marfan	O
17	syndrome	O
18	.	O

1	Hair	O
2	and	O
3	blood	O
4	samples	O
5	were	O
6	taken	O
7	before	O
8	vitamin	O
9	C	O
10	or	O
11	placebo	O
12	supplementation	O
13	was	O
14	started	O
15	and	O
16	at	O
17	monthly	O
18	intervals	O
19	thereafter	O
20	for	O
21	three	O
22	months	O
23	.	O

1	To	O
2	test	O
3	the	O
4	feasibility	O
5	of	O
6	using	O
7	liposomes	O
8	to	O
9	deliver	O
10	therapeutic	O
11	agents	O
12	to	O
13	the	O
14	lungs	O
15	,	O
16	the	O
17	effect	O
18	of	O
19	liposome	O
20	-	O
21	encapsulated	I
22	superoxide	I
23	dismutase	O
24	(	O
25	SOD	O
26	)	O
27	or	O
28	catalase	O
29	on	O
30	pulmonary	O
31	oxygen	O
32	toxicity	O
33	was	O
34	studied	O
35	in	O
36	rats	O
37	.	O

1	Although	O
2	not	O
3	consistently	O
4	identified	O
5	in	O
6	all	O
7	samples	O
8	,	O
9	secondary	O
10	Academic	O
11	,	O
12	Personal	O
13	Responsibility	O
14	,	O
15	and	O
16	Community	O
17	/	O
18	Vocational	O
19	dimensions	O
20	were	O
21	also	O
22	identified	O
23	.	O

1	Approximately	O
2	60	O
3	%	O
4	of	O
5	cell	O
6	bodies	O
7	of	O
8	primary	O
9	neurons	O
10	innervating	O
11	the	O
12	intra	O
13	and	O
14	perioral	O
15	structures	O
16	through	O
17	the	O
18	inferior	O
19	alveolar	O
20	,	O
21	lingual	O
22	,	O
23	mental	O
24	,	O
25	and	O
26	buccal	O
27	nerves	O
28	were	O
29	in	O
30	the	O
31	range	O
32	between	O
33	300	O
34	and	O
35	600	O
36	micron	O
37	2	O
38	in	O
39	cross	O
40	-	O
41	sectional	O
42	area	O
43	:	O
44	mean	O
45	+/-	O
46	SD	O
47	509	O
48	+/-	O
49	243	O
50	micron	O
51	2	O
52	,	O
53	420	O
54	+/-	O
55	181	O
56	micron	O
57	2	O
58	,	O
59	469	O
60	+/-	O
61	200	O
62	micron	O
63	2	O
64	,	O
65	and	O
66	444	O
67	+/-	O
68	186	O
69	micron	O
70	2	O
71	,	O
72	respectively	O
73	.	O

1	Finally	O
2	,	O
3	Cas	O
4	existed	O
5	mainly	O
6	in	O
7	cytosol	O
8	and	O
9	membrane	O
10	cytoskeleton	O
11	fractions	O
12	in	O
13	the	O
14	resting	O
15	state	O
16	,	O
17	and	O
18	remained	O
19	unchanged	O
20	during	O
21	platelet	O
22	aggregation	O
23	,	O
24	when	O
25	FAK	O
26	translocated	O
27	to	O
28	the	O
29	cytoskeletal	O
30	fraction	O
31	.	O

1	NOT4	O
2	interacts	O
3	with	O
4	NOT1	O
5	and	O
6	NOT3	O
7	in	O
8	the	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	,	O
14	and	O
15	overexpression	O
16	of	O
17	NOT3	O
18	or	O
19	NOT4	O
20	suppresses	O
21	not1	O
22	and	O
23	not2	O
24	mutations	O
25	.	O

1	Interferon	O
2	stimulated	O
3	gene	O
4	factor	O
5	3	O
6	(	O
7	ISGF3	O
8	)	O
9	is	O
10	a	O
11	trimeric	I
12	transcription	I
13	factor	I
14	activated	O
15	on	O
16	treatment	O
17	of	O
18	cells	O
19	with	B
20	interferon	I
21	-	I
22	alpha	I
23	and	I
24	beta	I
25	(	I
26	type	I
27	I	O
28	IFNs	O
29	).	O

1	Three	O
2	subgenomes	O
3	also	O
4	comprised	O
5	15	O
6	to	O
7	75	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'	O
14	part	O
15	of	O
16	the	B
17	NS2	I
18	gene	I
19	.	I

1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	mutant	O
6	desmin	O
7	in	O
8	SW13	O
9	(	O
10	vim	O
11	-)	O
12	cells	O
13	showed	O
14	aggregation	O
15	of	O
16	abnormal	O
17	coarse	O
18	clumps	O
19	of	O
20	desmin	O
21	positive	O
22	material	O
23	dispersed	O
24	throughout	O
25	the	O
26	cytoplasm	O
27	.	O

1	Attitudes	O
2	were	O
3	found	O
4	to	O
5	be	O
6	multidimensional	O
7	,	O
8	with	O
9	similar	O
10	dimensions	O
11	being	O
12	identified	O
13	in	O
14	both	O
15	samples	O
16	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	HA	O
7	gene	O
8	in	O
9	these	O
10	two	O
11	mutants	O
12	confirmed	O
13	the	O
14	HA	O
15	-	O
16	phenotype	O
17	.	O

1	CsA	O
2	alone	O
3	resulted	O
4	in	O
5	elevated	O
6	bone	O
7	turnover	O
8	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	cells	O
7	containing	O
8	a	B
9	PTP1C	O
10	in	O
11	which	O
12	the	O
13	catalytic	O
14	site	O
15	had	O
16	been	O
17	inactivated	O
18	through	O
19	mutagenesis	O
20	,	O
21	stably	O
22	phosphorylated	O
23	the	O
24	phosphatase	O
25	.	O

1	Significantly	O
2	,	O
3	pPKR	O
4	is	O
5	capable	O
6	of	O
7	specifically	O
8	phosphorylating	O
9	Ser51	O
10	in	O
11	a	O
12	synthetic	B
13	eIF	I
14	-	I
15	2alpha	I
16	peptide	O
17	,	O
18	a	O
19	key	O
20	characteristic	O
21	of	O
22	the	B
23	eIF	I
24	-	I
25	2alpha	I
26	kinase	I
27	family	I
28	.	I

1	Marked	O
2	thrombocytopenia	O
3	,	O
4	depletion	O
5	of	B
6	serum	B
7	fibrinogen	O
8	and	O
9	prolonged	B
10	prothrombin	O
11	and	O
12	activated	O
13	partial	O
14	thromboplastin	O
15	time	O
16	,	O
17	were	O
18	recorded	O
19	at	O
20	5	O
21	to	O
22	10	O
23	and	O
24	30	O
25	to	O
26	40	O
27	minutes	O
28	after	O
29	intravenous	O
30	envenomation	O
31	.	O

1	The	O
2	transactivation	O
3	function	O
4	of	O
5	EBNA2	O
6	was	O
7	also	O
8	observed	O
9	in	O
10	the	O
11	HeLa	O
12	epithelial	O
13	cell	O
14	line	O
15	,	O
16	which	O
17	suggests	O
18	that	O
19	EBV	O
20	and	O
21	HIV	O
22	-	O
23	1	O
24	infection	O
25	of	O
26	non	O
27	-	O
28	B	O
29	cells	O
30	may	O
31	result	O
32	in	B
33	HIV	I
34	-	I
35	1	I
36	promoter	I
37	activation	I
38	.	I

1	The	O
2	sequenced	O
3	genomic	O
4	region	O
5	thus	O
6	accounts	O
7	for	O
8	essentially	O
9	all	O
10	of	O
11	the	O
12	longest	O
13	known	O
14	transcript	O
15	(	O
16	4	O
17	.	O
18	5	O
19	kb	O
20	),	O
21	although	O
22	the	O
23	precise	O
24	ends	O
25	of	O
26	this	O
27	transcript	O
28	have	O
29	not	O
30	been	O
31	defined	O
32	.	O

1	A	O
2	new	O
3	non	O
4	-	O
5	LTR	O
6	retrotransposon	O
7	provides	O
8	evidence	O
9	for	O
10	multiple	O
11	distinct	O
12	site	O
13	-	O
14	specific	O
15	elements	O
16	in	O
17	Crithidia	O
18	fasciculata	O
19	miniexon	O
20	arrays	O
21	.	O

1	Therefore	O
2	,	O
3	analogs	O
4	of	O
5	vitamin	O
6	D3	O
7	have	O
8	been	O
9	investigated	O
10	in	O
11	a	O
12	number	O
13	of	O
14	trials	O
15	showing	O
16	improvement	O
17	of	O
18	psoriasis	O
19	.	O

1	The	B
2	cpc	I
3	-	I
4	1	I
5	-	I
6	encoded	I
7	transcript	O
8	contains	O
9	three	O
10	open	O
11	reading	O
12	frames	O
13	,	O
14	two	O
15	of	O
16	which	O
17	are	O
18	located	O
19	in	O
20	the	O
21	720	O
22	-	O
23	nucleotide	O
24	leader	O
25	segment	O
26	preceding	O
27	the	B
28	cpc	I
29	-	I
30	1	I
31	coding	I
32	region	I
33	.	I

1	The	O
2	comparison	O
3	of	O
4	the	O
5	expression	O
6	patterns	O
7	of	O
8	the	O
9	known	B
10	Kv4	I
11	family	O
12	members	O
13	shows	O
14	subtype	O
15	specificity	O
16	with	O
17	significant	O
18	overlaps	O
19	.	O

1	The	O
2	results	O
3	showed	O
4	that	B
5	IFN	I
6	-	I
7	gamma	O
8	stimulated	O
9	the	O
10	rapid	O
11	accumulation	O
12	of	B
13	interferon	I
14	regulated	I
15	factor	I
16	(	I
17	IRF	I
18	)-	I
19	1	I
20	mRNA	O
21	,	O
22	followed	O
23	by	O
24	a	O
25	delayed	O
26	and	O
27	dose	O
28	-	O
29	dependent	O
30	inhibition	O
31	of	O
32	alpha1	O
33	(	O
34	I	O
35	)	O
36	procollagen	O
37	mRNA	O
38	expression	O
39	in	O
40	skin	O
41	fibroblasts	O
42	from	O
43	several	O
44	different	O
45	donors	O
46	.	O

1	The	O
2	findings	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	the	O
10	genes	O
11	encoding	B
12	PDGF	I
13	receptors	O
14	in	O
15	glioma	O
16	cells	O
17	are	O
18	regulated	O
19	in	O
20	concert	O
21	with	O
22	other	O
23	genes	O
24	,	O
25	the	O
26	expression	O
27	of	O
28	which	O
29	may	O
30	reflect	O
31	the	O
32	developmental	O
33	program	O
34	of	O
35	normal	O
36	glia	O
37	cell	O
38	lineages	O
39	.	O

1	The	O
2	rho	O
3	genes	O
4	comprise	O
5	an	O
6	evolutionarily	O
7	conserved	O
8	family	O
9	with	O
10	significant	O
11	homology	O
12	to	O
13	the	B
14	ras	I
15	oncogene	I
16	family	I
17	.	I

1	Each	O
2	expressed	O
3	domain	O
4	,	O
5	as	O
6	well	O
7	as	O
8	FKBP	O
9	-	O
10	33	O
11	itself	O
12	,	O
13	possesses	B
14	peptidyl	I
15	-	I
16	prolyl	I
17	cis	I
18	-	I
19	trans	I
20	isomerase	O
21	activity	O
22	,	O
23	though	O
24	with	O
25	much	O
26	lower	O
27	specific	O
28	activities	O
29	than	B
30	FKBP	I
31	-	I
32	12	I
33	.	I

1	Susceptibilities	O
2	of	O
3	540	O
4	anaerobic	O
5	gram	O
6	-	O
7	negative	O
8	bacilli	O
9	to	O
10	amoxicillin	O
11	,	O
12	amoxicillin	O
13	-	O
14	BRL	O
15	42715	O
16	,	O
17	amoxicillin	O
18	-	O
19	clavulanate	O
20	,	O
21	temafloxacin	O
22	,	O
23	and	O
24	clindamycin	O
25	.	O

1	A	O
2	brief	O
3	account	O
4	of	O
5	the	O
6	1988	O
7	seminar	O
8	in	O
9	Shanghai	O
10	on	O
11	viral	O
12	hepatitis	O
13	A	O

1	Of	O
2	the	O
3	117	O
4	patients	O
5	(	O
6	out	O
7	of	O
8	the	O
9	136	O
10	)	O
11	with	O
12	serologic	O
13	evidence	O
14	of	O
15	chronic	O
16	thyroiditis	O
17	who	O
18	could	O
19	be	O
20	studied	O
21	,	O
22	eight	O
23	(	O
24	7	O
25	%)	O
26	had	O
27	hyperthyroidism	O
28	and	O
29	45	O
30	(	O
31	38	O
32	%)	O
33	were	O
34	hypothyroid	O
35	.	O

1	Continued	O
2	absorption	O
3	of	O
4	amino	O
5	acids	O
6	by	O
7	the	O
8	NBB	O
9	carrier	O
10	(	O
11	for	O
12	neutral	O
13	amino	O
14	acids	O
15	),	O
16	the	O
17	Y	O
18	+	O
19	system	O
20	(	O
21	for	O
22	dibasic	O
23	amino	O
24	acids	O
25	),	O
26	and	O
27	the	O
28	PHE	O
29	carrier	O
30	were	O
31	operative	O
32	even	O
33	during	O
34	the	O
35	actively	O
36	purging	O
37	stage	O
38	of	O
39	watery	O
40	diarrhoea	O
41	due	O
42	to	O
43	cholera	O
44	.	O

1	The	B
2	general	I
3	transcription	I
4	factor	I
5	IIA	I
6	(	I
7	TFIIA	O
8	)	O
9	interacts	O
10	with	O
11	the	O
12	TATA	O
13	binding	O
14	protein	O
15	(	O
16	TBP	O
17	)	O
18	and	O
19	promoter	O
20	DNA	O
21	to	O
22	mediate	O
23	transcription	O
24	activation	O
25	in	O
26	vitro	O
27	.	O

1	NERVTRACK	O
2	contains	O
3	4000	O
4	anatomical	O
5	data	O
6	items	O
7	arranged	O
8	in	O
9	a	O
10	tree	O
11	-	O
12	like	O
13	manner	O
14	reflecting	O
15	structural	O
16	and	O
17	functional	O
18	relationships	O
19	.	O

1	Genitography	O
2	in	O
3	intersexual	O
4	states	O
5	.	O

1	The	O
2	etiology	O
3	,	O
4	pathology	O
5	,	O
6	brain	O
7	CT	O
8	scan	O
9	features	O
10	,	O
11	clinical	O
12	manifestations	O
13	and	O
14	treatment	O
15	of	O
16	these	O
17	accidents	O
18	were	O
19	discussed	O
20	.	O

1	This	O
2	,	O
3	together	O
4	with	O
5	the	O
6	data	O
7	obtained	O
8	with	O
9	haloperidol	O
10	,	O
11	suggests	O
12	that	O
13	a	O
14	minimal	O
15	increase	O
16	in	O
17	the	O
18	firing	O
19	rate	O
20	of	O
21	LC	O
22	cells	O
23	(+	O
24	140	O
25	%)	O
26	is	O
27	required	O
28	before	O
29	it	O
30	could	O
31	influence	O
32	the	O
33	turnover	O
34	of	O
35	NA	O
36	,	O
37	as	O
38	measured	O
39	by	O
40	DOPAC	O
41	changes	O
42	.	O

1	This	O
2	constitutes	O
3	evidence	O
4	for	O
5	an	O
6	in	O
7	vivo	O
8	role	O
9	of	B
10	SRC	I
11	-	I
12	1	O
13	in	O
14	dimerization	O
15	-	O
16	induced	O
17	activation	O
18	by	O
19	OR1	O
20	/	B
21	RXRalpha	I
22	.	I

1	Seven	O
2	patients	O
3	(	O
4	8	O
5	.	O
6	3	O
7	percent	O
8	)	O
9	had	O
10	latent	O
11	hypothyroidism	O
12	only	O
13	discovered	O
14	by	O
15	hormonal	O
16	determinations	O
17	.	O

1	Phase	O
2	II	O
3	study	O
4	of	B
5	VP	I
6	-	O
7	16	O
8	(	O
9	capsule	O
10	)	O
11	in	O
12	solid	O
13	tumors	O
14	.	O

1	Stimulation	O
2	of	O
3	[	O
4	3H	O
5	]	O
6	PA	O
7	production	O
8	upon	O
9	CD3	O
10	cross	O
11	-	O
12	linking	O
13	was	O
14	77	O
15	%	O
16	lower	O
17	in	O
18	permeabilized	B
19	CD45	I
20	-	O
21	cells	O
22	than	O
23	in	B
24	CD45	I
25	+	O
26	cells	O
27	,	O
28	consistent	O
29	with	O
30	the	O
31	reduced	O
32	activity	O
33	of	B
34	p59fyn	B
35	in	B
36	CD45	I
37	-	O
38	cells	O
39	.	O

1	During	O
2	the	O
3	years	O
4	1980	O
5	-	O
6	87	O
7	a	O
8	total	O
9	of	O
10	287	O
11	persons	O
12	received	O
13	disability	O
14	pensions	O
15	in	O
16	the	O
17	municipality	O
18	of	O
19	Nordreisa	O
20	in	O
21	northern	O
22	Norway	O
23	.	O

1	The	O
2	two	O
3	genes	O
4	code	O
5	for	O
6	polypeptides	O
7	of	O
8	420	O
9	amino	O
10	acids	O
11	(	O
12	M	O
13	.	O
14	HgiCI	O
15	)	O
16	and	O
17	345	O
18	amino	O
19	acids	O
20	(	O
21	R	O
22	.	O
23	HgiCI	O
24	).	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	demonstrate	O
7	that	O
8	strongyloidiasis	O
9	was	O
10	the	O
11	cause	O
12	of	O
13	sudden	O
14	death	O
15	.	O

1	The	O
2	presence	O
3	of	O
4	PDZ	O
5	and	O
6	SAM	O
7	domains	O
8	in	O
9	the	O
10	KS5	O
11	protein	O
12	suggests	O
13	that	O
14	it	O
15	may	O
16	act	O
17	as	O
18	a	O
19	molecular	O
20	adaptor	O
21	,	O
22	promoting	O
23	and	O
24	relaying	O
25	information	O
26	in	O
27	a	O
28	signal	O
29	transduction	O
30	pathway	O
31	.	O

1	Removal	O
2	of	B
3	beta	I
4	2	I
5	-	I
6	microglobulin	O
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	To	O
2	assess	O
3	the	O
4	effects	O
5	of	O
6	alveolar	O
7	hypoxia	O
8	and	B
9	angiotensin	I
10	II	O
11	infusion	O
12	on	O
13	distribution	O
14	of	O
15	blood	O
16	flow	O
17	to	O
18	the	O
19	lung	O
20	we	O
21	performed	O
22	perfusion	O
23	lung	O
24	scans	O
25	on	O
26	anesthetized	O
27	mechanically	O
28	ventilated	O
29	lambs	O
30	.	O

1	Renin	O
2	secretion	O
3	in	O
4	essential	O
5	and	O
6	accelerated	O
7	hypertension	O
8	.	O

1	The	O
2	systolic	O
3	peak	O
4	of	O
5	pulmonary	O
6	vein	O
7	was	O
8	higher	O
9	than	O
10	the	O
11	diastolic	O
12	peak	O
13	in	O
14	45	O
15	out	O
16	of	O
17	56	O
18	cases	O
19	.	O

1	Oncostatin	O
2	M	O
3	stimulates	B
4	c	I
5	-	I
6	Fos	O
7	to	O
8	bind	O
9	a	O
10	transcriptionally	O
11	responsive	B
12	AP	I
13	-	I
14	1	I
15	element	O
16	within	O
17	the	O
18	tissue	O
19	inhibitor	O
20	of	O
21	metalloproteinase	I
22	-	I
23	1	I
24	promoter	I
25	.	I

1	The	O
2	transcription	O
3	factor	B
4	Sp1	O
5	bound	O
6	to	O
7	eight	O
8	sites	O
9	,	O
10	as	O
11	demonstrated	O
12	by	O
13	footprinting	O
14	assays	O
15	and	O
16	gel	O
17	shift	O
18	analysis	O
19	with	O
20	purified	B
21	Sp1	I
22	.	I

1	CONCLUSIONS	O
2	:	O
3	A	O
4	comparison	O
5	of	O
6	the	O
7	LysU	O
8	crystal	O
9	structure	O
10	with	O
11	the	O
12	structures	O
13	of	O
14	seryl	O
15	-	O
16	and	B
17	aspartyl	I
18	-	I
19	tRNA	I
20	synthetases	O
21	enables	O
22	a	O
23	conserved	O
24	core	O
25	to	O
26	be	O
27	identified	O
28	.	O

1	Toward	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	B
15	FAP	I
16	-	I
17	1	I
18	(	I
19	C	I
20	-	I
21	terminal	I
22	399	O
23	amino	O
24	acids	O
25	)	O
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	Cys2408	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	B
37	glutathione	I
38	-	I
39	S	I
40	-	I
41	transferase	O
42	(	O
43	GST	O
44	).	O

1	The	O
2	alpha	O
3	7A	O
4	form	O
5	RNA	O
6	contains	O
7	an	O
8	additional	O
9	113	O
10	nucleotides	O
11	compared	O
12	to	O
13	the	O
14	B	O
15	form	O
16	,	O
17	and	O
18	a	O
19	common	O
20	coding	O
21	region	O
22	in	O
23	the	O
24	A	O
25	and	O
26	B	O
27	form	O
28	RNAs	O
29	is	O
30	used	O
31	in	O
32	alternate	O
33	reading	O
34	frames	O
35	.	O

1	This	O
2	site	O
3	acts	O
4	as	O
5	a	O
6	negative	O
7	element	O
8	when	O
9	transferred	O
10	to	O
11	the	B
12	thymidine	I
13	kinase	I
14	promoter	O
15	,	O
16	but	O
17	does	O
18	not	O
19	confer	O
20	inducibility	O
21	.	O

1	In	O
2	the	O
3	posthospital	O
4	phase	O
5	of	O
6	AMI	O
7	,	O
8	as	O
9	well	O
10	as	O
11	in	O
12	CCHD	O
13	,	O
14	the	O
15	occurrence	O
16	of	O
17	high	O
18	-	O
19	grade	O
20	VPBs	O
21	usually	O
22	indicates	O
23	more	O
24	advanced	O
25	degrees	O
26	of	O
27	both	O
28	coronary	O
29	and	O
30	left	O
31	ventricular	O
32	disease	O
33	as	O
34	well	O
35	as	O
36	the	O
37	possibility	O
38	of	O
39	cardiac	O
40	and	O
41	/	O
42	or	O
43	sudden	O
44	death	O
45	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	B
8	SAP	I
9	-	I
10	1	I
11	cDNA	O
12	showed	O
13	that	O
14	mature	B
15	SAP	I
16	-	I
17	1	O
18	consisted	O
19	of	O
20	1093	O
21	amino	O
22	acids	O
23	and	O
24	a	O
25	transmembrane	O
26	-	O
27	type	O
28	PTP	O
29	,	O
30	which	O
31	possessed	O
32	a	O
33	single	O
34	PTP	O
35	-	O
36	conserved	O
37	domain	O
38	in	O
39	the	O
40	cytoplasmic	O
41	region	O
42	.	O

1	Though	O
2	the	B
3	BACTEC	B
4	9000	B
5	MB	O
6	system	O
7	is	O
8	recommended	O
9	for	O
10	respiratory	O
11	specimens	O
12	,	O
13	we	O
14	demonstrated	O
15	that	O
16	it	O
17	can	O
18	be	O
19	successfully	O
20	used	O
21	also	O
22	for	O
23	recovery	O
24	of	O
25	mycobacteria	O
26	from	O
27	clinical	O
28	specimens	O
29	from	O
30	various	O
31	extrapulmonary	O
32	sites	O
33	.	O

1	Microdetermination	O
2	of	O
3	adrenocortical	O
4	steroids	O
5	by	O
6	double	O
7	isotope	O
8	method	O
9	.	O

1	The	O
2	effectiveness	O
3	of	O
4	the	O
5	haemodialysate	O
6	Solcoseryl	O
7	for	O
8	second	O
9	-	O
10	intention	O
11	wound	O
12	healing	O
13	in	O
14	horses	O
15	and	O
16	ponies	O
17	.	O

1	These	O
2	data	O
3	indicate	O
4	that	B
5	RNK	I
6	-	I
7	Met	I
8	-	I
9	1	O
10	is	O
11	a	O
12	serine	O
13	protease	O
14	with	O
15	unique	O
16	activity	O
17	that	O
18	is	O
19	expressed	O
20	in	O
21	the	O
22	granules	O
23	of	O
24	large	O
25	granular	O
26	lymphocytes	O
27	.	O

1	Risks	O
2	of	O
3	chronicity	O
4	following	O
5	acute	O
6	hepatitis	O
7	B	O
8	virus	O
9	infection	O
10	:	O
11	a	O
12	review	O
13	.	O

1	Two	O
2	of	O
3	these	O
4	motifs	O
5	are	O
6	part	O
7	of	O
8	a	O
9	highly	O
10	conserved	O
11	and	O
12	inducible	O
13	dyad	O
14	symmetry	O
15	element	O
16	shown	O
17	previously	O
18	to	O
19	control	O
20	a	O
21	remote	B
22	IL	I
23	-	I
24	2	I
25	enhancer	O
26	and	O
27	the	B
28	CD18	I
29	promoter	I
30	.	I

1	Risk	O
2	of	O
3	HTLV	O
4	infection	O
5	in	O
6	patients	O
7	on	O
8	haemodialysis	O
9	.	O

1	The	O
2	relationship	O
3	between	O
4	the	O
5	rare	O
6	complications	O
7	mentioned	O
8	above	O
9	and	O
10	the	O
11	pathophysiology	O
12	of	O
13	Bartter	O
14	'	O
15	s	O
16	syndrome	O
17	is	O
18	still	O
19	obscure	O
20	.	O

1	Plasma	O
2	leptin	O
3	concentrations	O
4	were	O
5	higher	O
6	in	O
7	women	O
8	than	O
9	men	O
10	,	O
11	even	O
12	after	O
13	the	O
14	adjustment	O
15	for	O
16	differences	O
17	in	O
18	fat	O
19	mass	O
20	(	O
21	28	O
22	+/-	O
23	3	O
24	ng	O
25	/	O
26	ml	O
27	for	O
28	women	O
29	vs	O
30	.	O

1	The	O
2	DNA	O
3	binding	O
4	and	O
5	multimerization	O
6	activities	O
7	of	B
8	c	I
9	-	I
10	Myb	O
11	appear	O
12	to	O
13	be	O
14	unaffected	O
15	by	O
16	the	O
17	S528A	O
18	substitution	O
19	,	O
20	suggesting	O
21	that	O
22	phosphorylation	O
23	of	O
24	serine	O
25	528	O
26	may	O
27	mediate	O
28	its	O
29	effect	O
30	on	O
31	the	O
32	transcription	O
33	transactivating	O
34	activity	O
35	of	B
36	c	I
37	-	I
38	Myb	O
39	by	O
40	regulating	O
41	interactions	O
42	with	O
43	other	O
44	proteins	O
45	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	Elk	O
5	-	O
6	3	O
7	,	O
8	a	O
9	new	O
10	member	O
11	of	O
12	the	B
13	Ets	I
14	family	O
15	expressed	O
16	during	O
17	mouse	O
18	embryogenesis	O
19	and	O
20	analysis	O
21	of	O
22	its	O
23	transcriptional	O
24	repression	O
25	activity	O
26	.	O

1	Partial	O
2	engorgement	O
3	was	O
4	higher	O
5	in	O
6	the	O
7	treatments	O
8	.	O

1	RESULTS	O
2	:	O
3	Statistically	O
4	significant	O
5	differences	O
6	were	O
7	obtained	O
8	between	O
9	group	O
10	I	O
11	and	O
12	II	O
13	concerning	O
14	the	O
15	number	O
16	of	O
17	patients	O
18	in	O
19	whom	O
20	induced	O
21	atrial	O
22	fibrillation	O
23	with	O
24	conduction	O
25	by	O
26	the	O
27	accessory	O
28	pathway	O
29	and	O
30	RR	O
31	<	O
32	or	O
33	=	O
34	250	O
35	msec	O
36	was	O
37	found	O
38	(	O
39	0	O
40	vs	O
41	6	O
42	,	O
43	p	O
44	=	O
45	0	O
46	.	O
47	0045	O
48	).	O

1	Molecular	O
2	cloning	O
3	of	B
4	mouse	I
5	thioredoxin	I
6	reductases	I
7	.	I

1	Alanine	O
2	aminotransferase	O
3	in	O
4	clinical	O
5	practice	O
6	.	O

1	There	O
2	was	O
3	however	O
4	,	O
5	no	O
6	significant	O
7	difference	O
8	in	O
9	the	O
10	prevalence	O
11	of	O
12	chronic	O
13	respiratory	O
14	symptoms	O
15	between	O
16	animal	O
17	food	O
18	workers	O
19	with	O
20	positive	O
21	and	O
22	negative	O
23	skin	O
24	tests	O
25	to	O
26	house	O
27	dust	O
28	or	O
29	to	O
30	fish	O
31	flour	O
32	or	O
33	among	O
34	those	O
35	with	O
36	increased	O
37	or	O
38	normal	B
39	IgE	O
40	(	O
41	except	O
42	for	O
43	dyspnea	O
44	).	O

1	To	O
2	determine	O
3	the	O
4	genetic	O
5	basis	O
6	for	O
7	the	O
8	differences	O
9	between	O
10	the	O
11	cardiac	O
12	and	O
13	brain	O
14	AE3	O
15	variants	O
16	,	O
17	we	O
18	isolated	O
19	and	O
20	characterized	O
21	the	B
22	rat	I
23	gene	I
24	.	I

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	B
6	phosphatidyl	B
7	inositol	B
8	4	I
9	,	I
10	5	I
11	bisphosphate	I
12	(	I
13	PIP2	I
14	)	I
15	hydrolysis	O
16	requires	O
17	direct	O
18	phosphorylation	O
19	at	O
20	tyrosine	O
21	residue	O
22	of	O
23	the	B
24	PLC	I
25	-	I
26	gamma1	I
27	isozyme	I
28	.	I

1	The	O
2	splice	O
3	acceptor	O
4	site	O
5	is	O
6	ca	O
7	.	O

1	S1	O
2	nuclease	O
3	analysis	O
4	of	O
5	RNA	O
6	prepared	O
7	after	O
8	transfection	O
9	of	O
10	these	O
11	HIV	O
12	constructs	O
13	into	O
14	HeLa	O
15	cells	O
16	infected	O
17	with	O
18	wild	O
19	-	O
20	type	O
21	adenovirus	O
22	indicated	O
23	that	O
24	the	O
25	enhancer	O
26	,	B
27	SP1	O
28	,	O
29	TATA	O
30	,	O
31	and	O
32	a	O
33	portion	O
34	of	O
35	the	O
36	transactivation	O
37	-	O
38	responsive	O
39	element	O
40	were	O
41	each	O
42	required	O
43	for	O
44	complete	B
45	E1A	I
46	/	I
47	E1B	I
48	-	O
49	mediated	O
50	activation	O
51	of	O
52	the	O
53	HIV	O
54	LTR	O
55	.	O

1	Interestingly	O
2	,	O
3	one	B
4	IRF	I
5	binding	I
6	site	O
7	was	O
8	found	O
9	within	O
10	the	B
11	IRF	I
12	-	I
13	2	I
14	promoter	O
15	,	O
16	and	O
17	expression	O
18	of	O
19	the	B
20	IRF	I
21	-	I
22	2	I
23	gene	O
24	was	O
25	affected	O
26	by	O
27	both	O
28	transient	O
29	and	O
30	stable	B
31	IRF	I
32	-	I
33	1	O
34	expression	O
35	.	O

1	Effects	O
2	of	O
3	cortisone	O
4	,	O
5	starvation	O
6	,	O
7	and	O
8	rickets	O
9	on	O
10	oxidative	O
11	enzyme	O
12	activities	O
13	of	O
14	epiphyseal	O
15	cartilage	O
16	from	O
17	rats	O
18	.	O

1	However	O
2	,	O
3	the	O
4	same	B
5	U1A	I
6	peptide	O
7	,	O
8	when	O
9	conjugated	O
10	to	O
11	BSA	O
12	,	O
13	inhibits	O
14	vertebrate	O
15	PAP	O
16	.	O

1	CONCLUSION	O
2	:	O
3	Treatment	O
4	of	O
5	sepsis	O
6	with	O
7	the	B
8	platelet	I
9	-	I
10	activating	I
11	factor	I
12	antagonist	I
13	BB	I
14	-	O
15	882	O
16	offers	O
17	no	O
18	advantage	O
19	over	O
20	placebo	O
21	on	O
22	survival	O
23	,	O
24	hemodynamic	O
25	status	O
26	,	O
27	respiratory	O
28	function	O
29	,	O
30	or	O
31	organ	O
32	failure	O
33	scores	O
34	.	O

1	Molecular	O
2	cloning	O
3	of	B
4	mouse	I
5	glycolate	I
6	oxidase	I
7	.	I

1	Factors	O
2	influencing	O
3	semen	O
4	characteristics	O
5	in	O
6	young	O
7	boars	O
8	reared	O
9	in	O
10	a	O
11	subtropical	O
12	environment	O
13	were	O
14	studied	O
15	.	O

1	We	O
2	remain	O
3	convinced	O
4	that	B
5	antilymphocyte	I
6	globulin	O
7	(	O
8	ALG	O
9	)	O
10	is	O
11	a	O
12	potent	O
13	immunosuppressive	O
14	agent	O
15	in	O
16	humans	O
17	.	O

1	Electrochemical	O
2	detection	O
3	of	O
4	depressed	O
5	circulating	O
6	levels	O
7	of	O
8	vitamin	O
9	K1	O
10	in	O
11	osteoporosis	O
12	.	O

1	This	O
2	suggests	O
3	that	O
4	the	O
5	DcuS	O
6	-	O
7	DcuR	O
8	system	O
9	responds	O
10	to	O
11	external	O
12	substrates	O
13	.	O

1	These	O
2	observations	O
3	of	O
4	elevated	B
5	serum	I
6	lipase	O
7	and	O
8	serum	O
9	CA	O
10	19	O
11	-	O
12	9	O
13	in	O
14	Sjogren	O
15	'	O
16	s	O
17	syndrome	O
18	without	O
19	evidence	O
20	of	O
21	malignancy	O
22	may	O
23	reflect	O
24	pancreatic	O
25	involvement	O
26	in	O
27	this	O
28	disorder	O
29	.	O

1	Cytoprotection	O
2	with	O
3	amifostine	O
4	in	O
5	radiotherapy	O
6	or	O
7	radio	O
8	-	O
9	chemotherapy	O
10	of	O
11	head	O
12	and	O
13	neck	O
14	tumors	O

1	Following	O
2	seven	O
3	days	O
4	'	O
5	incubation	O
6	both	O
7	at	O
8	20	O
9	degrees	O
10	C	O
11	and	O
12	28	O
13	degrees	O
14	C	O
15	,	O
16	Ae	O
17	.	O
18	vexans	O
19	nip	O
20	.	O
21	was	O
22	capable	O
23	of	O
24	transmitting	O
25	the	O
26	virus	O
27	.	O

1	Weight	O
2	loss	O
3	reduces	O
4	arterial	O
5	pressure	O
6	by	O
7	a	O
8	decrease	O
9	in	O
10	intravascular	O
11	volume	O
12	and	O
13	cardiac	O
14	output	O
15	associated	O
16	with	O
17	a	O
18	fall	O
19	in	O
20	sympathetic	O
21	activity	O
22	.	O

1	When	O
2	comparing	O
3	the	O
4	barley	O
5	PSI	O
6	-	O
7	K	O
8	and	O
9	PSI	O
10	-	O
11	G	O
12	with	O
13	the	O
14	reported	O
15	PSI	O
16	-	O
17	K	O
18	sequence	O
19	from	O
20	Synechococcus	O
21	vulcanus	O
22	,	O
23	the	O
24	degree	O
25	of	O
26	similarity	O
27	is	O
28	equal	O
29	,	O
30	suggesting	O
31	that	O
32	an	O
33	ancestral	O
34	gene	O
35	has	O
36	been	O
37	duplicated	O
38	in	O
39	a	O
40	chloroplast	O
41	progenitor	O
42	but	O
43	not	O
44	in	O
45	a	O
46	cyanobacterial	O
47	.	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	tissue	O
7	-	O
8	restricted	O
9	transcription	O
10	factors	O
11	including	O
12	PU	O
13	.	O
14	1	O
15	and	O
16	PU	O
17	.	O
18	1	O
19	interaction	O
20	partner	O
21	(	O
22	PIP	O
23	)	O
24	function	O
25	synergistically	O
26	with	B
27	c	I
28	-	I
29	Fos	I
30	plus	I
31	c	I
32	-	I
33	Jun	O
34	to	O
35	stimulate	O
36	the	B
37	kappaE3	I
38	'-	I
39	enhancer	O
40	in	O
41	3T3	O
42	cells	O
43	.	O

1	Irradiation	O
2	of	O
3	human	O
4	blood	O
5	platelets	O
6	with	O
7	UV	O
8	-	O
9	A	O
10	in	O
11	vitro	O
12	impairs	O
13	their	O
14	ability	O
15	to	O
16	aggregate	O
17	after	O
18	challenge	O
19	with	B
20	collagen	I
21	.	I

1	Within	O
2	the	O
3	human	O
4	enhancer	O
5	,	O
6	these	O
7	two	O
8	sites	O
9	are	O
10	located	O
11	within	O
12	the	O
13	previously	O
14	defined	O
15	DNase	O
16	I	O
17	footprints	O
18	,	B
19	NFAT	I
20	-	I
21	1	I
22	and	I
23	NFIL	I
24	-	I
25	2B	O
26	,	O
27	respectively	O
28	.	O

1	After	O
2	hepatitis	O
3	B	O
4	vaccine	O
5	immunization	O
6	,	O
7	serum	O
8	antibody	O
9	response	O
10	was	O
11	of	O
12	primary	O
13	type	O
14	in	O
15	33	O
16	cases	O
17	with	O
18	anti	O
19	-	O
20	HBs	O
21	less	O
22	than	O
23	2	O
24	.	O
25	1	O
26	S	O
27	/	O
28	N	O
29	(	O
30	S	O
31	/	O
32	N	O
33	Ratio	O
34	Unit	O
35	)	O
36	at	O
37	T0	O
38	,	O
39	the	O
40	anti	O
41	-	O
42	HBs	O
43	positive	O
44	rate	O
45	was	O
46	39	O
47	.	O
48	4	O
49	%,	O
50	84	O
51	.	O
52	8	O
53	%,	O
54	96	O
55	.	O
56	7	O
57	%	O
58	and	O
59	96	O
60	.	O
61	7	O
62	%	O
63	in	O
64	T1	O
65	,	O
66	T2	O
67	,	O
68	T0	O
69	and	O
70	T12	O
71	respectively	O
72	.	O

1	In	O
2	contrast	O
3	to	O
4	behavioral	O
5	deviation	O
6	(	O
7	the	O
8	avoidance	O
9	conditioning	O
10	lost	O
11	),	O
12	the	O
13	haloperidol	O
14	intrastriatal	O
15	microinjections	O
16	did	O
17	not	O
18	affect	O
19	the	O
20	DA	O
21	synaptic	O
22	level	O
23	in	O
24	rostral	O
25	neostriatum	O
26	.	O

1	Drosophila	O
2	230	O
3	-	B
4	kD	B
5	TFIID	I
6	subunit	O
7	,	O
8	a	O
9	functional	O
10	homolog	O
11	of	O
12	the	O
13	human	O
14	cell	O
15	cycle	O
16	gene	O
17	product	O
18	,	O
19	negatively	O
20	regulates	O
21	DNA	O
22	binding	O
23	of	O
24	the	B
25	TATA	I
26	box	I
27	-	I
28	binding	I
29	subunit	I
30	of	I
31	TFIID	I
32	.	I

1	Naltrexone	O
2	has	O
3	been	O
4	recently	O
5	approved	O
6	by	O
7	the	O
8	Food	O
9	and	O
10	Drug	O
11	Administration	O
12	for	O
13	the	O
14	treatment	O
15	of	O
16	alcohol	O
17	dependence	O
18	.	O

1	Mn2	O
2	+	O
3	increased	O
4	both	O
5	the	O
6	junction	O
7	binding	O
8	and	O
9	cleaving	O
10	activities	O
11	of	O
12	the	O
13	mutant	O
14	proteins	O
15	.	O

1	DNA	O
2	-	O
3	dependent	B
4	protein	I
5	kinase	I
6	(	I
7	DNA	I
8	-	I
9	PK	O
10	)	O
11	consists	O
12	of	O
13	a	O
14	heterodimeric	O
15	protein	O
16	(	O
17	Ku	O
18	)	O
19	and	O
20	a	O
21	large	O
22	catalytic	O
23	subunit	O
24	(	O
25	DNA	O
26	-	B
27	PKcs	O
28	).	O

1	Mouse	B
2	growth	I
3	hormone	I
4	transcription	I
5	factor	I
6	Zn	I
7	-	O
8	16	O
9	:	O
10	unique	O
11	bipartite	O
12	structure	O
13	containing	O
14	tandemly	O
15	repeated	O
16	zinc	O
17	finger	O
18	domains	O
19	not	O
20	reported	O
21	in	O
22	rat	O
23	Zn	O
24	-	O
25	15	O
26	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	diagnostic	O
6	validity	O
7	of	B
8	NFPD	O
9	in	O
10	CP	O
11	/	O
12	NCA	O
13	patients	O
14	,	O
15	because	O
16	such	O
17	patients	O
18	had	O
19	a	O
20	family	O
21	history	O
22	of	O
23	panic	O
24	disorder	O
25	similar	O
26	to	O
27	patients	O
28	with	O
29	a	O
30	more	O
31	classical	O
32	panic	O
33	disorder	O
34	presentation	O
35	.	O

1	Morphologic	O
2	variables	O
3	included	O
4	cancer	O
5	volume	O
6	,	O
7	histologic	O
8	grade	O
9	,	O
10	capsular	O
11	penetration	O
12	,	O
13	seminal	O
14	vesicle	O
15	invasion	O
16	,	O
17	and	O
18	lymph	O
19	node	O
20	metastasis	O
21	.	O

1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O

1	Circulating	O
2	thrombomodulin	O
3	:	O
4	current	O
5	knowledge	O
6	and	O
7	future	O
8	prospects	O

1	Lesion	O
2	diameters	O
3	of	O
4	greater	O
5	than	O
6	20	O
7	mm	O
8	and	O
9	the	O
10	large	O
11	sessile	O
12	-	O
13	type	O
14	configurations	O
15	were	O
16	factors	O
17	that	O
18	were	O
19	associated	O
20	with	O
21	incomplete	O
22	removal	O
23	.	O

1	Axillary	O
2	nodal	O
3	status	O
4	,	O
5	tumour	O
6	progesterone	O
7	receptor	O
8	status	O
9	,	O
10	and	O
11	season	O
12	of	O
13	tumour	O
14	detection	O
15	significantly	O
16	influenced	O
17	survival	O
18	in	O
19	both	O
20	older	O
21	(	O
22	greater	O
23	than	O
24	50	O
25	yrs	O
26	)	O
27	and	O
28	younger	O
29	(	O
30	less	O
31	than	O
32	50	O
33	yrs	O
34	)	O
35	patients	O
36	.	O

1	The	O
2	pathogenicity	O
3	of	O
4	Achromobacter	O
5	puntatum	O
6	for	O
7	cold	O
8	blooded	O
9	and	O
10	warm	O
11	blooded	O
12	animals	O

1	Using	O
2	a	O
3	polymerase	O
4	chain	O
5	reaction	O
6	-	O
7	based	O
8	approach	O
9	,	O
10	we	O
11	cloned	O
12	a	O
13	150	O
14	-	O
15	base	O
16	pair	O
17	fragment	O
18	of	O
19	a	O
20	new	O
21	sialymotif	O
22	from	O
23	human	O
24	placenta	O
25	mRNA	O
26	,	O
27	which	O
28	was	O
29	then	O
30	used	O
31	as	O
32	a	O
33	probe	O
34	to	O
35	clone	O
36	the	O
37	complete	O
38	coding	O
39	sequence	O
40	of	O
41	the	O
42	corresponding	O
43	gene	O
44	from	O
45	a	O
46	cDNA	O
47	library	O
48	.	O

1	A	O
2	method	O
3	for	O
4	the	O
5	simultaneous	O
6	determination	O
7	of	O
8	de	O
9	(	B
10	N	I
11	-	I
12	methyl	I
13	)-	I
14	N	I
15	-	I
16	ethyl	I
17	-	O
18	8	O
19	,	O
20	9	O
21	-	O
22	anhydroerythromycin	O
23	A	O
24	6	O
25	,	O
26	9	O
27	-	O
28	hemiacetal	O
29	(	O
30	EM523	O
31	,	O
32	I	O
33	)	O
34	and	O
35	its	O
36	three	O
37	metabolites	O
38	in	O
39	human	O
40	plasma	O
41	and	O
42	urine	O
43	has	O
44	been	O
45	developed	O
46	using	O
47	high	O
48	-	O
49	performance	O
50	liquid	O
51	chromatography	O
52	(	O
53	HPLC	O
54	)	O
55	with	O
56	chemiluminescence	O
57	(	O
58	CL	O
59	)	O
60	detection	O
61	.	O

1	Prominent	O
2	findings	O
3	were	O
4	chronic	O
5	pancreatitis	O
6	with	O
7	acinar	O
8	and	O
9	ductal	O
10	plugs	O
11	,	O
12	granulomatous	O
13	and	O
14	necrotizing	O
15	peripancreatic	O
16	steatitis	O
17	,	O
18	degenerative	O
19	myopathy	O
20	,	O
21	testicular	O
22	atrophy	O
23	,	O
24	candidiasis	O
25	and	O
26	bacterial	O
27	necrotizing	O
28	glossitis	O
29	.	O

1	Overall	O
2	agreement	O
3	between	O
4	rest	O
5	/	O
6	postnitroglycerin	O
7	technetium	O
8	-	O
9	99m	O
10	tetrofosmin	O
11	SPET	O
12	studies	O
13	and	O
14	rest	O
15	/	O
16	redistribution	O
17	or	O
18	rest	O
19	/	O
20	reinjection	O
21	thallium	O
22	-	O
23	201	O
24	SPET	O
25	studies	O
26	,	O
27	regarding	O
28	the	O
29	presence	O
30	of	O
31	myocardial	O
32	viability	O
33	,	O
34	was	O
35	87	O
36	%	O
37	and	O
38	90	O
39	%,	O
40	respectively	O
41	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	XAB1	O
6	is	O
7	a	O
8	novel	O
9	cytoplasmic	B
10	GTPase	O
11	involved	O
12	in	O
13	nuclear	O
14	localization	O
15	of	O
16	XPA	O
17	.	O

1	Mild	O
2	orbital	O
3	discomfort	O
4	occurred	O
5	in	O
6	some	O
7	patients	O
8	.	O

1	Orientation	O
2	of	O
3	the	O
4	nuclear	O
5	spin	O
6	system	O
7	by	O
8	optical	O
9	pumping	O
10	causes	O
11	an	O
12	Overhauser	O
13	shift	O
14	of	O
15	the	O
16	excitonic	O
17	energy	O
18	levels	O
19	proportional	O
20	to	O
21	the	O
22	degree	O
23	of	O
24	nuclear	O
25	orientation	O
26	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	results	O
5	suggest	O
6	that	O
7	AIF	O
8	peak	O
9	saturation	O
10	leads	O
11	to	O
12	a	O
13	significant	O
14	systematic	O
15	error	O
16	in	O
17	the	O
18	determination	O
19	of	O
20	CBV	O
21	and	O
22	CBF	O
23	values	O
24	and	O
25	has	O
26	necessarily	O
27	to	O
28	be	O
29	taken	O
30	into	O
31	account	O
32	for	O
33	dynamic	O
34	contrast	O
35	-	O
36	enhanced	O
37	MR	O
38	perfusion	O
39	studies	O
40	.	O

1	Premature	O
2	initiation	O
3	of	O
4	mitosis	O
5	in	O
6	yeast	O
7	lacking	O
8	RCC1	O
9	or	O
10	an	O
11	interacting	B
12	GTPase	I
13	.	I

1	Leptinaemia	O
2	does	O
3	not	O
4	correlate	O
5	with	O
6	the	O
7	actual	O
8	or	O
9	mean	O
10	blood	O
11	pressure	O
12	reading	O
13	nor	O
14	with	O
15	stage	O
16	of	O
17	hypertension	O
18	according	O
19	to	O
20	the	O
21	WHO	O
22	classification	O
23	.	O

1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	B
8	Uzbekistan	I

1	The	O
2	loss	O
3	of	O
4	avirulence	O
5	activity	O
6	because	O
7	of	O
8	mutations	O
9	in	O
10	the	O
11	acidic	O
12	transcriptional	O
13	activation	O
14	domain	O
15	was	O
16	restored	O
17	by	O
18	addition	O
19	of	O
20	the	O
21	activation	O
22	domain	O
23	from	O
24	the	O
25	herpes	O
26	simplex	B
27	viral	I
28	protein	I
29	VP16	I
30	.	I

1	Pathophysiology	O
2	of	O
3	bone	O
4	loss	O
5	in	O
6	castrated	O
7	animals	O
8	.	O

1	The	O
2	chromosomal	O
3	localization	O
4	on	O
5	distal	O
6	chromosome	O
7	7	O
8	places	O
9	it	O
10	in	O
11	a	O
12	cluster	O
13	of	O
14	imprinted	O
15	genes	O
16	,	O
17	flanked	O
18	by	O
19	the	O
20	previously	O
21	described	O
22	Tapa1	O
23	and	B
24	Kcnq1	I
25	genes	I
26	.	I

1	Possible	O
2	factors	O
3	for	O
4	the	O
5	development	O
6	of	O
7	psychotic	O
8	symptomatology	O
9	during	O
10	group	O
11	activities	O
12	and	O
13	the	O
14	role	O
15	of	O
16	group	O
17	dynamics	O
18	acting	O
19	as	O
20	stress	O
21	factors	O
22	precipitating	O
23	functional	O
24	psychoses	O
25	,	O
26	especially	O
27	bipolar	O
28	manifestations	O
29	,	O
30	are	O
31	discussed	O
32	.	O

1	Evaluating	O
2	dietary	O
3	department	O
4	management	O
5	.	O

1	The	O
2	smallest	O
3	active	O
4	FecR	O
5	derivative	O
6	contained	O
7	59	O
8	amino	O
9	acid	O
10	residues	O
11	as	O
12	compared	O
13	to	O
14	the	O
15	317	O
16	residues	O
17	of	B
18	wild	I
19	-	I
20	type	I
21	FecR	I
22	.	I

1	Analysis	O
2	of	O
3	nucleotide	O
4	sequence	O
5	of	O
6	the	O
7	rightmost	O
8	43	O
9	kbp	O
10	of	O
11	herpesvirus	O
12	saimiri	O
13	(	O
14	HVS	O
15	)	O
16	L	O
17	-	O
18	DNA	O
19	:	O
20	general	O
21	conservation	O
22	of	O
23	genetic	O
24	organization	O
25	between	O
26	HVS	O
27	and	B
28	Epstein	I
29	-	I
30	Barr	I
31	virus	I
32	.	I

1	Epididymal	O
2	growth	O
3	was	O
4	retarded	O
5	in	O
6	animals	O
7	maintained	O
8	solely	O
9	on	O
10	chickpea	O
11	haulm	O
12	and	O
13	improved	O
14	with	O
15	supplementation	O
16	.	O

1	Transfection	O
2	of	O
3	cDNAs	O
4	for	O
5	three	O
6	mutant	O
7	enzymes	O
8	into	B
9	FPGS	I
10	-	I
11	null	O
12	Chinese	O
13	hamster	O
14	ovary	O
15	cells	O
16	restored	O
17	a	O
18	reduced	O
19	level	O
20	of	O
21	clonal	O
22	growth	O
23	,	O
24	whereas	O
25	a	O
26	T339I	O
27	mutant	O
28	supported	O
29	growth	O
30	at	O
31	a	O
32	level	O
33	comparable	O
34	to	O
35	that	O
36	of	O
37	the	B
38	wild	I
39	-	I
40	type	I
41	enzyme	I
42	.	I

1	HPLC	O
2	phosphopeptide	O
3	mapping	O
4	,	O
5	amino	O
6	acid	O
7	sequencing	O
8	,	O
9	and	O
10	site	O
11	-	O
12	directed	O
13	mutagenesis	O
14	determined	O
15	that	O
16	NCLK	O
17	phosphorylates	O
18	Ser	O
19	(	O
20	67	O
21	)	O
22	of	B
23	I	I
24	-	I
25	1	I
26	.	I

1	A	O
2	neonatal	O
3	alloimmune	O
4	thrombocytopenia	O
5	with	O
6	an	O
7	HPA	O
8	-	O
9	3a	O
10	(	O
11	Baka	O
12	)	O
13	incompatibility	O
14	was	O
15	confirmed	O
16	.	O

1	They	O
2	were	O
3	found	O
4	to	O
5	stimulate	O
6	at	O
7	nanomolar	O
8	concentrations	O
9	the	O
10	turnover	O
11	of	O
12	biosynthetically	O
13	labeled	O
14	ceramide	O
15	,	O
16	glucosylceramide	O
17	,	O
18	and	O
19	lactosylceramide	O
20	.	O

1	Accumulated	O
2	evidence	O
3	indicates	O
4	that	O
5	,	O
6	upon	O
7	stimulation	O
8	with	B
9	interferon	I
10	-	I
11	gamma	I
12	(	I
13	IFN	I
14	-	I
15	gamma	O
16	),	O
17	three	B
18	beta	I
19	-	I
20	type	I
21	subunits	O
22	,	O
23	designated	B
24	LMP2	O
25	,	B
26	LMP7	O
27	,	O
28	and	O
29	PSMB10	O
30	,	O
31	are	O
32	incorporated	O
33	into	O
34	the	O
35	20S	O
36	proteasome	O
37	by	O
38	displacing	O
39	the	O
40	housekeeping	I
41	beta	I
42	-	I
43	type	I
44	subunits	I
45	designated	I
46	PSMB6	O
47	,	O
48	PSMB5	O
49	,	O
50	and	O
51	PSMB7	O
52	,	O
53	respectively	O
54	.	O

1	A	O
2	suspected	O
3	hypothalamic	O
4	dysfunction	O
5	and	O
6	a	O
7	slightly	O
8	impaired	O
9	pituitary	O
10	function	O
11	manifested	O
12	as	O
13	GH	O
14	deficiency	O
15	were	O
16	their	O
17	common	O
18	endocrinological	O
19	features	O
20	.	O

1	The	O
2	administration	O
3	of	O
4	the	O
5	GnRH	O
6	agonist	O
7	reduced	O
8	the	O
9	bone	O
10	mineral	O
11	density	O
12	in	O
13	the	O
14	whole	O
15	femur	O
16	to	O
17	91	O
18	.	O
19	0	O
20	%	O
21	of	O
22	that	O
23	in	O
24	the	O
25	control	O
26	group	O
27	.	O

1	In	O
2	whole	O
3	sardine	O
4	,	O
5	domoic	O
6	acid	O
7	was	O
8	detected	O
9	in	O
10	levels	O
11	exceeding	O
12	sometimes	O
13	the	O
14	regulatory	O
15	limit	O
16	.	O

1	If	O
2	this	O
3	is	O
4	present	O
5	,	O
6	such	O
7	patients	O
8	should	O
9	be	O
10	closely	O
11	monitored	O
12	,	O
13	and	O
14	any	O
15	atypical	O
16	lesions	O
17	biopsied	O
18	.	O

1	This	O
2	exon	O
3	,	O
4	here	O
5	named	O
6	exon	O
7	0	O
8	,	O
9	contained	O
10	the	O
11	entire	O
12	5	O
13	'	O
14	untranslated	O
15	region	O
16	and	O
17	the	O
18	N	O
19	-	O
20	terminal	O
21	signal	O
22	sequence	O
23	of	O
24	the	O
25	polypeptide	O
26	.	O

1	Improvement	O
2	of	O
3	the	O
4	CRT	O
5	display	O
6	of	O
7	an	O
8	averager	O
9	.	O

1	To	O
2	determine	O
3	the	O
4	relationship	O
5	of	O
6	these	O
7	viruses	O
8	,	O
9	the	O
10	complete	O
11	DNA	O
12	sequence	O
13	of	O
14	KV	O
15	consisting	O
16	of	O
17	4754	O
18	bp	O
19	was	O
20	determined	O
21	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	patient	O
7	'	O
8	s	O
9	report	O
10	of	O
11	one	O
12	inaccurate	O
13	Clinitemp	O
14	,	O
15	we	O
16	undertook	O
17	to	O
18	investigate	O
19	the	O
20	accuracy	O
21	of	O
22	this	O
23	thermometer	O
24	.	O

1	Efficacy	O
2	of	O
3	a	O
4	three	O
5	-	O
6	versus	O
7	a	O
8	five	O
9	-	O
10	week	O
11	alcohol	O
12	treatment	O
13	program	O
14	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	Rat7p	O
9	/	O
10	Nup159p	O
11	is	O
12	anchored	O
13	within	O
14	the	O
15	NPC	O
16	through	O
17	its	O
18	coiled	O
19	-	O
20	coil	O
21	region	O
22	and	O
23	adjacent	O
24	sequences	O
25	.	O

1	Therefore	O
2	,	O
3	in	O
4	our	O
5	in	O
6	vitro	O
7	model	O
8	,	O
9	the	O
10	localization	O
11	of	O
12	the	O
13	mutation	O
14	in	O
15	the	B
16	K	I
17	-	I
18	ras	I
19	gene	I
20	predisposes	O
21	to	O
22	a	O
23	different	O
24	level	O
25	of	O
26	aggressiveness	O
27	in	O
28	the	O
29	transforming	O
30	phenotype	O
31	.	O

1	The	O
2	first	O
3	involved	O
4	measurements	O
5	of	O
6	the	O
7	steady	O
8	state	O
9	levels	O
10	of	O
11	mRNAs	O
12	for	O
13	subunit	O
14	5	O
15	of	B
16	cytochrome	I
17	oxidase	O
18	and	O
19	the	O
20	beta	O
21	subunit	O
22	of	B
23	F1	B
24	ATPase	O
25	in	O
26	wild	O
27	type	O
28	and	O
29	in	O
30	a	B
31	hem2	I
32	mutant	I
33	.	I

1	In	O
2	the	O
3	group	O
4	of	O
5	asthmatics	O
6	statistically	O
7	significant	O
8	correlation	O
9	was	O
10	found	O
11	between	B
12	PC20	B
13	PGF2	I
14	alpha	O
15	and	O
16	histamine	O
17	values	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	538	O
24	,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	05	O
31	).	O

1	Asthmatic	O
2	patients	O
3	showed	O
4	greater	O
5	responses	O
6	of	O
7	both	O
8	parameters	O
9	to	O
10	adrenaline	O
11	than	O
12	controls	O
13	indicating	O
14	that	O
15	long	O
16	-	O
17	term	O
18	corticosteroid	O
19	treatment	O
20	enhances	O
21	the	O
22	acute	O
23	responses	O
24	of	B
25	plasminogen	I
26	activator	I
27	and	I
28	clotting	I
29	factor	I
30	VIII	O
31	to	O
32	adrenaline	O
33	infusion	O
34	.	O

1	These	O
2	results	O
3	provide	O
4	direct	O
5	evidence	O
6	for	O
7	differential	O
8	susceptibility	O
9	to	O
10	endonuclease	O
11	-	O
12	mediated	O
13	mRNA	O
14	decay	O
15	resulting	O
16	from	O
17	the	O
18	differential	O
19	affinity	O
20	of	O
21	a	B
22	RNA	I
23	-	I
24	binding	I
25	protein	O
26	for	O
27	cis	O
28	-	O
29	acting	O
30	stability	O
31	determinants	O
32	.	O

1	A	O
2	centromere	O
3	in	O
4	S	O
5	.	O
6	cerevisiae	O
7	consists	O
8	of	O
9	a	O
10	region	O
11	of	O
12	DNA	O
13	,	O
14	approximately	O
15	150	O
16	bp	O
17	in	O
18	length	O
19	,	O
20	containing	O
21	three	O
22	important	O
23	sequence	O
24	elements	O
25	,	O
26	which	O
27	are	O
28	folded	O
29	with	O
30	proteins	O
31	into	O
32	a	O
33	specific	O
34	conformation	O
35	in	O
36	the	O
37	chromatin	O
38	(	O
39	the	O
40	yeast	O
41	kinetochore	O
42	).	O

1	While	O
2	no	O
3	significant	O
4	differences	O
5	in	O
6	the	O
7	tensile	O
8	responses	O
9	or	O
10	failure	O
11	characteristics	O
12	were	O
13	noted	O
14	for	O
15	irradiated	O
16	and	O
17	nonirradiated	O
18	grafts	O
19	in	O
20	the	O
21	drip	O
22	,	O
23	in	O
24	the	O
25	bath	O
26	environment	O
27	the	O
28	nonirradiated	O
29	tissues	O
30	had	O
31	greater	O
32	strength	O
33	and	O
34	modulus	O
35	.	O

1	For	O
2	smaller	O
3	vessels	O
4	up	O
5	to	O
6	a	O
7	diameter	O
8	of	O
9	0	O
10	.	O
11	5	O
12	mm	O
13	,	O
14	treatments	O
15	at	O
16	16	O
17	and	O
18	18	O
19	J	O
20	/	O
21	cm2	O
22	showed	O
23	good	O
24	results	O
25	in	O
26	60	O
27	and	O
28	82	O
29	%	O
30	respectively	O
31	;	O
32	for	O
33	vessels	O
34	up	O
35	to	O
36	1	O
37	mm	O
38	in	O
39	27	O
40	and	O
41	33	O
42	%.	O

1	The	O
2	close	O
3	proximity	O
4	of	O
5	the	O
6	two	B
7	neuropeptide	I
8	Y	I
9	receptor	I
10	genes	O
11	suggests	O
12	that	O
13	they	O
14	have	O
15	evolved	O
16	from	O
17	a	O
18	gene	O
19	duplication	O
20	event	O
21	with	O
22	the	O
23	small	O
24	intron	O
25	interrupting	O
26	the	O
27	coding	O
28	sequence	O
29	of	O
30	the	O
31	y1	O
32	gene	O
33	being	O
34	converted	O
35	into	O
36	a	O
37	functional	O
38	sequence	O
39	within	O
40	the	O
41	y5	O
42	gene	O
43	,	O
44	while	O
45	the	O
46	reverse	O
47	complementary	O
48	sequence	O
49	was	O
50	utilized	O
51	as	O
52	an	O
53	alternatively	O
54	spliced	O
55	5	O
56	'	O
57	exon	O
58	for	O
59	the	O
60	y1	I
61	gene	I
62	.	I

1	In	O
2	on	O
3	-	O
4	going	O
5	screening	O
6	programmes	O
7	,	O
8	the	O
9	Haemoccult	O
10	test	O
11	consists	O
12	of	O
13	six	O
14	slides	O
15	and	O
16	a	O
17	test	O
18	is	O
19	considered	O
20	positive	O
21	if	O
22	at	O
23	least	O
24	one	O
25	slide	O
26	is	O
27	coloured	O
28	.	O

1	Homozygous	O
2	mutant	O
3	mice	O
4	,	O
5	designated	O
6	Cux	O
7	/	B
8	CDPDeltaCR1	O
9	,	O
10	display	O
11	a	O
12	phenotype	O
13	characterized	O
14	by	O
15	curly	O
16	vibrissae	O
17	and	O
18	wavy	O
19	hair	O
20	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	in	O
6	addition	O
7	to	B
8	Grb2	I
9	-	O
10	mediated	O
11	activation	O
12	of	O
13	Ras	O
14	,	B
15	PLC	I
16	-	I
17	gamma1	I
18	-	O
19	mediated	O
20	DAG	O
21	production	O
22	is	O
23	required	O
24	for	B
25	EGF	I
26	-	O
27	and	B
28	PDGF	I
29	-	O
30	induced	O
31	S	O
32	-	O
33	phase	O
34	entry	O
35	and	O
36	gene	O
37	expression	O
38	,	O
39	possibly	O
40	through	O
41	activation	O
42	of	B
43	PKC	I
44	.	I

1	This	O
2	paper	O
3	brings	O
4	together	O
5	data	O
6	,	O
7	obtained	O
8	from	O
9	a	O
10	variety	O
11	of	O
12	sources	O
13	,	O
14	on	O
15	the	O
16	extent	O
17	of	O
18	prescription	O
19	and	O
20	use	O
21	of	O
22	psychotropic	O
23	drugs	O
24	in	O
25	the	O
26	late	O
27	1960s	O
28	and	O
29	early	O
30	1970s	O
31	.	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	several	O
6	E1	O
7	mutants	O
8	mapping	O
9	in	O
10	both	O
11	the	O
12	M	O
13	and	O
14	R	O
15	regions	O
16	and	O
17	a	O
18	single	O
19	mutant	O
20	of	O
21	the	O
22	upstream	O
23	regulatory	O
24	region	O
25	have	O
26	a	O
27	higher	O
28	transforming	O
29	activity	O
30	on	O
31	mouse	O
32	C127	O
33	cells	O
34	than	O
35	the	O
36	wild	O
37	-	O
38	type	O
39	genome	O
40	does	O
41	.	O

1	We	O
2	then	O
3	studied	O
4	four	O
5	unrelated	O
6	Japanese	O
7	families	O
8	with	O
9	GSD	O
10	-	O
11	Ib	O
12	,	O
13	and	O
14	found	O
15	three	O
16	novel	O
17	mutations	O
18	:	O
19	a	O
20	four	O
21	-	O
22	base	O
23	deletion	O
24	/	O
25	two	O
26	-	O
27	base	O
28	insertion	O
29	,	O
30	a	O
31	point	O
32	mutation	O
33	within	O
34	a	O
35	consensus	O
36	splicing	O
37	donor	O
38	site	O
39	,	O
40	and	O
41	a	O
42	missense	O
43	mutation	O
44	(	O
45	W118R	O
46	).	O

1	We	O
2	compare	O
3	the	O
4	results	O
5	of	O
6	this	O
7	algorithm	O
8	with	O
9	the	O
10	results	O
11	obtained	O
12	with	O
13	two	O
14	other	O
15	algorithms	O
16	,	O
17	the	O
18	optimal	O
19	algorithm	O
20	for	O
21	monochannel	O
22	nonoverlapping	O
23	noise	O
24	and	O
25	the	O
26	optimal	O
27	algorithm	O
28	for	O
29	multichannel	O
30	additive	O
31	noise	O
32	,	O
33	and	O
34	we	O
35	show	O
36	that	O
37	in	O
38	both	O
39	cases	O
40	improvement	O
41	can	O
42	be	O
43	obtained	O
44	.	O

1	Contributions	O
2	from	O
3	pairs	O
4	of	O
5	source	O
6	and	O
7	target	O
8	volume	O
9	elements	O
10	are	O
11	summed	O
12	for	O
13	the	O
14	S	O
15	values	O
16	between	O
17	the	O
18	tumor	O
19	and	O
20	itself	O
21	,	O
22	between	O
23	the	O
24	remaining	O
25	healthy	O
26	host	O
27	organ	O
28	and	O
29	itself	O
30	,	O
31	and	O
32	between	O
33	the	O
34	tumor	O
35	and	O
36	the	O
37	remaining	O
38	healthy	O
39	host	O
40	organ	O
41	,	O
42	with	O
43	the	O
44	reciprocity	O
45	theorem	O
46	assumed	O
47	for	O
48	the	O
49	last	O
50	.	O

1	Caries	O
2	prevention	O
3	in	O
4	the	O
5	dental	O
6	office	O
7	.	O

1	The	O
2	hypothesis	O
3	of	O
4	Geisler	O
5	(	O
6	Brain	O
7	Res	O
8	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	in	O
6	fusions	O
7	with	O
8	the	O
9	DNA	O
10	binding	O
11	domain	O
12	of	O
13	GAL4	O
14	,	O
15	full	O
16	activity	O
17	requires	O
18	the	O
19	entire	B
20	BHV	I
21	-	I
22	alpha	I
23	TIF	O
24	,	O
25	although	O
26	both	O
27	amino	O
28	and	O
29	carboxyl	O
30	termini	O
31	display	O
32	some	O
33	activity	O
34	on	O
35	their	O
36	own	O
37	.	O

1	Residual	O
2	urinary	O
3	abnormalities	O
4	were	O
5	significantly	O
6	more	O
7	frequent	O
8	in	O
9	patients	O
10	with	O
11	type	O
12	III	O
13	than	O
14	type	B
15	I	B
16	MPGN	I
17	.	I

1	During	O
2	a	O
3	28	O
4	-	O
5	week	O
6	promotion	O
7	bioassay	O
8	,	O
9	groups	O
10	of	O
11	30	O
12	male	B
13	CD	I
14	-	I
15	1	O
16	mice	O
17	were	O
18	treated	O
19	once	O
20	with	O
21	50	O
22	microliter	O
23	of	O
24	either	O
25	DMBA	O
26	(	O
27	1	O
28	.	O
29	0	O
30	mg	O
31	/	O
32	ml	O
33	)	O
34	or	O
35	acetone	O
36	,	O
37	rested	O
38	for	O
39	2	O
40	weeks	O
41	,	O
42	and	O
43	then	O
44	treated	O
45	twice	O
46	per	O
47	week	O
48	with	O
49	test	O
50	material	O
51	for	O
52	the	O
53	remaining	O
54	25	O
55	weeks	O
56	.	O

1	Simultaneous	O
2	determination	O
3	of	O
4	theophylline	O
5	and	O
6	its	O
7	metabolites	O
8	by	O
9	HPLC	O
10	]	O
11	A	O
12	high	O
13	performance	O
14	liquid	O
15	chromatography	O
16	(	O
17	HPLC	O
18	)	O
19	method	O
20	has	O
21	been	O
22	developed	O
23	for	O
24	the	O
25	simultaneous	O
26	determination	O
27	of	O
28	theophylline	O
29	and	O
30	its	O
31	metabolites	O
32	,	O
33	with	O
34	caffeine	O
35	and	O
36	its	O
37	metabolites	O
38	.	O

1	Identification	O
2	of	O
3	a	O
4	promoter	O
5	-	O
6	specific	O
7	transactivation	O
8	domain	O
9	in	O
10	the	O
11	herpes	B
12	simplex	I
13	virus	I
14	regulatory	I
15	protein	I
16	ICP4	I
17	.	I

1	Private	O
2	hospital	O
3	accreditation	O
4	.	O

1	REM	O
2	dream	O
3	content	O
4	was	O
5	scored	O
6	for	O
7	categories	O
8	suggesting	O
9	the	O
10	predominant	O
11	influence	O
12	of	O
13	the	O
14	left	O
15	hemisphere	O
16	,	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	good	O
22	ego	O
23	functioning	O
24	,	O
25	verbalization	O
26	,	O
27	or	O
28	the	O
29	right	O
30	hemisphere	O
31	,	O
32	e	O
33	.	O
34	g	O
35	.,	O
36	music	O
37	,	O
38	spatial	O
39	salience	O
40	,	O
41	bizarreness	O
42	.	O

1	This	O
2	sensitivity	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	practical	O
8	limits	O
9	of	O
10	the	O
11	accuracy	O
12	of	O
13	the	O
14	used	O
15	screening	O
16	test	O
17	jeopardize	O
18	the	O
19	estimation	O
20	of	O
21	the	O
22	true	O
23	herd	O
24	prevalence	O
25	within	O
26	reasonable	O
27	confidence	O
28	limits	O
29	,	O
30	because	O
31	the	O
32	within	O
33	-	O
34	herd	O
35	PTB	O
36	true	O
37	prevalence	O
38	was	O
39	low	O
40	.	O
41	For	O
42	this	O
43	reason	O
44	we	O
45	augmented	O
46	the	O
47	herd	O
48	specificity	O
49	for	O
50	herds	O
51	with	O
52	larger	O
53	adult	O
54	herd	O
55	size	O
56	(>	O
57	5	O
58	).	O

1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	GH3	O
7	cells	O
8	transfected	O
9	with	O
10	the	B
11	rat	B
12	GnRH	I
13	receptor	I
14	cDNA	I
15	(	I
16	GGH3	I
17	-	I
18	1	O
19	'	O
20	cells	O
21	)	O
22	support	O
23	the	O
24	expression	O
25	of	O
26	a	O
27	cotransfected	O
28	fusion	O
29	gene	O
30	composed	O
31	of	O
32	797	O
33	base	O
34	pairs	O
35	of	B
36	rat	B
37	LHbeta	I
38	gene	O
39	5	O
40	'-	O
41	flanking	O
42	sequence	O
43	and	O
44	the	O
45	first	O
46	5	O
47	base	O
48	pairs	O
49	of	O
50	the	O
51	5	O
52	'-	O
53	untranslated	O
54	region	O
55	fused	O
56	to	O
57	a	B
58	luciferase	I
59	reporter	I
60	(-	I
61	797	I
62	/+	I
63	5LHbetaLUC	O
64	)	O
65	and	O
66	respond	O
67	to	O
68	a	O
69	GnRH	O
70	agonist	O
71	with	O
72	a	O
73	10	O
74	-	O
75	fold	O
76	stimulation	O
77	of	O
78	activity	O
79	.	O

1	Sequence	O
2	requirements	O
3	for	O
4	premature	O
5	transcription	O
6	arrest	O
7	within	O
8	the	O
9	first	O
10	intron	O
11	of	O
12	the	B
13	mouse	B
14	c	I
15	-	I
16	fos	I
17	gene	I
18	.	I

1	We	O
2	previously	O
3	described	O
4	two	O
5	alanine	O
6	cluster	O
7	mutations	O
8	,	O
9	R77	O
10	to	O
11	A	O
12	(	O
13	R77A	O
14	)-	O
15	K79A	O
16	and	O
17	E192A	O
18	-	O
19	E194A	O
20	,	O
21	which	O
22	selectively	O
23	inactivated	O
24	the	B
25	triphosphatase	I
26	component	I
27	.	I

1	To	O
2	test	O
3	the	O
4	hypothesis	O
5	that	O
6	progestin	O
7	-	O
8	mediated	O
9	increases	O
10	in	O
11	resting	O
12	core	O
13	temperature	O
14	and	O
15	the	O
16	core	O
17	temperature	O
18	threshold	O
19	for	O
20	sweating	O
21	onset	O
22	are	O
23	counteracted	O
24	by	O
25	estrogen	O
26	,	O
27	we	O
28	studied	O
29	eight	O
30	women	O
31	(	O
32	24	O
33	+/-	O
34	2	O
35	yr	O
36	)	O
37	at	O
38	27	O
39	degrees	O
40	C	O
41	rest	O
42	,	O
43	during	O
44	20	O
45	min	O
46	of	O
47	passive	O
48	heating	O
49	(	O
50	35	O
51	degrees	O
52	C	O
53	),	O
54	and	O
55	during	O
56	40	O
57	min	O
58	of	O
59	exercise	O
60	at	O
61	35	O
62	degrees	O
63	C	O
64	.	O

1	Mg	O
2	-	O
3	chelatase	O
4	of	O
5	tobacco	O
6	:	O
7	identification	O
8	of	O
9	a	O
10	Chl	O
11	D	O
12	cDNA	O
13	sequence	O
14	encoding	O
15	a	O
16	third	O
17	subunit	O
18	,	O
19	analysis	O
20	of	O
21	the	O
22	interaction	O
23	of	O
24	the	O
25	three	O
26	subunits	O
27	with	O
28	the	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	system	O
34	,	O
35	and	O
36	reconstitution	O
37	of	O
38	the	O
39	enzyme	O
40	activity	O
41	by	O
42	co	O
43	-	O
44	expression	O
45	of	O
46	recombinant	O
47	CHL	O
48	D	O
49	,	O
50	CHL	O
51	H	O
52	and	O
53	CHL	O
54	I	O
55	.	O

1	A	O
2	decrease	O
3	of	O
4	the	B
5	lysozyme	O
6	activity	O
7	coincided	O
8	with	O
9	the	O
10	clinical	O
11	improvement	O
12	of	O
13	the	O
14	bacterial	O
15	meningitis	O
16	.	O

1	The	O
2	diagnostic	O
3	value	O
4	of	O
5	blood	O
6	serum	O
7	and	O
8	urinary	B
9	amylase	I
10	,	I
11	lipase	O
12	,	O
13	and	O
14	trypsin	O
15	in	O
16	exacerbations	O
17	of	O
18	chronic	O
19	relapsing	O
20	pancreatitis	O
21	is	O
22	discussed	O
23	.	O

1	Recurrent	O
2	G	O
3	-	O
4	to	O
5	-	O
6	A	O
7	substitution	O
8	in	O
9	a	O
10	single	O
11	codon	O
12	of	B
13	SREBP	I
14	cleavage	I
15	-	I
16	activating	I
17	protein	O
18	causes	O
19	sterol	O
20	resistance	O
21	in	O
22	three	O
23	mutant	O
24	Chinese	O
25	hamster	O
26	ovary	O
27	cell	O
28	lines	O
29	.	O

1	Praziquantel	O
2	and	O
3	Albendazole	O
4	were	O
5	found	O
6	effective	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	neurocysticercosis	O
12	,	O
13	but	O
14	because	O
15	of	O
16	serious	O
17	side	O
18	effects	O
19	encountered	O
20	in	O
21	some	O
22	cases	O
23	,	O
24	the	O
25	drugs	O
26	should	O
27	be	O
28	used	O
29	cautiously	O
30	in	O
31	selected	O
32	cases	O
33	only	O
34	.	O

1	A	O
2	simple	O
3	method	O
4	for	O
5	measuring	O
6	urinary	O
7	iron	O
8	following	O
9	the	O
10	administration	O
11	of	O
12	desferrioxamine	O
13	(	O
14	DF	O
15	)	O
16	is	O
17	described	O
18	.	O

1	The	B
2	RAD6	I
3	/	I
4	UBC2	I
5	gene	O
6	from	O
7	Saccharomyces	O
8	cerevisiae	O
9	encodes	O
10	a	O
11	ubiquitin	O
12	-	O
13	conjugating	O
14	enzyme	O
15	involved	O
16	in	O
17	DNA	O
18	repair	O
19	,	O
20	induced	O
21	mutagenesis	O
22	,	O
23	and	O
24	sporulation	O
25	.	O

1	Among	O
2	82	O
3	superficial	O
4	lesions	O
5	34	O
6	were	O
7	classified	O
8	as	O
9	showing	O
10	CR	O
11	and	O
12	another	O
13	23	O
14	as	O
15	showing	O
16	PR	O
17	,	O
18	with	O
19	a	O
20	response	O
21	rate	O
22	of	O
23	69	O
24	.	O
25	5	O
26	%.	O

1	Most	O
2	important	O
3	,	O
4	infection	O
5	of	O
6	the	O
7	cells	O
8	with	O
9	an	O
10	adenoviral	O
11	construct	O
12	expressing	O
13	this	O
14	mutant	O
15	inhibited	O
16	the	O
17	induction	O
18	of	O
19	VEGF	I
20	mRNA	O
21	under	O
22	conditions	O
23	that	O
24	mimic	O
25	hypoxia	O
26	.	O

1	Transcriptional	O
2	control	O
3	signals	O
4	of	O
5	a	O
6	herpes	B
7	simplex	I
8	virus	I
9	type	I
10	1	I
11	late	I
12	(	I
13	gamma	I
14	2	I
15	)	I
16	gene	I
17	lie	O
18	within	O
19	bases	O
20	-	O
21	34	O
22	to	O
23	+	O
24	124	O
25	relative	O
26	to	O
27	the	O
28	5	O
29	'	O
30	terminus	O
31	of	O
32	the	O
33	mRNA	O
34	.	O

1	To	O
2	study	O
3	the	O
4	significance	O
5	of	O
6	these	O
7	domains	O
8	and	O
9	the	O
10	overall	O
11	evolutionary	O
12	conservation	O
13	of	O
14	the	O
15	gene	O
16	,	O
17	the	O
18	homolog	O
19	from	O
20	Drosophila	O
21	melanogaster	O
22	was	O
23	isolated	O
24	by	O
25	low	O
26	stringency	O
27	hybridizations	O
28	using	O
29	two	O
30	flanking	O
31	probes	O
32	of	O
33	the	B
34	human	B
35	ERCC3	I
36	cDNA	I
37	.	I

1	Urinary	O
2	excretion	O
3	of	O
4	oestrone	O
5	,	O
6	oestradiol	O
7	-	O
8	17	O
9	beta	O
10	and	O
11	oestriol	O
12	in	O
13	pregnancies	O
14	complicated	O
15	by	B
16	steroid	B
17	sulphatase	O
18	deficiency	O
19	.	O

1	The	O
2	associations	O
3	between	B
4	sex	I
5	-	I
6	hormone	I
7	-	I
8	binding	I
9	globulin	O
10	capacity	O
11	(	O
12	SHBG	O
13	),	O
14	age	O
15	,	O
16	body	O
17	mass	O
18	index	O
19	(	O
20	BMI	O
21	),	O
22	and	O
23	physical	O
24	fitness	O
25	have	O
26	been	O
27	studied	O
28	in	O
29	34	O
30	men	O
31	and	O
32	36	O
33	women	O
34	.	O

1	J	O
2	.	O

1	These	O
2	results	O
3	indicate	O
4	that	B
5	Rb	I
6	protein	O
7	is	O
8	interacting	O
9	with	O
10	some	O
11	component	O
12	(	O
13	s	O
14	)	O
15	of	O
16	the	O
17	cell	O
18	cycle	O
19	-	O
20	regulatory	O
21	machinery	O
22	during	O
23	G2	O
24	phase	O
25	.	O

1	The	O
2	method	O
3	requires	O
4	a	O
5	reversed	O
6	-	O
7	phase	O
8	column	O
9	and	O
10	a	O
11	paired	O
12	-	O
13	ion	O
14	technique	O
15	to	O
16	separate	O
17	docusate	O
18	sodium	O
19	from	O
20	other	O
21	components	O
22	.	O

1	However	O
2	,	O
3	the	O
4	history	O
5	of	O
6	acute	O
7	severe	O
8	complications	O
9	from	O
10	otitis	O
11	media	O
12	revealed	O
13	a	O
14	higher	O
15	frequency	O
16	in	O
17	those	O
18	individuals	O
19	with	B
20	alpha	I
21	1	I
22	-	I
23	antitrypsin	O
24	deficiency	O
25	as	O
26	compared	O
27	to	O
28	normals	O
29	.	O

1	Treatment	O
2	with	O
3	heparin	O
4	,	B
5	plasminogen	I
6	activators	O
7	and	B
8	fibrinogenolytic	O
9	agents	O
10	was	O
11	disappointing	O
12	although	O
13	renal	O
14	function	O
15	has	O
16	stabilized	O
17	in	O
18	one	O
19	patient	O
20	on	O
21	long	O
22	term	O
23	oral	O
24	anticoagulant	O
25	therapy	O
26	.	O

1	The	O
2	mechanism	O
3	by	O
4	which	O
5	large	O
6	molecules	O
7	,	O
8	such	O
9	as	O
10	the	O
11	diphosphonate	O
12	99mTc	O
13	-	O
14	labeled	O
15	EHDP	O
16	or	O
17	99mTc	O
18	-	O
19	labeled	O
20	pyrophosphate	O
21	,	O
22	pass	O
23	through	O
24	capillaries	O
25	in	O
26	bone	O
27	is	O
28	by	O
29	passive	O
30	diffusion	O
31	.	O

1	A	O
2	gas	O
3	-	O
4	liquid	O
5	chromatographic	O
6	method	O
7	for	O
8	the	O
9	determination	O
10	of	O
11	p	O
12	-	O
13	chlorophenoxyisobutyric	O
14	(	O
15	CPIB	O
16	)	O
17	acid	O
18	in	O
19	blood	O
20	plasma	O
21	is	O
22	described	O
23	.	O

1	The	O
2	COOH	O
3	-	O
4	terminus	O
5	of	O
6	this	O
7	new	O
8	isoform	O
9	,	O
10	which	O
11	we	O
12	designate	O
13	beta	O
14	4	O
15	,	O
16	lacks	O
17	a	O
18	22	O
19	amino	O
20	acid	O
21	lysine	O
22	-	O
23	rich	O
24	sequence	O
25	common	O
26	to	O
27	both	O
28	the	O
29	human	O
30	red	O
31	cell	B
32	alpha	I
33	-	I
34	and	I
35	beta	I
36	-	I
37	adducin	I
38	subunits	O
39	and	O
40	homologous	O
41	to	O
42	a	O
43	highly	O
44	conserved	O
45	region	O
46	in	O
47	MARCKS	O
48	,	O
49	a	O
50	filamentous	O
51	actin	O
52	-	O
53	cross	O
54	linking	O
55	protein	O
56	regulated	O
57	by	O
58	protein	O
59	kinase	O
60	C	O
61	and	O
62	calcium	O
63	/	O
64	calmodulin	O
65	.	B
66	beta	B
67	4	I
68	-	I
69	adducin	I
70	preserves	O
71	a	O
72	previously	O
73	identified	O
74	calmodulin	O
75	binding	O
76	domain	O
77	.	O

1	The	B
2	p20	I
3	-	I
4	CGGBP	I
5	gene	O
6	is	O
7	conserved	O
8	among	O
9	mammals	O
10	but	O
11	shows	O
12	no	O
13	homology	O
14	to	O
15	non	O
16	-	O
17	vertebrate	O
18	species	O
19	.	O

1	Cholesterol	O
2	side	O
3	-	O
4	chain	O
5	cleavage	B
6	cytochrome	B
7	P450	O
8	(	B
9	CYP11A	O
10	;	B
11	P450scc	I
12	)	I
13	gene	O
14	expression	O
15	is	O
16	regulated	O
17	by	O
18	gonadotropins	O
19	via	O
20	cAMP	O
21	in	O
22	the	O
23	ovary	O
24	and	O
25	by	O
26	ACTH	O
27	via	O
28	cAMP	O
29	in	O
30	adrenal	O
31	cortical	O
32	cells	O
33	.	O

1	S	O
2	.,	O
3	and	O
4	Walter	O
5	,	O
6	P	O
7	.	O

1	No	O
2	previous	O
3	studies	O
4	have	O
5	determined	O
6	the	O
7	pharmaco	O
8	-	O
9	dynamics	O
10	of	O
11	intravenous	O
12	procainamide	O
13	when	O
14	administered	O
15	in	O
16	a	O
17	dose	O
18	of	O
19	15	O
20	mg	O
21	/	O
22	kg	O
23	and	O
24	at	O
25	a	O
26	rate	O
27	of	O
28	50	O
29	mg	O
30	/	O
31	min	O
32	,	O
33	as	O
34	is	O
35	common	O
36	practice	O
37	during	O
38	electropharmacologic	O
39	testing	O
40	.	O

1	Internal	O
2	biliary	O
3	drainage	O
4	,	O
5	unlike	O
6	external	O
7	drainage	O
8	,	O
9	does	O
10	not	O
11	suppress	O
12	the	O
13	regeneration	O
14	of	O
15	cholestatic	O
16	rat	O
17	liver	O
18	after	O
19	partial	O
20	hepatectomy	O
21	.	O

1	The	B
2	PDH	I
3	complex	I
4	-	I
5	encoding	I
6	genes	O
7	were	O
8	identified	O
9	by	O
10	hybridization	O
11	experiments	O
12	and	O
13	sequence	O
14	analysis	O
15	in	O
16	two	O
17	separate	O
18	gene	O
19	regions	O
20	in	O
21	the	O
22	genome	O
23	of	O
24	Z	O
25	.	O
26	mobilis	O
27	.	O

1	Independent	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	cassette	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O

1	Three	O
2	of	O
3	the	O
4	short	O
5	ORFs	O
6	in	O
7	the	O
8	central	O
9	region	O
10	of	O
11	BIV	O
12	have	O
13	been	O
14	identified	O
15	by	O
16	location	O
17	and	O
18	structural	O
19	similarity	O
20	to	O
21	the	O
22	nonstructural	O
23	/	O
24	regulatory	O
25	genes	O
26	(	O
27	vif	O
28	,	O
29	tat	O
30	,	O
31	and	O
32	rev	O
33	)	O
34	of	O
35	other	O
36	lentiviruses	O
37	;	O
38	we	O
39	also	O
40	discovered	O
41	two	O
42	unique	O
43	ORFs	O
44	,	O
45	termed	O
46	W	O
47	and	O
48	Y	O
49	,	O
50	which	O
51	may	O
52	serve	O
53	as	O
54	exons	O
55	for	O
56	novel	O
57	genes	O
58	.	O

1	The	O
2	multiple	O
3	functions	O
4	of	O
5	Pmt3p	O
6	described	O
7	here	O
8	suggest	O
9	that	O
10	several	O
11	nuclear	O
12	proteins	O
13	are	O
14	regulated	O
15	by	O
16	Pmt3p	O
17	conjugation	O
18	.	O

1	In	O
2	addition	O
3	to	O
4	protein	O
5	binding	O
6	at	O
7	sequences	O
8	known	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	the	O
14	regulation	O
15	of	O
16	transcription	O
17	,	O
18	genomic	O
19	footprinting	O
20	of	O
21	the	O
22	entire	O
23	promoter	O
24	region	O
25	also	O
26	showed	O
27	that	O
28	a	O
29	protein	O
30	factor	O
31	is	O
32	constitutively	O
33	bound	O
34	to	O
35	the	O
36	first	O
37	intron	O
38	of	O
39	the	B
40	rep3	I
41	gene	I
42	.	I

1	These	O
2	data	O
3	suggest	O
4	that	O
5	a	O
6	major	O
7	part	O
8	of	O
9	the	O
10	reduction	O
11	in	O
12	food	O
13	intake	O
14	in	O
15	hyperphagic	O
16	rats	O
17	eating	O
18	a	O
19	quinine	O
20	-	O
21	adulterated	O
22	diet	O
23	is	O
24	due	O
25	to	O
26	postingestional	O
27	events	O
28	.	O

1	The	O
2	eluent	O
3	from	O
4	the	O
5	column	O
6	was	O
7	mixed	O
8	with	O
9	the	O
10	chemiluminescent	O
11	solution	O
12	containing	B
13	lucigenin	O
14	and	O
15	Triton	O
16	X	O
17	-	O
18	100	O
19	and	O
20	a	O
21	0	O
22	.	O
23	28	O
24	M	O
25	KOH	O
26	solution	O
27	by	O
28	pumps	O
29	and	O
30	monitored	O
31	by	O
32	a	O
33	chemiluminescence	O
34	detector	O
35	.	O

1	Current	O
2	evidence	O
3	for	O
4	this	O
5	type	O
6	of	O
7	DNA	O
8	supercoiling	O
9	-	O
10	dependent	O
11	transcriptional	O
12	coupling	O
13	,	O
14	based	O
15	largely	O
16	on	O
17	the	O
18	in	O
19	vivo	O
20	activities	O
21	of	O
22	promoters	O
23	contained	O
24	in	O
25	engineered	O
26	DNA	O
27	constructs	O
28	,	O
29	suggests	O
30	that	O
31	the	O
32	transcription	O
33	complex	O
34	must	O
35	be	O
36	physically	O
37	hindered	O
38	to	O
39	generate	O
40	DNA	O
41	supercoils	O
42	and	O
43	to	O
44	prevent	O
45	their	O
46	diffusion	O
47	throughout	O
48	the	O
49	DNA	O
50	duplex	O
51	.	O

1	The	O
2	sense	O
3	of	O
4	self	O
5	.	O

1	Evoked	O
2	potential	O
3	and	O
4	single	O
5	unit	O
6	responses	O
7	to	O
8	olfactory	O
9	nerve	O
10	volleys	O
11	in	O
12	the	O
13	isolated	O
14	turtle	O
15	olfactory	O
16	bulb	O
17	.	O

1	Furthermore	O
2	,	O
3	the	O
4	3	O
5	'-	O
6	untranslated	O
7	regions	O
8	of	O
9	pmGT10	O
10	display	O
11	a	O
12	marked	O
13	degree	O
14	of	O
15	homology	O
16	to	O
17	the	O
18	3	O
19	'	O
20	region	O
21	of	O
22	the	B
23	rat	B
24	Yb1	I
25	gene	O
26	,	O
27	while	O
28	this	O
29	region	O
30	of	O
31	pmGT2	O
32	displays	O
33	marked	O
34	homology	O
35	to	O
36	the	O
37	corresponding	O
38	region	O
39	of	O
40	the	B
41	rat	B
42	Yb2	I
43	gene	I
44	.	I

1	Liver	O
2	TG	O
3	and	O
4	serum	O
5	NEFA	O
6	concentrations	O
7	were	O
8	positively	O
9	correlated	O
10	.	O

1	All	O
2	loci	O
3	have	O
4	a	O
5	similar	O
6	organization	O
7	,	O
8	except	O
9	for	O
10	H1	O
11	.	O
12	8	O
13	that	O
14	harbors	O
15	two	B
16	TcP2beta	I
17	genes	O
18	arranged	O
19	in	O
20	tandem	O
21	and	O
22	separated	O
23	by	O
24	a	O
25	short	O
26	repetitive	O
27	sequence	O
28	,	O
29	named	O
30	SIRE	O
31	(	O
32	short	O
33	interspersed	O
34	repetitive	O
35	element	O
36	),	O
37	which	O
38	is	O
39	also	O
40	found	O
41	upstream	O
42	of	O
43	the	O
44	first	O
45	gene	O
46	of	O
47	the	O
48	tandem	O
49	and	O
50	downstream	O
51	of	O
52	the	O
53	second	O
54	.	O

1	In	O
2	conclusion	O
3	,	O
4	marmoset	O
5	monkey	O
6	LHR	O
7	seems	O
8	to	O
9	lack	O
10	the	O
11	sequence	O
12	corresponding	O
13	to	O
14	exon	O
15	10	O
16	of	O
17	the	B
18	LHR	I
19	gene	O
20	in	O
21	other	O
22	mammalian	O
23	species	O
24	.	O

1	Thus	O
2	,	O
3	SOX8	O
4	is	O
5	a	O
6	good	O
7	candidate	O
8	gene	O
9	contributing	O
10	to	O
11	the	O
12	mental	O
13	retardation	O
14	phenotype	O
15	seen	O
16	in	O
17	ATR	O
18	-	O
19	16	O
20	patients	O
21	.	O

1	Like	O
2	other	O
3	members	O
4	of	O
5	this	O
6	family	O
7	,	O
8	the	B
9	AP	I
10	-	I
11	4	I
12	HLH	I
13	motif	O
14	and	O
15	the	O
16	adjacent	O
17	basic	O
18	domain	O
19	are	O
20	necessary	O
21	and	O
22	sufficient	O
23	to	O
24	confer	O
25	site	O
26	-	O
27	specific	O
28	DNA	O
29	binding	O
30	.	O

1	Sources	O
2	of	O
3	noise	O
4	in	O
5	these	O
6	signals	O
7	were	O
8	evaluated	O
9	in	O
10	preparations	O
11	stained	O
12	with	O
13	the	O
14	potentiometric	O
15	probe	O
16	RH	O
17	-	O
18	414	O
19	.	O

1	The	B
2	Klebsiella	I
3	aerogenes	I
4	gene	I
5	maoA	O
6	,	O
7	which	O
8	is	O
9	involved	O
10	in	O
11	the	O
12	synthesis	O
13	of	O
14	monoamine	I
15	oxidase	O
16	,	O
17	was	O
18	induced	O
19	by	O
20	tyramine	O
21	and	O
22	the	O
23	related	O
24	compounds	O
25	,	O
26	subjected	O
27	to	O
28	catabolite	O
29	and	O
30	ammonium	O
31	ion	O
32	repression	O
33	,	O
34	and	O
35	cloned	O
36	.	O

1	Neither	O
2	is	O
3	it	O
4	a	O
5	major	O
6	cause	O
7	of	O
8	rehydration	O
9	-	O
10	induced	O
11	renal	O
12	Na	O
13	retention	O
14	.	O

1	A	O
2	raised	O
3	amplitude	O
4	of	O
5	the	O
6	aggregation	O
7	of	O
8	plates	O
9	and	O
10	a	O
11	decrease	O
12	in	O
13	the	O
14	threshold	O
15	of	O
16	their	O
17	sensitivity	O
18	to	O
19	ADP	O
20	were	O
21	established	O
22	in	O
23	the	O
24	persons	O
25	with	O
26	types	O
27	IIa	O
28	and	O
29	IIb	O
30	HLP	O
31	and	O
32	in	O
33	CHD	O
34	without	O
35	HLP	O
36	.	O

1	Both	O
2	GH	O
3	deficiency	O
4	and	O
5	impaired	O
6	spinal	O
7	growth	O
8	may	O
9	result	O
10	in	O
11	short	O
12	stature	O
13	,	O
14	whereas	O
15	the	O
16	occurrence	O
17	of	O
18	early	O
19	puberty	O
20	in	O
21	association	O
22	with	O
23	GH	O
24	deficiency	O
25	reduces	O
26	the	O
27	time	O
28	available	O
29	for	O
30	GH	O
31	therapy	O
32	.	O

1	In	O
2	18	O
3	%	O
4	lymphography	O
5	was	O
6	clearly	O
7	positive	O
8	and	O
9	CT	O
10	negative	O
11	.	O

1	The	O
2	organization	O
3	of	B
4	SPP1	I
5	genes	O
6	involved	O
7	in	O
8	the	O
9	replication	O
10	,	O
11	DNA	O
12	packaging	O
13	and	O
14	phage	O
15	assembly	O
16	proteins	O
17	resembles	O
18	the	O
19	organization	O
20	of	O
21	genes	O
22	of	O
23	equivalent	O
24	regions	O
25	of	O
26	different	O
27	E	O
28	.	O
29	coli	O
30	double	O
31	-	O
32	stranded	O
33	DNA	O
34	phages	O
35	.	O

1	We	O
2	characterized	O
3	the	O
4	structure	O
5	of	O
6	this	O
7	leader	O
8	mRNA	O
9	by	O
10	using	O
11	the	O
12	program	O
13	Mfold	O
14	and	O
15	a	O
16	combination	O
17	of	O
18	nested	O
19	and	O
20	internal	O
21	deletions	O
22	transcriptionally	O
23	fused	O
24	to	O
25	a	O
26	promoterless	B
27	lac	I
28	operon	I
29	.	I

1	Today	O
2	there	O
3	is	O
4	no	O
5	doubt	O
6	that	O
7	elevated	O
8	plasma	O
9	cholesterol	O
10	levels	O
11	should	O
12	be	O
13	lowered	O
14	first	O
15	by	O
16	dietary	O
17	modification	O
18	even	O
19	in	O
20	early	O
21	childhood	O
22	,	O
23	beginning	O
24	at	O
25	the	O
26	age	O
27	of	O
28	two	O
29	years	O
30	.	O

1	Follow	O
2	-	O
3	up	O
4	study	O
5	showed	O
6	85	O
7	%	O
8	of	O
9	these	O
10	patients	O
11	with	O
12	effectiveness	O
13	.	O

1	The	O
2	existence	O
3	of	O
4	these	O
5	two	O
6	categories	O
7	of	O
8	strains	O
9	offers	O
10	a	O
11	new	O
12	genetic	O
13	system	O
14	in	O
15	which	O
16	the	O
17	properties	O
18	of	O
19	a	O
20	potential	O
21	invertebrate	O
22	retrovirus	O
23	can	O
24	be	O
25	tested	O
26	.	O

1	Cramps	O
2	in	O
3	extrapyramidal	O
4	disorders	O
5	.	O

1	Under	O
2	the	O
3	same	O
4	hematocrit	O
5	and	O
6	flow	O
7	conditions	O
8	,	O
9	the	O
10	rate	O
11	of	O
12	oxygen	O
13	saturation	O
14	decrease	O
15	was	O
16	significantly	O
17	higher	O
18	for	O
19	the	O
20	sickle	O
21	cells	O
22	than	O
23	for	O
24	normal	O
25	cells	O
26	.	O

1	The	O
2	aim	O
3	of	O
4	our	O
5	study	O
6	was	O
7	to	O
8	evaluate	O
9	the	O
10	level	O
11	of	O
12	oxidative	O
13	stress	O
14	in	O
15	healthy	O
16	controls	O
17	(	O
18	CTL	O
19	)	O
20	compared	O
21	with	B
22	CRF	O
23	and	O
24	HD	O
25	patients	O
26	before	O
27	(	O
28	pre	O
29	-	O
30	HD	O
31	)	O
32	and	O
33	after	O
34	(	O
35	post	O
36	-	O
37	HD	O
38	)	O
39	the	O
40	dialysis	O
41	session	O
42	,	O
43	carried	O
44	out	O
45	on	O
46	a	O
47	high	O
48	biocompatible	O
49	polyacrylonitrile	O
50	membrane	O
51	AN69	O
52	.	O

1	Assays	O
2	of	O
3	total	O
4	cholesterol	O
5	as	O
6	well	O
7	as	O
8	the	O
9	HDL	O
10	,	O
11	HDL2	O
12	,	O
13	LDL	O
14	,	O
15	triglycerides	O
16	,	O
17	endothelin	I
18	-	I
19	1	I
20	,	I
21	lipoprotein	O
22	(	O
23	a	O
24	),	O
25	estradiol	O
26	and	O
27	FSH	O
28	were	O
29	also	O
30	obtained	O
31	at	O
32	baseline	O
33	before	O
34	receiving	O
35	ERT	O
36	and	O
37	after	O
38	3	O
39	months	O
40	of	O
41	ERT	O
42	.	O

1	T	O
2	-	O
3	cell	O
4	hybridomas	O
5	,	O
6	thymocytes	O
7	,	O
8	and	O
9	T	O
10	cells	O
11	can	O
12	be	O
13	induced	O
14	to	O
15	undergo	O
16	apoptotic	O
17	cell	O
18	death	O
19	by	O
20	activation	O
21	through	O
22	the	B
23	T	I
24	-	I
25	cell	I
26	receptor	I
27	.	I

1	This	O
2	inhibition	O
3	can	O
4	be	O
5	overcome	O
6	by	O
7	mutating	O
8	either	O
9	the	O
10	exon	O
11	'	O
12	s	O
13	5	O
14	'	O
15	or	O
16	3	O
17	'	O
18	splice	O
19	site	O
20	to	O
21	make	O
22	it	O
23	correspond	O
24	more	O
25	closely	O
26	to	O
27	the	O
28	relevant	O
29	consensus	O
30	sequence	O
31	.	O

1	CONCLUSIONS	O
2	:	O
3	XCoe2	O
4	may	O
5	play	O
6	a	O
7	pivotal	O
8	role	O
9	in	O
10	the	O
11	transcriptional	O
12	cascade	O
13	that	O
14	specifies	O
15	primary	O
16	neurons	O
17	in	O
18	Xenopus	O
19	embryos	O
20	:	O
21	by	O
22	maintaining	O
23	Delta	O
24	-	O
25	Notch	O
26	signalling	O
27	,	O
28	XCoe2	O
29	stabilises	O
30	the	O
31	higher	O
32	neural	O
33	potential	O
34	of	O
35	selected	O
36	progenitor	O
37	cells	O
38	that	O
39	express	O
40	X	O
41	-	O
42	ngnr	I
43	-	I
44	1	O
45	,	O
46	ensuring	O
47	the	O
48	transition	O
49	between	O
50	neural	O
51	competence	O
52	and	O
53	irreversible	O
54	commitment	O
55	to	O
56	a	O
57	neural	O
58	fate	O
59	;	O
60	and	O
61	it	O
62	promotes	O
63	neuronal	O
64	differentiation	O
65	by	O
66	activating	O
67	XNeuroD	O
68	expression	O
69	,	O
70	directly	O
71	or	O
72	indirectly	O
73	.	O

1	These	O
2	results	O
3	suggest	O
4	that	B
5	Rho1p	O
6	regulates	O
7	cytoskeletal	O
8	reorganization	O
9	at	O
10	least	O
11	through	B
12	Bni1p	O
13	and	B
14	Pkc1p	I
15	.	I

1	Recombinant	O
2	Leishmania	O
3	surface	O
4	glycoprotein	O
5	GP63	O
6	is	O
7	secreted	O
8	in	O
9	the	O
10	baculovirus	O
11	expression	O
12	system	O
13	as	O
14	a	O
15	latent	O
16	metalloproteinase	I
17	.	I

1	Deletion	O
2	of	O
3	both	B
4	prfA	O
5	and	O
6	ponA	O
7	resulted	O
8	in	O
9	extremely	O
10	slow	O
11	growth	O
12	and	O
13	a	O
14	reduction	O
15	in	O
16	sporulation	O
17	efficiency	O
18	.	O

1	Within	O
2	their	O
3	polypeptide	O
4	chain	O
5	,	O
6	they	O
7	all	O
8	contain	O
9	those	O
10	conserved	O
11	features	O
12	that	O
13	define	O
14	a	O
15	plant	B
16	CDPK	I
17	;	I
18	kinase	O
19	catalytic	O
20	sequences	O
21	are	O
22	linked	O
23	to	O
24	a	O
25	calmodulin	I
26	-	I
27	like	I
28	regulatory	I
29	domain	O
30	through	O
31	a	O
32	junction	O
33	region	O
34	.	O

1	Transcriptional	O
2	activation	O
3	by	O
4	the	B
5	HIV	I
6	-	I
7	1	I
8	Tat	I
9	protein	O
10	requires	O
11	specific	O
12	residues	O
13	in	O
14	the	O
15	hexanucleotide	O
16	loop	O
17	and	O
18	trinucleotide	O
19	bulge	O
20	of	O
21	the	O
22	TAR	O
23	RNA	O
24	stem	O
25	-	O
26	loop	O
27	structure	O
28	found	O
29	in	O
30	the	O
31	5	O
32	'-	O
33	untranslated	O
34	leader	O
35	of	O
36	all	O
37	viral	O
38	transcripts	O
39	.	O

1	The	O
2	pharmacokinetic	O
3	parameters	O
4	which	O
5	helped	O
6	predict	O
7	these	O
8	toxicities	O
9	included	O
10	area	O
11	under	O
12	the	O
13	curve	O
14	and	O
15	peak	O
16	plasma	O
17	level	O
18	.	O

1	DNA	O
2	-	B
3	STAT	I
4	complexes	O
5	were	O
6	detected	O
7	in	O
8	all	B
9	Bcr	I
10	/	I
11	Abl	I
12	-	O
13	transformed	O
14	cell	O
15	lines	O
16	and	O
17	they	O
18	were	O
19	supershifted	O
20	by	O
21	antibodies	O
22	against	B
23	STAT1	I
24	and	I
25	STAT5	I
26	.	I

1	Type	O
2	2	O
3	genomes	O
4	containing	O
5	this	O
6	sequence	O
7	presumably	O
8	more	O
9	closely	O
10	reflect	O
11	the	O
12	structure	O
13	of	O
14	the	O
15	infectious	O
16	,	O
17	replication	O
18	-	O
19	competent	O
20	retrovirus	O
21	ancestors	O
22	of	O
23	the	O
24	HERV	I
25	-	I
26	K	I
27	family	O
28	than	O
29	do	O
30	type	O
31	1	O
32	genomes	O
33	that	O
34	lack	O
35	the	O
36	sequence	O
37	.	O

1	Amisulpride	O
2	400	O
3	mg	O
4	had	O
5	several	O
6	adverse	O
7	effects	O
8	on	O
9	psychomotor	O
10	and	O
11	,	O
12	although	O
13	less	O
14	severe	O
15	,	O
16	on	O
17	cognitive	O
18	performance	O
19	on	O
20	the	O
21	fifth	O
22	day	O
23	only	O
24	.	O

1	The	O
2	VirR	O
3	response	O
4	regulator	O
5	from	O
6	Clostridium	O
7	perfringens	O
8	binds	O
9	independently	O
10	to	O
11	two	O
12	imperfect	O
13	direct	O
14	repeats	O
15	located	O
16	upstream	O
17	of	O
18	the	B
19	pfoA	I
20	promoter	I
21	.	I

1	The	O
2	transcriptional	O
3	unit	O
4	spans	O
5	a	O
6	chromosomal	O
7	region	O
8	of	O
9	about	O
10	55	O
11	kilobase	O
12	pairs	O
13	(	O
14	kbp	O
15	).	O

1	Gene	O
2	expression	O
3	occurs	O
4	in	O
5	a	O
6	circadian	O
7	rhythm	O
8	and	O
9	induced	O
10	by	O
11	light	O
12	in	O
13	leaves	O
14	of	O
15	dark	O
16	-	O
17	adapted	O
18	plants	O
19	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	patients	O
6	with	O
7	IS	O
8	,	O
9	67	O
10	%	O
11	had	O
12	significantly	O
13	greater	O
14	values	O
15	of	O
16	directional	O
17	preponderance	O
18	on	O
19	the	O
20	OVAR	O
21	test	O
22	(	O
23	a	O
24	measure	O
25	of	O
26	otolith	O
27	system	O
28	imbalance	O
29	)	O
30	compared	O
31	with	O
32	control	O
33	subjects	O
34	.	O

1	Airflow	O
2	through	O
3	the	O
4	dust	O
5	trap	O
6	was	O
7	controlled	O
8	with	O
9	a	O
10	vacuum	O
11	pump	O
12	.	O

1	Although	O
2	there	O
3	is	O
4	little	O
5	evidence	O
6	that	O
7	diet	O
8	composition	O
9	plays	O
10	a	O
11	clinically	O
12	important	O
13	role	O
14	in	O
15	the	O
16	absorption	O
17	or	O
18	expenditure	O
19	of	O
20	energy	O
21	,	O
22	it	O
23	does	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	food	O
31	intake	O
32	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	B
9	human	B
10	DSG3	I
11	gene	O
12	and	O
13	examined	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	its	O
19	expression	O
20	.	O

1	A	O
2	developmentally	O
3	regulated	O
4	4	O
5	.	O
6	6	O
7	kb	O
8	mRNA	O
9	is	O
10	recognized	O
11	on	O
12	Northern	O
13	blots	O
14	of	O
15	oocyte	O
16	RNA	O
17	using	O
18	the	O
19	X	O
20	.	O
21	laevis	O
22	cDNA	O
23	.	O

1	We	O
2	used	O
3	oligonucleotide	O
4	-	O
5	directed	O
6	mutagenesis	O
7	to	O
8	alter	O
9	a	O
10	site	O
11	in	O
12	MucA	O
13	homologous	O
14	to	O
15	the	O
16	Ala	O
17	-	O
18	Gly	O
19	cleavage	O
20	site	O
21	of	O
22	LexA	O
23	.	O

1	Induction	O
2	of	O
3	CD86	O
4	expression	O
5	by	O
6	stimulation	O
7	of	O
8	U937	O
9	cells	O
10	with	B
11	IFN	I
12	-	I
13	gamma	O
14	revealed	O
15	the	O
16	presence	O
17	of	O
18	two	O
19	functional	O
20	GAS	O
21	(	B
22	gamma	I
23	-	I
24	interferon	I
25	activation	I
26	site	I
27	)	I
28	elements	I
29	.	I

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	gene	O
9	has	O
10	significant	O
11	homology	O
12	to	O
13	the	B
14	interferon	I
15	regulatory	I
16	factors	O
17	(	O
18	IRFs	O
19	).	O

1	Four	O
2	full	O
3	-	O
4	thickness	O
5	skin	O
6	incisions	O
7	were	O
8	made	O
9	in	O
10	the	O
11	back	O
12	of	O
13	10	O
14	female	O
15	pigs	O
16	that	O
17	treated	O
18	twice	O
19	a	O
20	day	O
21	for	O
22	14	O
23	days	O
24	with	O
25	2	O
26	ml	O
27	of	B
28	epidermal	I
29	growth	I
30	factor	O
31	(	O
32	300	O
33	ng	O
34	/	O
35	ml	O
36	)	O
37	or	O
38	2	O
39	ml	O
40	of	O
41	Ringer	O
42	'	O
43	s	O
44	lactate	O
45	solution	O
46	in	O
47	a	O
48	single	O
49	-	O
50	blind	O
51	,	O
52	randomized	O
53	fashion	O
54	.	O

1	Exposure	O
2	of	O
3	peripheral	O
4	blood	O
5	T	O
6	cells	O
7	from	O
8	young	O
9	subjects	O
10	to	O
11	PHA	O
12	or	O
13	cross	O
14	-	O
15	linked	B
16	anti	I
17	-	I
18	CD3	I
19	monoclonal	O
20	antibodies	O
21	stimulated	O
22	rapid	O
23	increases	O
24	in	O
25	MAPK	O
26	and	O
27	MEK	O
28	enzymatic	O
29	activity	O
30	.	O

1	A	O
2	DNA	O
3	motif	O
4	related	O
5	to	O
6	the	O
7	cAMP	O
8	-	O
9	responsive	O
10	element	O
11	and	O
12	an	O
13	exon	O
14	-	O
15	located	B
16	activator	I
17	protein	I
18	-	I
19	2	I
20	binding	I
21	site	O
22	in	O
23	the	B
24	human	B
25	tissue	I
26	-	I
27	type	I
28	plasminogen	I
29	activator	I
30	gene	I
31	promoter	O
32	cooperate	O
33	in	O
34	basal	O
35	expression	O
36	and	O
37	convey	O
38	activation	O
39	by	O
40	phorbol	O
41	ester	O
42	and	O
43	cAMP	O
44	.	O

1	Furthermore	O
2	,	O
3	competitor	O
4	containing	O
5	the	O
6	YY1	O
7	consensus	O
8	sequence	O
9	competed	O
10	for	O
11	protein	O
12	B	O
13	binding	O
14	,	O
15	whereas	O
16	competitor	O
17	containing	O
18	a	O
19	perfect	B
20	yeast	B
21	ABF	I
22	-	I
23	1	O
24	consensus	O
25	sequence	O
26	did	O
27	not	O
28	.(	O
29	ABSTRACT	O
30	TRUNCATED	O
31	AT	O
32	400	O
33	WORDS	O
34	)	O

1	We	O
2	couldn	O
3	'	O
4	t	O
5	detect	O
6	any	O
7	effect	O
8	of	O
9	n	O
10	-	O
11	3	O
12	FA	O
13	supplementation	O
14	on	O
15	total	O
16	cholesterol	O
17	,	O
18	HDL	O
19	cholesterol	O
20	,	O
21	LDL	O
22	cholesterol	O
23	,	B
24	apo	B
25	A1	O
26	,	O
27	Lp	O
28	(	O
29	a	O
30	),	B
31	HbA1C	O
32	,	O
33	glucose	O
34	,	B
35	fibrinogen	I
36	,	I
37	factor	I
38	VIII	O
39	,	B
40	antithrombin	I
41	III	I
42	,	I
43	plasminogen	I
44	activator	I
45	inhibitor	I
46	,	I
47	tissue	I
48	plasminogen	I
49	activator	I
50	and	I
51	von	I
52	Willebrand	I
53	factor	O
54	concentration	O
55	,	O
56	on	O
57	bleeding	O
58	time	O
59	or	O
60	on	O
61	systolic	O
62	or	O
63	diastolic	O
64	blood	O
65	pressure	O
66	.	O

1	ACTH	O
2	release	O
3	is	O
4	transiently	O
5	suppressed	O
6	in	O
7	some	O
8	children	O
9	after	O
10	exogenous	O
11	ACTH	O
12	treatment	O
13	.	O

1	METHOD	O
2	:	O
3	50	O
4	consecutive	O
5	children	O
6	aged	O
7	from	O
8	6	O
9	months	O
10	to	O
11	17	O
12	years	O
13	were	O
14	included	O
15	into	O
16	the	O
17	study	O
18	which	O
19	comprised	O
20	questionnaires	O
21	of	O
22	patient	O
23	and	O
24	family	O
25	histories	O
26	,	O
27	serological	O
28	screening	O
29	tests	O
30	for	O
31	common	O
32	inhalational	O
33	allergens	O
34	(	O
35	CAP	O
36	SX1	O
37	),	O
38	and	O
39	determination	O
40	of	O
41	total	B
42	serum	I
43	immunoglobulin	I
44	E	I
45	(	I
46	IgE	O
47	)	O
48	and	O
49	of	O
50	latex	O
51	-	O
52	specific	B
53	serum	B
54	IgE	O
55	by	O
56	solid	O
57	-	O
58	phase	O
59	immunoassays	O
60	.	O

1	During	O
2	this	O
3	time	O
4	,	O
5	the	O
6	patients	O
7	all	O
8	had	O
9	the	O
10	characteristic	O
11	plasma	O
12	thyroid	O
13	hormone	O
14	changes	O
15	associated	O
16	with	O
17	amiodarone	O
18	therapy	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	increased	O
25	T4	O
26	,	O
27	free	O
28	T4	O
29	,	O
30	and	O
31	rT3	O
32	and	O
33	decreased	O
34	T3	O
35	,	O
36	while	O
37	remaining	O
38	clinically	O
39	euthyroid	O
40	.	O

1	The	O
2	ability	O
3	of	O
4	SMRT	O
5	to	O
6	associate	O
7	with	O
8	these	O
9	transcription	O
10	factors	O
11	and	O
12	thereby	O
13	to	O
14	mediate	O
15	repression	O
16	is	O
17	strongly	O
18	inhibited	O
19	by	O
20	activation	O
21	of	B
22	tyrosine	I
23	kinase	O
24	signaling	O
25	pathways	O
26	,	O
27	such	O
28	as	O
29	that	O
30	represented	O
31	by	O
32	the	B
33	epidermal	I
34	growth	I
35	factor	I
36	receptor	I
37	.	I

1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	responses	O
5	are	O
6	impaired	O
7	in	O
8	heart	O
9	failure	O
10	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	HAPE	O
6	-	O
7	S	O
8	-	O
9	S	O
10	are	O
11	prone	O
12	to	O
13	irregular	O
14	nocturnal	O
15	breathing	O
16	patterns	O
17	at	O
18	high	O
19	altitude	O
20	,	O
21	which	O
22	is	O
23	associated	O
24	with	O
25	the	O
26	development	O
27	of	O
28	AMS	O
29	,	O
30	but	O
31	it	O
32	was	O
33	not	O
34	possible	O
35	to	O
36	determine	O
37	whether	O
38	these	O
39	abnormal	O
40	breathing	O
41	patterns	O
42	are	O
43	a	O
44	cause	O
45	or	O
46	an	O
47	effect	O
48	of	O
49	AMS	O
50	.	O

1	Recombinant	O
2	AROM	O
3	-	B
4	p64	O
5	displayed	O
6	high	O
7	binding	O
8	to	O
9	single	O
10	-	O
11	stranded	O
12	DNA	O
13	and	O
14	poly	O
15	(	O
16	A	O
17	)	O
18	homopolymers	O
19	suggesting	O
20	that	O
21	this	O
22	protein	O
23	could	O
24	play	O
25	a	O
26	role	O
27	in	O
28	mRNA	O
29	maturation	O
30	/	O
31	metabolism	O
32	.	O

1	The	O
2	number	O
3	of	O
4	lactotropes	O
5	,	O
6	somatotropes	O
7	,	O
8	thyrotropes	O
9	,	O
10	and	O
11	gonadotropes	O
12	was	O
13	not	O
14	altered	O
15	compared	O
16	with	O
17	controls	O
18	,	O
19	indicating	O
20	that	O
21	in	O
22	the	O
23	adult	O
24	pituitary	O
25	,	O
26	POMC	O
27	products	O
28	are	O
29	not	O
30	required	O
31	to	O
32	maintain	O
33	the	O
34	distribution	O
35	of	O
36	cell	O
37	types	O
38	.	O

1	Within	O
2	Stage	O
3	IA	O
4	,	O
5	141	O
6	patients	O
7	had	O
8	well	O
9	differentiated	O
10	tumor	O
11	(	O
12	G1	O
13	),	O
14	20	O
15	had	O
16	moderately	O
17	well	O
18	differentiated	O
19	tumor	O
20	(	O
21	G2	O
22	),	O
23	and	O
24	12	O
25	patients	O
26	had	O
27	poorly	O
28	differentiated	O
29	(	O
30	G3	O
31	).	O

1	Splice	O
2	-	O
3	junction	O
4	elements	O
5	and	O
6	intronic	O
7	sequences	O
8	regulate	O
9	alternative	O
10	splicing	O
11	of	O
12	the	B
13	Drosophila	B
14	myosin	I
15	heavy	I
16	chain	I
17	gene	I
18	transcript	I
19	.	I

1	However	O
2	,	O
3	essential	O
4	contrast	O
5	differences	O
6	existing	O
7	between	O
8	the	O
9	FSE	O
10	sequences	O
11	and	O
12	their	O
13	routine	O
14	asymmetric	O
15	dual	O
16	SE	O
17	counterpart	O
18	can	O
19	be	O
20	identified	O
21	.	O

1	A	O
2	mutant	O
3	(	O
4	residues	O
5	1	O
6	-	O
7	332	O
8	)	O
9	showed	O
10	complete	B
11	Ca2	I
12	+/	I
13	CaM	I
14	-	I
15	dependent	O
16	activity	O
17	.	O

1	After	O
2	that	O
3	report	O
4	,	B
5	carboxypeptidase	O
6	D	O
7	(	O
8	CPD	O
9	)	O
10	was	O
11	subsequently	O
12	purified	O
13	from	O
14	bovine	O
15	pituitary	O
16	and	O
17	characterized	O
18	as	O
19	a	O
20	novel	B
21	carboxypeptidase	I
22	E	I
23	(	I
24	CPE	I
25	)-	I
26	like	I
27	enzyme	O
28	,	O
29	with	O
30	many	O
31	characteristics	O
32	in	O
33	common	O
34	with	B
35	duck	B
36	gp180	O
37	(	O
38	Song	O
39	,	O
40	L	O
41	.,	O
42	Fricker	O
43	,	O
44	L	O
45	.	O
46	D	O
47	.,	O
48	1995	O
49	.	O

1	Focused	O
2	beams	O
3	of	O
4	classical	O
5	light	O
6	ablate	O
7	elements	O
8	of	O
9	the	O
10	cell	O
11	division	O
12	machinery	O
13	and	O
14	switch	O
15	the	O
16	beating	O
17	of	O
18	hearts	O
19	on	O
20	a	O
21	cellular	O
22	basis	O
23	.	O

1	Resources	O
2	for	O
3	helping	O
4	patients	O
5	to	O
6	quit	O
7	smoking	O
8	.	O

1	Possibly	O
2	,	O
3	the	B
4	scr1	I
5	-	I
6	1	I
7	mutation	O
8	does	O
9	not	O
10	affect	O
11	signal	O
12	recognition	O
13	or	O
14	translational	O
15	arrest	O
16	but	O
17	instead	O
18	results	O
19	in	O
20	maintenance	O
21	of	O
22	translational	O
23	arrest	O
24	of	O
25	AEP	O
26	synthesis	O
27	.	O

1	The	O
2	Saccharomyces	O
3	cerevisiae	O
4	spindle	O
5	pole	O
6	body	O
7	duplication	I
8	gene	I
9	MPS1	O
10	is	O
11	part	O
12	of	O
13	a	O
14	mitotic	O
15	checkpoint	O
16	.	O

1	In	O
2	contrast	O
3	,	O
4	Y239	O
5	/	O
6	240F	B
7	Shc	O
8	,	O
9	but	O
10	not	O
11	Y317F	B
12	Shc	O
13	,	O
14	reduced	O
15	the	B
16	EGF	I
17	-	I
18	induced	I
19	c	I
20	-	I
21	myc	I
22	message	I
23	.	I

1	Flap	O
2	survival	O
3	depends	O
4	on	O
5	the	O
6	development	O
7	of	O
8	a	O
9	small	O
10	number	O
11	of	O
12	vascular	O
13	connections	O
14	between	O
15	vessels	O
16	arising	O
17	from	O
18	the	O
19	pedicle	O
20	and	O
21	preexisting	O
22	dermal	O
23	vessels	O
24	.	O

1	The	O
2	risk	O
3	factors	O
4	studied	O
5	were	O
6	male	O
7	sex	O
8	,	O
9	hypertension	O
10	,	O
11	diabetes	O
12	mellitus	O
13	,	O
14	hypercholesterolemia	O
15	,	O
16	cigarette	O
17	smoking	O
18	,	O
19	sedentary	O
20	life	O
21	-	O
22	style	O
23	,	O
24	and	O
25	family	O
26	history	O
27	.	O

1	Furthermore	O
2	,	O
3	we	O
4	notice	O
5	two	O
6	potential	O
7	consensus	O
8	motifs	O
9	which	O
10	are	O
11	also	O
12	found	O
13	in	O
14	corresponding	O
15	positions	O
16	in	O
17	the	O
18	genes	O
19	for	O
20	the	B
21	nerve	I
22	growth	I
23	factor	I
24	receptor	O
25	and	O
26	the	O
27	68	O
28	-	O
29	kDa	O
30	neurofilament	O
31	protein	O
32	.	O

1	Pharmacokinetic	O
2	profile	O
3	of	O
4	clonazepam	O
5	in	O
6	rhesus	O
7	monkeys	O
8	.	O

1	Release	O
2	of	O
3	this	O
4	selective	O
5	pressure	O
6	,	O
7	however	O
8	,	O
9	gave	O
10	way	O
11	to	O
12	homologous	O
13	resolution	O
14	of	O
15	the	O
16	cointegrate	O
17	structures	O
18	.	O

1	In	O
2	these	O
3	vectors	O
4	the	O
5	chimeric	O
6	long	O
7	terminal	O
8	repeat	O
9	(	O
10	chLTR	O
11	)	O
12	drives	O
13	the	O
14	expression	O
15	of	O
16	the	B
17	chloramphenicol	I
18	acetyl	I
19	transferase	I
20	(	I
21	CAT	I
22	)	I
23	reporter	I
24	gene	O
25	that	O
26	is	O
27	followed	O
28	by	O
29	an	O
30	internal	O
31	SV40	O
32	virus	O
33	early	O
34	region	O
35	promoter	O
36	linked	O
37	to	O
38	the	O
39	neomycin	I
40	phosphotransferase	I
41	II	I
42	(	I
43	NEO	I
44	)	I
45	gene	I
46	.	I

1	A	O
2	population	O
3	pharmacokinetic	O
4	study	O
5	of	O
6	cyclosporin	O
7	in	O
8	organ	O
9	transplant	O
10	patients	O
11	,	O
12	including	O
13	elderly	O
14	allograft	O
15	recipients	O
16	up	O
17	to	O
18	75	O
19	years	O
20	of	O
21	age	O
22	,	O
23	did	O
24	not	O
25	identify	O
26	age	O
27	as	O
28	a	O
29	covariable	O
30	influencing	O
31	cyclosporin	O
32	pharmacokinetics	O
33	.	O

1	Comparison	O
2	with	O
3	a	O
4	recently	O
5	described	O
6	c	O
7	-	O
8	sis	O
9	cDNA	O
10	clone	O
11	(	O
12	Collins	O
13	et	O
14	al	O
15	.,	O
16	Nature	O
17	316	O
18	,	O
19	748	O
20	-	O
21	750	O
22	(	O
23	1985	O
24	))	O
25	revealed	O
26	that	O
27	the	O
28	1	O
29	.	O
30	9	O
31	kbp	O
32	DNA	O
33	region	O
34	contained	O
35	a	O
36	large	O
37	5	O
38	'	O
39	c	O
40	-	O
41	sis	O
42	exon	O
43	of	O
44	at	O
45	least	O
46	1050	O
47	bp	O
48	.	O

1	Treatment	O
2	with	O
3	amphotericin	O
4	B	O
5	and	O
6	flucytosine	O
7	led	O
8	to	O
9	improvement	O
10	of	O
11	the	O
12	symptoms	O
13	but	O
14	did	O
15	not	O
16	eradicate	O
17	the	O
18	micro	O
19	-	O
20	organisms	O
21	from	O
22	the	O
23	cerebrospinal	O
24	fluid	O
25	(	O
26	CSF	O
27	).	O

1	Samples	O
2	from	O
3	1415	O
4	neurological	O
5	patients	O
6	were	O
7	used	O
8	to	O
9	study	O
10	the	O
11	diagnostic	O
12	value	O
13	of	O
14	acid	B
15	alpha	I
16	1	I
17	-	I
18	glycoprotein	O
19	in	O
20	the	O
21	lumbar	O
22	cerebrospinal	O
23	fluid	O
24	.	O

1	YAC	O
2	and	O
3	cosmid	O
4	contigs	O
5	spanning	O
6	the	O
7	Batten	O
8	disease	O
9	(	O
10	CLN3	O
11	)	O
12	region	O
13	at	O
14	16p12	I
15	.	I
16	1	I
17	-	I
18	p11	O
19	.	O
20	2	O
21	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	the	O
6	ubiquitous	O
7	expression	O
8	of	O
9	2	O
10	.	O
11	9	O
12	kb	O
13	and	O
14	3	O
15	.	O

1	Subcutaneous	O
2	administration	O
3	of	O
4	the	B
5	somatostatin	O
6	analogue	O
7	,	O
8	octreotide	O
9	,	O
10	100	O
11	micrograms	O
12	thrice	O
13	daily	O
14	,	O
15	resulted	O
16	in	O
17	a	O
18	sustained	O
19	improvement	O
20	in	O
21	diarrhoea	O
22	and	O
23	disappearance	O
24	of	O
25	faecal	O
26	incontinence	O
27	without	O
28	reducing	B
29	calcitonin	O
30	levels	O
31	.	O

1	Independent	O
2	protrudor	O
3	muscle	O
4	stimulation	O
5	increased	O
6	VI	O
7	,	O
8	max	O
9	(	O
10	peak	O
11	increase	O
12	61	O
13	%,	O
14	P	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	did	O
21	not	O
22	change	O
23	Pcrit	O
24	,	O
25	and	O
26	decreased	O
27	Rn	O
28	(	O
29	peak	O
30	decrease	O
31	of	O
32	41	O
33	%,	O
34	P	O
35	<	O
36	0	O
37	.	O
38	05	O
39	).	O

1	Velocity	O
2	sedimentation	O
3	,	O
4	cross	O
5	-	O
6	linking	O
7	,	O
8	and	O
9	immunoprecipitation	O
10	analyses	O
11	of	O
12	detergent	O
13	-	O
14	solubilized	O
15	rat	O
16	brain	O
17	revealed	O
18	that	O
19	the	O
20	32	O
21	and	O
22	34	O
23	kDa	O
24	polypeptides	O
25	reside	O
26	within	O
27	heterotetramers	O
28	.	O

1	Recent	O
2	application	O
3	of	O
4	recombinant	O
5	canarypox	O
6	ALVAC	O
7	/	O
8	HIV	O
9	-	O
10	1	O
11	vectors	O
12	as	O
13	vaccine	O
14	immunogens	O
15	in	O
16	HIV	O
17	-	O
18	1	O
19	,-	O
20	noninfected	O
21	volunteers	O
22	has	O
23	produced	O
24	CTL	O
25	responses	O
26	in	O
27	a	O
28	significant	O
29	number	O
30	of	O
31	vaccinees	O
32	.	O

1	Staphylococcus	O
2	aureus	O
3	and	O
4	CNS	O
5	showed	O
6	high	O
7	or	O
8	moderate	O
9	resistance	O
10	rates	O
11	to	O
12	methicillin	O
13	(	O
14	DMPPC	O
15	).	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	loss	O
6	of	O
7	MAD2	O
8	staining	O
9	in	O
10	meiosis	O
11	was	O
12	not	O
13	correlated	O
14	with	O
15	initial	O
16	microtubule	O
17	attachment	O
18	but	O
19	was	O
20	correlated	O
21	with	O
22	a	O
23	measure	O
24	of	O
25	tension	O
26	:	O
27	the	O
28	distance	O
29	between	O
30	homologous	O
31	or	O
32	sister	O
33	kinetochores	O
34	(	O
35	in	O
36	meiosis	O
37	I	O
38	and	O
39	II	O
40	,	O
41	respectively	O
42	).	O

1	Results	O
2	from	O
3	transient	O
4	assays	O
5	using	O
6	these	O
7	mutants	O
8	showed	O
9	that	O
10	the	O
11	DE1	O
12	received	O
13	signals	O
14	from	B
15	phytochromes	O
16	A	O
17	and	O
18	B	O
19	,	O
20	demonstrating	O
21	that	O
22	this	O
23	element	O
24	is	O
25	indeed	O
26	a	O
27	light	O
28	-	O
29	responsive	O
30	element	O
31	.	O

1	In	O
2	addition	B
3	serum	B
4	IgE	O
5	concentrations	O
6	were	O
7	not	O
8	statistically	O
9	different	O
10	.	O

1	S6K2	O
2	is	O
3	highly	O
4	homologous	O
5	to	O
6	S6K1	O
7	in	O
8	the	O
9	core	O
10	kinase	O
11	and	O
12	linker	O
13	regulatory	O
14	domains	O
15	but	O
16	differs	O
17	from	O
18	S6K1	O
19	in	O
20	the	O
21	N	O
22	-	O
23	and	O
24	C	O
25	-	O
26	terminal	O
27	regions	O
28	and	O
29	is	O
30	differently	O
31	localized	O
32	primarily	O
33	to	O
34	the	O
35	nucleus	O
36	because	O
37	of	O
38	a	O
39	C	O
40	-	O
41	terminal	O
42	nuclear	O
43	localization	O
44	signal	O
45	unique	O
46	to	O
47	S6K2	I
48	.	I

1	The	O
2	2	O
3	cDNAs	O
4	differed	O
5	in	O
6	the	O
7	length	O
8	of	O
9	their	O
10	respective	O
11	3	O
12	'	O
13	untranslated	O
14	regions	O
15	,	O
16	of	O
17	577	O
18	bp	O
19	in	O
20	Cp	O
21	.	O
22	F6	O
23	and	O
24	72	O
25	bp	O
26	in	O
27	Cp	O
28	.	O
29	F10	O
30	,	O
31	in	O
32	both	O
33	of	O
34	which	O
35	a	O
36	putative	O
37	polyadenylation	O
38	signal	O
39	was	O
40	identified	O
41	.	O

1	To	O
2	determine	O
3	the	O
4	true	O
5	molecular	O
6	identity	O
7	of	O
8	SFD	O
9	,	O
10	both	O
11	the	O
12	50	O
13	-	O
14	and	O
15	57	O
16	-	O
17	kDa	O
18	polypeptides	O
19	were	O
20	directly	O
21	sequenced	O
22	.	O

1	Changes	O
2	following	O
3	periodontal	O
4	surgery	O
5	.	O

1	OODG	O
2	is	O
3	a	O
4	diagnostic	O
5	method	O
6	permitting	O
7	assessment	O
8	of	O
9	ocular	O
10	pulse	O
11	curves	O
12	and	O
13	objective	O
14	determination	O
15	of	O
16	blood	O
17	pressures	O
18	in	O
19	the	O
20	ophthalmic	O
21	circulatory	O
22	system	O
23	(	O
24	retinal	O
25	and	O
26	ciliary	O
27	arterial	O
28	blood	O
29	pressures	O
30	)	O
31	simultaneously	O
32	for	O
33	both	O
34	eyes	O
35	,	O
36	without	O
37	dilatation	O
38	of	O
39	the	O
40	pupils	O
41	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	expression	O
7	of	B
8	Cktsf1b1	O
9	,	O
10	a	O
11	gene	O
12	associated	O
13	with	O
14	early	O
15	development	O
16	and	O
17	cell	O
18	transformation	O
19	,	O
20	is	O
21	sensitive	O
22	to	O
23	MKK	O
24	levels	O
25	and	O
26	may	O
27	be	O
28	regulated	O
29	via	O
30	multiple	O
31	transcription	O
32	factor	O
33	complexes	O
34	.	O

1	Specimens	O
2	were	O
3	assayed	O
4	for	B
5	alpha	I
6	-	I
7	fetoprotein	O
8	,	O
9	unconjugated	O
10	estriol	O
11	,	O
12	free	O
13	alpha	O
14	hCG	O
15	,	O
16	and	O
17	total	O
18	hCG	O
19	.	O

1	Hyaluronan	O
2	treatment	O
3	stimulated	B
4	collagen	O
5	remodeling	O
6	in	O
7	the	O
8	peripheral	O
9	region	O
10	and	O
11	inhibited	O
12	swelling	O
13	of	O
14	the	O
15	meniscus	O
16	repaired	O
17	in	O
18	the	O
19	inner	O
20	region	O
21	.	O

1	Thus	O
2	,	O
3	SAG	O
4	appears	O
5	to	O
6	control	O
7	cell	O
8	cycle	O
9	progression	O
10	in	O
11	yeast	O
12	by	O
13	promoting	O
14	ubiquitination	O
15	and	O
16	degradation	O
17	of	O
18	cell	O
19	cycle	O
20	regulatory	O
21	proteins	O
22	.	O

1	Our	O
2	data	O
3	showed	O
4	that	O
5	activation	O
6	of	O
7	the	B
8	raf	I
9	-	I
10	ERK	O
11	pathway	O
12	led	O
13	to	O
14	activation	O
15	of	O
16	TF	O
17	expression	O
18	in	O
19	breast	O
20	carcinoma	O
21	cells	O
22	and	O
23	suggested	O
24	that	O
25	constitutive	O
26	activation	O
27	of	O
28	this	O
29	pathway	O
30	leads	O
31	to	O
32	high	O
33	TF	O
34	expression	O
35	in	B
36	MDA	I
37	-	I
38	MB	I
39	-	I
40	231	O
41	cells	O
42	.	O

1	After	O
2	i	O
3	.	O
4	v	O
5	.	O

1	Quantitative	O
2	evaluation	O
3	of	O
4	magneto	O
5	-	O
6	optical	O
7	parameters	O
8	is	O
9	necessary	O
10	in	O
11	order	O
12	to	O
13	apply	O
14	scanning	O
15	near	O
16	-	O
17	field	O
18	optical	O
19	microscope	O
20	(	O
21	SNOM	O
22	)	O
23	technology	O
24	to	O
25	the	O
26	study	O
27	of	O
28	magnetism	O
29	on	O
30	the	O
31	mesoscopic	O
32	scale	O
33	.	O

1	Significant	O
2	GMBF	O
3	reductions	O
4	occurred	O
5	in	O
6	early	O
7	shock	O
8	in	O
9	both	O
10	treatment	O
11	groups	O
12	.	O

1	Regulation	O
2	of	O
3	the	B
4	alpha	B
5	inhibin	I
6	gene	O
7	by	O
8	cyclic	O
9	adenosine	O
10	3	O
11	',	O
12	5	O
13	'-	O
14	monophosphate	O
15	after	O
16	transfection	O
17	into	O
18	rat	O
19	granulosa	O
20	cells	O
21	.	O

1	Effect	O
2	of	O
3	indomethacin	O
4	and	O
5	prostaglandin	B
6	F2	I
7	alpha	O
8	on	O
9	parturition	O
10	in	O
11	swine	O
12	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	chromosomal	O
5	segment	O
6	64AB	O
7	,	O
8	a	O
9	region	O
10	containing	O
11	the	B
12	glutamic	I
13	acid	I
14	decarboxylase	I
15	gene	I
16	.	I

1	The	O
2	distribution	O
3	of	O
4	their	B
5	fibrinogen	O
6	levels	O
7	was	O
8	Gaussian	O
9	,	O
10	but	O
11	more	O
12	wide	O
13	-	O
14	based	O
15	than	O
16	the	O
17	distribution	O
18	of	O
19	our	O
20	normal	O
21	controls	O
22	.	O

1	However	O
2	,	O
3	a	O
4	strongly	O
5	increased	O
6	frequency	O
7	of	O
8	CpG	O
9	dinucleotides	O
10	was	O
11	found	O
12	.	O

1	Disruption	O
2	of	O
3	the	B
4	HOG1	I
5	and	I
6	PBS2	I
7	genes	O
8	leads	O
9	to	O
10	a	O
11	dramatic	O
12	decrease	O
13	of	O
14	the	O
15	HSP12	O
16	inducibility	O
17	in	O
18	osmostressed	O
19	cells	O
20	,	O
21	whereas	O
22	overproduction	O
23	of	B
24	Hog1	O
25	produces	O
26	a	O
27	fivefold	O
28	increase	O
29	in	O
30	wild	O
31	-	O
32	type	O
33	induced	O
34	levels	O
35	upon	O
36	a	O
37	shift	O
38	to	O
39	a	O
40	high	O
41	salt	O
42	concentration	O
43	.	O

1	Perceptual	O
2	learning	O
3	for	O
4	a	O
5	pattern	O
6	discrimination	O
7	task	O
8	.	O

1	In	O
2	some	O
3	of	O
4	the	O
5	cases	O
6	of	O
7	solitary	O
8	lesion	O
9	,	O
10	serum	O
11	TSH	O
12	levels	O
13	,	B
14	serum	B
15	thyroglobulin	O
16	values	O
17	,	O
18	and	O
19	131I	I
20	protein	I
21	bounded	I
22	iodine	I
23	(	I
24	131I	I
25	-	I
26	PBI	O
27	)	O
28	were	O
29	measured	O
30	,	O
31	but	O
32	there	O
33	were	O
34	no	O
35	significant	O
36	differences	O
37	between	O
38	successful	O
39	and	O
40	unsuccessful	O
41	therapy	O
42	.	O

1	Is	O
2	desensitization	O
3	'	O
4	for	O
5	ragweed	O
6	hay	O
7	fever	O
8	immunologically	O
9	specific	O
10	?	O

1	Roles	O
2	of	O
3	the	O
4	Candida	O
5	albicans	B
6	mitogen	I
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	homolog	O
12	,	O
13	Cek1p	O
14	,	O
15	in	O
16	hyphal	O
17	development	O
18	and	O
19	systemic	O
20	candidiasis	O
21	.	O

1	Mammalian	O
2	ABPs	O
3	and	O
4	SHBGs	O
5	bind	O
6	sex	O
7	steroids	O
8	with	O
9	high	O
10	affinity	O
11	,	O
12	but	O
13	some	O
14	binding	O
15	properties	O
16	differ	O
17	among	O
18	species	O
19	.	O

1	Effect	O
2	of	O
3	proteolytic	O
4	enzymes	O
5	and	O
6	polypeptides	O
7	on	O
8	the	O
9	antacid	O
10	activity	O
11	of	O
12	almagate	O
13	and	O
14	other	O
15	antacids	O
16	.	O

1	D	O
2	.	O
3	melanogaster	O
4	HeT	O
5	-	O
6	A	O
7	coding	O
8	sequences	O
9	have	O
10	a	O
11	polymorphic	O
12	region	O
13	with	O
14	insertions	O
15	/	O
16	deletions	O
17	of	O
18	1	O
19	-	O
20	31	O
21	codons	O
22	and	O
23	many	O
24	nucleotide	O
25	changes	O
26	.	O

1	The	B
2	Rlm1	I
3	protein	O
4	,	O
5	a	O
6	member	O
7	of	O
8	the	O
9	MADS	O
10	box	O
11	family	O
12	of	O
13	transcription	O
14	factors	O
15	,	O
16	functions	O
17	downstream	O
18	of	O
19	Mpk1	O
20	in	O
21	the	O
22	pathway	O
23	.	O

1	A	O
2	statistically	O
3	significant	O
4	improvement	O
5	due	O
6	to	O
7	the	O
8	administration	O
9	of	O
10	Bromergon	O
11	was	O
12	observed	O
13	in	O
14	symptoms	O
15	associated	O
16	with	O
17	overreactiveness	O
18	to	O
19	normal	B
20	prolactin	O
21	levels	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	abdominal	O
28	tension	O
29	,	O
30	edema	O
31	,	O
32	weight	O
33	gain	O
34	and	O
35	breast	O
36	tenderness	O
37	.	O

1	Increasing	O
2	the	O
3	phosphorus	O
4	content	O
5	of	O
6	the	O
7	diet	O
8	improved	O
9	the	O
10	reabsorption	O
11	of	O
12	calcium	O
13	and	O
14	magnesium	O
15	.	O

1	Wave	O
2	cybernetics	O
3	:	O
4	A	O
5	simple	O
6	model	O
7	of	O
8	wave	O
9	-	O
10	controlled	O
11	nonlinear	O
12	and	O
13	nonlocal	O
14	cooperative	O
15	phenomena	O
16	.	O

1	The	O
2	U17	O
3	/	O
4	U16	O
5	and	O
6	the	B
7	U16	I
8	+	I
9	gene	I
10	products	I
11	transactivated	O
12	the	O
13	HIV	O
14	LTR	O
15	.	O

1	The	O
2	transforming	O
3	gene	O
4	of	O
5	the	O
6	avian	O
7	sarcoma	O
8	virus	O
9	CT10	O
10	encodes	O
11	a	O
12	fusion	O
13	protein	O
14	(	B
15	p47gag	I
16	-	I
17	crk	I
18	or	I
19	v	I
20	-	I
21	Crk	O
22	)	O
23	containing	O
24	viral	O
25	Gag	O
26	sequences	O
27	fused	O
28	to	O
29	cellular	O
30	sequences	O
31	consisting	O
32	primarily	O
33	of	B
34	Src	I
35	homology	I
36	regions	I
37	2	I
38	and	I
39	3	I
40	(	I
41	SH2	I
42	and	I
43	SH3	I
44	sequences	O
45	).	O

1	The	B
2	euglobulin	O
3	clot	O
4	lysis	O
5	time	O
6	was	O
7	slightly	O
8	longer	O
9	in	O
10	the	O
11	smokers	O
12	than	O
13	in	O
14	the	O
15	non	O
16	-	O
17	smokers	O
18	in	O
19	all	O
20	three	O
21	experimental	O
22	situations	O
23	,	O
24	but	O
25	the	O
26	differences	O
27	were	O
28	not	O
29	significant	O
30	.	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	predicted	O
8	RfbA	O
9	and	O
10	RfbB	O
11	homologs	O
12	showed	O
13	identities	O
14	of	O
15	75	O
16	.	O
17	7	O
18	%	O
19	(	O
20	87	O
21	.	O
22	9	O
23	%	O
24	total	O
25	similarity	O
26	)	O
27	and	O
28	78	O
29	.	O
30	0	O
31	%	O
32	(	O
33	86	O
34	.	O
35	5	O
36	%	O
37	total	O
38	similarity	O
39	),	O
40	respectively	O
41	.	O

1	Histamine	O
2	reactivity	O
3	was	O
4	significantly	O
5	reduced	O
6	after	O
7	the	O
8	nifedipine	O
9	aerosol	O
10	,	O
11	the	O
12	geometric	O
13	mean	O
14	provocative	O
15	concentration	O
16	causing	O
17	a	O
18	35	O
19	%	O
20	fall	O
21	in	O
22	specific	O
23	airway	O
24	conductance	O
25	,	O
26	rising	O
27	from	O
28	5	O
29	.	O
30	0	O
31	to	O
32	10	O
33	.	O
34	9	O
35	mg	O
36	/	O
37	ml	O
38	of	O
39	histamine	O
40	(	O
41	p	O
42	less	O
43	than	O
44	0	O
45	.	O
46	05	O
47	).	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	used	O
7	footprinting	O
8	and	O
9	gel	O
10	mobility	O
11	retardation	O
12	assays	O
13	to	O
14	reveal	O
15	that	O
16	bacterially	O
17	synthesized	B
18	Zta	I
19	fusion	I
20	proteins	O
21	bound	O
22	directly	O
23	to	O
24	six	B
25	TGTGCAA	I
26	-	I
27	like	O
28	motifs	O
29	within	O
30	DSL	O
31	.	O

1	Ketanserin	O
2	,	O
3	a	O
4	hypotensive	O
5	drug	O
6	with	B
7	5	I
8	-	I
9	HT2	I
10	receptor	O
11	antagonism	O
12	,	O
13	when	O
14	administered	O
15	by	O
16	topical	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	w	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	corneal	O
30	and	O
31	scleral	O
32	applications	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	intraocular	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	metabolite	O
48	,	O
49	ketanserinol	O
50	.	O

1	Platelet	O
2	function	O
3	and	O
4	platelet	O
5	-	O
6	polymorphonuclear	O
7	-	O
8	neutrophil	O
9	interaction	O
10	in	O
11	patients	O
12	with	O
13	deficient	B
14	platelet	I
15	lipoxygenase	O
16	activity	O
17	.	O

1	Technique	O
2	for	O
3	obtaining	O
4	refined	O
5	ceramics	O
6	with	O
7	dense	O
8	mass	O

1	Nevertheless	O
2	,	O
3	inactivation	O
4	of	O
5	the	B
6	cyclin	I
7	E	I
8	-	I
9	Cdk2	I
10	complex	O
11	in	O
12	response	O
13	to	O
14	mitogen	O
15	starvation	O
16	occurs	O
17	normally	O
18	in	O
19	MEFs	O
20	that	O
21	have	O
22	a	O
23	homozygous	O
24	deletion	O
25	of	O
26	the	B
27	p27	I
28	gene	I
29	.	I

1	G	O
2	-	O
3	box	O
4	-	O
5	directed	O
6	expression	O
7	in	O
8	leaves	O
9	required	O
10	the	O
11	presence	O
12	of	O
13	an	O
14	enhancer	O
15	region	O
16	from	O
17	the	O
18	cauliflower	O
19	mosaic	O
20	virus	O
21	(	O
22	CaMV	O
23	)	O
24	35S	O
25	promoter	O
26	.	O

1	The	O
2	bovine	O
3	papillomavirus	O
4	E2	O
5	protein	O
6	can	O
7	inhibit	O
8	the	O
9	proliferation	O
10	of	O
11	HT	O
12	-	O
13	3	O
14	cells	O
15	,	O
16	a	B
17	p53	I
18	-	O
19	negative	O
20	cervical	O
21	carcinoma	O
22	cell	O
23	line	O
24	containing	O
25	integrated	O
26	human	O
27	papillomavirus	O
28	type	O
29	30	O
30	DNA	O
31	.	O

1	Despite	O
2	the	O
3	absence	O
4	of	O
5	exercise	O
6	-	O
7	induced	O
8	asthma	O
9	(	O
10	EIA	O
11	)	O
12	while	O
13	breathing	O
14	WH	O
15	air	O
16	,	O
17	asthmatic	O
18	patients	O
19	still	O
20	had	O
21	significantly	O
22	higher	O
23	mean	O
24	GH	O
25	increments	O
26	than	O
27	normal	O
28	subjects	O
29	(	O
30	9	O
31	.	O
32	2	O
33	vs	O
34	2	O
35	.	O
36	3	O
37	ng	O
38	/	O
39	ml	O
40	,	O
41	P	O
42	less	O
43	than	O
44	0	O
45	.	O
46	05	O
47	).	O

1	In	O
2	comparison	O
3	with	O
4	normal	O
5	pregnant	O
6	women	O
7	and	O
8	normal	O
9	non	O
10	-	O
11	pregnant	O
12	women	O
13	,	O
14	women	O
15	with	O
16	PIH	O
17	showed	O
18	an	O
19	increase	O
20	in	O
21	heart	O
22	rate	O
23	,	O
24	suggesting	O
25	an	O
26	increased	O
27	peripheral	O
28	sympathetic	O
29	tone	O
30	,	O
31	and	O
32	an	O
33	initial	O
34	derangement	O
35	in	O
36	renal	O
37	function	O
38	as	O
39	shown	O
40	by	O
41	the	O
42	increase	O
43	in	O
44	serum	O
45	uric	O
46	acid	O
47	and	O
48	reduction	O
49	in	O
50	sodium	O
51	excretion	O
52	and	O
53	total	O
54	and	O
55	fractional	O
56	calcium	O
57	excretion	O
58	at	O
59	any	O
60	given	O
61	level	O
62	of	O
63	sodium	O
64	excretion	O
65	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	identification	O
6	and	O
7	characterization	O
8	of	O
9	several	O
10	Sp100	O
11	splice	O
12	variant	O
13	proteins	O
14	and	O
15	support	O
16	their	O
17	existence	O
18	by	O
19	elucidation	O
20	of	O
21	the	O
22	3	O
23	'-	O
24	end	O
25	of	O
26	the	O
27	Sp100	O
28	gene	O
29	.	O

1	JNK	O
2	is	O
3	additionally	O
4	regulated	O
5	by	O
6	the	B
7	Ras	I
8	-	I
9	related	I
10	G	I
11	proteins	I
12	Rac	O
13	and	B
14	Cdc42	I
15	.	I

1	This	O
2	negative	O
3	element	O
4	may	O
5	,	O
6	at	O
7	least	O
8	in	O
9	part	O
10	,	O
11	be	O
12	responsible	O
13	for	O
14	the	O
15	cell	O
16	type	O
17	-	O
18	specific	O
19	expression	O
20	of	O
21	the	B
22	DGK	I
23	gene	I
24	.	I

1	Altogether	O
2	these	O
3	results	O
4	suggest	O
5	that	O
6	,	O
7	in	O
8	KG1a	O
9	cells	O
10	,	O
11	TNFalpha	O
12	can	O
13	stimulate	O
14	in	O
15	parallel	O
16	PC	O
17	-	O
18	PLC	O
19	and	O
20	PLD	O
21	,	O
22	whose	O
23	lipid	O
24	products	O
25	activate	O
26	in	O
27	turn	B
28	mitogen	I
29	-	I
30	activated	I
31	protein	I
32	kinase	I
33	(	I
34	MAP	I
35	kinase	O
36	)	O
37	and	B
38	NF	I
39	-	I
40	kappaB	O
41	signalling	O
42	respectively	O
43	.	O

1	We	O
2	also	O
3	observed	O
4	that	O
5	the	O
6	predictive	O
7	ability	O
8	of	O
9	the	O
10	selected	O
11	attitudes	O
12	and	O
13	orientations	O
14	increased	O
15	considerably	O
16	from	O
17	1975	O
18	to	O
19	1982	O
20	.	O

1	Classical	O
2	ligand	O
3	-	O
4	activated	O
5	nuclear	O
6	receptors	O
7	(	O
8	e	O
9	.	O
10	g	O
11	.	B
12	thyroid	I
13	hormone	I
14	receptor	I
15	,	I
16	retinoic	I
17	acid	I
18	receptor	O
19	),	O
20	orphan	O
21	nuclear	O
22	receptors	O
23	(	O
24	e	O
25	.	O
26	g	O
27	.	O

1	RACK1	O
2	,	O
3	a	O
4	receptor	O
5	for	O
6	activated	B
7	C	I
8	kinase	O
9	and	O
10	a	O
11	homolog	O
12	of	O
13	the	O
14	beta	O
15	subunit	O
16	of	O
17	G	O
18	proteins	O
19	,	O
20	inhibits	O
21	activity	O
22	of	B
23	src	I
24	tyrosine	I
25	kinases	O
26	and	O
27	growth	O
28	of	O
29	NIH	O
30	3T3	O
31	cells	O
32	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	kinetics	O
6	of	O
7	the	O
8	recovery	O
9	of	O
10	mRNA	O
11	synthesis	O
12	in	O
13	the	O
14	inducible	O
15	GAL10	O
16	and	B
17	RNR3	I
18	genes	O
19	after	O
20	exposure	O
21	of	O
22	yeast	O
23	cells	O
24	to	O
25	ultraviolet	O
26	(	O
27	UV	O
28	)	O
29	radiation	O
30	.	O

1	The	B
2	protooncogene	I
3	c	I
4	-	I
5	myb	O
6	encodes	O
7	a	O
8	nuclear	O
9	transcription	O
10	factor	O
11	that	O
12	binds	O
13	to	O
14	DNA	O
15	in	O
16	a	O
17	sequence	O
18	-	O
19	specific	O
20	manner	O
21	and	O
22	transactivates	O
23	transcription	O
24	of	O
25	several	O
26	viral	O
27	and	O
28	cellular	O
29	genes	O
30	.	O

1	This	O
2	indicates	O
3	that	O
4	the	O
5	mechanism	O
6	by	O
7	which	O
8	CX	O
9	blocks	O
10	rapid	O
11	degradation	O
12	of	O
13	tubulin	O
14	mRNA	O
15	in	O
16	vivo	O
17	is	O
18	not	O
19	simply	O
20	by	O
21	preventing	O
22	its	O
23	translation	O
24	and	O
25	suggests	O
26	the	O
27	involvement	O
28	of	O
29	an	O
30	altered	O
31	trans	O
32	-	O
33	factor	O
34	.	O

1	The	O
2	E6	O
3	/	O
4	E7	O
5	promoter	O
6	of	O
7	all	O
8	genital	O
9	human	O
10	papillomaviruses	O
11	is	O
12	responsible	O
13	for	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	transforming	O
19	genes	O
20	.	O

1	Proximal	O
2	CBD	O
3	was	O
4	inversely	O
5	correlated	O
6	with	O
7	bone	B
8	alkaline	I
9	phosphatase	O
10	(	O
11	r	O
12	=	O
13	-	O
14	0	O
15	.	O
16	71	O
17	,	O
18	p	O
19	<	O
20	0	O
21	.	O
22	01	O
23	)	O
24	and	O
25	intact	O
26	PTH	O
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	59	O
34	,	O
35	p	O
36	<	O
37	0	O
38	.	O
39	05	O
40	).	O

1	One	O
2	linker	O
3	-	O
4	peptide	O
5	insertion	O
6	in	O
7	the	O
8	RsaA	O
9	C	O
10	terminus	O
11	(	O
12	amino	O
13	acid	O
14	784	O
15	)	O
16	had	O
17	no	O
18	effect	O
19	on	O
20	S	O
21	-	O
22	layer	O
23	biogenesis	O
24	,	O
25	while	O
26	another	O
27	(	O
28	amino	O
29	acid	O
30	907	O
31	)	O
32	disrupted	O
33	secretion	O
34	of	O
35	the	O
36	protein	O
37	,	O
38	suggesting	O
39	that	O
40	RsaA	O
41	possesses	O
42	a	O
43	secretion	O
44	signal	O
45	lying	O
46	C	O
47	terminal	O
48	to	O
49	amino	O
50	acid	O
51	784	O
52	,	O
53	near	O
54	or	O
55	including	O
56	amino	O
57	acid	O
58	907	O
59	.	O

1	Two	O
2	classes	O
3	of	O
4	mutations	O
5	were	O
6	obtained	O
7	:	O
8	(	O
9	i	O
10	)	O
11	those	O
12	that	O
13	altered	O
14	the	O
15	coding	O
16	region	O
17	of	O
18	HOL1	O
19	,	O
20	conferring	O
21	the	O
22	ability	O
23	to	O
24	take	O
25	up	O
26	histidinol	O
27	;	O
28	and	O
29	(	O
30	ii	O
31	)	O
32	cis	O
33	-	O
34	acting	O
35	mutations	O
36	(	O
37	selected	O
38	in	O
39	a	O
40	mutant	O
41	HOL1	O
42	-	O
43	1	O
44	background	O
45	)	O
46	that	O
47	increased	O
48	expression	O
49	of	O
50	the	O
51	Hol1	O
52	protein	O
53	.	O

1	Expression	O
2	and	O
3	regulation	O
4	by	B
5	interferon	I
6	of	I
7	a	I
8	double	I
9	-	I
10	stranded	I
11	-	I
12	RNA	I
13	-	I
14	specific	I
15	adenosine	I
16	deaminase	O
17	from	O
18	human	O
19	cells	O
20	:	O
21	evidence	O
22	for	O
23	two	O
24	forms	O
25	of	O
26	the	B
27	deaminase	I
28	.	I

1	The	O
2	importance	O
3	of	O
4	this	O
5	new	O
6	epidemiological	O
7	profile	O
8	of	O
9	schistosomiasis	O
10	in	O
11	the	O
12	State	O
13	of	O
14	Pernambuco	O
15	relies	O
16	on	O
17	the	O
18	fact	O
19	that	O
20	it	O
21	can	O
22	be	O
23	related	O
24	with	O
25	the	O
26	drastic	O
27	human	O
28	interference	O
29	on	O
30	the	O
31	environment	O
32	.	O

1	Homodimers	O
2	of	O
3	the	O
4	three	O
5	proteins	O
6	specifically	O
7	recognize	O
8	the	O
9	G	O
10	-	O
11	box	O
12	motif	O
13	,	O
14	with	O
15	GBF1	O
16	and	O
17	GBF3	O
18	binding	O
19	symmetrically	O
20	to	O
21	this	O
22	palindromic	O
23	sequence	O
24	.	O

1	Sequence	O
2	analysis	O
3	identified	O
4	some	O
5	of	O
6	these	O
7	cDNA	O
8	clones	O
9	as	O
10	Dlc	O
11	-	O
12	1	O
13	,	O
14	a	O
15	sequence	O
16	encoding	O
17	a	O
18	small	O
19	,	O
20	9	O
21	-	O
22	kDa	O
23	human	O
24	homolog	O
25	of	O
26	the	O
27	outer	O
28	-	O
29	arm	B
30	dynein	I
31	light	I
32	-	I
33	chain	I
34	protein	I
35	.	I

1	Clinically	O
2	meaningful	O
3	decreases	O
4	due	O
5	to	O
6	alkalinization	O
7	alone	O
8	within	O
9	30	O
10	minutes	O
11	are	O
12	unlikely	O
13	.	O

1	The	O
2	repetitive	O
3	ETn	O
4	(	O
5	early	O
6	transposon	O
7	)	O
8	family	O
9	of	O
10	sequences	O
11	represents	O
12	an	O
13	active	O
14	"	O
15	mobile	O
16	mutagen	O
17	"	O
18	in	O
19	the	O
20	mouse	O
21	genome	O
22	.	O

1	When	O
2	the	O
3	cervical	O
4	Pap	O
5	smear	O
6	is	O
7	positive	O
8	.	O

1	The	O
2	pWP	O
3	-	O
4	19	O
5	also	O
6	encodes	O
7	the	O
8	AAV	O
9	inverted	O
10	terminal	O
11	repeats	O
12	for	O
13	integration	O
14	and	O
15	replication	O
16	and	O
17	the	O
18	herpes	O
19	virus	B
20	thymidine	I
21	kinase	I
22	promoter	I
23	-	I
24	driven	I
25	gene	O
26	for	O
27	neomycin	O
28	resistance	O
29	(	O
30	neoR	O
31	).	O

1	The	O
2	conditions	O
3	for	O
4	obtaining	O
5	titanium	O
6	dioxide	O
7	from	O
8	the	O
9	substrates	O
10	titanium	O
11	tetrachloride	O
12	and	O
13	oxygen	O
14	and	O
15	applying	O
16	this	O
17	to	O
18	a	O
19	surgical	O
20	stainless	O
21	steel	O
22	of	O
23	the	O
24	type	O
25	316L	O
26	by	O
27	the	O
28	plasma	O
29	assisted	O
30	chemical	O
31	vapour	O
32	deposition	O
33	method	O
34	have	O
35	been	O
36	determined	O
37	.	O

1	Although	O
2	no	O
3	statistical	O
4	significance	O
5	was	O
6	achieved	O
7	,	O
8	it	O
9	is	O
10	remarkable	O
11	that	O
12	there	O
13	was	O
14	a	O
15	clear	O
16	trend	O
17	for	O
18	the	O
19	superiority	O
20	of	O
21	Galphimia	O
22	D6	O
23	while	O
24	the	O
25	Galphimia	O
26	dilution	O
27	10	O
28	(-	O
29	6	O
30	)	O
31	was	O
32	about	O
33	equally	O
34	effective	O
35	compared	O
36	with	O
37	placebo	O
38	.	O

1	Patients	O
2	with	O
3	apparently	O
4	minor	O
5	CT	O
6	abnormalities	O
7	may	O
8	have	O
9	significant	O
10	epidural	O
11	disease	O
12	.	O

1	Transfection	O
2	of	O
3	increasing	O
4	amounts	O
5	of	O
6	delta5ERalpha	O
7	expression	O
8	vector	O
9	into	O
10	[	O
11	ERalpha	O
12	+]	O
13	OS	O
14	cells	O
15	resulted	O
16	in	O
17	potentiation	O
18	of	O
19	E2	O
20	-	O
21	stimulated	O
22	ERELuc	O
23	activity	O
24	in	O
25	a	O
26	synergistic	O
27	,	O
28	dose	O
29	-	O
30	dependent	O
31	manner	O
32	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	binding	O
6	affinity	O
7	for	O
8	the	O
9	motifs	O
10	is	O
11	different	O
12	.	O

1	LON	O
2	-	O
3	72	O
4	(	O
5	34	O
6	isolates	O
7	),	O
8	LON	O
9	-	O
10	73	O
11	(	O
12	1	O
13	),	O
14	LON	O
15	-	O
16	71	O
17	(	O
18	2	O
19	)	O
20	and	O
21	LON	O
22	-	O
23	10	O
24	(	O
25	2	O
26	)	O
27	were	O
28	found	O
29	at	O
30	altitudes	O
31	around	O
32	2000	O
33	m	O
34	,	O
35	3	O
36	of	O
37	them	O
38	in	O
39	a	O
40	single	O
41	village	O
42	.	O

1	A	O
2	three	O
3	-	O
4	phased	O
5	analysis	O
6	of	O
7	treatment	O
8	plans	O
9	for	O
10	45	O
11	patients	O
12	was	O
13	undertaken	O
14	.	O

1	Purified	O
2	CarP	O
3	binds	O
4	in	O
5	vitro	O
6	to	O
7	the	O
8	carAB	O
9	control	O
10	region	O
11	and	O
12	protects	O
13	against	O
14	DNase	O
15	I	O
16	two	O
17	approximately	O
18	25	O
19	bp	O
20	long	O
21	stretches	O
22	,	O
23	one	O
24	of	O
25	which	O
26	is	O
27	located	O
28	just	O
29	downstream	O
30	of	O
31	the	B
32	GATC	I
33	sequence	I
34	.	I

1	ULKs	O
2	and	O
3	UNC	O
4	-	O
5	51	O
6	share	O
7	a	O
8	typical	O
9	domain	O
10	structure	O
11	of	O
12	an	O
13	amino	O
14	-	O
15	terminal	O
16	kinase	O
17	domain	O
18	,	O
19	a	O
20	central	O
21	proline	O
22	/	O
23	serine	O
24	rich	O
25	(	O
26	PS	O
27	)	O
28	domain	O
29	,	O
30	and	O
31	a	O
32	carboxy	O
33	-	O
34	terminal	O
35	(	O
36	C	O
37	)	O
38	domain	O
39	.	O

1	C	O
2	.	O
3	D2	O
4	-	O
5	Chr	O
6	4	O
7	congenic	O
8	strains	O
9	harboring	O
10	DBA	O
11	/	O
12	2	O
13	alleles	O
14	associated	O
15	with	O
16	the	B
17	Pctr1	I
18	locus	O
19	contained	O
20	DBA	O
21	/	O
22	2	O
23	"	O
24	resistant	O
25	"	O
26	alleles	O
27	of	O
28	the	B
29	CDK4	I
30	/	I
31	CDK6	I
32	inhibitors	I
33	p16	I
34	and	I
35	p15	I
36	.	I

1	RESULTS	O
2	:	O
3	Soluble	O
4	CD23	O
5	levels	O
6	were	O
7	significantly	O
8	higher	O
9	in	O
10	women	O
11	with	O
12	endometriosis	O
13	before	O
14	treatment	O
15	than	O
16	in	O
17	ten	O
18	normal	O
19	controls	O
20	.	O

1	Although	B
2	E2FBP1	O
3	lacks	O
4	the	O
5	transactivation	O
6	domain	O
7	,	O
8	it	O
9	stimulates	B
10	E2F	I
11	site	I
12	-	I
13	dependent	I
14	transcription	O
15	in	O
16	cooperation	O
17	with	B
18	E2F	I
19	-	I
20	1	I
21	.	I

1	Multiple	O
2	single	O
3	-	O
4	stranded	O
5	cis	O
6	elements	O
7	are	O
8	associated	O
9	with	O
10	activated	O
11	chromatin	O
12	of	O
13	the	B
14	human	B
15	c	I
16	-	I
17	myc	I
18	gene	O
19	in	O
20	vivo	O
21	.	O

1	Identification	O
2	of	B
3	p40x	I
4	-	I
5	responsive	I
6	regulatory	I
7	sequences	O
8	within	O
9	the	B
10	human	B
11	T	I
12	-	I
13	cell	I
14	leukemia	I
15	virus	I
16	type	I
17	I	I
18	long	I
19	terminal	I
20	repeat	I
21	.	I

1	We	O
2	cloned	O
3	and	O
4	sequenced	O
5	the	O
6	cDNAs	O
7	against	O
8	genomic	O
9	RNA	O
10	and	O
11	mRNA	O
12	for	O
13	phosphoprotein	O
14	(	O
15	P	O
16	)	O
17	of	O
18	human	O
19	parainfluenza	I
20	type	I
21	2	I
22	virus	I
23	(	I
24	PIV	I
25	-	I
26	2	O
27	).	O
28	cDNA	O
29	clone	O
30	from	O
31	genomic	O
32	RNA	O
33	was	O
34	1439	O
35	nucleotides	O
36	in	O
37	length	O
38	excluding	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	and	O
44	was	O
45	found	O
46	to	O
47	have	O
48	two	O
49	small	O
50	open	O
51	reading	O
52	frames	O
53	encoding	O
54	proteins	O
55	of	O
56	233	O
57	and	O
58	249	O
59	amino	O
60	acids	O
61	.	O

1	Male	O
2	contraception	O
3	:	O
4	ideas	O
5	for	O
6	the	O
7	future	O
8	.	O

1	Interestingly	O
2	,	O
3	this	O
4	activation	O
5	occurred	O
6	only	O
7	when	O
8	the	O
9	regions	O
10	were	O
11	cloned	O
12	in	O
13	the	O
14	same	O
15	relative	O
16	orientation	O
17	in	O
18	which	O
19	they	O
20	exist	O
21	on	B
22	wild	I
23	-	I
24	type	I
25	pCF10	O
26	.	O

1	Structural	O
2	organization	O
3	and	O
4	expression	O
5	of	O
6	the	B
7	mouse	B
8	estrogen	I
9	receptor	I
10	.	I

1	Radionuclide	O
2	study	O
3	and	O
4	endomyocardial	O
5	biopsy	O
6	revealed	O
7	remarkable	O
8	degeneration	O
9	of	O
10	myocardium	O
11	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	carbon	O
7	-	O
8	perfused	O
9	areas	O
10	and	B
11	MBF	O
12	in	O
13	the	O
14	liver	O
15	,	O
16	renal	O
17	cortex	O
18	,	O
19	spleen	O
20	,	O
21	and	O
22	small	O
23	intestinal	O
24	serosa	O
25	(	O
26	only	B
27	MBF	O
28	)	O
29	increased	O
30	significantly	O
31	5	O
32	h	O
33	after	O
34	CLP	O
35	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	revealed	O
6	that	B
7	Sp1	O
8	binds	O
9	to	O
10	two	O
11	different	O
12	regions	O
13	in	O
14	the	O
15	proximal	O
16	promoter	O
17	,	O
18	a	O
19	typical	B
20	Sp1	I
21	site	O
22	located	O
23	at	O
24	(-	O
25	38	O
26	;	O
27	-	O
28	33	O
29	)	O
30	and	O
31	a	O
32	G	O
33	/	O
34	C	O
35	-	O
36	rich	O
37	region	O
38	between	O
39	(-	O
40	67	O
41	;	O
42	-	O
43	62	O
44	).	O

1	Although	O
2	inactive	O
3	in	O
4	cells	O
5	under	O
6	normal	O
7	conditions	O
8	,	O
9	the	O
10	CHOP	O
11	gene	O
12	is	O
13	markedly	O
14	induced	O
15	by	O
16	a	O
17	variety	O
18	of	O
19	cellular	O
20	stresses	O
21	,	O
22	including	O
23	nutrient	O
24	deprivation	O
25	and	O
26	metabolic	O
27	perturbations	O
28	.	O

1	Chem	O
2	.	O

1	DNA	O
2	sequence	O
3	and	O
4	functions	O
5	of	O
6	the	O
7	actVI	O
8	region	O
9	of	O
10	the	O
11	actinorhodin	O
12	biosynthetic	O
13	gene	O
14	cluster	O
15	of	O
16	Streptomyces	O
17	coelicolor	O
18	A3	O
19	(	O
20	2	O
21	).	O

1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	substituted	O
7	and	O
8	wild	O
9	type	O
10	peptides	O
11	were	O
12	observed	O
13	,	O
14	suggesting	O
15	that	O
16	this	O
17	substitution	O
18	in	O
19	the	O
20	intact	O
21	protein	O
22	may	O
23	cause	O
24	disruption	O
25	of	O
26	global	O
27	rather	O
28	than	O
29	local	O
30	structures	O
31	.	O

1	Variability	O
2	within	O
3	Down	O
4	'	O
5	s	O
6	syndrome	O
7	(	O
8	trisomy	O
9	-	O
10	21	O
11	):	O
12	empirically	O
13	observed	O
14	sex	O
15	differences	O
16	in	O
17	IQs	O
18	.	O

1	Interestingly	O
2	,	O
3	the	O
4	RNA	O
5	sequences	O
6	selected	O
7	by	O
8	the	O
9	mutated	O
10	zinc	O
11	knuckle	O
12	9G8	O
13	variant	O
14	are	O
15	efficiently	O
16	recognized	O
17	by	B
18	SRp20	O
19	,	O
20	in	O
21	agreement	O
22	with	O
23	the	O
24	fact	O
25	that	O
26	the	O
27	RBD	O
28	of	O
29	9G8	O
30	and	B
31	SRp20	O
32	are	O
33	similar	O
34	.	O

1	The	O
2	requirement	O
3	of	O
4	Tyr	O
5	-	O
6	19	O
7	dephosphorylation	O
8	for	O
9	spindle	O
10	assembly	O
11	is	O
12	also	O
13	observed	O
14	under	O
15	conditions	O
16	in	O
17	which	O
18	spindle	O
19	formation	O
20	is	O
21	independent	O
22	of	O
23	mitosis	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	involvement	O
29	of	B
30	Cdc28	I
31	/	I
32	Clb	I
33	kinase	O
34	in	O
35	SPB	O
36	separation	O
37	is	O
38	direct	O
39	.	O

1	Splicing	O
2	of	O
3	the	O
4	K	O
5	-	O
6	SAM	O
7	alternative	O
8	exon	O
9	of	O
10	the	B
11	fibroblast	I
12	growth	I
13	factor	I
14	receptor	I
15	2	I
16	gene	O
17	is	O
18	heavily	O
19	dependent	O
20	on	O
21	the	O
22	U	O
23	-	O
24	rich	O
25	sequence	O
26	IAS1	O
27	lying	O
28	immediately	O
29	downstream	O
30	from	O
31	its	O
32	5	O
33	'	O
34	splice	O
35	site	O
36	.	O

1	It	O
2	has	O
3	been	O
4	established	O
5	that	O
6	preoperative	O
7	irradiation	O
8	in	O
9	the	O
10	form	O
11	of	O
12	the	O
13	fractionation	O
14	of	O
15	a	O
16	single	O
17	focal	O
18	dose	O
19	of	O
20	6	O
21	Gy	O
22	every	O
23	other	O
24	day	O
25	,	O
26	the	O
27	summary	O
28	dose	O
29	of	O
30	24	O
31	Gy	O
32	within	O
33	8	O
34	-	O
35	10	O
36	days	O
37	followed	O
38	by	O
39	surgery	O
40	1	O
41	-	O
42	3	O
43	days	O
44	after	O
45	irradiation	O
46	does	O
47	not	O
48	either	O
49	complicate	O
50	its	O
51	performance	O
52	or	O
53	the	O
54	course	O
55	of	O
56	the	O
57	postoperative	O
58	period	O
59	,	O
60	and	O
61	by	O
62	the	O
63	short	O
64	-	O
65	and	O
66	long	O
67	-	O
68	term	O
69	results	O
70	it	O
71	is	O
72	no	O
73	worse	O
74	than	O
75	the	O
76	routine	O
77	dose	O
78	fractionation	O
79	.	O

1	A	O
2	role	O
3	for	O
4	the	B
5	small	B
6	GTPase	B
7	Rac	B
8	in	B
9	polyomavirus	I
10	middle	I
11	-	I
12	T	I
13	antigen	I
14	-	O
15	mediated	O
16	activation	O
17	of	O
18	the	O
19	serum	O
20	response	O
21	element	O
22	and	O
23	in	O
24	cell	O
25	transformation	O
26	.	O

1	The	O
2	Babcock	O
3	Surgical	O
4	Clinic	O
5	.	O

1	STK	I
2	/	I
3	RON	I
4	-	I
5	expressing	I
6	Ba	I
7	/	I
8	F3	I
9	pro	I
10	-	I
11	B	O
12	cells	O
13	(	O
14	BaF	O
15	/	O
16	STK	O
17	)	O
18	exhibited	B
19	MSP	I
20	-	I
21	dependent	I
22	growth	O
23	,	O
24	whereas	O
25	STK	O
26	/	O
27	RON	O
28	-	O
29	expressing	O
30	mouse	O
31	erythroleukaemia	O
32	cells	O
33	(	O
34	MEL	O
35	/	O
36	STK	O
37	)	O
38	displayed	O
39	MSP	O
40	-	O
41	induced	O
42	apoptosis	O
43	.	O

1	The	O
2	dying	O
3	tTG	O
4	-	O
5	transfected	O
6	cells	O
7	exhibit	O
8	both	O
9	cytoplasmic	O
10	and	O
11	nuclear	O
12	changes	O
13	characteristic	O
14	of	O
15	cells	O
16	undergoing	O
17	apoptosis	O
18	.	O

1	These	O
2	REPs	O
3	,	O
4	or	O
5	clusters	O
6	of	O
7	paralogous	O
8	loci	O
9	,	O
10	are	O
11	15	O
12	-	O
13	100	O
14	kb	O
15	and	O
16	harbor	O
17	at	O
18	least	O
19	four	O
20	ESTs	O
21	and	O
22	an	O
23	expressed	B
24	SH3GL	I
25	pseudogene	I
26	.	I

1	In	O
2	NASCIS	O
3	III	O
4	,	O
5	a	O
6	randomization	O
7	imbalance	O
8	occurred	O
9	that	O
10	allocated	O
11	a	O
12	disproportionate	O
13	number	O
14	of	O
15	patients	O
16	with	O
17	no	O
18	motor	O
19	deficit	O
20	(	O
21	and	O
22	therefore	O
23	no	O
24	chance	O
25	for	O
26	recovery	O
27	)	O
28	to	O
29	the	O
30	lower	O
31	dose	O
32	control	O
33	group	O
34	.	O

1	The	O
2	results	O
3	presented	O
4	in	O
5	this	O
6	report	O
7	suggest	O
8	that	O
9	the	O
10	SV40	O
11	G	O
12	-	O
13	C	O
14	-	O
15	rich	O
16	sequences	O
17	can	O
18	function	O
19	as	O
20	independent	B
21	RNA	I
22	polymerase	I
23	II	I
24	transcriptional	I
25	-	O
26	control	O
27	elements	O
28	.	O

1	MEK	O
2	itself	O
3	is	O
4	activated	O
5	via	O
6	serine	O
7	phosphorylation	O
8	by	O
9	upstream	O
10	activator	O
11	kinases	O
12	,	O
13	including	B
14	c	I
15	-	I
16	raf	O
17	,	O
18	mos	O
19	and	B
20	MEK	I
21	kinase	I
22	.	I

1	A	O
2	mutant	O
3	form	O
4	of	B
5	Vps1p	O
6	lacking	O
7	the	O
8	entire	I
9	GTP	I
10	-	I
11	binding	I
12	domain	O
13	interfered	O
14	with	O
15	vacuolar	O
16	protein	O
17	sorting	O
18	in	O
19	wild	O
20	-	O
21	type	O
22	cells	O
23	.	O

1	Several	O
2	different	O
3	oncogenes	O
4	and	O
5	growth	O
6	factors	O
7	promote	O
8	G1	O
9	phase	O
10	progression	O
11	.	O

1	Update	O
2	:	O
3	diphtheria	O
4	epidemic	O
5	in	O
6	the	O
7	newly	O
8	independent	O
9	states	O
10	of	O
11	the	O
12	former	O
13	USSR	O
14	,	O
15	January	O
16	1995	O
17	-	O
18	March	O
19	1996	O
20	.	O

1	The	O
2	methylation	O
3	of	O
4	nuclear	O
5	and	O
6	chloroplast	O
7	DNAs	O
8	has	O
9	been	O
10	examined	O
11	in	O
12	relation	O
13	to	O
14	the	O
15	known	O
16	differential	O
17	expression	O
18	of	O
19	C4	O
20	photosynthesis	O
21	genes	O
22	in	O
23	the	O
24	bundle	O
25	sheath	O
26	and	O
27	mesophyll	O
28	cells	O
29	of	O
30	etiolated	O
31	,	O
32	greening	O
33	,	O
34	and	O
35	fully	O
36	green	O
37	maize	O
38	leaves	O
39	.	O

1	This	O
2	organization	O
3	suggests	O
4	that	O
5	duplication	O
6	events	O
7	that	O
8	have	O
9	generated	O
10	the	O
11	primate	O
12	FUT3	O
13	-	O
14	FUT5	O
15	-	O
16	FUT6	O
17	cluster	O
18	might	O
19	have	O
20	occurred	O
21	through	O
22	a	O
23	long	O
24	-	O
25	interspersed	O
26	-	O
27	nuclear	O
28	-	O
29	element	O
30	-	O
31	based	O
32	mechanism	O
33	of	O
34	unequal	O
35	crossing	O
36	over	O
37	,	O
38	as	O
39	described	O
40	for	O
41	the	B
42	globin	I
43	cluster	I
44	.	I

1	Unexpectedly	O
2	,	O
3	ALK7	O
4	signaling	O
5	produced	O
6	a	O
7	remarkable	O
8	change	O
9	in	O
10	cell	O
11	morphology	O
12	characterized	O
13	by	O
14	cell	O
15	flattening	O
16	and	O
17	elaboration	O
18	of	O
19	blunt	O
20	,	O
21	short	O
22	cell	O
23	processes	O
24	.	O

1	The	B
2	yeast	B
3	LPD1	I
4	gene	I
5	encoding	I
6	lipoamide	I
7	dehydrogenase	O
8	is	O
9	subject	O
10	to	O
11	the	O
12	general	O
13	control	O
14	of	O
15	amino	O
16	acid	O
17	biosynthesis	O
18	mediated	O
19	by	O
20	the	B
21	GCN4	I
22	transcription	I
23	factor	I
24	.	I

1	Sequences	O
2	needed	O
3	for	O
4	iron	O
5	-	O
6	regulated	O
7	expression	O
8	of	O
9	sid1	O
10	were	O
11	localized	O
12	to	O
13	a	O
14	306	O
15	bp	O
16	region	O
17	mapping	O
18	2	O
19	.	O
20	3	O
21	and	O
22	2	O
23	.	O
24	6	O
25	kb	O
26	upstream	O
27	of	O
28	the	O
29	ATG	O
30	.	O

1	Effect	O
2	of	O
3	2	O
4	-(	O
5	p	O
6	-	O
7	chlorophenyl	O
8	)	O
9	cyclopropylamine	O
10	on	O
11	5	O
12	-	O
13	hydroxyindole	O
14	concentration	O
15	and	O
16	monoamine	I
17	oxidase	O
18	activity	O
19	in	O
20	rat	O
21	brain	O
22	.	O

1	In	O
2	cases	O
3	of	O
4	1	O
5	degrees	O
6	HPT	O
7	,	O
8	the	O
9	plasma	O
10	1	O
11	,	O
12	25	O
13	-(	O
14	OH	O
15	)	O
16	2D	O
17	level	O
18	rose	O
19	significantly	O
20	in	O
21	all	O
22	cases	O
23	(	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	05	O
30	),	O
31	although	O
32	the	O
33	pattern	O
34	of	O
35	the	O
36	increase	O
37	was	O
38	not	O
39	uniform	O
40	.	O

1	Only	O
2	fully	O
3	processed	O
4	Pra	O
5	(	O
6	N0	O
7	and	O
8	Nb	O
9	)	O
10	and	O
11	ICP35	O
12	(	O
13	ICP35	O
14	e	O
15	,	O
16	f	O
17	)	O
18	are	O
19	present	O
20	in	O
21	B	O
22	capsids	O
23	,	O
24	which	O
25	are	O
26	believed	O
27	to	O
28	be	O
29	precursors	O
30	of	O
31	mature	O
32	virions	O
33	.	O

1	Despite	O
2	the	O
3	high	O
4	frequency	O
5	of	O
6	natural	O
7	infection	O
8	,	O
9	the	O
10	seropositive	O
11	rates	O
12	of	O
13	JEV	O
14	antibody	O
15	still	O
16	correlated	O
17	well	O
18	with	O
19	the	O
20	dose	O
21	of	O
22	vaccine	O
23	received	O
24	,	O
25	i	O
26	.	O
27	e	O
28	.,	O
29	67	O
30	%	O
31	(	O
32	1122	O
33	/	O
34	1664	O
35	),	O
36	66	O
37	%	O
38	(	O
39	65	O
40	/	O
41	97	O
42	),	O
43	33	O
44	%	O
45	(	O
46	4	O
47	/	O
48	12	O
49	)	O
50	and	O
51	40	O
52	%	O
53	(	O
54	19	O
55	/	O
56	47	O
57	)	O
58	for	O
59	children	O
60	receiving	O
61	3	O
62	,	O
63	2	O
64	,	O
65	1	O
66	,	O
67	and	O
68	0	O
69	dose	O
70	of	O
71	JE	O
72	vaccines	O
73	,	O
74	respectively	O
75	(	O
76	P	O
77	<	O
78	0	O
79	.	O
80	0001	O
81	Chi	O
82	-	O
83	square	O
84	for	O
85	trend	O
86	test	O
87	).	O

1	Insulin	I
2	receptor	I
3	substrate	I
4	-	I
5	1	I
6	-	O
7	mediated	O
8	enhancement	O
9	of	O
10	growth	O
11	hormone	O
12	-	O
13	induced	B
14	mitogen	I
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	activation	I
20	.	I

1	Routine	O
2	blood	O
3	examination	O
4	showed	O
5	leukocytosis	O
6	,	O
7	thrombocytopenia	O
8	,	O
9	positive	O
10	CRP	O
11	,	O
12	and	O
13	elevated	O
14	myocardial	O
15	enzymes	O
16	.	O

1	Atherosclerosis	O

1	METHODS	O
2	:	O
3	We	O
4	retrospectively	O
5	reviewed	O
6	242	O
7	adult	O
8	cadaveric	O
9	renal	O
10	transplant	O
11	recipients	O
12	treated	O
13	between	O
14	11	O
15	/	O
16	91	O
17	and	O
18	5	O
19	/	O
20	97	O
21	.	O

1	The	O
2	alternative	O
3	splice	O
4	sites	O
5	for	O
6	the	O
7	smallest	O
8	adducin	I
9	isoform	I
10	,	I
11	beta	I
12	-	I
13	3	O
14	,	O
15	are	O
16	alternative	O
17	donor	O
18	and	O
19	acceptor	O
20	sites	O
21	within	O
22	exons	O
23	7	O
24	and	O
25	12	O
26	.	O

1	The	O
2	infection	O
3	rate	O
4	was	O
5	five	O
6	times	O
7	greater	O
8	in	O
9	patients	O
10	with	O
11	Hickman	O
12	catheters	O
13	than	O
14	in	O
15	those	O
16	with	O
17	Broviac	O
18	catheters	O
19	(	O
20	p	O
21	=	O
22	0	O
23	.	O
24	01	O
25	).	O

1	Native	B
2	human	B
3	fibrinogen	O
4	was	O
5	brought	O
6	to	O
7	coagulation	O
8	by	O
9	adding	O
10	thrombin	O
11	.	O

1	About	O
2	20	O
3	kb	O
4	upstream	O
5	of	O
6	LAMB2	O
7	we	O
8	found	O
9	a	O
10	gene	O
11	encoding	O
12	a	O
13	transcribed	O
14	,	O
15	non	O
16	-	O
17	processed	B
18	LAMB2	I
19	-	I
20	like	I
21	pseudogene	I
22	(	I
23	LAMB2L	O
24	).	O

1	As	O
2	opposed	O
3	to	O
4	in	O
5	vitro	O
6	co	O
7	-	O
8	precipitation	O
9	studies	O
10	,	O
11	the	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screen	O
17	reveals	O
18	in	O
19	vivo	O
20	protein	O
21	-	O
22	protein	O
23	interactions	O
24	.	O

1	The	O
2	gene	O
3	is	O
4	1	O
5	,	O
6	139	O
7	base	O
8	pairs	O
9	(	O
10	bp	O
11	)	O
12	long	O
13	,	O
14	and	O
15	,	O
16	like	O
17	other	O
18	members	O
19	of	O
20	the	B
21	SIG	I
22	family	O
23	,	O
24	the	B
25	beta	B
26	TG	I
27	gene	O
28	is	O
29	divided	O
30	into	O
31	3	O
32	exons	O
33	.	O

1	Truncations	O
2	composed	O
3	of	O
4	78	O
5	and	O
6	64	O
7	amino	O
8	acids	O
9	were	O
10	translocated	O
11	across	O
12	the	O
13	endoplasmic	O
14	reticulum	O
15	membrane	O
16	,	O
17	and	O
18	translocation	O
19	was	O
20	found	O
21	to	O
22	be	O
23	strictly	O
24	co	O
25	-	O
26	translational	O
27	and	B
28	SRP	I
29	-	I
30	dependent	I
31	.	I

1	There	O
2	was	O
3	also	O
4	a	O
5	highly	O
6	significant	O
7	correlation	O
8	between	O
9	total	O
10	selenium	O
11	intake	O
12	and	O
13	liver	O
14	selenium	O
15	concentration	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	99	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	01	O
28	)	O
29	after	O
30	1	O
31	mo	O
32	of	O
33	treatment	O
34	,	O
35	but	O
36	this	O
37	time	O
38	liver	O
39	selenium	O
40	did	O
41	not	O
42	change	O
43	with	O
44	time	O
45	,	O
46	and	O
47	the	O
48	correlation	O
49	remained	O
50	highly	O
51	significant	O
52	throughout	O
53	the	O
54	investigation	O
55	.	O

1	Apparent	O
2	loss	O
3	of	O
4	differentiation	O
5	markers	O
6	characterizes	O
7	advanced	O
8	malignant	O
9	neoplasms	O
10	.	O

1	All	O
2	groups	O
3	were	O
4	challenged	O
5	subsequently	O
6	with	O
7	naloxone	O
8	(	O
9	0	O
10	.	O
11	4	O
12	mg	O
13	/	O
14	kg	O
15	)	O
16	in	O
17	the	O
18	distinctive	O
19	environment	O
20	and	O
21	then	O
22	observed	O
23	for	O
24	signs	O
25	of	O
26	opiate	O
27	withdrawal	O
28	.	O

1	These	O
2	findings	O
3	suggest	O
4	one	O
5	potential	O
6	mechanism	O
7	for	O
8	direct	O
9	recruitment	O
10	of	O
11	distal	O
12	regulatory	O
13	regions	O
14	of	O
15	the	B
16	globin	I
17	loci	O
18	to	O
19	the	O
20	individual	O
21	promoters	O
22	.	O

1	All	O
2	numbers	O
3	refer	O
4	to	O
5	nucleotide	O
6	positions	O
7	on	O
8	the	B
9	wild	I
10	-	I
11	type	I
12	HIV	I
13	-	I
14	1	I
15	transcript	I
16	.	I

1	Full	O
2	-	O
3	length	O
4	FLAP	O
5	clones	O
6	were	O
7	isolated	O
8	from	O
9	a	O
10	mouse	O
11	skeletal	O
12	muscle	O
13	cDNA	O
14	library	O
15	.	O

1	1	O
2	A	O
3	colonic	O
4	delivery	O
5	system	O
6	is	O
7	described	O
8	to	O
9	deliver	O
10	orally	O
11	ingested	O
12	drugs	O
13	to	O
14	the	O
15	colon	O
16	and	O
17	release	O
18	them	O
19	at	O
20	that	O
21	site	O
22	by	O
23	coating	O
24	with	O
25	an	O
26	acrylic	O
27	based	O
28	resin	O
29	(	O
30	Eudragit	O
31	S	O
32	).	O

1	Regional	O
2	insertional	O
3	mutagenesis	O
4	of	O
5	specific	O
6	genes	O
7	on	O
8	the	O
9	CIC5F11	I
10	/	I
11	CIC2B9	I
12	locus	O
13	of	O
14	Arabidopsis	O
15	thaliana	O
16	chromosome	O
17	5	O
18	using	O
19	the	O
20	Ac	O
21	/	O
22	Ds	O
23	transposon	O
24	in	O
25	combination	O
26	with	O
27	the	O
28	cDNA	O
29	scanning	O
30	method	O
31	.	O

1	The	O
2	alternative	B
3	sigma	I
4	factor	I
5	sigmaB	O
6	in	O
7	Staphylococcus	O
8	aureus	O
9	:	O
10	regulation	O
11	of	O
12	the	B
13	sigB	I
14	operon	O
15	in	O
16	response	O
17	to	O
18	growth	O
19	phase	O
20	and	B
21	heat	I
22	shock	I

1	Prevention	O
2	of	O
3	acute	O
4	paraquat	O
5	toxicity	O
6	in	O
7	rats	O
8	by	B
9	superoxide	I
10	dismutase	I
11	.	I

1	The	O
2	morphological	O
3	effects	O
4	of	O
5	two	O
6	snake	O
7	venoms	O
8	,	O
9	N	O
10	.	O
11	naja	O
12	and	O
13	A	O
14	.	O
15	piscivorus	O
16	,	O
17	and	O
18	of	O
19	the	O
20	Direct	O
21	Lytic	O
22	Factor	O
23	and	B
24	Phospholipase	I
25	-	O
26	A	O
27	,	O
28	compounds	O
29	purified	O
30	from	O
31	N	O
32	.	O
33	naja	O
34	crude	O
35	venom	O
36	,	O
37	were	O
38	investigated	O
39	on	O
40	lung	O
41	and	O
42	cremaster	O
43	vessels	O
44	of	O
45	rats	O
46	.	O

1	Thus	O
2	,	O
3	transcriptional	O
4	regulation	O
5	,	O
6	splicing	O
7	,	O
8	kinase	O
9	interaction	O
10	sites	O
11	,	O
12	and	O
13	tyrosine	O
14	phosphorylation	O
15	of	O
16	the	B
17	LMP2A	O
18	homologs	O
19	have	O
20	been	O
21	conserved	O
22	despite	O
23	significant	O
24	sequences	O
25	heterogeneity	O
26	in	O
27	the	O
28	preterminal	O
29	repeat	O
30	regions	O
31	of	O
32	these	O
33	human	O
34	and	O
35	nonhuman	O
36	primate	O
37	EBVs	O
38	.	O

1	EMBO	O
2	J	O
3	.	O

1	The	O
2	relative	O
3	importance	O
4	of	O
5	these	O
6	two	O
7	mechanisms	O
8	differed	O
9	in	O
10	a	O
11	response	O
12	element	O
13	-	O
14	specific	O
15	manner	O
16	.	O

1	A	O
2	genomic	O
3	DNA	O
4	clone	O
5	encoding	O
6	oryzacystatin	O
7	(	O
8	Oc	O
9	),	O
10	a	B
11	cysteine	I
12	proteinase	I
13	inhibitor	O
14	(	O
15	cystatin	O
16	)	O
17	of	O
18	rice	O
19	,	O
20	was	O
21	isolated	O
22	from	O
23	a	O
24	lambda	O
25	EMBL3	O
26	phage	O
27	library	O
28	constructed	O
29	with	O
30	Sau3AI	O
31	partial	O
32	digests	O
33	of	O
34	rice	O
35	chromosomal	O
36	DNA	O
37	,	O
38	by	O
39	screening	O
40	with	O
41	an	O
42	oc	O
43	cDNA	O
44	as	O
45	a	O
46	probe	O
47	.	O

1	GnRH	O
2	treatment	O
3	was	O
4	found	O
5	to	O
6	increase	O
7	the	O
8	phosphorylation	O
9	of	O
10	tyrosine	O
11	residues	O
12	of	O
13	MAPK	O
14	and	O
15	to	O
16	increase	O
17	MAPK	O
18	activity	O
19	,	O
20	as	O
21	determined	O
22	by	O
23	an	O
24	immune	O
25	complex	O
26	kinase	O
27	assay	O
28	.	O

1	It	O
2	was	O
3	also	O
4	found	O
5	that	O
6	there	O
7	is	O
8	no	O
9	significant	O
10	difference	O
11	between	O
12	the	O
13	prevalence	O
14	of	O
15	nasal	O
16	carriage	O
17	of	O
18	S	O
19	.	O
20	aureus	O
21	amongst	O
22	the	O
23	hospital	O
24	staff	O
25	and	O
26	the	O
27	patients	O
28	.	O

1	Expression	O
2	of	O
3	h6	O
4	.	O
5	1	O
6	in	O
7	COS	O
8	-	O
9	1	O
10	cells	O
11	led	O
12	to	O
13	the	O
14	production	O
15	of	O
16	a	O
17	typical	O
18	type	O
19	IV	O
20	PDE	O
21	activity	O
22	in	O
23	that	O
24	cAMP	O
25	,	O
26	but	O
27	not	O
28	cGMP	O
29	,	O
30	served	O
31	as	O
32	substrate	O
33	and	O
34	its	O
35	activity	O
36	was	O
37	insensitive	O
38	to	O
39	either	O
40	Ca2	O
41	+/	O
42	CaM	O
43	or	O
44	cGMP	O
45	but	O
46	was	O
47	inhibited	O
48	by	O
49	low	O
50	concentrations	O
51	of	O
52	rolipram	O
53	.(	O
54	ABSTRACT	O
55	TRUNCATED	O
56	AT	O
57	400	O
58	WORDS	O
59	)	O

1	Methods	O
2	of	O
3	clinical	O
4	and	O
5	experimental	O
6	algesimetry	O
7	are	O
8	described	O
9	that	O
10	have	O
11	been	O
12	used	O
13	to	O
14	evaluate	O
15	effects	O
16	of	O
17	peripherally	O
18	and	O
19	centrally	O
20	acting	O
21	analgesics	O
22	.	O

1	The	O
2	sequence	O
3	data	O
4	now	O
5	permit	O
6	a	O
7	detailed	O
8	interpretation	O
9	of	O
10	the	O
11	X	O
12	-	O
13	ray	O
14	crystallographic	O
15	structure	O
16	of	O
17	the	O
18	enzyme	O
19	and	O
20	the	O
21	cloning	O
22	and	O
23	expression	O
24	of	O
25	the	O
26	clostridial	O
27	gene	O
28	will	O
29	facilitate	O
30	site	O
31	-	O
32	directed	O
33	mutagenesis	O
34	.	O

1	Intensive	O
2	synthesis	O
3	of	O
4	PNA	O
5	in	O
6	the	O
7	cells	O
8	of	O
9	microvascular	O
10	wall	O
11	evidenced	O
12	of	O
13	their	O
14	high	O
15	functional	O
16	activity	O
17	,	O
18	and	O
19	the	O
20	synthesis	O
21	of	O
22	DNA	O
23	in	O
24	them	O
25	showed	O
26	their	O
27	ability	O
28	for	O
29	proliferation	O
30	,	O
31	i	O
32	.	O
33	g	O
34	.--	O
35	for	O
36	growth	O
37	.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	assess	O
7	the	O
8	effects	O
9	of	O
10	hypothermia	O
11	and	O
12	chemical	O
13	cardioplegia	O
14	on	O
15	the	O
16	functional	O
17	recovery	O
18	of	O
19	hypertrophied	O
20	non	O
21	-	O
22	failing	O
23	rat	O
24	hearts	O
25	subjected	O
26	to	O
27	an	O
28	extended	O
29	period	O
30	of	O
31	global	O
32	ischaemia	O
33	.	O

1	(	O
2	total	O
3	soluble	O
4	solids	O
5	)	O
6	and	O
7	organoleptic	O
8	characteristics	O
9	under	O
10	the	O
11	influence	O
12	of	O
13	different	O
14	treatments	O
15	.	O

1	We	O
2	conclude	O
3	that	B
4	c	I
5	-	I
6	Myb	O
7	regulates	O
8	the	B
9	RAG	I
10	-	I
11	2	I
12	promoter	O
13	in	O
14	T	O
15	cells	O
16	by	O
17	binding	O
18	to	O
19	this	O
20	consensus	B
21	c	I
22	-	I
23	Myb	I
24	binding	I
25	site	I
26	.	I

1	We	O
2	consider	O
3	that	O
4	DIL	O
5	-	O
6	CP	O
7	is	O
8	a	O
9	safe	O
10	and	O
11	excellent	O
12	CP	O
13	in	O
14	CABG	O
15	surgery	O
16	and	O
17	we	O
18	are	O
19	now	O
20	utilizing	O
21	this	O
22	CP	O
23	in	O
24	all	O
25	patients	O
26	requiring	O
27	CABG	O
28	surgery	O
29	.	O

1	The	O
2	major	B
3	PKC	I
4	beta	I
5	transcription	I
6	initiation	I
7	site	O
8	was	O
9	identified	O
10	by	O
11	primer	O
12	extension	O
13	and	B
14	S1	I
15	nuclease	O
16	protection	O
17	.	O

1	The	B
2	SEB1	I
3	homologue	O
4	thus	O
5	isolated	O
6	,	O
7	SEB2	O
8	,	O
9	encodes	O
10	a	O
11	protein	O
12	53	O
13	%	O
14	identical	O
15	to	B
16	Seb1p	I
17	.	I

1	On	O
2	admission	O
3	to	O
4	our	O
5	department	O
6	in	O
7	September	O
8	,	O
9	1987	O
10	,	O
11	the	O
12	patient	O
13	was	O
14	alert	O
15	and	O
16	had	O
17	spastic	O
18	paraparesis	O
19	,	O
20	the	O
21	impairment	O
22	of	O
23	all	O
24	sensory	O
25	modalities	O
26	below	O
27	the	O
28	level	O
29	of	O
30	Th	O
31	10	O
32	and	O
33	urinary	O
34	disturbance	O
35	.	O

1	Specific	O
2	binding	O
3	of	O
4	the	O
5	protein	O
6	factors	O
7	to	O
8	the	O
9	sites	O
10	,	O
11	possibly	O
12	to	O
13	the	O
14	three	O
15	Mt	O
16	sequences	O
17	,	O
18	may	O
19	play	O
20	an	O
21	important	O
22	role	O
23	in	O
24	the	O
25	coordinate	O
26	regulation	O
27	of	O
28	the	O
29	transcription	O
30	of	O
31	nuclear	O
32	genes	O
33	encoding	O
34	subunits	O
35	responsible	O
36	for	O
37	mitochondrial	O
38	oxidative	O
39	phosphorylation	O
40	.	O

1	The	O
2	N	O
3	terminus	O
4	of	O
5	beta	O
6	(	O
7	95	O
8	kDa	O
9	)	O
10	corresponds	O
11	to	O
12	alpha	O
13	with	O
14	the	O
15	integrase	O
16	domain	O
17	attached	O
18	to	O
19	the	O
20	C	O
21	terminus	O
22	(	O
23	32	O
24	kDa	O
25	).	O

1	The	O
2	ability	O
3	of	B
4	U6	I
5	-	I
6	U57	I
7	mutants	O
8	to	O
9	influence	O
10	the	O
11	fidelity	O
12	of	O
13	both	O
14	branch	O
15	site	O
16	and	O
17	3	O
18	'	O
19	splice	O
20	site	O
21	recognition	O
22	suggests	O
23	that	O
24	this	O
25	nucleotide	O
26	may	O
27	participate	O
28	in	O
29	the	O
30	formation	O
31	of	O
32	the	O
33	active	O
34	site	O
35	(	O
36	s	O
37	)	O
38	of	O
39	the	O
40	spliceosome	O
41	.	O

1	Thus	O
2	,	O
3	the	O
4	CCAAT	O
5	box	O
6	also	O
7	has	O
8	tissue	O
9	-	O
10	specific	O
11	characteristics	O
12	that	O
13	assist	O
14	in	O
15	targeting	O
16	expression	O
17	of	O
18	the	B
19	alpha	I
20	-	I
21	subunit	I
22	gene	O
23	to	O
24	trophoblasts	O
25	.	O

1	Effects	O
2	of	O
3	repeated	O
4	exposures	O
5	of	O
6	hydrogen	O
7	sulphide	O
8	on	O
9	rat	O
10	hippocampal	O
11	EEG	O
12	.	O

1	The	O
2	nonconsensus	O
3	TATA	O
4	box	O
5	in	O
6	promoter	O
7	B	O
8	plays	O
9	a	O
10	more	O
11	important	O
12	role	O
13	in	O
14	promoter	O
15	activity	O
16	than	O
17	the	O
18	TATA	O
19	box	O
20	in	O
21	promoter	O
22	A	O
23	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	have	O
7	analyzed	O
8	the	O
9	structure	O
10	of	O
11	human	O
12	gene	O
13	for	O
14	Gx	O
15	alpha	O
16	,	O
17	which	O
18	spans	O
19	more	O
20	than	O
21	60	O
22	kilobases	O
23	.	O

1	Arm	O
2	function	O
3	tests	O
4	.	O

1	Under	O
2	these	O
3	conditions	O
4	,	O
5	transfections	O
6	with	O
7	cDNAs	O
8	of	O
9	the	B
10	NF	I
11	-	I
12	kappa	I
13	B	I
14	p50	O
15	and	O
16	serum	O
17	response	O
18	factor	O
19	(	B
20	SRF	O
21	)	O
22	produced	O
23	a	O
24	factor	O
25	(	O
26	s	O
27	)	O
28	that	O
29	mediated	O
30	Tax	O
31	binding	O
32	to	O
33	the	B
34	NF	I
35	-	I
36	kappa	I
37	B	I
38	site	O
39	and	O
40	the	O
41	CArG	O
42	box	O
43	respectively	O
44	.	O

1	D	O
2	.	O

1	These	B
2	IgG	I
3	antibodies	O
4	in	O
5	the	O
6	babies	O
7	diminished	O
8	rapidly	O
9	after	O
10	delivery	O
11	,	O
12	and	O
13	were	O
14	detectable	O
15	only	O
16	in	O
17	3	O
18	cases	O
19	at	O
20	2	O
21	,	O
22	3	O
23	,	O
24	and	O
25	5	O
26	months	O
27	of	O
28	ages	O
29	out	O
30	of	O
31	38	O
32	babies	O
33	up	O
34	to	O
35	21	O
36	months	O
37	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	the	O
9	cooperation	O
10	of	O
11	transcription	O
12	factors	B
13	NF	I
14	-	I
15	kappaB	I
16	and	I
17	AP	I
18	-	I
19	1	O
20	is	O
21	essential	O
22	for	O
23	transactivation	O
24	of	B
25	IL	I
26	-	I
27	8	I
28	gene	O
29	by	O
30	HTLV	I
31	-	I
32	I	I
33	Tax	I
34	.	I

1	In	O
2	study	O
3	2	O
4	,	O
5	the	O
6	correlation	O
7	coefficients	O
8	between	O
9	the	O
10	ISO2	O
11	measurements	O
12	obtained	O
13	at	O
14	the	O
15	ulcer	O
16	margin	O
17	and	O
18	at	O
19	the	O
20	adjacent	O
21	normal	O
22	mucosa	O
23	,	O
24	and	O
25	delta	O
26	ISO2	O
27	obtained	O
28	by	O
29	the	O
30	experienced	O
31	observer	O
32	and	O
33	one	O
34	of	O
35	the	O
36	three	O
37	learners	O
38	were	O
39	0	O
40	.	O
41	94	O
42	,	O
43	0	O
44	.	O
45	97	O
46	,	O
47	and	O
48	0	O
49	.	O
50	94	O
51	,	O
52	respectively	O
53	.	O

1	We	O
2	have	O
3	cloned	O
4	cDNA	O
5	and	O
6	genomic	O
7	DNA	O
8	for	O
9	a	O
10	mouse	O
11	gene	O
12	encoding	O
13	a	O
14	protein	O
15	with	O
16	significant	O
17	sequence	O
18	similarity	O
19	to	O
20	conserved	O
21	domains	O
22	found	O
23	in	O
24	proteins	O
25	of	O
26	the	O
27	Spo11p	I
28	family	I
29	.	I

1	These	O
2	results	O
3	suggest	O
4	that	O
5	5	O
6	KE	O
7	X	O
8	3	O
9	/	O
10	W	O
11	may	O
12	be	O
13	the	O
14	optimal	O
15	regimen	O
16	to	O
17	augment	O
18	the	O
19	antitumor	O
20	immunity	O
21	of	O
22	RNL	O
23	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	if	O
7	the	O
8	measured	O
9	angle	O
10	ANB	O
11	is	O
12	smaller	O
13	than	O
14	the	O
15	calculated	O
16	angle	O
17	,	O
18	the	O
19	skeletal	O
20	relation	O
21	is	O
22	Class	O
23	III	O
24	.	O

1	Subretinal	O
2	fluid	O
3	was	O
4	punctured	O
5	on	O
6	the	O
7	poorer	O
8	eye	O
9	in	O
10	19	O
11	eyes	O
12	(	O
13	52	O
14	.	O
15	7	O
16	%)	O
17	and	O
18	on	O
19	the	O
20	better	O
21	eye	O
22	in	O
23	7	O
24	eyes	O
25	(	O
26	19	O
27	.	O
28	4	O
29	%).	O

1	Southern	O
2	analysis	O
3	on	O
4	genomic	O
5	DNA	O
6	isolated	O
7	from	O
8	tissues	O
9	and	O
10	cell	O
11	lines	O
12	from	O
13	several	O
14	mouse	O
15	strains	O
16	using	B
17	mCD22	I
18	cDNA	O
19	demonstrated	O
20	that	O
21	the	B
22	Cd22	I
23	locus	I
24	encoding	I
25	mCD22	O
26	is	O
27	a	O
28	single	O
29	copy	O
30	gene	O
31	of	O
32	<	O
33	or	O
34	=	O
35	30	O
36	kb	O
37	.	O

1	Genes	O
2	for	O
3	ocs	O
4	element	O
5	binding	O
6	factors	O
7	(	O
8	OBFs	O
9	),	O
10	belonging	O
11	to	O
12	a	O
13	specific	O
14	class	O
15	of	B
16	basic	I
17	-	I
18	region	I
19	leucine	I
20	zipper	I
21	(	I
22	bZIP	I
23	)	I
24	transcription	I
25	factors	O
26	,	O
27	have	O
28	been	O
29	isolated	O
30	in	O
31	a	O
32	number	O
33	of	O
34	plants	O
35	.	O

1	A	O
2	215	O
3	-	O
4	base	O
5	-	O
6	pair	O
7	(	O
8	bp	O
9	)	O
10	region	O
11	of	O
12	the	B
13	mouse	B
14	MOPC	B
15	41	I
16	kappa	I
17	light	I
18	-	I
19	chain	I
20	immunoglobulin	I
21	gene	I
22	enhancer	O
23	has	O
24	been	O
25	analyzed	O
26	for	O
27	specific	O
28	binding	O
29	of	O
30	lymphoid	O
31	and	O
32	nonlymphoid	O
33	nuclear	O
34	factors	O
35	.	O

1	In	O
2	contrast	O
3	,	O
4	over	O
5	-	O
6	expression	O
7	of	B
8	RAR	I
9	beta	O
10	only	O
11	poorly	O
12	restored	O
13	differentiation	O
14	,	O
15	although	O
16	it	O
17	could	O
18	replace	B
19	RAR	I
20	gamma	O
21	for	O
22	the	O
23	activation	O
24	of	O
25	target	O
26	genes	O
27	.	O

1	ATP	O
2	-	O
3	dependent	O
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	mismatch	O
14	and	O
15	the	O
16	yeast	O
17	MSH2	O
18	-	O
19	MSH6	O
20	and	O
21	MLH1	I
22	-	I
23	PMS1	I
24	protein	I
25	complexes	I
26	.	I

1	Unitary	O
2	-	O
3	group	O
4	approach	O
5	to	O
6	spin	O
7	-	O
8	dependent	O
9	operators	O
10	.	O

1	Two	O
2	patients	O
3	with	O
4	recurrent	O
5	tumors	O
6	had	O
7	high	O
8	S	O
9	-	O
10	phase	O
11	fractions	O
12	both	O
13	on	O
14	the	O
15	first	O
16	resected	O
17	specimens	O
18	and	O
19	at	O
20	the	O
21	time	O
22	of	O
23	the	O
24	second	O
25	operation	O
26	.	O

1	Mean	O
2	total	O
3	lung	O
4	capacity	O
5	,	O
6	functional	O
7	residual	O
8	capacity	O
9	,	O
10	and	O
11	residual	O
12	volume	O
13	increased	O
14	significantly	O
15	,	O
16	and	O
17	the	O
18	mean	O
19	closing	O
20	volume	O
21	,	O
22	the	O
23	lung	O
24	volume	O
25	above	O
26	residual	O
27	volume	O
28	at	O
29	which	O
30	phase	O
31	IV	O
32	begins	O
33	,	O
34	decreased	O
35	significantly	O
36	with	O
37	11	O
38	cm	O
39	H20	O
40	continuous	O
41	positive	O
42	airway	O
43	pressure	O
44	;	O
45	differences	O
46	at	O
47	5	O
48	cm	O
49	H20	O
50	were	O
51	not	O
52	significant	O
53	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	the	O
8	production	O
9	of	O
10	active	B
11	recombinant	B
12	telomerase	O
13	requires	O
14	a	O
15	factor	O
16	in	O
17	rabbit	O
18	reticulocyte	O
19	lysate	O
20	that	O
21	promotes	O
22	ribonucleoprotein	O
23	assembly	O
24	.	O

1	RESULTS	O
2	:	O
3	Neither	O
4	basal	O
5	FSH	O
6	level	O
7	nor	O
8	stimulated	O
9	FSH	O
10	level	O
11	alone	O
12	were	O
13	statistically	O
14	significant	O
15	predictors	O
16	of	O
17	IVF	O
18	success	O
19	;	O
20	however	O
21	,	O
22	no	O
23	patient	O
24	with	O
25	a	O
26	day	O
27	3	O
28	FSH	O
29	level	O
30	>	O
31	11	O
32	.	O
33	1	O
34	mIU	O
35	/	O
36	ml	O
37	or	O
38	a	O
39	stimulated	O
40	day	O
41	10	O
42	FSH	O
43	level	O
44	>	O
45	13	O
46	.	O
47	5	O
48	mIU	O
49	/	O
50	ml	O
51	conceived	O
52	and	O
53	carried	O
54	a	O
55	pregnancy	O
56	.	O

1	The	O
2	eating	O
3	and	O
4	drinking	O
5	patterns	O
6	of	O
7	pygmy	O
8	goats	O
9	fed	O
10	ad	O
11	lib	O
12	and	O
13	kept	O
14	on	O
15	a	O
16	12	O
17	h	O
18	light	O
19	/	O
20	12	O
21	h	O
22	dark	O
23	cycle	O
24	were	O
25	recorded	O
26	and	O
27	analyzed	O
28	.	O

1	Amounts	O
2	of	O
3	glucose	O
4	infused	O
5	during	O
6	the	O
7	last	O
8	20	O
9	min	O
10	of	O
11	each	O
12	2	O
13	hour	B
14	insulin	O
15	infusion	O
16	were	O
17	(	O
18	at	O
19	1	O
20	and	O
21	10	O
22	m	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	respectively	O
28	):	O
29	before	O
30	treatment	O
31	(	O
32	K	O
33	+	O
34	=	O
35	2	O
36	.	O
37	7	O
38	mmol	O
39	/	O
40	l	O
41	):	O
42	2	O
43	.	O
44	4	O
45	and	O
46	8	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	kg	O
52	/	O
53	min	O
54	;	O
55	after	O
56	spironolactone	O
57	(	O
58	K	O
59	+	O
60	=	O
61	3	O
62	.	O
63	9	O
64	mmol	O
65	/	O
66	l	O
67	):	O
68	3	O
69	.	O
70	3	O
71	and	O
72	15	O
73	.	O
74	4	O
75	mg	O
76	/	O
77	kg	O
78	/	O
79	min	O
80	;	O
81	after	O
82	indomethacine	O
83	(	O
84	K	O
85	+	O
86	=	O
87	3	O
88	.	O
89	7	O
90	mmol	O
91	/	O
92	l	O
93	):	O
94	5	O
95	and	O
96	19	O
97	mg	O
98	/	O
99	kg	O
100	/	O
101	min	O
102	after	O
103	stopping	O
104	drugs	O
105	(	O
106	K	O
107	+	O
108	=	O
109	2	O
110	.	O
111	9	O
112	mmol	O
113	/	O
114	l	O
115	):	O
116	2	O
117	.	O
118	5	O
119	and	O
120	5	O
121	.	O
122	3	O
123	mg	O
124	/	O
125	kg	O
126	/	O
127	min	O
128	.	O

1	Pentane	O
2	and	O
3	ethane	O
4	,	O
5	which	O
6	arise	O
7	during	O
8	lipid	O
9	peroxidation	O
10	in	O
11	vivo	O
12	,	O
13	were	O
14	measured	O
15	by	O
16	gas	O
17	chromatography	O
18	in	O
19	breath	O
20	samples	O
21	of	O
22	rats	O
23	fed	O
24	for	O
25	8	O
26	weeks	O
27	a	O
28	vitamin	O
29	E	O
30	-	O
31	deficient	O
32	diet	O
33	to	O
34	which	O
35	had	O
36	been	O
37	added	O
38	0	O
39	,	O
40	11	O
41	,	O
42	or	O
43	40	O
44	IU	O
45	vitamin	O
46	E	O
47	acetate	O
48	per	O
49	kg	O
50	.	O

1	Based	O
2	on	O
3	subcellular	O
4	fractionation	O
5	,	O
6	the	B
7	47	I
8	-	I
9	kDa	I
10	P	I
11	-	I
12	CIP2	I
13	protein	O
14	is	O
15	mostly	O
16	cytosolic	O
17	.	O

1	Survival	O
2	rates	O
3	for	O
4	the	O
5	original	O
6	treatment	O
7	group	O
8	were	O
9	84	O
10	.	O
11	5	O
12	%	O
13	and	O
14	57	O
15	.	O
16	6	O
17	%	O
18	at	O
19	12	O
20	and	O
21	21	O
22	months	O
23	,	O
24	respectively	O
25	;	O
26	for	O
27	the	O
28	delayed	O
29	treatment	O
30	group	O
31	,	O
32	78	O
33	.	O
34	8	O
35	%	O
36	and	O
37	64	O
38	.	O
39	6	O
40	%	O
41	at	O
42	12	O
43	and	O
44	21	O
45	months	O
46	,	O
47	respectively	O
48	,	O
49	and	O
50	78	O
51	.	O
52	8	O
53	%	O
54	and	O
55	47	O
56	.	O
57	5	O
58	%	O
59	at	O
60	12	O
61	and	O
62	21	O
63	months	O
64	,	O
65	respectively	O
66	,	O
67	for	O
68	77	O
69	subjects	O
70	with	O
71	AIDS	O
72	and	O
73	93	O
74	.	O
75	0	O
76	%	O
77	and	O
78	71	O
79	.	O
80	8	O
81	%,	O
82	respectively	O
83	,	O
84	for	O
85	50	O
86	subjects	O
87	with	O
88	AIDS	O
89	-	O
90	related	O
91	complex	O
92	in	O
93	the	O
94	original	O
95	treatment	O
96	group	O
97	.	O

1	In	O
2	CV	O
3	-	O
4	1	O
5	cells	O
6	,	O
7	cotransfection	O
8	of	O
9	the	O
10	retinoid	O
11	and	O
12	estrogen	O
13	receptors	O
14	led	O
15	to	O
16	mutual	O
17	inhibition	O
18	of	O
19	the	O
20	other	O
21	'	O
22	s	O
23	activity	O
24	,	O
25	while	O
26	an	O
27	RA	O
28	-	O
29	dependent	O
30	inhibition	O
31	of	O
32	ER	O
33	activity	O
34	was	O
35	observed	O
36	in	O
37	breast	O
38	cancer	O
39	cells	O
40	.	O

1	In	O
2	endemic	O
3	BL	O
4	,	O
5	the	B
6	RB2	I
7	/	I
8	p130	I
9	gene	O
10	is	O
11	mutated	O
12	in	O
13	most	O
14	of	O
15	the	O
16	cases	O
17	,	O
18	and	O
19	the	O
20	protein	O
21	is	O
22	restricted	O
23	to	O
24	the	O
25	cytoplasm	O
26	.	O

1	In	O
2	contrast	O
3	,	O
4	we	O
5	observed	O
6	high	O
7	concentrations	O
8	in	O
9	29	O
10	of	O
11	75	O
12	patients	O
13	with	O
14	tumors	O
15	of	O
16	the	O
17	central	O
18	nervous	O
19	system	O
20	,	O
21	especially	O
22	in	O
23	meningioma	O
24	(	O
25	6	O
26	/	O
27	9	O
28	),	O
29	glioblastoma	O
30	(	O
31	9	O
32	/	O
33	23	O
34	),	O
35	and	O
36	neurinoma	O
37	(	O
38	5	O
39	/	O
40	5	O
41	).	O

1	Of	O
2	600	O
3	mediastinoscopies	O
4	carried	O
5	out	O
6	from	O
7	1966	O
8	to	O
9	1973	O
10	,	O
11	479	O
12	were	O
13	performed	O
14	to	O
15	assess	O
16	the	O
17	operability	O
18	of	O
19	a	O
20	pulmonary	O
21	carcinoma	O
22	.	O

1	A	O
2	large	O
3	increase	O
4	of	O
5	serum	O
6	ketones	O
7	occurred	O
8	under	O
9	all	O
10	conditions	O
11	,	O
12	and	O
13	the	O
14	exercise	O
15	respiratory	O
16	quotient	O
17	suggested	O
18	some	O
19	increase	O
20	of	O
21	fat	O
22	utilization	O
23	,	O
24	WW	O
25	(	O
26	0	O
27	.	O
28	85	O
29	)	O
30	through	O
31	CW	O
32	(	O
33	0	O
34	.	O
35	84	O
36	)	O
37	to	O
38	CC	O
39	(	O
40	0	O
41	.	O
42	83	O
43	).	O

1	1	O
2	.	O

1	Effects	O
2	of	O
3	a	O
4	perfluorochemical	O
5	blood	O
6	substitute	O
7	on	O
8	diazepam	O
9	binding	O
10	by	B
11	human	B
12	albumin	O
13	.	O

1	Cytochrome	O
2	b	O
3	in	B
4	human	I
5	complex	I
6	II	I
7	(	I
8	succinate	I
9	-	I
10	ubiquinone	I
11	oxidoreductase	O
12	):	O
13	cDNA	O
14	cloning	O
15	of	O
16	the	O
17	components	O
18	in	O
19	liver	O
20	mitochondria	O
21	and	O
22	chromosome	O
23	assignment	O
24	of	O
25	the	O
26	genes	O
27	for	O
28	the	O
29	large	O
30	(	O
31	SDHC	O
32	)	O
33	and	O
34	small	O
35	(	O
36	SDHD	O
37	)	O
38	subunits	O
39	to	O
40	1q21	O
41	and	O
42	11q23	O
43	.	O

1	Development	O
2	of	O
3	a	O
4	provisional	O
5	information	O
6	-	O
7	retrieval	O
8	descriptor	O
9	language	O
10	for	O
11	"	O
12	Roentgenology	O
13	and	O
14	Medical	O
15	Radiology	O
16	"	O
17	for	O
18	use	O
19	in	O
20	the	O
21	Medinform	O
22	system	O

1	The	O
2	effects	O
3	of	O
4	glutaraldehyde	O
5	on	O
6	dimensions	O
7	and	O
8	ultrastructure	O
9	of	O
10	microvascular	O
11	beds	O
12	in	O
13	rat	O
14	mesentery	O
15	were	O
16	studied	O
17	in	O
18	two	O
19	kinds	O
20	of	O
21	experiment	O
22	,	O
23	administering	O
24	the	O
25	fixative	O
26	by	O
27	intra	O
28	-	O
29	arterial	O
30	perfusion	O
31	at	O
32	a	O
33	pressure	O
34	of	O
35	80	O
36	mm	O
37	Hg	O
38	and	O
39	by	O
40	superfusion	O
41	of	O
42	the	O
43	exteriorized	O
44	mesenteric	O
45	membrane	O
46	.	O

1	Auditory	O
2	threshold	O
3	shifts	O
4	,	O
5	as	O
6	measured	O
7	by	O
8	the	O
9	auditory	O
10	evoked	O
11	brainstem	O
12	response	O
13	,	O
14	were	O
15	measured	O
16	at	O
17	2	O
18	,	O
19	4	O
20	,	O
21	8	O
22	,	O
23	12	O
24	,	O
25	16	O
26	,	O
27	20	O
28	and	O
29	24	B
30	kHz	I
31	.	I

1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	haemodialysis	O
6	patients	O
7	with	O
8	chronic	O
9	hepatitis	O
10	C	O
11	respond	O
12	well	O
13	to	B
14	interferon	O
15	treatment	O
16	and	O
17	that	O
18	a	O
19	long	O
20	-	O
21	term	O
22	response	O
23	is	O
24	achieved	O
25	in	O
26	a	O
27	high	O
28	proportion	O
29	of	O
30	patients	O
31	.	O

1	It	O
2	has	O
3	been	O
4	previously	O
5	shown	O
6	that	O
7	genes	O
8	transcribed	O
9	by	B
10	RNA	I
11	polymerase	I
12	II	I
13	(	I
14	RNAP	I
15	II	O
16	)	O
17	are	O
18	subject	O
19	to	O
20	position	O
21	effect	O
22	variegation	O
23	when	O
24	located	O
25	near	O
26	yeast	O
27	telomeres	O
28	.	O

1	Phosphorylation	O
2	analyses	O
3	indicated	O
4	that	O
5	inhibition	O
6	of	B
7	ERK	I
8	-	I
9	1	I
10	/	I
11	2	O
12	decreased	O
13	okadaic	O
14	acid	O
15	-	O
16	elevated	O
17	phosphorylation	O
18	of	O
19	JunD	O
20	and	O
21	FosB	O
22	.	O

1	Scmh1	B
2	maps	O
3	to	B
4	4D1	I
5	-	I
6	D2	O
7	.	O
8	1	O
9	in	O
10	mice	O
11	.	O

1	We	O
2	have	O
3	been	O
4	studying	O
5	the	O
6	interaction	O
7	of	O
8	the	O
9	oncogenic	B
10	human	B
11	polyomavirus	I
12	BK	I
13	(	I
14	BKV	O
15	)	O
16	with	O
17	the	B
18	tumor	I
19	-	I
20	suppressor	I
21	protein	I
22	p53	O
23	to	O
24	understand	O
25	the	O
26	biology	O
27	of	O
28	this	O
29	virus	O
30	as	O
31	well	O
32	as	O
33	to	O
34	understand	O
35	the	O
36	basic	O
37	mechanisms	O
38	of	B
39	p53	O
40	transactivation	O
41	.	O

1	These	O
2	studies	O
3	indicate	O
4	that	O
5	the	O
6	acidimetric	O
7	test	O
8	was	O
9	less	O
10	sensitive	O
11	than	O
12	the	O
13	chromogenic	O
14	cephalosporin	O
15	substrates	O
16	and	O
17	that	O
18	nitrocefin	O
19	and	O
20	S1	O
21	could	O
22	be	O
23	used	O
24	to	O
25	screen	O
26	for	O
27	beta	O
28	-	O
29	lactamase	O
30	production	O
31	in	O
32	these	O
33	tested	O
34	species	O
35	.	O

1	Monospecific	O
2	antibodies	O
3	,	O
4	eluted	O
5	from	O
6	the	B
7	beta	I
8	-	I
9	galactosidase	I
10	fusion	I
11	protein	O
12	of	O
13	either	O
14	clone	O
15	reacted	O
16	with	O
17	the	B
18	U1	I
19	snRNP	I
20	-	I
21	specific	I
22	A	I
23	antigen	I
24	.	I

1	Thus	O
2	,	O
3	the	O
4	PCE	O
5	binds	O
6	a	O
7	Pbx	O
8	dimer	O
9	partner	O
10	that	O
11	behaves	O
12	unlike	O
13	Class	B
14	I	B
15	Hox	I
16	proteins	I
17	.	I

1	Suppression	O
2	of	O
3	food	O
4	intake	O
5	in	O
6	the	O
7	rat	O
8	by	O
9	tung	O
10	oil	O
11	.	O

1	Next	O
2	,	O
3	to	O
4	identify	O
5	regions	O
6	of	O
7	the	O
8	promoter	O
9	involved	O
10	,	O
11	we	O
12	examined	O
13	a	O
14	series	O
15	of	O
16	tenascin	O
17	-	O
18	C	O
19	promoter	O
20	constructs	O
21	with	O
22	5	O
23	'	O
24	deletions	O
25	and	O
26	showed	O
27	that	O
28	denatured	B
29	collagen	I
30	-	I
31	dependent	I
32	promoter	O
33	activity	O
34	was	O
35	retained	O
36	by	O
37	a	O
38	122	O
39	-	O
40	base	O
41	pair	O
42	element	O
43	,	O
44	located	O
45	-	O
46	43	O
47	to	O
48	-	O
49	165	O
50	bp	O
51	upstream	O
52	of	O
53	the	O
54	RNA	O
55	start	O
56	site	O
57	.	O

1	In	O
2	nine	O
3	patients	O
4	with	O
5	renal	O
6	failure	O
7	routine	O
8	haemodialysis	O
9	was	O
10	accompanied	O
11	by	O
12	a	O
13	30	O
14	per	O
15	cent	O
16	reduction	O
17	in	O
18	plasma	O
19	ANP	O
20	concentration	O
21	.	O

1	However	O
2	,	O
3	overexpression	O
4	of	O
5	both	O
6	the	O
7	STE4	O
8	and	O
9	STE18	O
10	proteins	O
11	did	O
12	not	O
13	generate	O
14	a	O
15	stronger	O
16	pheromone	O
17	response	O
18	than	O
19	overexpression	O
20	of	O
21	STE4	O
22	in	O
23	the	O
24	presence	O
25	of	O
26	wild	O
27	-	O
28	type	O
29	levels	O
30	of	O
31	STE18	O
32	.	O

1	Endoscopic	O
2	examinations	O
3	,	O
4	peripheral	O
5	white	O
6	blood	O
7	cell	O
8	(	O
9	WBC	O
10	)	O
11	counts	O
12	,	O
13	and	O
14	assays	O
15	of	O
16	myeloperoxidase	O
17	activity	O
18	(	O
19	MPO	O
20	)	O
21	in	O
22	homogenates	O
23	of	O
24	colon	O
25	mucosa	O
26	were	O
27	performed	O
28	after	O
29	one	O
30	week	O
31	(	O
32	4	O
33	%	O
34	DSS	O
35	model	O
36	)	O
37	and	O
38	eight	O
39	weeks	O
40	(	O
41	1	O
42	%	O
43	DSS	O
44	model	O
45	).	O

1	Mutations	O
2	within	B
3	human	I
4	UTR1	I
5	modulate	I
6	NRF	I
7	-	I
8	1	O
9	expression	O
10	by	O
11	interfering	O
12	with	O
13	mRNA	O
14	translational	O
15	efficiency	O
16	in	O
17	transfected	O
18	cells	O
19	and	O
20	in	O
21	an	O
22	in	O
23	vitro	O
24	translation	O
25	system	O
26	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	indicated	O
5	that	O
6	the	O
7	transcription	O
8	initiation	O
9	site	O
10	mapped	O
11	to	O
12	a	O
13	position	O
14	on	O
15	gene	O
16	IV	O
17	that	O
18	was	O
19	analogous	O
20	to	O
21	that	O
22	reported	O
23	for	O
24	the	O
25	structurally	O
26	similar	B
27	P	I
28	-	I
29	450e	I
30	gene	I
31	.	I

1	The	O
2	psychological	O
3	tests	O
4	consisted	O
5	of	O
6	a	O
7	free	O
8	-	O
9	recall	O
10	task	O
11	,	O
12	a	O
13	test	O
14	for	O
15	visuomotor	O
16	coordination	O
17	and	O
18	a	O
19	recognition	O
20	task	O
21	.	O

1	These	O
2	data	O
3	further	O
4	define	O
5	a	O
6	role	O
7	for	O
8	TRADD	O
9	and	B
10	TRAF2	B
11	in	B
12	JNK	O
13	activation	O
14	and	O
15	confirm	O
16	that	B
17	LMP1	O
18	utilizes	O
19	signalling	O
20	mechanisms	O
21	used	O
22	by	O
23	the	B
24	TNF	I
25	receptor	I
26	/	I
27	CD40	I
28	family	O
29	to	O
30	elicit	O
31	its	O
32	pleiotropic	O
33	activities	O
34	.	O

1	The	O
2	accumulation	O
3	of	O
4	both	O
5	LHA4	O
6	and	B
7	LHA2	I
8	mRNAs	O
9	is	O
10	induced	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	exogenous	O
16	sugars	O
17	and	O
18	this	O
19	induction	O
20	appears	O
21	to	O
22	be	O
23	dependent	O
24	on	O
25	sugar	O
26	uptake	O
27	and	O
28	metabolism	O
29	,	O
30	because	O
31	mannitol	O
32	and	B
33	3	I
34	-	I
35	O	I
36	-	I
37	methylglucose	O
38	do	O
39	not	O
40	stimulate	O
41	mRNA	O
42	accumulation	O
43	.	O

1	Besides	O
2	,	O
3	it	O
4	was	O
5	considered	O
6	that	O
7	the	O
8	NPF	O
9	was	O
10	a	O
11	useful	O
12	tool	O
13	for	O
14	activation	O
15	of	O
16	velopharyngeal	O
17	activity	O
18	by	O
19	way	O
20	of	O
21	visual	O
22	feed	O
23	-	O
24	back	O
25	control	O
26	.	O

1	Conversely	O
2	,	O
3	when	O
4	VDR	O
5	is	O
6	overexpressed	O
7	,	O
8	vitamin	O
9	D3	O
10	attenuates	O
11	9	O
12	-	O
13	cis	O
14	RA	O
15	induction	O
16	from	O
17	an	B
18	RXR	I
19	-	I
20	responsive	I
21	element	I
22	.	I

1	The	O
2	clinico	O
3	-	O
4	pathological	O
5	data	O
6	from	O
7	a	O
8	patient	O
9	with	O
10	irreversible	O
11	post	O
12	-	O
13	partum	O
14	renal	O
15	failure	O
16	(	O
17	IPRF	O
18	)	O
19	are	O
20	presented	O
21	.	O

1	First	O
2	,	O
3	the	O
4	finding	O
5	of	O
6	a	O
7	monomeric	B
8	Alu	I
9	family	I
10	repeat	O
11	at	O
12	the	O
13	junction	O
14	between	O
15	nonhomology	O
16	block	O
17	I	O
18	and	O
19	homology	O
20	block	O
21	Y	O
22	of	O
23	the	B
24	alpha	I
25	2	I
26	gene	I
27	-	O
28	containing	O
29	unit	O
30	in	O
31	rhesus	O
32	macaque	O
33	suggests	O
34	that	O
35	the	O
36	dimeric	O
37	Alu	O
38	family	O
39	repeat	O
40	,	O
41	Alu	O
42	3	O
43	,	O
44	at	O
45	the	O
46	orthologous	O
47	position	O
48	in	O
49	human	O
50	was	O
51	generated	O
52	by	O
53	insertion	O
54	of	O
55	a	O
56	monomeric	B
57	Alu	I
58	family	I
59	repeat	O
60	into	O
61	the	O
62	3	O
63	'	O
64	end	O
65	of	O
66	another	O
67	preexisting	B
68	Alu	I
69	family	I
70	repeat	I
71	.	I

1	Mutation	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	motif	O
7	TCCCCT	O
8	is	O
9	critical	O
10	for	O
11	PyRo1	O
12	interaction	O
13	.	O

1	We	O
2	and	O
3	others	O
4	have	O
5	demonstrated	O
6	that	O
7	the	B
8	c	I
9	-	I
10	cbl	I
11	proto	I
12	-	I
13	oncogene	I
14	product	O
15	is	O
16	one	O
17	of	O
18	the	O
19	earliest	O
20	targets	O
21	of	O
22	tyrosine	O
23	phosphorylation	O
24	upon	O
25	T	O
26	cell	O
27	receptor	O
28	stimulation	O
29	.	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	the	O
6	genomic	O
7	organization	O
8	of	O
9	the	B
10	human	B
11	TrxR2	I
12	gene	O
13	,	O
14	which	O
15	consists	O
16	of	O
17	18	O
18	exons	O
19	spanning	O
20	about	O
21	67	O
22	kb	O
23	,	O
24	and	O
25	its	O
26	chromosomal	O
27	localization	O
28	at	O
29	position	O
30	22q11	O
31	.	O
32	2	O
33	.	O

1	Null	O
2	alleles	O
3	of	O
4	SAS4	O
5	and	O
6	SAS5	O
7	bypassed	O
8	the	O
9	role	O
10	of	O
11	the	B
12	Abf1p	I
13	binding	I
14	site	O
15	of	O
16	the	B
17	HMR	I
18	-	I
19	E	O
20	silencer	O
21	but	O
22	not	O
23	the	O
24	role	O
25	of	O
26	the	O
27	ACS	O
28	or	B
29	Rap1p	I
30	binding	I
31	site	I
32	.	I

1	The	O
2	recovery	O
3	value	O
4	of	O
5	systolic	O
6	pressure	O
7	was	O
8	higher	O
9	than	O
10	diastolic	O
11	pressure	O
12	and	O
13	pulse	O
14	pressure	O
15	increased	O
16	.	O

1	This	O
2	distinction	O
3	was	O
4	based	O
5	upon	O
6	whether	O
7	the	O
8	diagnosis	O
9	provided	O
10	a	O
11	straightforward	O
12	range	O
13	of	O
14	prognoses	O
15	or	O
16	an	O
17	ambiguous	O
18	clinical	O
19	implication	O
20	.	O

1	In	O
2	the	O
3	ultramarathon	O
4	runner	O
5	the	O
6	testosterone	O
7	levels	O
8	sharply	O
9	rose	O
10	at	O
11	the	O
12	beginning	O
13	of	O
14	the	O
15	training	O
16	session	O
17	(	O
18	from	O
19	the	O
20	7	O
21	,	O
22	20	O
23	ng	O
24	/	O
25	ml	O
26	to	O
27	11	O
28	,	O
29	50	O
30	ng	O
31	/	O
32	ml	O
33	after	O
34	20	O
35	'	O
36	training	O
37	),	O
38	and	O
39	subsequently	O
40	decrease	O
41	after	O
42	3	O
43	hours	O
44	(	O
45	9	O
46	,	O
47	20	O
48	ng	O
49	/	O
50	ml	O
51	)	O
52	and	O
53	at	O
54	the	O
55	end	O
56	of	O
57	the	O
58	6	O
59	hours	O
60	training	O
61	(	O
62	4	O
63	,	O
64	60	O
65	ng	O
66	/	O
67	ml	O
68	).	O

1	The	O
2	minimum	O
3	and	O
4	essential	O
5	subunits	O
6	for	O
7	RNA	O
8	synthesis	O
9	have	O
10	not	O
11	yet	O
12	been	O
13	identified	O
14	.	O

1	The	B
2	human	B
3	RAD30B	O
4	and	B
5	mouse	B
6	Rad30b	I
7	mRNA	I
8	transcripts	O
9	,	O
10	like	O
11	many	O
12	repair	O
13	proteins	O
14	,	O
15	are	O
16	highly	O
17	expressed	O
18	in	O
19	the	O
20	testis	O
21	.	O

1	This	O
2	intracellular	O
3	signaling	O
4	,	O
5	known	O
6	as	O
7	the	O
8	unfolded	O
9	protein	O
10	response	O
11	(	O
12	UPR	O
13	),	O
14	is	O
15	mediated	O
16	by	O
17	the	O
18	cis	O
19	-	O
20	acting	O
21	ER	O
22	stress	O
23	response	O
24	element	O
25	(	O
26	ERSE	O
27	)	O
28	in	O
29	mammals	O
30	.	O

1	The	B
2	mammalian	B
3	homeodomain	I
4	proteins	O
5	encoded	O
6	by	B
7	Hox	I
8	genes	O
9	play	O
10	an	O
11	important	O
12	role	O
13	in	O
14	embryonic	O
15	development	O
16	by	O
17	providing	O
18	positional	O
19	queues	O
20	which	O
21	define	O
22	developmental	O
23	identities	O
24	along	O
25	the	O
26	anteroposterior	O
27	axis	O
28	of	O
29	developing	O
30	organisms	O
31	.	O

1	ORFA	O
2	and	O
3	ccdA	O
4	were	O
5	constitutively	O
6	cotranscribed	O
7	as	O
8	determined	O
9	by	O
10	primer	O
11	extension	O
12	analysis	O
13	.	O

1	Mechanism	O
2	of	O
3	immunogenesis	O
4	in	O
5	vaccination	O
6	with	O
7	streptomycin	O
8	-	O
9	dependent	O
10	mutants	O
11	of	O
12	salmonellae	O
13	and	O
14	shigellae	O
15	.	O

1	In	O
2	addition	O
3	,	B
4	CaMig1	O
5	formed	O
6	specific	O
7	complexes	O
8	with	O
9	the	O
10	URS1	O
11	region	O
12	of	O
13	the	O
14	S	O
15	.	O
16	cerevisiae	B
17	FBP1	I
18	gene	I
19	.	I

1	Similarly	O
2	,	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	U2	O
8	RNA	O
9	region	O
10	shown	O
11	to	O
12	be	O
13	involved	O
14	in	O
15	pre	O
16	-	O
17	mRNA	O
18	branchpoint	O
19	recognition	O
20	in	O
21	yeast	O
22	,	O
23	and	O
24	exactly	O
25	conserved	O
26	in	O
27	metazoan	O
28	U2	O
29	RNAs	O
30	,	O
31	was	O
32	totally	O
33	divergent	O
34	in	O
35	trypanosomes	O
36	.	O

1	A	O
2	preoperative	O
3	teaching	O
4	booklet	O
5	for	O
6	pediatric	O
7	patients	O
8	.	O

1	Spinal	O
2	cord	O
3	representation	O
4	of	O
5	the	O
6	micturition	O
7	reflex	O
8	.	O

1	A	O
2	major	O
3	pool	O
4	of	O
5	Dsg	O
6	-	B
7	plakoglobin	I
8	complexes	O
9	sedimented	O
10	at	O
11	8S	O
12	and	O
13	exhibited	O
14	a	O
15	1	O
16	:	O
17	1	O
18	stoichiometry	O
19	.	O

1	The	O
2	centromeric	O
3	YAC	O
4	contig	O
5	,	O
6	which	O
7	consists	O
8	of	O
9	23	O
10	overlapping	O
11	YACs	O
12	and	O
13	orders	O
14	19	O
15	sequence	O
16	-	O
17	tagged	O
18	sites	O
19	(	O
20	STSs	O
21	),	O
22	covers	O
23	a	O
24	minimum	O
25	of	O
26	2	O
27	.	O
28	2	O
29	Mb	O
30	and	O
31	spans	O
32	the	O
33	Ewing	O
34	sarcoma	O
35	breakpoint	O
36	.	B
37	c	I
38	-	I
39	ets	I
40	1	I
41	and	I
42	Fli	I
43	-	I
44	1	O
45	,	O
46	two	O
47	members	O
48	of	O
49	the	B
50	ets	I
51	family	O
52	,	O
53	have	O
54	been	O
55	linked	O
56	within	O
57	400	O
58	kb	O
59	of	O
60	intervening	O
61	DNA	O
62	within	O
63	this	O
64	contig	O
65	,	O
66	which	O
67	also	O
68	comprises	O
69	a	O
70	polymorphic	O
71	microsatellite	O
72	,	B
73	D11S912	O
74	(	O
75	CA	O
76	)	O
77	n	O
78	,	O
79	which	O
80	we	O
81	have	O
82	localized	O
83	within	O
84	the	B
85	Fli	I
86	-	I
87	1	I
88	gene	I
89	.	I

1	Activation	O
2	was	O
3	biphasic	O
4	;	O
5	peaking	O
6	at	O
7	5	O
8	-	O
9	10	O
10	min	O
11	and	O
12	24	O
13	h	O
14	after	O
15	treatment	O
16	.	O

1	These	O
2	genes	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	Saccharomyces	O
8	cerevisiae	O
9	mutant	O
10	in	O
11	which	O
12	the	B
13	endogenous	I
14	ferrochelatase	I
15	gene	O
16	(	O
17	HEM15	O
18	)	O
19	had	O
20	been	O
21	deleted	O
22	,	O
23	and	O
24	the	O
25	phenotypes	O
26	of	O
27	the	O
28	transformants	O
29	were	O
30	characterized	O
31	.	O

1	The	O
2	Sarns	O
3	51F	O
4	cavoatrial	O
5	cannula	O
6	decompressed	O
7	the	O
8	venous	O
9	system	O
10	as	O
11	efficiently	O
12	as	O
13	the	O
14	double	O
15	caval	O
16	cannulas	O
17	.	O

1	Because	O
2	the	B
3	high	I
4	-	I
5	density	I
6	lipoprotein	I
7	receptor	I
8	(	I
9	HDL	I
10	-	I
11	R	O
12	)	O
13	is	O
14	a	O
15	key	O
16	element	O
17	in	O
18	cholesterol	O
19	homeostasis	O
20	and	O
21	a	O
22	potential	O
23	therapeutic	O
24	target	O
25	for	O
26	hypercholesterolemic	O
27	drugs	O
28	,	O
29	an	O
30	understanding	O
31	of	O
32	HDL	O
33	-	O
34	R	O
35	regulation	O
36	is	O
37	essential	O
38	.	O

1	Alternatively	O
2	,	O
3	the	O
4	similarity	O
5	in	O
6	apparent	O
7	regulatory	O
8	action	O
9	of	O
10	the	O
11	genes	O
12	may	O
13	indicate	O
14	allelic	O
15	differences	O
16	wherein	O
17	the	O
18	IS1112C	B
19	Rf3	I
20	allele	O
21	may	O
22	differ	O
23	from	O
24	alleles	O
25	of	O
26	maintainer	O
27	lines	O
28	by	O
29	the	O
30	capability	O
31	to	O
32	regulate	O
33	both	O
34	orf107	O
35	and	O
36	urf209	O
37	processing	O
38	activities	O
39	.	O

1	Members	O
2	of	O
3	the	B
4	Ras	I
5	subfamily	I
6	of	I
7	small	I
8	GTP	I
9	-	I
10	binding	I
11	proteins	O
12	have	O
13	been	O
14	shown	O
15	to	O
16	be	O
17	promiscuous	O
18	towards	O
19	a	O
20	variety	O
21	of	O
22	putative	O
23	effector	O
24	molecules	O
25	such	O
26	as	O
27	the	B
28	protein	I
29	kinase	I
30	c	I
31	-	I
32	Raf	O
33	and	O
34	the	B
35	Ral	I
36	-	I
37	specific	I
38	guanine	I
39	nucleotide	I
40	exchange	I
41	factor	O
42	(	O
43	Ral	O
44	-	O
45	GEF	O
46	).	O

1	EMSA	O
2	with	O
3	crude	O
4	nuclear	O
5	extracts	O
6	demonstrated	O
7	that	O
8	stimulation	O
9	with	B
10	CD40L	O
11	results	O
12	in	O
13	the	O
14	induction	O
15	of	B
16	NF	I
17	-	I
18	kappaB	I
19	complexes	O
20	that	O
21	bind	O
22	to	O
23	each	O
24	of	O
25	the	O
26	three	B
27	NF	I
28	-	I
29	kappaB	I
30	sites	O
31	and	O
32	are	O
33	composed	O
34	mainly	O
35	of	B
36	p50	O
37	and	O
38	RelB	O
39	,	O
40	but	O
41	also	O
42	include	O
43	c	O
44	-	O
45	Rel	O
46	and	B
47	p65	I
48	.	I

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	prostate	O
9	carcinomas	O
10	with	O
11	the	B
12	Ras	I
13	/	I
14	MAPK	O
15	pathway	O
16	activation	O
17	might	O
18	have	O
19	a	O
20	selective	O
21	growth	O
22	advantage	O
23	by	O
24	autocrine	B
25	TGF	I
26	-	I
27	beta1	O
28	production	O
29	.	O

1	The	O
2	yeast	O
3	RER2	O
4	gene	O
5	,	O
6	identified	O
7	by	O
8	endoplasmic	O
9	reticulum	O
10	protein	O
11	localization	O
12	mutations	O
13	,	O
14	encodes	O
15	cis	O
16	-	B
17	prenyltransferase	O
18	,	O
19	a	O
20	key	O
21	enzyme	O
22	in	O
23	dolichol	O
24	synthesis	O
25	.	O

1	Individual	O
2	alcohol	O
3	reaction	O
4	profiles	O
5	.	O

1	Forty	O
2	-	O
3	five	O
4	cases	O
5	were	O
6	surgically	O
7	by	O
8	direct	O
9	approach	O
10	to	O
11	the	O
12	tumour	O
13	,	O
14	while	O
15	two	O
16	cases	O
17	were	O
18	treated	O
19	only	O
20	with	O
21	a	O
22	shunt	O
23	.	O

1	After	O
2	cells	O
3	were	O
4	stably	O
5	transfected	O
6	with	O
7	CIITA	O
8	,	B
9	endogenous	B
10	MHC	I
11	class	I
12	II	I
13	genes	O
14	were	O
15	constitutively	O
16	expressed	O
17	,	O
18	and	B
19	MHC	I
20	class	I
21	II	I
22	promoters	O
23	,	O
24	delivered	O
25	by	O
26	transfection	O
27	,	O
28	were	O
29	actively	O
30	transcribed	O
31	in	O
32	CIITA	O
33	-	O
34	expressing	O
35	cells	O
36	.	O

1	Methyllevamisole	O
2	was	O
3	used	O
4	as	O
5	the	O
6	internal	O
7	standard	O
8	.	O

1	However	O
2	,	O
3	by	O
4	an	O
5	NS35	O
6	-	O
7	specific	O
8	RNA	O
9	capture	O
10	assay	O
11	,	O
12	the	O
13	multimers	O
14	were	O
15	shown	O
16	to	O
17	possess	O
18	the	O
19	RNA	O
20	-	O
21	binding	O
22	activity	O
23	previously	O
24	demonstrated	O
25	for	O
26	NS35	O
27	.	O

1	The	O
2	MRS	B
3	II	B
4	meets	O
5	a	O
6	high	O
7	methodological	O
8	standard	O
9	as	O
10	an	O
11	instrument	O
12	standardized	O
13	in	O
14	the	O
15	population	O
16	.	O

1	Porcelain	O
2	to	O
3	dentin	O
4	bond	O
5	strength	O
6	with	O
7	a	O
8	dentin	O
9	adhesive	O
10	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	R	O
6	has	O
7	revealed	O
8	similarities	O
9	to	O
10	the	O
11	R1	O
12	plasmid	O
13	found	O
14	in	O
15	some	O
16	South	O
17	American	O
18	maize	O
19	races	O
20	with	O
21	RU	O
22	cytoplasm	O
23	,	O
24	to	O
25	the	O
26	M1	O
27	plasmid	O
28	found	O
29	in	O
30	one	O
31	source	O
32	of	O
33	Zea	O
34	luxurians	O
35	teosinte	O
36	,	O
37	to	O
38	the	O
39	atp9	O
40	mitochondrial	O
41	gene	O
42	and	O
43	its	O
44	3	O
45	'	O
46	flanking	O
47	sequence	O
48	,	O
49	and	O
50	also	O
51	to	O
52	a	O
53	region	O
54	3	O
55	'	O
56	to	O
57	the	O
58	orf221	I
59	gene	I
60	.	I

1	Sp1	O
2	can	O
3	activate	O
4	transcription	O
5	through	B
6	immunoglobulin	I
7	kappa	I
8	-	I
9	chain	I
10	enhancer	I
11	or	I
12	P	I
13	-	I
14	selectin	I
15	promoter	I
16	NF	I
17	-	I
18	kappaB	I
19	sites	I
20	.	I
21	p50	I
22	homodimers	I
23	replace	I
24	Sp1	O
25	from	O
26	the	B
27	P	I
28	-	I
29	selectin	I
30	promoter	O
31	by	O
32	binding	O
33	site	O
34	competition	O
35	and	O
36	thereby	O
37	either	O
38	inhibit	O
39	basal	B
40	Sp1	I
41	-	O
42	driven	O
43	expression	O
44	or	O
45	,	O
46	in	O
47	concert	O
48	with	B
49	Bcl	I
50	-	I
51	3	O
52	,	O
53	stimulate	O
54	expression	O
55	.	O

1	TPTA	O
2	produced	O
3	brain	O
4	congestion	O
5	,	O
6	and	O
7	hepatic	O
8	and	O
9	pulmonary	O
10	petechial	O
11	and	O
12	generalized	O
13	hemorrhages	O
14	.	O

1	METHODS	O
2	:	O
3	Rats	O
4	received	O
5	continuous	O
6	intragastric	O
7	infusion	O
8	of	O
9	elemental	O
10	diet	O
11	or	O
12	with	O
13	supplementation	O
14	of	O
15	oatbase	O
16	,	O
17	Lactobacillus	O
18	reuteri	O
19	R2LC	O
20	,	O
21	and	O
22	Lactobacillus	O
23	plantarum	O
24	DSM	O
25	9843	O
26	,	O
27	with	O
28	and	O
29	without	O
30	fermentation	O
31	,	O
32	from	O
33	the	O
34	beginning	O
35	of	O
36	the	O
37	study	O
38	.	O

1	The	O
2	major	O
3	neurological	O
4	manifestations	O
5	of	O
6	brain	O
7	injury	O
8	in	O
9	these	O
10	babies	O
11	are	O
12	spastic	O
13	motor	O
14	deficits	O
15	.	O

1	Imposed	O
2	angular	O
3	displacements	O
4	of	O
5	monkey	O
6	'	O
7	s	O
8	wrist	O
9	produce	O
10	three	O
11	major	O
12	peaks	O
13	of	O
14	activity	O
15	(	O
16	terms	O
17	M1	O
18	,	O
19	M2	O
20	,	O
21	and	O
22	M3	O
23	peaks	O
24	)	O
25	in	O
26	the	O
27	averaged	O
28	gross	O
29	EMG	O
30	activity	O
31	ot	O
32	the	O
33	stretched	O
34	muscles	O
35	.	O

1	The	O
2	absolute	O
3	concentrations	O
4	of	B
5	alpha	I
6	2	I
7	-	I
8	plasmin	I
9	inhibitor	I
10	,	I
11	alpha	I
12	2	I
13	-	I
14	macroglobulin	O
15	,	O
16	and	B
17	antithrombin	I
18	III	O
19	increased	O
20	with	O
21	exercise	O
22	(	O
23	all	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	005	O
30	),	O
31	but	O
32	when	O
33	concentrations	O
34	were	O
35	corrected	O
36	for	O
37	acute	O
38	shifts	O
39	of	O
40	plasma	O
41	water	O
42	during	O
43	exercise	O
44	,	O
45	the	O
46	quantity	O
47	of	O
48	these	O
49	inhibitors	O
50	actually	O
51	decreased	O
52	(	O
53	all	O
54	P	O
55	less	O
56	than	O
57	0	O
58	.	O
59	005	O
60	).	O

1	The	O
2	relationships	O
3	between	O
4	the	O
5	partial	O
6	pressures	O
7	of	O
8	O2	O
9	and	O
10	CO2	O
11	as	O
12	well	O
13	as	O
14	between	O
15	their	O
16	gradients	O
17	,	O
18	become	O
19	stronger	O
20	with	O
21	the	O
22	increase	O
23	of	O
24	the	O
25	ventilation	O
26	-	O
27	perfusion	O
28	ratio	O
29	.	O

1	Recording	O
2	of	O
3	the	O
4	digital	O
5	sphygmic	O
6	activity	O
7	in	O
8	the	O
9	lower	O
10	extremities	O
11	with	O
12	the	O
13	photoplethysmographic	O
14	and	O
15	strain	O
16	-	O
17	gauge	O
18	methods	O
19	.	O

1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	O
16	and	O
17	a	O
18	17	O
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	O
25	R7G	O
26	family	O
27	of	B
28	G	I
29	-	I
30	protein	I
31	coupled	I
32	membrane	I
33	-	I
34	bound	I
35	receptors	I
36	.	I

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	an	B
8	AP	I
9	-	I
10	2	O
11	but	O
12	not	O
13	an	B
14	Egr	I
15	-	I
16	1	O
17	expression	O
18	vector	O
19	activated	B
20	VPF	O
21	/	O
22	VEGF	O
23	transcription	O
24	,	O
25	thus	O
26	indicating	O
27	that	B
28	AP	I
29	-	I
30	2	I
31	protein	O
32	is	O
33	functionally	O
34	important	O
35	in	B
36	TGF	I
37	alpha	I
38	-	O
39	induced	B
40	VPF	O
41	/	O
42	VEGF	I
43	gene	O
44	expression	O
45	.	O

1	Biologically	O
2	significant	O
3	amounts	O
4	of	B
5	platelet	I
6	activating	I
7	factor	O
8	were	O
9	eluted	O
10	from	O
11	the	O
12	sorbent	O
13	during	O
14	the	O
15	entire	O
16	treatment	O
17	time	O
18	.	O

1	Effects	O
2	of	O
3	cisapride	O
4	on	O
5	upper	O
6	-	O
7	gastrointestinal	O
8	motility	O
9	and	O
10	digestive	O
11	hormones	O

1	We	O
2	demonstrate	O
3	that	O
4	both	O
5	R	O
6	and	O
7	Z	O
8	activate	O
9	the	O
10	cellular	O
11	stress	B
12	mitogen	I
13	-	I
14	activated	I
15	protein	I
16	(	I
17	MAP	I
18	)	I
19	kinases	O
20	,	O
21	p38	O
22	and	B
23	JNK	O
24	,	O
25	resulting	O
26	in	O
27	phosphorylation	O
28	(	O
29	and	O
30	activation	O
31	)	O
32	of	O
33	the	O
34	cellular	O
35	transcription	O
36	factor	O
37	ATF2	O
38	.	O

1	Repression	O
2	is	O
3	alleviated	O
4	when	O
5	the	O
6	two	O
7	(	O
8	for	O
9	E2	O
10	)	O
11	or	O
12	three	O
13	(	O
14	for	B
15	E2	I
16	-	I
17	C	I
18	)	I
19	promoter	I
20	-	I
21	proximal	O
22	copies	O
23	of	O
24	E2	O
25	-	O
26	RS	O
27	are	O
28	mutated	O
29	.	O

1	Pure	O
2	T1	O
3	and	O
4	dual	O
5	-	O
6	T1	O
7	images	O
8	were	O
9	visually	O
10	evaluated	O
11	for	O
12	image	O
13	quality	O
14	(	O
15	IQ	O
16	)	O
17	on	O
18	a	O
19	five	O
20	-	O
21	point	O
22	scale	O
23	(	O
24	0	O
25	=	O
26	unacceptable	O
27	to	O
28	4	O
29	=	O
30	excellent	O
31	).	O

1	Forty	O
2	-	O
3	one	O
4	ASA	O
5	physical	O
6	status	O
7	I	O
8	or	O
9	II	O
10	adult	O
11	patients	O
12	undergoing	O
13	a	O
14	variety	O
15	of	O
16	1	O
17	-	O
18	1	O
19	.	O
20	5	O
21	h	O
22	surgical	O
23	procedures	O
24	were	O
25	randomly	O
26	allocated	O
27	to	O
28	receive	O
29	CCA	O
30	with	O
31	desflurane	O
32	or	O
33	isoflurane	O
34	with	O
35	ventilation	O
36	being	O
37	either	O
38	spontaneous	O
39	or	O
40	controlled	O
41	.	O

1	A	O
2	transcript	O
3	of	O
4	about	O
5	2	O
6	kb	O
7	is	O
8	expected	O
9	for	O
10	each	O
11	PPO	O
12	.	O

1	In	O
2	a	O
3	man	O
4	with	O
5	myelomonocytic	O
6	leukemia	O
7	,	O
8	the	O
9	association	O
10	of	O
11	increased	O
12	prostatic	O
13	acid	O
14	phosphatase	O
15	activity	O
16	in	O
17	serum	O
18	and	O
19	the	O
20	presence	O
21	of	O
22	typical	O
23	bone	O
24	lesions	O
25	on	O
26	roentgenography	O
27	suggested	O
28	the	O
29	existence	O
30	of	O
31	disseminated	O
32	prostatic	O
33	carcinoma	O
34	.	O

1	Members	O
2	of	O
3	the	B
4	C	I
5	/	I
6	EBP	I
7	family	I
8	of	I
9	basic	I
10	-	I
11	leucine	I
12	zipper	I
13	(	I
14	bZip	I
15	)	I
16	transcription	I
17	factors	O
18	form	O
19	heterodimers	O
20	and	O
21	bind	O
22	to	O
23	the	O
24	CAAT	O
25	box	O
26	and	O
27	other	O
28	sequence	O
29	-	O
30	related	O
31	enhancer	O
32	motifs	O
33	.	O

1	Five	O
2	experiments	O
3	examined	O
4	the	O
5	influence	O
6	of	O
7	opiate	O
8	antagonists	O
9	on	O
10	both	O
11	the	O
12	short	O
13	-	O
14	term	O
15	analgesic	O
16	reaction	O
17	resulting	O
18	30	O
19	min	O
20	after	O
21	exposure	O
22	to	O
23	inescapable	O
24	shock	O
25	and	O
26	the	O
27	long	O
28	-	O
29	term	O
30	analgesic	O
31	reaction	O
32	resulting	O
33	after	O
34	reexposure	O
35	to	O
36	shock	O
37	24	O
38	hr	O
39	after	O
40	inescapable	O
41	shock	O
42	exposure	O
43	.	O

1	We	O
2	further	O
3	demonstrate	O
4	that	O
5	RU486	I
6	-	I
7	PR	I
8	-	I
9	B	O
10	interacts	O
11	physically	O
12	with	O
13	NCoR	O
14	in	O
15	vitro	O
16	.	O

1	Optical	O
2	-	O
3	absorption	O
4	spectra	O
5	,	O
6	crystal	O
7	-	O
8	field	O
9	energy	O
10	levels	O
11	,	O
12	and	O
13	transition	O
14	line	O
15	strengths	O
16	of	O
17	holmium	O
18	in	O
19	trigonal	B
20	Na3	B

1	This	O
2	last	O
3	region	O
4	contains	O
5	two	O
6	sites	O
7	that	O
8	bind	B
9	Ets	I
10	-	I
11	related	I
12	proteins	O
13	present	O
14	in	O
15	liver	O
16	nuclear	O
17	extracts	O
18	as	O
19	well	O
20	as	B
21	recombinant	B
22	purified	B
23	Ets	I
24	-	I
25	1	I
26	protein	I
27	.	I

1	A	O
2	patient	O
3	suffering	O
4	from	O
5	heparin	O
6	-	O
7	associated	O
8	thrombocytopenia	O
9	(	O
10	HAT	O
11	),	O
12	recurrent	O
13	arteriothromboses	O
14	,	O
15	and	O
16	acute	O
17	renal	O
18	failure	O
19	after	O
20	treatment	O
21	with	O
22	standard	O
23	heparin	O
24	is	O
25	described	O
26	.	O

1	PDGF	I
2	A	I
3	-	I
4	chain	O
5	levels	O
6	increase	O
7	in	O
8	cultured	O
9	vascular	O
10	smooth	O
11	muscle	O
12	cells	O
13	(	O
14	SMCs	O
15	)	O
16	exposed	O
17	to	O
18	ATII	O
19	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	decreased	O
6	class	O
7	I	O
8	enhancer	O
9	activity	O
10	in	O
11	Ad12	O
12	-	O
13	transformed	O
14	cells	O
15	may	O
16	,	O
17	at	O
18	least	O
19	in	O
20	part	O
21	,	O
22	be	O
23	due	O
24	to	O
25	the	O
26	higher	O
27	levels	O
28	of	O
29	an	O
30	enhancer	O
31	-	O
32	specific	O
33	factor	O
34	,	O
35	possibly	O
36	acting	O
37	as	O
38	a	O
39	repressor	O
40	.	O

1	Chirality	O
2	-	O
3	glass	O
4	and	O
5	spin	O
6	-	O
7	glass	O
8	correlations	O
9	in	O
10	the	O
11	two	O
12	-	O
13	dimensional	O
14	random	O
15	-	O
16	bond	O
17	XY	O
18	model	O
19	.	O

1	Finally	O
2	,	O
3	three	O
4	new	O
5	missense	O
6	mutations	O
7	,	O
8	E138V	O
9	,	O
10	R254G	O
11	,	O
12	and	O
13	P362R	O
14	,	O
15	were	O
16	identified	O
17	in	O
18	the	B
19	human	B
20	AC	I
21	gene	O
22	from	O
23	FD	O
24	patients	O
25	.	O

1	Objective	O
2	:	O
3	To	O
4	evaluate	O
5	endometrial	O
6	thickness	O
7	and	O
8	the	O
9	incidence	O
10	of	O
11	uterine	O
12	bleeding	O
13	in	O
14	postmenopausal	O
15	women	O
16	using	O
17	either	O
18	tibolone	O
19	2	O
20	.	O
21	5	O
22	mg	O
23	or	O
24	continuous	O
25	combined	O
26	2	O
27	mg	O
28	estradiol	O
29	and	O
30	1	O
31	mg	O
32	norethisterone	O
33	acetate	O
34	(	O
35	E	O
36	+	O
37	NETA	O
38	)	O
39	daily	O
40	as	O
41	hormone	O
42	replacement	O
43	therapy	O
44	.	O

1	This	O
2	study	O
3	examines	O
4	the	O
5	cooperative	O
6	effects	O
7	of	O
8	a	B
9	human	B
10	estrogen	I
11	receptor	I
12	-	I
13	alpha	I
14	(	I
15	ERalpha	I
16	)	I
17	isoform	O
18	on	O
19	estrogen	O
20	(	O
21	E2	O
22	)-	O
23	mediated	O
24	gene	O
25	activation	O
26	in	O
27	U2	O
28	-	O
29	OS	O
30	osteosarcoma	O
31	cells	O
32	.	O

1	Using	B
2	GST	I
3	-	I
4	PKR	I
5	fusion	O
6	chromatography	O
7	,	O
8	direct	O
9	physical	O
10	interaction	O
11	between	O
12	the	O
13	mouse	O
14	and	B
15	human	B
16	PKR	I
17	homologs	O
18	was	O
19	established	O
20	.	O

1	Among	O
2	38	O
3	patients	O
4	with	O
5	inducible	O
6	reentrant	O
7	VTs	O
8	who	O
9	underwent	O
10	electrophysiologic	O
11	study	O
12	(	O
13	EPS	O
14	),	O
15	10	O
16	VTs	O
17	of	O
18	six	O
19	patients	O
20	were	O
21	selected	O
22	.	O

1	Emergency	O
2	treatment	O
3	of	O
4	facial	O
5	and	O
6	maxillary	O
7	/	O
8	mandibular	O
9	injuries	O

1	IRF	I
2	-	I
3	1	O
4	acts	O
5	as	O
6	a	O
7	transcriptional	O
8	activator	O
9	,	O
10	while	B
11	IRF	I
12	-	I
13	2	O
14	acts	O
15	as	O
16	a	O
17	repressor	O
18	.	O

1	Sequencing	O
2	of	O
3	a	O
4	1	O
5	.	O
6	3	O
7	-	O
8	kilobase	O
9	fragment	O
10	of	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	TSG6	O
19	gene	O
20	identified	O
21	TATA	O
22	-	O
23	like	O
24	and	O
25	CAAT	O
26	sequences	O
27	near	O
28	the	O
29	transcription	O
30	start	O
31	site	O
32	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	29	O
6	patients	O
7	who	O
8	received	O
9	concurrent	O
10	chemotherapy	O
11	and	B
12	G	I
13	-	I
14	CSF	O
15	,	O
16	ten	O
17	(	O
18	34	O
19	%;	O
20	95	O
21	%	O
22	confidence	O
23	interval	O
24	[	O
25	CI	O
26	],	O
27	17	O
28	.	O
29	9	O
30	to	O
31	54	O
32	.	O
33	3	O
34	%)	O
35	were	O
36	believed	O
37	to	O
38	have	O
39	clinically	O
40	significant	O
41	bleomycin	O
42	toxicity	O
43	.	O

1	They	O
2	consisted	O
3	of	O
4	behavioural	O
5	disorders	O
6	,	O
7	tetraparesis	O
8	,	O
9	incontinence	O
10	and	O
11	oculomotor	O
12	paralysis	O
13	.	O

1	In	O
2	transient	O
3	cotransfections	B
4	E1A	O
5	could	O
6	induce	O
7	the	O
8	activity	O
9	of	O
10	the	B
11	p53	I
12	promoter	O
13	to	O
14	a	O
15	high	O
16	level	O
17	;	O
18	12S	B
19	E1A	O
20	was	O
21	threefold	O
22	as	O
23	efficient	O
24	as	O
25	13S	B
26	E1A	O
27	in	O
28	this	O
29	activity	O
30	,	O
31	and	O
32	YY1	O
33	bound	O
34	to	O
35	the	O
36	composite	O
37	element	O
38	was	O
39	shown	O
40	to	O
41	mediate	O
42	55	O
43	%	O
44	of	O
45	this	O
46	induction	O
47	.	O

1	This	O
2	correlated	O
3	with	O
4	reduced	O
5	levels	O
6	of	O
7	secreted	O
8	hepatitis	O
9	B	O
10	e	O
11	antigen	O
12	and	O
13	increased	O
14	intracellular	O
15	levels	O
16	of	O
17	core	O
18	and	O
19	Pol	O
20	proteins	O
21	and	O
22	replicative	O
23	HBV	O
24	DNA	O
25	intermediates	O
26	.	O

1	[	O
2	Treatment	O
3	of	O
4	early	O
5	T1	O
6	small	O
7	T2N	O
8	breast	O
9	cancers	O
10	.	O

1	Computer	O
2	analysis	O
3	included	O
4	digital	O
5	averaging	O
6	,	O
7	followed	O
8	by	O
9	digital	O
10	filtering	O
11	in	O
12	different	O
13	frequency	O
14	bands	O
15	in	O
16	order	O
17	to	O
18	determine	O
19	the	O
20	frequency	O
21	range	O
22	corresponding	O
23	to	O
24	notches	O
25	and	O
26	slurs	O
27	.	O

1	Hops	O
2	,	O
3	and	O
4	L	O
5	.	O

1	There	O
2	was	O
3	either	O
4	no	O
5	change	O
6	or	O
7	an	O
8	improvement	O
9	in	O
10	renographic	O
11	findings	O
12	(	O
13	t1	O
14	/	O
15	2	O
16	time	O
17	and	O
18	/	O
19	or	O
20	split	O
21	function	O
22	)	O
23	in	O
24	40	O
25	patients	O
26	(	O
27	93	O
28	%).	O

1	Comparison	O
2	of	O
3	the	O
4	genomic	O
5	DNA	O
6	sequence	O
7	with	O
8	that	O
9	of	O
10	the	O
11	four	O
12	different	O
13	mRNAs	O
14	indicates	O
15	that	O
16	these	O
17	transcripts	O
18	are	O
19	produced	O
20	by	O
21	alternative	O
22	splicing	O
23	of	O
24	the	O
25	murine	O
26	pre	O
27	-	O
28	mRNA	O
29	according	O
30	to	O
31	a	O
32	cassette	O
33	model	O
34	.	O

1	Component	O
2	P100	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	frontal	O
8	negativity	O
9	of	O
10	similar	O
11	latency	O
12	favoring	O
13	the	O
14	hypothesis	O
15	of	O
16	a	O
17	dipolar	O
18	occipital	O
19	generator	O
20	.	O

1	In	O
2	support	O
3	of	O
4	clinical	O
5	antianginal	O
6	studies	O
7	,	O
8	the	O
9	vasodilator	O
10	nicorandil	O
11	(	O
12	NIC	O
13	)	O
14	was	O
15	combined	O
16	with	O
17	the	B
18	beta	I
19	-	I
20	adrenergic	I
21	receptor	O
22	antagonists	O
23	propranolol	O
24	(	O
25	PRO	O
26	)	O
27	and	O
28	atenolol	O
29	(	O
30	ATN	O
31	)	O
32	and	O
33	with	O
34	the	O
35	calcium	O
36	channel	O
37	blocker	O
38	diltiazem	O
39	(	O
40	DTZ	O
41	)	O
42	to	O
43	determine	O
44	their	O
45	cardiovascular	O
46	and	O
47	pharmacokinetic	O
48	interactions	O
49	.	O

1	After	O
2	the	O
3	meal	O
4	containing	O
5	potato	O
6	,	O
7	plasma	O
8	glucose	O
9	levels	O
10	rose	O
11	sharply	O
12	,	O
13	peaked	O
14	at	O
15	30	O
16	-	O
17	45	O
18	min	O
19	and	O
20	fell	O
21	below	O
22	initial	O
23	levels	O
24	2	O
25	to	O
26	3	O
27	h	O
28	later	O
29	.	O

1	Equine	O
2	amnion	O
3	and	O
4	live	O
5	yeast	O
6	cell	O
7	derivative	O
8	were	O
9	evaluated	O
10	as	O
11	a	O
12	biological	O
13	dressing	O
14	and	O
15	as	O
16	a	O
17	topical	O
18	wound	O
19	medicament	O
20	respectively	O
21	,	O
22	in	O
23	the	O
24	treatment	O
25	of	O
26	granulating	O
27	wounds	O
28	of	O
29	the	O
30	distal	O
31	portion	O
32	of	O
33	the	O
34	limbs	O
35	of	O
36	horses	O
37	.	O

1	Constitutive	O
2	protection	O
3	of	B
4	E2F	I
5	recognition	I
6	sequences	O
7	in	O
8	the	B
9	human	B
10	thymidine	I
11	kinase	I
12	promoter	O
13	during	O
14	cell	O
15	cycle	O
16	progression	O
17	.	O

1	We	O
2	describe	O
3	a	O
4	novel	O
5	method	O
6	using	O
7	Saccharomyces	O
8	cerevisiae	O
9	for	O
10	detecting	O
11	protein	O
12	-	O
13	truncating	O
14	mutations	O
15	in	O
16	any	O
17	gene	O
18	of	O
19	interest	O
20	.	O

1	Institution	O
2	of	O
3	both	O
4	intravenous	O
5	and	O
6	intracisternal	O
7	administration	O
8	of	O
9	amphotericin	O
10	B	O
11	and	O
12	possibly	O
13	concomitant	O
14	intravenous	O
15	administration	O
16	of	O
17	dexamethasone	O
18	may	O
19	be	O
20	warranted	O
21	in	O
22	situations	O
23	in	O
24	which	O
25	the	O
26	association	O
27	of	O
28	C	O
29	.	O
30	immitis	O
31	with	O
32	CNS	O
33	vasculitis	O
34	or	O
35	encephalitis	O
36	appears	O
37	likely	O
38	before	O
39	serologic	O
40	or	O
41	cultural	O
42	confirmation	O
43	of	O
44	C	O
45	.	O
46	immitis	O
47	infection	O
48	involving	O
49	the	O
50	CNS	O
51	is	O
52	available	O
53	.	O

1	The	O
2	range	O
3	of	O
4	eosinophils	O
5	was	O
6	22	O
7	-	O
8	56	O
9	%	O
10	of	O
11	the	O
12	number	O
13	of	O
14	peripheral	O
15	white	O
16	blood	O
17	cells	O
18	(	O
19	mean	B
20	nadir	B
21	33	B
22	%).	B

1	The	O
2	purpose	O
3	of	O
4	this	O
5	article	O
6	is	O
7	to	O
8	discuss	O
9	the	O
10	factors	O
11	involved	O
12	in	O
13	the	O
14	selection	O
15	of	O
16	antibodies	O
17	,	O
18	radionuclides	O
19	and	O
20	labeling	O
21	methods	O
22	in	O
23	the	O
24	development	O
25	of	O
26	radioimmunotherapy	O
27	(	O
28	RIT	O
29	)	O
30	for	O
31	non	O
32	-	O
33	Hodgkin	O
34	'	O
35	s	O
36	lymphoma	O
37	(	O
38	NHL	O
39	)	O
40	from	O
41	a	O
42	single	O
43	clinical	O
44	study	O
45	site	O
46	through	O
47	multicenter	O
48	trials	O
49	and	O
50	commercialization	O
51	.	O

1	Investigation	O
2	of	O
3	the	O
4	structural	O
5	basis	O
6	of	O
7	the	O
8	interaction	O
9	between	B
10	human	B
11	Igs	O
12	and	O
13	gp120	O
14	shows	O
15	that	O
16	the	B
17	viral	B
18	gp120	B
19	SAg	O
20	can	O
21	interact	O
22	only	O
23	with	O
24	a	O
25	subset	O
26	of	B
27	human	B
28	V	I
29	(	I
30	H	I
31	)	I
32	3	I
33	+	I
34	Igs	I
35	.	I

1	The	O
2	models	O
3	were	O
4	tested	O
5	by	O
6	studying	O
7	their	O
8	response	O
9	to	O
10	disturbances	O
11	of	O
12	the	O
13	afferent	O
14	signal	O
15	from	O
16	the	O
17	bladder	O
18	.	O

1	The	O
2	effect	O
3	of	O
4	osmotic	O
5	flow	O
6	on	O
7	the	O
8	distribution	O
9	of	O
10	horseradish	I
11	peroxidase	O
12	within	O
13	the	O
14	intercellular	O
15	spaces	O
16	of	O
17	toad	O
18	bladder	O
19	epithelium	O
20	.	O

1	The	O
2	outcome	O
3	of	O
4	the	O
5	optimization	O
6	of	O
7	the	O
8	seven	O
9	-	O
10	field	O
11	plan	O
12	prompted	O
13	an	O
14	investigation	O
15	into	O
16	the	O
17	best	O
18	results	O
19	that	O
20	could	O
21	be	O
22	achieved	O
23	by	O
24	an	O
25	"	O
26	ideal	O
27	"	O
28	conformal	O
29	radiotherapy	O
30	technique	O
31	.	O

1	Replacing	O
2	residues	O
3	405	O
4	-	O
5	419	O
6	on	O
7	delta419	O
8	with	O
9	the	O
10	conserved	B
11	AF	I
12	-	I
13	2	I
14	domain	O
15	from	O
16	the	O
17	vitamin	B
18	D3	I
19	receptor	O
20	or	O
21	the	O
22	estrogen	O
23	receptor	O
24	results	O
25	in	O
26	a	O
27	receptor	O
28	with	O
29	wild	O
30	-	O
31	type	O
32	or	O
33	low	O
34	transcriptional	O
35	activity	O
36	,	O
37	respectively	O
38	.	O

1	A	O
2	recently	O
3	described	O
4	protein	O
5	,	O
6	metaxin	O
7	1	O
8	,	O
9	serves	O
10	as	O
11	a	O
12	component	O
13	of	O
14	a	O
15	preprotein	O
16	import	O
17	complex	O
18	in	O
19	the	O
20	outer	O
21	membrane	O
22	of	O
23	the	O
24	mammalian	O
25	mitochondrion	O
26	.	O

1	The	O
2	smaller	O
3	uptake	O
4	rate	O
5	and	O
6	faster	O
7	clearance	O
8	rate	O
9	resulted	O
10	in	O
11	the	O
12	lower	O
13	BCF	O
14	for	O
15	SWA	O
16	killifish	I
17	.	I

1	This	O
2	analysis	O
3	revealed	O
4	that	O
5	SAP	O
6	145	O
7	,	O
8	together	O
9	with	O
10	four	O
11	other	O
12	SF3a	O
13	/	B
14	SF3b	I
15	subunits	O
16	,	O
17	UV	O
18	cross	O
19	-	O
20	links	O
21	to	O
22	pre	O
23	-	O
24	mRNA	O
25	in	O
26	a	O
27	20	O
28	-	O
29	nucleotide	O
30	region	O
31	upstream	O
32	of	O
33	the	O
34	BPS	O
35	.	O

1	Absorption	O
2	varied	O
3	between	O
4	65	O
5	and	O
6	95	O
7	per	O
8	cent	O
9	,	O
10	with	O
11	a	O
12	mean	O
13	absorption	O
14	of	O
15	80	O
16	per	O
17	cent	O
18	,	O
19	in	O
20	both	O
21	pregnant	O
22	and	O
23	non	O
24	-	O
25	pregnant	O
26	subjects	O
27	.	O

1	Halothane	O
2	is	O
3	metabolized	O
4	by	O
5	an	O
6	oxidative	O
7	pathway	O
8	to	O
9	stable	O
10	,	O
11	nonvolatile	O
12	end	O
13	products	O
14	,	O
15	trifluoroacetic	O
16	acid	O
17	(	O
18	TFAA	O
19	)	O
20	and	O
21	bromide	O
22	(	O
23	Br	O
24	-),	O
25	and	O
26	by	O
27	reductive	O
28	pathways	O
29	to	O
30	Br	O
31	-	O
32	and	O
33	inorganic	O
34	fluoride	O
35	(	O
36	F	O
37	-).	O

1	The	O
2	progression	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	hepatitis	O
12	to	O
13	chronic	O
14	diseases	O
15	,	O
16	and	O
17	the	O
18	transformation	O
19	to	O
20	hepatocellular	O
21	carcinoma	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	spv	O
7	virulence	O
8	genes	O
9	belong	O
10	simultaneously	O
11	to	O
12	several	O
13	regulons	O
14	in	O
15	the	O
16	cell	O
17	,	O
18	raising	O
19	the	O
20	possibility	O
21	that	O
22	spv	O
23	expression	O
24	can	O
25	be	O
26	fine	O
27	-	O
28	tuned	O
29	in	O
30	response	O
31	to	O
32	multiple	O
33	environmental	O
34	inputs	O
35	.	O

1	Here	O
2	we	O
3	characterize	O
4	an	O
5	S	O
6	.	O
7	cerevisiae	O
8	Swi3	O
9	homolog	O
10	(	O
11	Swh3	O
12	)	O
13	and	O
14	present	O
15	evidence	O
16	that	O
17	it	O
18	associates	O
19	in	O
20	a	O
21	complex	O
22	with	O
23	a	B
24	Snf2	I
25	homolog	I
26	,	I
27	Sthl	I
28	.	I

1	Thirty	O
2	Class	O
3	I	O
4	and	O
5	Class	O
6	II	O
7	recessions	O
8	in	O
9	30	O
10	patients	O
11	were	O
12	treated	O
13	with	O
14	a	O
15	modified	O
16	subepithelial	O
17	connective	O
18	tissue	O
19	graft	O
20	procedure	O
21	.	O

1	Diethylene	O
2	benzene	O

1	In	O
2	addition	O
3	,	O
4	carp	B
5	JAK1	O
6	shows	O
7	higher	O
8	sequence	O
9	homology	O
10	to	B
11	mammalian	B
12	JAK1	O
13	in	O
14	both	O
15	the	O
16	kinase	O
17	-	O
18	like	O
19	(	O
20	JH2	O
21	)	O
22	and	O
23	kinase	O
24	(	O
25	JH1	O
26	)	O
27	domains	O
28	(	O
29	approximately	O
30	70	O
31	%	O
32	identity	O
33	).	O

1	Although	O
2	both	O
3	transfected	O
4	cell	O
5	lines	O
6	contain	B
7	FGF	I
8	-	I
9	1	I
10	cell	I
11	surface	I
12	receptors	O
13	as	O
14	judged	O
15	by	O
16	crosslinking	O
17	studies	O
18	,	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	transfectants	O
24	are	O
25	refractory	O
26	to	O
27	exogenous	B
28	FGF	I
29	-	I
30	1	O
31	,	O
32	whereas	O
33	the	O
34	mutant	O
35	transfectants	O
36	respond	O
37	normally	O
38	.(	O
39	ABSTRACT	O
40	TRUNCATED	O
41	AT	O
42	250	O
43	WORDS	O
44	)	O

1	Low	O
2	NA	O
3	and	O
4	A	O
5	may	O
6	participate	O
7	in	O
8	lowering	O
9	the	O
10	plasma	B
11	renin	O
12	activity	O
13	which	O
14	in	O
15	PA	O
16	in	O
17	suppressed	O
18	,	O
19	sometimes	O
20	disproportionately	O
21	to	O
22	the	O
23	actual	O
24	body	O
25	sodium	O
26	content	O
27	.	O

1	In	O
2	AcMNPV	O
3	-	O
4	infected	O
5	Sf9	O
6	cells	O
7	,	O
8	late	O
9	transcription	O
10	initiation	O
11	is	O
12	detected	O
13	from	O
14	only	O
15	two	O
16	upstream	O
17	TAAG	O
18	sites	O
19	and	O
20	not	O
21	from	O
22	three	O
23	downstream	B
24	TAAG	I
25	sites	I
26	.	I

1	Systemic	O
2	impact	O
3	of	O
4	risk	O
5	-	O
6	sharing	O
7	arrangements	O
8	.	O

1	Here	O
2	,	O
3	we	O
4	correlate	O
5	Dox	O
6	effects	O
7	on	O
8	cell	O
9	cycle	O
10	with	O
11	changes	O
12	of	B
13	E2F	I
14	/	I
15	DP	I
16	complexes	O
17	and	O
18	activity	O
19	in	O
20	differentiating	B
21	C2C12	B
22	myocytes	O
23	.	O

1	Tumor	O
2	necrosis	I
3	factor	I
4	-	I
5	alpha	I
6	(	I
7	TNF	I
8	alpha	O
9	),	O
10	a	O
11	proinflammatory	O
12	cytokine	O
13	,	O
14	inhibits	O
15	cAMP	O
16	-	O
17	stimulated	O
18	testosterone	O
19	production	O
20	in	O
21	mouse	O
22	Leydig	O
23	cells	O
24	.	O

1	To	O
2	compare	O
3	the	O
4	PAX3	O
5	and	O
6	putative	B
7	PAX3	I
8	-	I
9	FKHR	O
10	transactivation	O
11	domains	O
12	,	O
13	we	O
14	fused	O
15	C	O
16	-	O
17	terminal	O
18	test	O
19	fragments	O
20	to	O
21	the	O
22	heterologous	B
23	GAL4	I
24	DNA	I
25	-	I
26	binding	I
27	domain	O
28	and	O
29	tested	O
30	activation	O
31	of	O
32	a	O
33	reporter	O
34	gene	O
35	co	O
36	-	O
37	transfected	O
38	into	O
39	four	O
40	cell	O
41	types	O
42	.	O

1	Basal	O
2	promoter	O
3	activity	O
4	is	O
5	enhanced	O
6	by	O
7	a	O
8	functional	B
9	M1	I
10	domain	I
11	in	I
12	LHR	I
13	-	O
14	expressing	O
15	mouse	O
16	Leydig	O
17	tumor	O
18	cells	O
19	(	O
20	MLTC	O
21	)	O
22	but	O
23	not	O
24	in	O
25	non	O
26	-	O
27	expressing	O
28	CHO	O
29	cells	O
30	.	O

1	Clinical	O
2	findings	O
3	were	O
4	:	O
5	height	O
6	183	O
7	cm	O
8	,	O
9	weight	O
10	62	O
11	kg	O
12	,	O
13	increased	O
14	length	O
15	of	O
16	lower	O
17	limbs	O
18	,	B
19	P2	I
20	-	I
21	A2	I
22	pilosity	O
23	and	O
24	micropenis	O
25	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	en	O
6	stripes	O
7	expand	O
8	anteriorly	O
9	in	B
10	slp	I
11	mutant	O
12	embryos	O
13	and	O
14	that	O
15	slp	O
16	activity	O
17	is	O
18	an	O
19	absolute	O
20	requirement	O
21	for	O
22	maintenance	O
23	of	O
24	wg	O
25	expression	O
26	at	O
27	the	O
28	same	O
29	time	O
30	that	O
31	wg	O
32	transcription	O
33	is	O
34	dependent	O
35	on	O
36	hh	O
37	.	O

1	The	O
2	ability	O
3	of	O
4	A20	O
5	to	O
6	block	B
7	NF	I
8	-	I
9	kappaB	O
10	activation	O
11	was	O
12	mapped	O
13	to	O
14	its	B
15	C	I
16	-	I
17	terminal	I
18	zinc	I
19	finger	I
20	domain	I
21	.	I

1	Our	O
2	results	O
3	show	O
4	that	O
5	,	O
6	from	O
7	a	O
8	thermodynamical	O
9	standpoint	O
10	,	O
11	melatonin	O
12	may	O
13	directly	O
14	scavenge	O
15	hydroxyl	O
16	radicals	O
17	both	O
18	in	O
19	vacuum	O
20	and	O
21	in	O
22	aqueous	O
23	solution	O
24	.	O

1	In	O
2	this	O
3	paper	O
4	we	O
5	describe	O
6	properties	O
7	of	O
8	the	B
9	cdc10	I
10	-	I
11	C4	I
12	mutant	O
13	of	O
14	the	O
15	fission	O
16	yeast	O
17	Schizosaccharomyces	O
18	pombe	O
19	.	O

1	All	O
2	of	O
3	the	O
4	elements	O
5	exhibited	O
6	a	O
7	uniform	O
8	structure	O
9	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	reduce	O
6	the	O
7	incidence	O
8	of	O
9	NSAID	O
10	-	O
11	induced	O
12	gastrointestinal	O
13	lesions	O
14	,	O
15	the	O
16	following	O
17	approaches	O
18	have	O
19	been	O
20	proposed	O
21	:	O
22	(	O
23	i	O
24	)	O
25	use	O
26	of	O
27	the	O
28	prostaglandin	O
29	analogue	O
30	misoprostol	O
31	,	O
32	which	O
33	is	O
34	an	O
35	antiulcer	O
36	drug	O
37	which	O
38	has	O
39	been	O
40	proven	O
41	to	O
42	be	O
43	as	O
44	effective	O
45	in	O
46	the	O
47	prevention	O
48	of	O
49	NSAID	O
50	-	O
51	induced	O
52	gastric	O
53	and	O
54	duodenal	O
55	ulcers	O
56	as	O
57	in	O
58	the	O
59	reduction	O
60	of	O
61	serious	O
62	upper	O
63	gastrointestinal	O
64	complications	O
65	;	O
66	(	O
67	ii	O
68	)	O
69	histamine	O
70	H2	O
71	receptor	O
72	antagonists	O
73	(	O
74	H2	O
75	antagonists	O
76	),	O
77	e	O
78	.	O
79	g	O
80	.	O
81	ranitidine	O
82	,	O
83	cimetidine	O
84	and	O
85	famotidine	O
86	,	O
87	which	O
88	are	O
89	useful	O
90	in	O
91	the	O
92	prevention	O
93	of	O
94	NSAID	O
95	-	O
96	induced	O
97	duodenal	O
98	ulcers	O
99	during	O
100	long	O
101	term	O
102	treatment	O
103	,	O
104	but	O
105	not	O
106	in	O
107	the	O
108	prevention	O
109	of	O
110	NSAID	O
111	-	O
112	induced	O
113	gastric	O
114	ulcers	O
115	;	O
116	(	O
117	iii	O
118	)	O
119	proton	O
120	pump	O
121	inhibitors	O
122	,	O
123	e	O
124	.	O
125	g	O
126	omeprazole	O
127	,	O
128	and	O
129	pantoprazole	O
130	,	O
131	whose	O
132	efficacy	O
133	in	O
134	preventing	O
135	NSAID	O
136	-	O
137	associated	O
138	ulcers	O
139	has	O
140	been	O
141	recently	O
142	demonstrated	O
143	;	O
144	and	O
145	(	O
146	iv	O
147	)	O
148	barrier	O
149	agents	O
150	,	O
151	e	O
152	.	O
153	g	O
154	.	O
155	sucralfate	O
156	,	O
157	which	O
158	cannot	O
159	be	O
160	recommended	O
161	as	O
162	prophylactic	O
163	agents	O
164	to	O
165	prevent	O
166	NSAID	O
167	-	O
168	induced	O
169	gastropathy	O
170	.	O

1	The	O
2	specific	O
3	interaction	O
4	between	O
5	a	O
6	defined	O
7	structural	O
8	element	O
9	of	O
10	the	B
11	human	I
12	immunodeficiency	I
13	virus	I
14	mRNA	I
15	(	I
16	RRE	O
17	,	O
18	the	O
19	Rev	O
20	response	O
21	element	O
22	)	O
23	and	O
24	the	O
25	virus	O
26	-	O
27	encoded	O
28	protein	O
29	Rev	O
30	has	O
31	been	O
32	implicated	O
33	in	O
34	the	O
35	regulation	O
36	of	O
37	the	O
38	export	O
39	of	O
40	unspliced	O
41	or	O
42	singly	O
43	spliced	O
44	mRNA	O
45	from	O
46	the	O
47	nucleus	O
48	to	O
49	the	O
50	cytoplasm	O
51	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Although	O
2	human	O
3	infections	O
4	with	O
5	bacteraemia	O
6	due	O
7	to	O
8	Pasteurella	O
9	multocida	O
10	are	O
11	not	O
12	uncommon	O
13	,	O
14	endocarditis	O
15	associated	O
16	with	O
17	P	O
18	.	O
19	haemolytica	O
20	is	O
21	rare	O
22	.	O

1	AGO1	O
2	is	O
3	similar	O
4	to	O
5	QDE	O
6	-	O
7	2	O
8	required	O
9	for	O
10	quelling	O
11	and	O
12	RDE	O
13	-	O
14	1	O
15	required	O
16	for	O
17	RNAi	O
18	.	O

1	Not	O
2	even	O
3	extensive	O
4	pancreatic	O
5	resection	O
6	could	O
7	prevent	O
8	pancreatic	O
9	remnant	O
10	infection	O
11	.	O

1	The	B
2	Saccharomyces	I
3	cerevisiae	I
4	APS1	I
5	gene	O
6	encodes	O
7	a	O
8	homolog	O
9	of	O
10	the	O
11	small	O
12	subunit	O
13	of	O
14	the	B
15	mammalian	B
16	clathrin	B
17	AP	I
18	-	I
19	1	I
20	complex	O
21	:	O
22	evidence	O
23	for	O
24	functional	O
25	interaction	O
26	with	B
27	clathrin	O
28	at	O
29	the	O
30	Golgi	O
31	complex	O
32	.	O

1	LMP2A	O
2	enhances	O
3	Lyn	O
4	and	O
5	Syk	O
6	ubiquitination	O
7	in	O
8	vivo	O
9	in	O
10	a	O
11	fashion	O
12	that	O
13	depends	O
14	on	O
15	the	O
16	activity	O
17	of	O
18	Nedd4	O
19	family	O
20	members	O
21	and	O
22	correlates	O
23	with	O
24	destabilization	O
25	of	O
26	the	O
27	Lyn	I
28	tyrosine	I
29	kinase	I
30	.	I

1	A	O
2	coiled	O
3	-	O
4	coil	O
5	related	O
6	protein	O
7	specific	O
8	for	O
9	synapsed	O
10	regions	O
11	of	O
12	meiotic	O
13	prophase	O
14	chromosomes	O
15	.	O

1	A	O
2	case	O
3	of	O
4	manifest	O
5	latent	O
6	nystagmus	O
7	of	O
8	late	O
9	onset	O
10	in	O
11	a	O
12	13	O
13	-	O
14	year	O
15	-	O
16	old	O
17	girl	O
18	is	O
19	reported	O
20	.	O

1	PET	O
2	activation	O
3	studies	O
4	are	O
5	performed	O
6	widely	O
7	to	O
8	study	O
9	human	O
10	brain	O
11	function	O
12	.	O

1	Reactive	O
2	lymphoid	O
3	hyperplasia	O
4	was	O
5	found	O
6	in	O
7	15	O
8	cases	O
9	,	O
10	2	O
11	cases	O
12	had	O
13	angiofollicular	O
14	lymphoid	O
15	hyperplasia	O
16	or	O
17	Castleman	O
18	'	O
19	s	O
20	disease	O
21	,	O
22	atypical	O
23	lymphoid	O
24	hyperplasia	O
25	suggestive	O
26	of	O
27	malignant	O
28	lymphoma	O
29	was	O
30	observed	O
31	in	O
32	3	O
33	cases	O
34	,	O
35	and	O
36	malignant	O
37	lymphoma	O
38	was	O
39	diagnosed	O
40	in	O
41	the	O
42	remaining	O
43	4	O
44	cases	O
45	.	O

1	To	O
2	determine	O
3	if	O
4	the	B
5	NF	I
6	(	I
7	H	I
8	)	I
9	promoter	O
10	can	O
11	be	O
12	activated	O
13	in	O
14	a	O
15	tissue	O
16	specific	O
17	manner	O
18	during	O
19	development	O
20	transgenic	O
21	mice	O
22	containing	O
23	the	O
24	promoter	O
25	region	O
26	linked	O
27	to	O
28	a	B
29	beta	I
30	-	I
31	galactosidase	I
32	reporter	I
33	gene	O
34	were	O
35	generated	O
36	.	O

1	These	O
2	results	O
3	strongly	O
4	suggest	O
5	that	O
6	locally	O
7	-	O
8	applied	O
9	TTC	O
10	in	O
11	combination	O
12	with	O
13	FDBA	O
14	enhances	O
15	new	O
16	bone	O
17	formation	O
18	in	O
19	experimental	O
20	alveolar	O
21	bone	O
22	defects	O
23	.	O

1	Absorption	O
2	of	O
3	electrolytes	O
4	from	O
5	the	O
6	colon	O
7	in	O
8	cases	O
9	of	O
10	ulcerative	O
11	colitis	O
12	and	O
13	in	O
14	control	O
15	subjects	O
16	.	O

1	Some	O
2	research	O
3	studies	O
4	have	O
5	related	O
6	this	O
7	kind	O
8	of	O
9	tumors	O
10	with	O
11	prolonged	O
12	ingestion	O
13	of	O
14	H2	O
15	inhibitors	O
16	and	O
17	others	O
18	antacid	O
19	.	O

1	In	O
2	a	O
3	reconstituted	O
4	human	O
5	DNA	O
6	repair	O
7	system	O
8	containing	B
9	DNA	I
10	polymerase	I
11	beta	I
12	and	I
13	DNA	I
14	ligase	I
15	III	I
16	-	I
17	XRCC1	O
18	,	O
19	accurate	O
20	rejoining	O
21	of	O
22	a	O
23	3	O
24	'	O
25	mismatched	O
26	base	O
27	residue	O
28	at	O
29	a	O
30	single	O
31	-	O
32	strand	O
33	break	O
34	is	O
35	dependent	O
36	on	O
37	addition	O
38	of	O
39	the	O
40	exonuclease	O
41	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	requirements	O
8	for	O
9	induction	O
10	of	B
11	PEPCK	O
12	by	O
13	PKA	O
14	and	O
15	inhibition	O
16	by	B
17	insulin	O
18	include	O
19	:	O
20	1	O
21	)	O
22	the	B
23	CREB	O
24	activation	O
25	domain	O
26	,	O
27	2	O
28	)	O
29	the	B
30	PEPCK	O
31	TATA	O
32	sequence	O
33	,	O
34	and	O
35	3	O
36	)	B
37	insulin	I
38	-	I
39	responsive	O
40	hepatoma	O
41	cells	O
42	.	O

1	Fetal	O
2	growth	O
3	retardation	O
4	as	O
5	a	O
6	cause	O
7	of	O
8	impaired	O
9	ovarian	O
10	development	O
11	.	O

1	A	O
2	catalytic	O
3	domain	O
4	of	B
5	eukaryotic	I
6	DNA	I
7	topoisomerase	I
8	I	I
9	.	I

1	M	O
2	-	O
3	66	O
4	identified	O
5	the	O
6	14	O
7	-	O
8	kDa	O
9	protein	O
10	in	O
11	another	O
12	MMTV	O
13	bearing	O
14	T	O
15	-	O
16	cell	O
17	lymphoma	O
18	,	O
19	EL	O
20	-	O
21	4	O
22	.	O

1	The	O
2	prevalence	O
3	of	O
4	opportunistic	O
5	infection	O
6	among	O
7	surviving	O
8	AIDS	O
9	patients	O
10	and	O
11	the	O
12	probability	O
13	of	O
14	being	O
15	in	O
16	tumour	O
17	response	O
18	following	O
19	cancer	O
20	therapy	O
21	conditional	O
22	on	O
23	being	O
24	alive	O
25	are	O
26	two	O
27	examples	O
28	of	O
29	such	O
30	functions	O
31	.	O

1	A	O
2	deletion	O
3	mutation	O
4	analysis	O
5	of	O
6	the	O
7	recombinant	O
8	protein	O
9	has	O
10	shown	O
11	that	O
12	the	O
13	N	O
14	-	O
15	terminal	O
16	region	O
17	and	O
18	the	O
19	two	O
20	leucine	O
21	zippers	O
22	are	O
23	necessary	O
24	for	O
25	the	O
26	binding	O
27	.	O

1	Organisms	O
2	were	O
3	recovered	O
4	from	O
5	the	O
6	conjunctiva	O
7	for	O
8	several	O
9	weeks	O
10	,	O
11	and	O
12	persistent	O
13	genital	O
14	and	O
15	gastrointestinal	O
16	infection	O
17	also	O
18	resulted	O
19	from	O
20	the	O
21	ocular	O
22	infection	O
23	in	O
24	some	O
25	cats	O
26	.	O

1	One	O
2	hundred	O
3	units	O
4	/	O
5	kg	O
6	of	B
7	recombinant	B
8	human	B
9	erythropoietin	O
10	(	O
11	rhEPO	O
12	)	O
13	was	O
14	given	O
15	subcutaneously	O
16	3	O
17	times	O
18	a	O
19	week	O
20	for	O
21	3	O
22	weeks	O
23	.	O

1	The	O
2	fatigue	O
3	exercise	O
4	showed	O
5	relatively	O
6	high	O
7	blood	O
8	lactate	O
9	concentration	O
10	[	O
11	12	O
12	.	O
13	5	O
14	(	O
15	SD	O
16	2	O
17	.	O
18	6	O
19	)	O
20	mmol	O
21	x	O
22	l	O
23	(-	O
24	1	O
25	)]	O
26	and	O
27	an	O
28	increase	O
29	of	B
30	serum	B
31	creatine	I
32	kinase	O
33	(	O
34	CK	O
35	)	O
36	activity	O
37	delayed	O
38	by	O
39	2	O
40	days	O
41	[	O
42	540	O
43	(	O
44	SD	O
45	407	O
46	)	O
47	U	O
48	x	O
49	l	O
50	(-	O
51	1	O
52	)].	O

1	Their	O
2	hydropathic	O
3	plots	O
4	are	O
5	very	O
6	similar	O
7	and	O
8	both	O
9	possess	O
10	three	O
11	hydrophobic	O
12	segments	O
13	that	O
14	are	O
15	likely	O
16	alpha	O
17	-	O
18	helical	O
19	transmembrane	O
20	segments	O
21	.	O

1	Functional	O
2	effects	O
3	following	O
4	subacute	O
5	administration	O
6	.	O

1	Laboratory	O
2	aspects	O
3	with	O
4	particular	O
5	reference	O
6	to	O
7	chemotherapy	O
8	and	O
9	control	O
10	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	yeast	O
6	PHO8	O
7	promoter	O
8	in	O
9	comparison	O
10	to	O
11	the	O
12	coregulated	B
13	PHO5	I
14	promoter	I
15	.	I

1	Five	O
2	-	O
3	year	O
4	prospective	O
5	study	O
6	of	O
7	peripheral	O
8	white	O
9	blood	O
10	cells	O
11	in	O
12	infectious	O
13	mononucleosis	O
14	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pCLU1	O
5	from	O
6	the	O
7	yeast	O
8	Kluyveromyces	O
9	lactis	O
10	normally	O
11	replicates	O
12	in	O
13	the	O
14	cytoplasm	O
15	,	O
16	with	O
17	the	O
18	aid	O
19	of	O
20	the	O
21	helper	O
22	linear	O
23	plasmid	O
24	pGKL2	O
25	,	O
26	using	O
27	terminal	O
28	protein	O
29	(	O
30	TP	O
31	)	O
32	as	O
33	a	O
34	primer	O
35	.	O

1	The	O
2	criterion	O
3	was	O
4	reached	O
5	after	O
6	two	O
7	sessions	O
8	and	O
9	generalization	O
10	to	O
11	a	O
12	variety	O
13	of	O
14	pills	O
15	and	O
16	capsules	O
17	occurred	O
18	.	O

1	CONCLUSION	O
2	:	O
3	NBP	O
4	pre	O
5	-	O
6	treatment	O
7	or	O
8	post	O
9	-	O
10	treatment	O
11	markedly	O
12	enhanced	O
13	the	O
14	rCBF	O
15	to	O
16	striatum	O
17	in	O
18	RMCAO	O
19	rats	O
20	.	O

1	We	O
2	determined	O
3	whether	O
4	regional	O
5	myocardial	O
6	work	O
7	efficiency	O
8	(	O
9	segment	O
10	work	O
11	/	O
12	regional	O
13	O2	O
14	consumption	O
15	)	O
16	would	O
17	be	O
18	elevated	O
19	by	O
20	surgically	O
21	-	O
22	augmented	O
23	inflow	O
24	.	O

1	KFC	O
2	,	O
3	a	B
4	Ste20	I
5	-	I
6	like	I
7	kinase	O
8	with	O
9	mitogenic	O
10	potential	O
11	and	O
12	capability	O
13	to	O
14	activate	O
15	the	B
16	SAPK	I
17	/	I
18	JNK	O
19	pathway	O
20	.	O

1	As	O
2	hypothesized	O
3	,	O
4	believers	O
5	showed	O
6	relatively	O
7	higher	O
8	right	O
9	hemispheric	O
10	activation	O
11	and	O
12	reduced	O
13	hemispheric	O
14	asymmetry	O
15	of	O
16	functional	O
17	complexity	O
18	.	O

1	Harel	O
2	,	O
3	E	O
4	.	O
5	M	O
6	.	O

1	Superoxide	O
2	dismutase	O
3	(	O
4	SOD	O
5	)	O
6	activity	O
7	decreased	O
8	significantly	O
9	in	O
10	sperm	O
11	subjected	O
12	to	O
13	direct	O
14	electric	O
15	current	O
16	in	O
17	comparison	O
18	to	O
19	the	O
20	control	O
21	or	O
22	the	O
23	sample	O
24	incubated	O
25	with	O
26	electrolyzed	O
27	medium	O
28	.	O

1	This	O
2	region	O
3	also	O
4	contains	O
5	a	O
6	gene	O
7	specifying	O
8	a	B
9	Leu	I
10	-	I
11	tRNA	I
12	precursor	O
13	and	O
14	a	O
15	remnant	O
16	of	O
17	a	B
18	tau	I
19	element	I
20	.	I

1	Genotoxic	O
2	activity	O
3	of	O
4	a	O
5	tobacco	O
6	-	O
7	specific	O
8	nitrosamine	O
9	.	O

1	Finally	O
2	,	O
3	antibody	O
4	binding	O
5	to	O
6	site	O
7	IIIa	O
8	on	O
9	the	O
10	hCG	O
11	-	O
12	ectodomain	O
13	complex	O
14	was	O
15	also	O
16	hindered	O
17	by	O
18	an	O
19	anti	O
20	-	O
21	peptide	O
22	mAb	O
23	directed	O
24	against	O
25	a	O
26	peptide	O
27	encoded	O
28	by	O
29	the	O
30	eighth	O
31	exon	O
32	(	O
33	pE	O
34	x	O
35	8	O
36	)	O
37	of	O
38	the	B
39	LHR	I
40	.	I

1	Protease	O
2	activities	O
3	in	O
4	cultures	O
5	of	O
6	the	O
7	streptococcal	O
8	strains	O
9	were	O
10	associated	O
11	with	O
12	species	O
13	of	O
14	different	O
15	molecular	O
16	masses	O
17	ranging	O
18	from	O
19	130	O
20	to	O
21	200	O
22	kDa	O
23	,	O
24	suggesting	O
25	posttranslational	O
26	processing	O
27	possibly	O
28	as	O
29	a	O
30	result	O
31	of	O
32	autoproteolysis	O
33	at	O
34	post	O
35	-	O
36	proline	O
37	peptide	O
38	bonds	O
39	in	O
40	the	O
41	N	O
42	-	O
43	terminal	O
44	parts	O
45	of	O
46	the	O
47	molecules	O
48	.	O

1	The	O
2	recombinant	O
3	vaccinia	O
4	virus	O
5	-	O
6	expressed	O
7	mutant	B
8	P1	I
9	polyproteins	O
10	were	O
11	analyzed	O
12	for	O
13	proteolytic	O
14	processing	O
15	defects	O
16	in	O
17	cells	O
18	coinfected	O
19	with	O
20	a	O
21	recombinant	O
22	vaccinia	O
23	virus	O
24	(	B
25	VVP3	O
26	)	O
27	that	O
28	expresses	O
29	the	B
30	poliovirus	I
31	3CD	I
32	protease	O
33	and	O
34	for	O
35	processing	O
36	and	O
37	assembly	O
38	defects	O
39	by	O
40	using	O
41	a	O
42	trans	O
43	complementation	O
44	system	O
45	in	O
46	which	O
47	P1	O
48	-	O
49	expressing	O
50	recombinant	O
51	vaccinia	O
52	viruses	O
53	provide	O
54	capsid	O
55	precursor	O
56	to	O
57	a	O
58	defective	O
59	poliovirus	O
60	genome	O
61	that	O
62	does	O
63	not	O
64	express	O
65	functional	O
66	capsid	O
67	proteins	O
68	(	O
69	D	O
70	.	O

1	The	O
2	mean	O
3	extracted	O
4	concentration	O
5	of	O
6	flucloxacillin	O
7	obtained	O
8	at	O
9	operation	O
10	was	O
11	12	O
12	.	O
13	9	O
14	micrograms	O
15	/	O
16	ml	O
17	(	O
18	SD	O
19	5	O
20	.	O
21	25	O
22	)	O
23	in	O
24	synovial	O
25	fluid	O
26	;	O
27	2	O
28	.	O
29	9	O
30	micrograms	O
31	/	O
32	g	O
33	(	O
34	SD	O
35	3	O
36	.	O
37	59	O
38	)	O
39	in	O
40	synovium	O
41	;	O
42	2	O
43	.	O
44	0	O
45	micrograms	O
46	/	O
47	g	O
48	(	O
49	SD	O
50	1	O
51	.	O
52	48	O
53	)	O
54	in	O
55	cancellous	O
56	bone	O
57	and	O
58	1	O
59	.	O
60	3	O
61	micrograms	O
62	/	O
63	g	O
64	(	O
65	SD	O
66	1	O
67	.	O
68	25	O
69	)	O
70	in	O
71	cortical	O
72	bone	O
73	.	O

1	Transformed	O
2	bacterial	O
3	colonies	O
4	were	O
5	screened	O
6	for	O
7	recombinant	O
8	plasmids	O
9	containing	O
10	cDNA	O
11	coding	O
12	for	O
13	BiP	O
14	by	O
15	hybrid	O
16	-	O
17	selected	O
18	mRNA	O
19	translation	O
20	.	O

1	The	O
2	mutants	O
3	were	O
4	obtained	O
5	by	O
6	substitution	O
7	into	O
8	a	O
9	molecular	O
10	clone	O
11	of	O
12	M	O
13	-	O
14	MuLV	O
15	DNA	O
16	by	O
17	DNA	O
18	from	O
19	two	O
20	acutely	O
21	transforming	O
22	viruses	O
23	,	O
24	Ableson	O
25	MuLV	O
26	(	O
27	Ab	O
28	-	O
29	MuLV	O
30	)	O
31	and	O
32	Moloney	O
33	murine	O
34	sarcoma	O
35	virus	O
36	(	O
37	M	O
38	-	O
39	MSV	O
40	).	O

1	Many	O
2	cytokine	O
3	receptors	O
4	employ	B
5	Janus	I
6	protein	I
7	tyrosine	I
8	kinases	O
9	(	O
10	Jaks	O
11	)	O
12	and	O
13	signal	O
14	transducers	O
15	and	O
16	activators	O
17	of	O
18	transcription	O
19	(	O
20	Stats	O
21	)	O
22	for	O
23	nuclear	O
24	signaling	O
25	.	O

1	Gestational	O
2	trophoblastic	O
3	diseases	O
4	:	O
5	recent	O
6	advances	O
7	in	O
8	the	O
9	understanding	O
10	of	O
11	cytogenetics	O
12	,	O
13	histopathology	O
14	,	O
15	and	O
16	natural	O
17	history	O
18	.	O

1	SETTING	O
2	:	O
3	University	O
4	of	O
5	Paris	O
6	VII	O
7	hospital	O
8	.	O
9	Patient	O
10	(	O
11	s	O
12	):	O
13	Nine	O
14	women	O
15	had	O
16	embolization	O
17	for	O
18	symptomatic	O
19	myoma	O
20	,	O
21	with	O
22	12	O
23	pregnancies	O
24	observed	O
25	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	first	O
6	two	O
7	genes	O
8	located	O
9	in	O
10	this	O
11	unit	O
12	(	B
13	c	I
14	-	I
15	gvpD	I
16	and	I
17	c	I
18	-	I
19	gvpE	O
20	)	O
21	was	O
22	also	O
23	monitored	O
24	by	O
25	Western	O
26	blot	O
27	(	O
28	immunoblot	O
29	)	O
30	analyses	O
31	using	O
32	antisera	O
33	raised	O
34	against	O
35	these	O
36	proteins	O
37	synthesized	O
38	in	O
39	Escherichia	O
40	coli	O
41	.	O

1	The	O
2	heart	O
3	rate	O
4	,	O
5	respiratory	O
6	rate	O
7	,	O
8	arterial	O
9	O2	O
10	and	O
11	systemic	O
12	vascular	O
13	resistance	O
14	were	O
15	not	O
16	significantly	O
17	altered	O
18	.	O

1	The	O
2	bases	O
3	of	O
4	this	O
5	comparison	O
6	are	O
7	reviewed	O
8	and	O
9	discussed	O
10	.	O

1	The	O
2	objectives	O
3	of	O
4	the	O
5	present	O
6	study	O
7	were	O
8	to	O
9	evaluate	O
10	the	O
11	effects	O
12	of	O
13	adding	O
14	Equex	O
15	to	O
16	a	O
17	TRIS	O
18	-	O
19	extender	O
20	,	O
21	diluting	O
22	the	O
23	semen	O
24	in	O
25	1	O
26	or	O
27	2	O
28	steps	O
29	,	O
30	freezing	O
31	according	O
32	to	O
33	2	O
34	methods	O
35	,	O
36	thawing	O
37	at	O
38	2	O
39	rates	O
40	,	O
41	and	O
42	the	O
43	interactions	O
44	between	O
45	these	O
46	treatments	O
47	,	O
48	on	O
49	the	O
50	post	O
51	-	O
52	thaw	O
53	survival	O
54	of	O
55	dog	O
56	spermatozoa	O
57	at	O
58	38	O
59	degrees	O
60	C	O
61	.	O

1	High	O
2	-	O
3	resolution	O
4	computed	O
5	tomography	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	miliary	O
11	tuberculosis	O
12	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	targeting	O
6	of	B
7	Ras	I
8	-	I
9	GAP	O
10	could	O
11	represent	O
12	a	O
13	novel	O
14	anticancer	O
15	approach	O
16	.	O

1	Molecular	O
2	characterization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	Erwinia	O
8	carotovora	B
9	hrpNEcc	I
10	gene	O
11	,	O
12	which	O
13	encodes	O
14	an	O
15	elicitor	O
16	of	O
17	the	O
18	hypersensitive	O
19	reaction	O
20	.	O

1	Elevated	O
2	expression	O
3	of	O
4	a	O
5	previously	O
6	uncharacterized	O
7	gene	O
8	,	B
9	SPP381	O
10	,	O
11	efficiently	O
12	suppresses	O
13	the	O
14	growth	O
15	and	O
16	splicing	O
17	defects	O
18	of	O
19	a	O
20	temperature	O
21	-	O
22	sensitive	O
23	(	O
24	Ts	O
25	)	O
26	mutant	B
27	prp38	I
28	-	I
29	1	I
30	.	I

1	Taken	O
2	together	O
3	,	O
4	these	O
5	observations	O
6	indicate	O
7	that	O
8	inhibition	O
9	of	O
10	p27	O
11	(	O
12	KIP1	O
13	)	O
14	transcription	O
15	through	O
16	PI3K	O
17	-	O
18	induced	B
19	FKHR	I
20	-	I
21	L1	O
22	phosphorylation	O
23	provides	O
24	a	O
25	novel	O
26	mechanism	O
27	of	O
28	regulating	O
29	cytokine	O
30	-	O
31	mediated	O
32	survival	O
33	and	O
34	proliferation	O
35	.	O

1	Overexpression	O
2	of	O
3	mcl	O
4	-	O
5	1	O
6	is	O
7	sufficient	O
8	to	O
9	protect	O
10	against	O
11	apoptosis	O
12	,	O
13	while	O
14	transfection	O
15	of	O
16	a	O
17	mcl	O
18	-	O
19	1	O
20	antisense	O
21	plasmid	O
22	causes	O
23	cell	O
24	death	O
25	.	O

1	Despite	O
2	this	O
3	DNA	O
4	binding	O
5	activity	O
6	,	B
7	AP	I
8	-	I
9	1	I
10	reporter	O
11	activity	O
12	was	O
13	suppressed	O
14	in	O
15	these	O
16	cells	O
17	.	O

1	Tests	O
2	of	O
3	the	O
4	method	O
5	indicate	O
6	(	O
7	1	O
8	)	O
9	the	O
10	Mossbauer	O
11	source	O
12	can	O
13	be	O
14	placed	O
15	on	O
16	the	O
17	basilar	O
18	membrane	O
19	without	O
20	altering	O
21	the	O
22	signal	O
23	-	O
24	transmission	O
25	properties	O
26	of	O
27	the	O
28	cochlea	O
29	,	O
30	and	O
31	(	O
32	2	O
33	)	O
34	the	O
35	source	O
36	adheres	O
37	to	O
38	the	O
39	basilar	O
40	membrane	O
41	.	O

1	We	O
2	propose	O
3	that	O
4	CTS1	O
5	and	O
6	CTS2	O
7	of	O
8	Ci	O
9	are	O
10	members	O
11	of	O
12	two	O
13	distinct	O
14	classes	O
15	of	O
16	fungal	O
17	chitinases	O
18	,	O
19	an	O
20	observation	O
21	not	O
22	previously	O
23	reported	O
24	for	O
25	a	O
26	single	O
27	fungus	O
28	.	O

1	Identification	O
2	of	O
3	eotaxin	O
4	-	O
5	3	O
6	will	O
7	further	O
8	promote	O
9	our	O
10	understanding	O
11	of	O
12	the	O
13	control	O
14	of	O
15	eosinophil	O
16	trafficking	O
17	and	O
18	other	O
19	CCR3	O
20	-	O
21	mediated	O
22	biological	O
23	phenomena	O
24	.	O

1	Below	O
2	50	O
3	%	O
4	decrease	O
5	of	O
6	PaO2	O
7	,	O
8	NADH	O
9	was	O
10	reduced	O
11	largely	O
12	.	O

1	The	O
2	interaction	O
3	of	B
4	U1	I
5	-	I
6	70K	O
7	with	O
8	the	B
9	SRZ	I
10	proteins	O
11	is	O
12	confirmed	O
13	further	O
14	in	O
15	vitro	O
16	using	O
17	a	O
18	blot	O
19	overlay	O
20	assay	O
21	.	O

1	Role	O
2	of	O
3	NH	O
4	(	O
5	2	O
6	)-	O
7	and	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	of	O
13	the	O
14	P	O
15	protein	O
16	of	O
17	human	O
18	parainfluenza	O
19	virus	O
20	type	O
21	3	O
22	in	O
23	transcription	O
24	and	O
25	replication	O
26	.	O

1	The	O
2	customary	O
3	coupling	O
4	reagent	O
5	sulfanilic	O
6	acid	O
7	has	O
8	been	O
9	replaced	O
10	by	O
11	1	O
12	,	O
13	3	O
14	-	O
15	dimethylbarbituric	O
16	acid	O
17	;	O
18	CNCl	O
19	is	O
20	produced	O
21	in	O
22	the	O
23	flow	O
24	through	O
25	system	O
26	directly	O
27	from	O
28	KCN	O
29	and	O
30	chloramine	O
31	T	O
32	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	16	O
6	full	O
7	-	O
8	scale	O
9	fire	O
10	tests	O
11	,	O
12	investigators	O
13	at	O
14	the	O
15	IIT	O
16	Research	O
17	Institute	O
18	have	O
19	concluded	O
20	that	O
21	automatic	O
22	door	O
23	control	O
24	in	O
25	the	O
26	room	O
27	of	O
28	fire	O
29	origin	O
30	can	O
31	significantly	O
32	reduce	O
33	the	O
34	spread	O
35	of	O
36	toxic	O
37	smoke	O
38	and	O
39	gases	O
40	.	O

1	An	O
2	unusual	O
3	cysteine	O
4	triplet	O
5	conserved	O
6	in	O
7	the	O
8	sequences	O
9	of	O
10	TB	O
11	domains	O
12	is	O
13	localized	O
14	to	O
15	the	O
16	hydrophobic	O
17	core	O
18	,	O
19	at	O
20	the	O
21	C	O
22	-	O
23	terminus	O
24	of	O
25	an	B
26	alpha	I
27	-	I
28	helix	I
29	.	I

1	In	O
2	14	O
3	of	O
4	21	O
5	infant	O
6	hearts	O
7	(	O
8	66	O
9	%)	O
10	with	O
11	aortic	O
12	arch	O
13	interruption	O
14	between	O
15	the	O
16	left	O
17	common	O
18	carotid	O
19	and	O
20	left	O
21	subclavian	O
22	arteries	O
23	(	O
24	type	O
25	B	O
26	of	O
27	Celoria	O
28	and	O
29	Patton	O
30	),	O
31	the	O
32	right	O
33	subclavian	O
34	artery	O
35	(	O
36	SA	O
37	)	O
38	arose	O
39	anomalously	O
40	.	O

1	16	O
2	percent	O
3	,	O
4	P	O
5	<	O
6	0	O
7	.	O
8	001	O
9	),	O
10	and	O
11	sustained	O
12	normalization	O
13	of	B
14	serum	I
15	alanine	I
16	aminotransferase	O
17	levels	O
18	(	O
19	41	O
20	percent	O
21	vs	O
22	.	O

1	A	O
2	recombinant	O
3	with	O
4	a	O
5	5	O
6	'	O
7	end	O
8	from	B
9	src	O
10	and	O
11	a	O
12	3	O
13	'	O
14	end	O
15	from	O
16	ros	O
17	,	O
18	called	B
19	SRC	B
20	x	B
21	ROS	O
22	,	O
23	transformed	O
24	chicken	O
25	embryo	O
26	fibroblasts	O
27	(	O
28	CEF	O
29	)	O
30	to	O
31	a	O
32	spindle	O
33	shape	O
34	morphology	O
35	,	O
36	mimicking	O
37	that	O
38	of	O
39	UR2	O
40	.	O

1	Pneumonia	O
2	in	O
3	children	O

1	The	O
2	effect	O
3	of	O
4	sodium	O
5	saccharin	O
6	in	O
7	the	O
8	diet	O
9	on	O
10	caecal	O
11	microflora	O
12	.	O

1	This	O
2	test	O
3	should	O
4	provide	O
5	another	O
6	practical	O
7	means	O
8	to	O
9	study	O
10	leprosy	O
11	.	O

1	We	O
2	present	O
3	the	O
4	preliminary	O
5	results	O
6	obtained	O
7	on	O
8	36	O
9	patients	O
10	which	O
11	were	O
12	followed	O
13	for	O
14	a	O
15	mean	O
16	period	O
17	of	O
18	12	O
19	months	O
20	.	O

1	The	O
2	measurement	O
3	of	O
4	the	O
5	areas	O
6	of	O
7	fibrin	O
8	,	O
9	of	O
10	tissue	O
11	and	O
12	fibrinolysis	O
13	,	O
14	at	O
15	the	O
16	above	O
17	mentioned	O
18	times	O
19	,	O
20	has	O
21	been	O
22	effected	O
23	at	O
24	standard	O
25	magnification	O
26	(	O
27	15	O
28	X	O
29	)	O
30	by	O
31	an	O
32	image	O
33	analyser	O
34	(	O
35	Videoplan	O
36	)	O
37	scale	O
38	1	O
39	:	O
40	8	O
41	.	O

1	Intraperitoneal	O
2	administration	O
3	of	B
4	L	I
5	-	I
6	5	I
7	-	I
8	hydroxytryptophan	I
9	(	I
10	L	I
11	-	I
12	5	I
13	-	I
14	HTP	O
15	)	O
16	at	O
17	doses	O
18	of	O
19	25	O
20	to	O
21	100	O
22	mg	O
23	/	O
24	kg	O
25	dramatically	O
26	increase	O
27	defecation	O
28	in	O
29	mice	O
30	.	O

1	Moreover	O
2	,	O
3	promoters	O
4	containing	O
5	a	O
6	TATA	O
7	box	O
8	in	O
9	the	O
10	absence	O
11	of	B
12	Sp1	I
13	sites	I
14	or	I
15	Sp1	I
16	sites	O
17	in	O
18	the	O
19	absence	O
20	of	O
21	a	O
22	TATA	O
23	box	O
24	were	O
25	equally	O
26	inducible	O
27	in	O
28	vitro	O
29	,	O
30	as	O
31	was	O
32	an	B
33	RNA	I
34	polymerase	I
35	III	I
36	promoter	I
37	.	I

1	The	O
2	level	O
3	of	O
4	carboxyl	O
5	-	O
6	terminal	O
7	parathyroid	O
8	hormone	O
9	in	O
10	the	O
11	patients	O
12	with	O
13	thyroid	O
14	carcinoma	O
15	was	O
16	higher	O
17	than	O
18	that	O
19	in	O
20	the	O
21	patients	O
22	without	O
23	thyroid	O
24	carcinoma	O
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	05	O
32	).	O

1	Pathological	O
2	processes	O
3	in	O
4	the	O
5	cervix	O
6	uteri	O

1	After	O
2	acclimation	O
3	,	O
4	resting	O
5	supine	O
6	and	O
7	sitting	O
8	DPB	O
9	decreased	O
10	(	O
11	P	O
12	less	O
13	than	O
14	0	O
15	.	O
16	05	O
17	)	O
18	by	O
19	6	O
20	and	O
21	9	O
22	mmHg	O
23	,	O
24	respectively	O
25	.	O

1	Multilayer	O
2	-	O
3	relaxation	O
4	geometry	O
5	and	O
6	electronic	O
7	structure	O
8	of	O
9	a	O
10	W	O
11	(	O
12	111	O
13	)	O
14	surface	O
15	.	O

1	Regulation	O
2	of	O
3	avian	B
4	fibroblast	I
5	growth	I
6	factor	I
7	receptor	I
8	1	I
9	(	I
10	FGFR	I
11	-	I
12	1	I
13	)	I
14	gene	O
15	expression	O
16	during	O
17	skeletal	O
18	muscle	O
19	differentiation	O
20	.	O

1	Extreme	O
2	potency	O
3	of	O
4	botulinum	I
5	toxin	I
6	.	I

1	Mechanism	O
2	of	O
3	enhancement	O
4	of	O
5	DNA	O
6	expression	O
7	consequent	O
8	to	O
9	cointernalization	O
10	of	O
11	a	O
12	replication	O
13	-	O
14	deficient	O
15	adenovirus	O
16	and	O
17	unmodified	O
18	plasmid	O
19	DNA	O
20	.	O

1	The	O
2	histochemistry	O
3	and	O
4	ultrastructure	O
5	of	O
6	calcified	O
7	cerebellar	O
8	deposits	O
9	described	O
10	by	O
11	Tonge	O
12	et	O
13	al	O
14	.	O

1	The	B
2	avidin	I
3	-	I
4	biotin	I
5	complex	I
6	peroxidase	I
7	(	I
8	ABC	I
9	-	I
10	P	O
11	)	O
12	method	O
13	was	O
14	used	O
15	to	O
16	detect	O
17	Mycobacterium	O
18	bovis	O
19	,	O
20	and	O
21	the	O
22	results	O
23	were	O
24	compared	O
25	with	O
26	those	O
27	obtained	O
28	by	O
29	the	B
30	Ziehl	I
31	-	I
32	Neelsen	O
33	(	O
34	ZN	O
35	)	O
36	technique	O
37	.	O

1	The	O
2	presence	O
3	of	O
4	an	O
5	additional	O
6	sequence	O
7	of	O
8	nucleotides	O
9	145	O
10	-	O
11	165	O
12	from	O
13	the	O
14	3	O
15	'	O
16	end	O
17	of	O
18	RNA3	O
19	enhanced	O
20	template	O
21	recognition	O
22	by	O
23	RdRp	O
24	in	O
25	vitro	O
26	and	O
27	accumulation	O
28	of	O
29	RNA3	O
30	in	O
31	vivo	O
32	to	O
33	wild	O
34	-	O
35	type	O
36	levels	O
37	.	O

1	Complete	O
2	recovery	O
3	of	O
4	liver	O
5	function	O
6	after	O
7	this	O
8	surgery	O
9	tended	O
10	to	O
11	be	O
12	slow	O
13	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	the	O
6	GAL7	O
7	5	O
8	'	O
9	flanking	O
10	region	O
11	has	O
12	many	O
13	features	O
14	common	O
15	to	O
16	those	O
17	of	O
18	multicellular	O
19	eukaryotic	O
20	genes	O
21	.	O

1	Pol32Delta	O
2	strains	O
3	are	O
4	weak	O
5	antimutators	O
6	and	O
7	are	O
8	defective	O
9	for	O
10	damage	O
11	-	O
12	induced	O
13	mutagenesis	O
14	.	O

1	T	O
2	-	O
3	cell	O
4	receptor	O
5	beta	O
6	(	B
7	TCR	I
8	beta	I
9	)	I
10	gene	O
11	rearrangements	O
12	occur	O
13	in	O
14	a	O
15	third	O
16	of	O
17	early	O
18	B	O
19	-	O
20	cell	O
21	acute	O
22	lymphoblastic	O
23	leukemias	O
24	(	O
25	ALLs	O
26	).	O

1	Neither	O
2	gene	O
3	possesses	O
4	a	O
5	distinct	O
6	transcriptional	O
7	start	O
8	site	O
9	as	O
10	shown	O
11	by	O
12	nuclease	O
13	S1	O
14	analysis	O
15	.	O

1	Recognition	O
2	mechanisms	O
3	of	O
4	the	O
5	minus	O
6	-	O
7	strand	O
8	origin	O
9	of	O
10	phage	O
11	f1	O
12	by	B
13	Escherichia	I
14	coli	I
15	RNA	I
16	polymerase	I
17	.	I

1	These	O
2	findings	O
3	were	O
4	reinforced	O
5	by	O
6	an	O
7	analysis	O
8	that	O
9	was	O
10	restricted	O
11	to	O
12	living	O
13	donor	O
14	transplants	O
15	without	O
16	acute	O
17	rejection	O
18	.	O

1	A	O
2	cDNA	O
3	clone	O
4	was	O
5	isolated	O
6	from	O
7	a	O
8	chicken	O
9	embryo	O
10	cDNA	O
11	library	O
12	employing	O
13	a	O
14	PCR	O
15	-	O
16	generated	O
17	radiolabeled	O
18	probe	O
19	specific	O
20	for	O
21	the	O
22	U3	O
23	region	O
24	of	O
25	the	O
26	Rous	O
27	sarcoma	O
28	virus	O
29	LTR	O
30	.	O

1	Plasma	O
2	thromboxane	O
3	B2	O
4	levels	O
5	in	O
6	the	O
7	older	O
8	group	O
9	were	O
10	about	O
11	double	O
12	those	O
13	in	O
14	younger	O
15	piglets	O
16	.	O

1	K	O
2	.	O

1	Here	O
2	we	O
3	review	O
4	progress	O
5	to	O
6	date	O
7	in	O
8	this	O
9	area	O
10	.	O

1	It	O
2	is	O
3	mainly	O
4	transcribed	O
5	in	O
6	neural	O
7	structures	O
8	and	O
9	in	O
10	developing	O
11	organs	O
12	characterized	O
13	by	O
14	epithelial	O
15	-	O
16	mesenchymal	O
17	interactions	O
18	.	O

1	Furthermore	O
2	,	O
3	the	O
4	PH	O
5	and	O
6	PTB	O
7	domains	O
8	are	O
9	highly	O
10	homologous	O
11	(	O
12	at	O
13	least	O
14	40	O
15	%	O
16	identical	O
17	)	O
18	to	O
19	those	O
20	found	O
21	in	B
22	insulin	I
23	receptor	O
24	substrates	O
25	1	O
26	,	O
27	2	O
28	,	O
29	and	O
30	3	O
31	(	O
32	IRS	O
33	-	O
34	1	O
35	,	O
36	IRS	O
37	-	O
38	2	O
39	,	O
40	and	O
41	IRS	O
42	-	O
43	3	O
44	).	O

1	Thyrotropin	O
2	-	O
3	induced	O
4	expression	O
5	of	O
6	a	O
7	gene	O
8	for	O
9	a	O
10	ribosomal	O
11	protein	O
12	related	O
13	to	O
14	the	B
15	trk	I
16	oncogene	I
17	.	I

1	Recipients	O
2	with	O
3	acute	O
4	leukaemia	O
5	in	O
6	first	O
7	remission	O
8	or	O
9	chronic	O
10	myeloid	O
11	leukaemia	O
12	in	O
13	first	O
14	chronic	O
15	phase	O
16	were	O
17	analysed	O
18	as	O
19	good	O
20	risk	O
21	,	O
22	and	O
23	those	O
24	beyond	O
25	these	O
26	stages	O
27	,	O
28	as	O
29	poor	O
30	risk	O
31	patients	O
32	.	O

1	A	O
2	promising	O
3	new	O
4	cement	O
5	,	B
6	4	I
7	-	I
8	META	I
9	/	I
10	MMA	I
11	-	I
12	TBB	I
13	opaque	O
14	resin	O
15	,	O
16	has	O
17	shown	O
18	remarkable	O
19	adhesive	O
20	properties	O
21	as	O
22	a	O
23	bone	O
24	cement	O
25	in	O
26	vivo	O
27	.	O

1	Krox	O
2	-	O
3	20	O
4	,	O
5	a	B
6	zinc	I
7	finger	I
8	gene	O
9	,	O
10	has	O
11	a	O
12	highly	O
13	conserved	O
14	pattern	O
15	of	O
16	expression	O
17	in	O
18	r3	O
19	and	O
20	r5	O
21	and	O
22	is	O
23	functionally	O
24	required	O
25	for	O
26	their	O
27	maintenance	O
28	in	O
29	mouse	O
30	embryos	O
31	.	O

1	NuA4	O
2	has	O
3	an	O
4	apparent	O
5	molecular	O
6	mass	O
7	of	O
8	1	O
9	.	O
10	3	O
11	MDa	O
12	.	O

1	Location	O
2	and	O
3	orientation	O
4	of	O
5	an	O
6	activating	O
7	region	O
8	in	O
9	the	B
10	Escherichia	I
11	coli	I
12	transcription	I
13	factor	O
14	,	B
15	FNR	I
16	.	I

1	Intracellular	O
2	localization	O
3	studies	O
4	using	O
5	the	B
6	mDAP	I
7	-	I
8	3	I
9	/	I
10	EGFP	I
11	fusion	I
12	protein	O
13	,	O
14	cell	O
15	fractionation	O
16	and	O
17	protease	O
18	protection	O
19	experiments	O
20	localized	B
21	mDAP	I
22	-	I
23	3	O
24	to	O
25	the	O
26	mitochondrial	O
27	matrix	O
28	.	O

1	The	O
2	shift	O
3	to	O
4	the	O
5	nonpermissive	O
6	temperature	O
7	is	O
8	accompanied	O
9	by	O
10	the	O
11	loss	O
12	of	B
13	guanyl	I
14	nucleotide	I
15	-	I
16	dependent	O
17	activity	O
18	of	B
19	adenylylcyclase	O
20	in	O
21	vitro	O
22	.	O

1	Relation	O
2	between	O
3	mixing	O
4	ratio	O
5	of	O
6	raw	O
7	materials	O
8	and	O
9	composition	O
10	of	O
11	products	O
12	in	O
13	the	O
14	synthesis	O
15	of	O
16	aluminosilicates	O

1	A	O
2	single	O
3	five	O
4	minute	O
5	period	O
6	of	O
7	rapid	O
8	atrial	O
9	pacing	O
10	fails	O
11	to	O
12	limit	O
13	infarct	O
14	size	O
15	in	O
16	the	O
17	in	O
18	situ	O
19	rabbit	O
20	heart	O
21	.	O

1	The	O
2	efficacy	O
3	of	O
4	these	O
5	immunosuppressive	O
6	drugs	O
7	is	O
8	clinical	O
9	proven	O
10	.	O

1	Degenerate	O
2	primers	O
3	homologous	O
4	to	O
5	highly	O
6	conserved	O
7	regions	O
8	of	O
9	known	O
10	CYP3A	O
11	sequences	O
12	were	O
13	used	O
14	for	O
15	initial	O
16	RT	O
17	-	O
18	PCRs	O
19	.	O

1	The	O
2	sequence	O
3	contains	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	1744	O
10	nt	O
11	in	O
12	the	O
13	virus	O
14	-	O
15	sense	O
16	strand	O
17	,	O
18	a	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	of	O
24	1360	O
25	nt	O
26	and	O
27	a	O
28	3	O
29	'	O
30	poly	O
31	(	O
32	A	O
33	)	O
34	tail	O
35	.	O

1	The	B
2	protein	I
3	-	I
4	tyrosine	I
5	kinase	O
6	fer	O
7	associates	O
8	with	O
9	signaling	O
10	complexes	O
11	containing	B
12	insulin	I
13	receptor	I
14	substrate	I
15	-	I
16	1	O
17	and	B
18	phosphatidylinositol	I
19	3	I
20	-	I
21	kinase	I
22	.	I

1	The	O
2	effects	O
3	of	O
4	intracisternal	O
5	injection	O
6	(	O
7	i	O
8	.	O
9	c	O
10	.	O
11	i	O
12	.)	O
13	of	O
14	clonidine	O
15	(	O
16	1	O
17	microgram	O
18	kg	O
19	-	O
20	1	O
21	)	O
22	on	O
23	blood	O
24	pressure	O
25	and	O
26	heart	O
27	rate	O
28	were	O
29	studied	O
30	in	O
31	conscious	O
32	rabbits	O
33	with	O
34	an	O
35	implanted	O
36	catheter	O
37	in	O
38	the	O
39	cisterna	O
40	magna	O
41	.	O

1	Levels	O
2	of	B
3	serum	B
4	IgE	O
5	were	O
6	measured	O
7	monthly	O
8	,	O
9	and	O
10	nasal	B
11	IgE	O
12	was	O
13	measured	O
14	at	O
15	the	O
16	height	O
17	and	O
18	end	O
19	of	O
20	the	O
21	season	O
22	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	mRNA	O
5	capping	O
6	enzyme	O
7	identifies	O
8	amino	O
9	acids	O
10	involved	O
11	in	O
12	GTP	O
13	binding	O
14	,	O
15	enzyme	O
16	-	O
17	guanylate	O
18	formation	O
19	,	O
20	and	O
21	GMP	O
22	transfer	O
23	to	O
24	RNA	O
25	.	O

1	Unlike	B
2	p59v	I
3	-	I
4	rel	O
5	,	O
6	which	O
7	is	O
8	a	O
9	nuclear	O
10	protein	O
11	in	O
12	CEF	O
13	,	O
14	indirect	O
15	immunofluorescence	O
16	showed	O
17	that	B
18	p68c	I
19	-	I
20	rel	I
21	in	I
22	JD214c	I
23	-	I
24	rel	O
25	infected	O
26	CEF	O
27	is	O
28	located	O
29	exclusively	O
30	in	O
31	the	O
32	cytoplasm	O
33	of	O
34	these	O
35	cells	O
36	,	O
37	even	O
38	though	O
39	the	O
40	sequence	O
41	of	B
42	p68c	I
43	-	I
44	rel	O
45	showed	O
46	that	O
47	it	O
48	contains	O
49	a	O
50	nuclear	O
51	localizing	O
52	sequence	O
53	identical	O
54	to	O
55	the	O
56	one	O
57	previously	O
58	identified	O
59	in	B
60	p59v	I
61	-	I
62	rel	I
63	.	I

1	Nursing	O
2	education	O
3	--	O
4	the	O
5	computer	O
6	obligation	O
7	.	O

1	Growth	O
2	factors	O
3	induce	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	immediate	I
9	early	I
10	gene	I
11	products	I
12	MAP	I
13	kinase	I
14	phosphatase	I
15	-	I
16	1	I
17	(	I
18	MKP	I
19	-	I
20	1	I
21	),	I
22	c	I
23	-	I
24	Fos	I
25	and	I
26	c	I
27	-	I
28	Jun	I
29	.	I

1	Following	O
2	intravenous	O
3	administration	O
4	,	O
5	the	O
6	myocardial	O
7	concentration	O
8	of	O
9	tracer	O
10	thallium	O
11	-	O
12	201	O
13	,	O
14	potassium	O
15	-	O
16	43	O
17	,	O
18	and	O
19	rubidium	O
20	-	O
21	81	O
22	were	O
23	determined	O
24	in	O
25	mice	O
26	;	O
27	thallium	O
28	was	O
29	present	O
30	in	O
31	the	O
32	greatest	O
33	concentration	O
34	in	O
35	the	O
36	myocardium	O
37	(	O
38	2	O
39	.	O
40	08	O
41	%	O
42	compared	O
43	1	O
44	.	O
45	25	O
46	%	O
47	for	O
48	potassium	O
49	and	O
50	1	O
51	.	O
52	15	O
53	%	O
54	for	O
55	rubidium	O
56	at	O
57	10	O
58	minutes	O
59	).	O

1	The	O
2	cDNA	O
3	segment	O
4	is	O
5	flanked	O
6	by	O
7	the	B
8	immunoglobulin	I
9	gene	O
10	recombination	O
11	signal	O
12	sequences	O
13	so	O
14	that	O
15	the	O
16	cDNA	O
17	segment	O
18	can	O
19	invert	O
20	and	O
21	the	B
22	human	B
23	IL	I
24	-	I
25	2R	I
26	L	I
27	chain	O
28	is	O
29	subsequently	O
30	expressed	O
31	under	O
32	the	O
33	control	O
34	of	O
35	the	O
36	SV40	O
37	promoter	O
38	.	O

1	Cloning	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	specific	B
7	human	I
8	alpha	I
9	1	I
10	,	I
11	2	I
12	-	I
13	mannosidase	O
14	that	O
15	trims	O
16	Man9GlcNAc2	O
17	to	O
18	Man8GlcNAc2	I
19	isomer	I
20	B	O
21	during	O
22	N	O
23	-	O
24	glycan	O
25	biosynthesis	O
26	.	O

1	The	O
2	brackets	O
3	were	O
4	bonded	O
5	to	O
6	100	O
7	freshly	O
8	extracted	O
9	bovine	O
10	incisors	O
11	,	O
12	and	O
13	,	O
14	after	O
15	storage	O
16	in	O
17	tap	O
18	water	O
19	at	O
20	room	O
21	temperature	O
22	for	O
23	24	O
24	hours	O
25	,	O
26	they	O
27	were	O
28	subsequently	O
29	tested	O
30	in	O
31	a	O
32	shear	O
33	mode	O
34	using	O
35	a	O
36	universal	O
37	testing	O
38	machine	O
39	.	O

1	The	O
2	complete	O
3	response	O
4	(	O
5	CR	O
6	)	O
7	rate	O
8	was	O
9	34	O
10	%	O
11	in	O
12	the	O
13	CODE	O
14	with	B
15	rhG	I
16	-	I
17	CSF	O
18	group	O
19	and	O
20	23	O
21	%	O
22	in	O
23	the	O
24	CODE	O
25	alone	O
26	group	O
27	;	O
28	the	O
29	median	O
30	survival	O
31	was	O
32	59	O
33	and	O
34	32	O
35	weeks	O
36	,	O
37	respectively	O
38	,	O
39	in	O
40	these	O
41	groups	O
42	(	O
43	P	O
44	=	O
45	0	O
46	.	O
47	004	O
48	).	O

1	In	O
2	cell	O
3	lines	O
4	transformed	O
5	by	B
6	BCR	I
7	/	I
8	ABL	O
9	,	O
10	CRKL	O
11	was	O
12	tyrosine	O
13	phosphorylated	O
14	,	O
15	while	O
16	CRK	O
17	was	O
18	not	O
19	.	O

1	The	O
2	December	O
3	armed	O
4	revolt	O
5	in	O
6	Moscow	O
7	and	O
8	the	O
9	paramedical	O
10	personnel	B

1	Protein	O
2	cHMGI	O
3	binds	O
4	preferentially	O
5	to	O
6	AT	O
7	-	O
8	rich	O
9	DNA	O
10	with	O
11	a	O
12	half	O
13	-	O
14	saturation	O
15	value	O
16	of	O
17	1	O
18	.	O
19	1	O
20	nM	O
21	.	O

1	Instead	O
2	,	O
3	they	O
4	contained	O
5	dendritic	O
6	cells	O
7	that	O
8	express	O
9	melanogenic	O
10	marker	O
11	proteins	O
12	such	O
13	as	O
14	tyrosinase	I
15	and	I
16	tyrosinase	I
17	-	I
18	related	I
19	protein	I
20	1	I
21	.	I

1	Thus	O
2	,	O
3	multiple	O
4	myogenic	O
5	factors	O
6	that	O
7	vary	O
8	qualitatively	O
9	and	O
10	quantitatively	O
11	may	O
12	be	O
13	responsible	O
14	for	O
15	the	O
16	different	O
17	and	O
18	complex	O
19	modulatory	O
20	programs	O
21	of	B
22	actin	I
23	gene	O
24	expression	O
25	observed	O
26	during	O
27	in	O
28	vivo	O
29	muscle	O
30	differentiation	O
31	.	O

1	She	O
2	had	O
3	been	O
4	receiving	O
5	MTX	O
6	7	O
7	.	O
8	5	O
9	mg	O
10	/	O
11	week	O
12	for	O
13	2	O
14	.	O
15	5	O
16	months	O
17	because	O
18	of	O
19	her	O
20	vasculitis	O
21	symptoms	O
22	.	O

1	Our	O
2	results	O
3	implicate	B
4	TGF	I
5	-	I
6	beta	I
7	RII	O
8	as	O
9	a	O
10	direct	O
11	target	O
12	of	B
13	EWS	I
14	-	I
15	FLI1	I
16	.	I

1	In	O
2	recent	O
3	years	O
4	,	O
5	successful	O
6	physiological	O
7	models	O
8	have	O
9	been	O
10	developed	O
11	for	O
12	a	O
13	variety	O
14	of	O
15	volatile	O
16	and	O
17	nonvolatile	O
18	chemicals	O
19	,	O
20	and	O
21	their	O
22	ability	O
23	to	O
24	perform	O
25	the	O
26	extrapolations	O
27	needed	O
28	in	O
29	risk	O
30	assessment	O
31	has	O
32	been	O
33	demonstrated	O
34	.	O

1	Despite	O
2	this	O
3	there	O
4	was	O
5	no	O
6	difference	O
7	in	O
8	the	O
9	intubating	O
10	conditions	O
11	at	O
12	one	O
13	minute	O
14	with	O
15	25	O
16	excellent	O
17	/	O
18	5	O
19	good	O
20	in	O
21	the	O
22	suxamethonium	O
23	group	O
24	and	O
25	27	O
26	excellent	O
27	/	O
28	3	O
29	good	O
30	in	O
31	the	O
32	rocuronium	O
33	group	O
34	.	O

1	To	O
2	accomplish	O
3	this	O
4	,	O
5	actin	O
6	cables	O
7	and	O
8	patches	O
9	are	O
10	redistributed	O
11	during	O
12	the	O
13	cell	O
14	cycle	O
15	to	O
16	direct	O
17	secretory	O
18	components	O
19	to	O
20	appropriate	O
21	sites	O
22	for	O
23	cell	O
24	growth	O
25	.	O

1	Genomic	O
2	DNA	O
3	clones	O
4	containing	O
5	the	O
6	T	O
7	-	O
8	cell	O
9	-	O
10	specific	O
11	human	O
12	MAL	O
13	gene	O
14	were	O
15	isolated	O
16	.	O

1	In	O
2	10	O
3	patients	O
4	with	O
5	subacute	O
6	cardiac	O
7	tamponade	O
8	,	O
9	pulmonary	O
10	wedge	O
11	pressure	O
12	(	O
13	PWP	O
14	),	O
15	RAP	O
16	,	O
17	and	O
18	IPP	O
19	were	O
20	measured	O
21	along	O
22	with	O
23	indexes	O
24	of	O
25	systolic	O
26	function	O
27	.	O

1	We	O
2	have	O
3	identified	O
4	in	O
5	the	O
6	5	O
7	'	O
8	untranslated	O
9	region	O
10	of	O
11	the	O
12	Drosophila	O
13	copia	O
14	retrotransposon	O
15	,	O
16	3	O
17	'	O
18	to	O
19	the	O
20	left	O
21	LTR	O
22	,	O
23	a	O
24	sequence	O
25	for	O
26	transcriptional	O
27	regulation	O
28	by	B
29	homeoproteins	I
30	.	I

1	59	O
2	cases	O
3	of	O
4	surgically	O
5	resectable	O
6	cancers	O
7	(	O
8	T1	O
9	,	O
10	T2	O
11	,	O
12	T3	O
13	,	O
14	N0	O
15	,	O
16	N1	O
17	)	O
18	had	O
19	a	O
20	minimum	O
21	followup	O
22	of	O
23	two	O
24	years	O
25	(	O
26	average	O
27	4	O
28	years	O
29	+/-	O
30	3	O
31	months	O
32	).	O

1	The	O
2	effects	O
3	produced	O
4	by	O
5	oral	O
6	administration	O
7	of	O
8	500	O
9	mg	O
10	/	O
11	kg	O
12	p	O
13	-	O
14	xylene	O
15	or	O
16	toluene	O
17	lasted	O
18	at	O
19	least	O
20	8	O
21	hr	O
22	,	O
23	while	O
24	the	O
25	effect	O
26	of	O
27	inhaled	O
28	p	O
29	-	O
30	xylene	O
31	dissipated	O
32	within	O
33	75	O
34	min	O
35	of	O
36	removal	O
37	from	O
38	the	O
39	exposure	O
40	.	O

1	Dopamine	O
2	receptor	O
3	blockade	O
4	and	O
5	the	O
6	neuroleptics	O
7	,	O
8	a	O
9	crystallographic	O
10	study	O
11	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	,	O
6	despite	O
7	their	O
8	structural	O
9	and	O
10	functional	O
11	similarities	O
12	,	O
13	the	O
14	pop1	O
15	and	O
16	pop2	O
17	genes	O
18	fail	O
19	to	O
20	complement	O
21	each	O
22	other	O
23	'	O
24	s	O
25	deletion	O
26	phenotypes	O
27	,	O
28	indicating	O
29	that	O
30	they	O
31	perform	O
32	non	O
33	-	O
34	redundant	O
35	,	O
36	but	O
37	potentially	O
38	interdependent	O
39	,	O
40	functions	O
41	in	O
42	proteolysis	O
43	.	O

1	Similarly	O
2	,	O
3	comparison	O
4	of	O
5	percentage	O
6	reductions	O
7	of	O
8	heart	O
9	rate	O
10	at	O
11	supine	O
12	,	O
13	sitting	O
14	and	O
15	exercise	O
16	by	O
17	repeated	O
18	measure	O
19	analysis	O
20	showed	O
21	the	O
22	Malays	O
23	to	O
24	have	O
25	significantly	O
26	higher	O
27	change	O
28	compared	O
29	to	O
30	the	O
31	Chinese	O
32	(	O
33	p	O
34	=	O
35	0	O
36	.	O
37	040	O
38	).	O

1	The	O
2	Mean	O
3	was	O
4	74	O
5	,	O
6	3	O
7	+/-	O
8	53	O
9	,	O
10	6	O
11	micrograms	O
12	J	O
13	/	O
14	g	O
15	Cr	O
16	,	O
17	the	O
18	Median	O
19	61	O
20	micrograms	O
21	J	O
22	/	O
23	g	O
24	Cr	O
25	.	O

1	Testing	O
2	gravity	O
3	to	O
4	second	O
5	post	O
6	-	O
7	Newtonian	O
8	order	O
9	:	O
10	A	O
11	field	O
12	-	O
13	theory	O
14	approach	O
15	.	O

1	Exchange	O
2	of	O
3	the	O
4	LPL	O
5	and	O
6	HL	O
7	lids	O
8	resulted	O
9	in	O
10	a	O
11	reversal	O
12	of	O
13	the	B
14	phospholipase	I
15	/	I
16	neutral	I
17	lipase	O
18	ratio	O
19	,	O
20	establishing	O
21	the	O
22	important	O
23	role	O
24	of	O
25	this	O
26	region	O
27	in	O
28	mediating	O
29	substrate	O
30	specificity	O
31	.	O

1	The	B
2	p53	B
3	tumor	I
4	suppressor	I
5	gene	I
6	product	I
7	,	I
8	a	I
9	sequence	I
10	-	I
11	specific	I
12	DNA	I
13	-	I
14	binding	I
15	protein	O
16	,	O
17	has	O
18	been	O
19	shown	O
20	to	O
21	act	O
22	as	O
23	a	O
24	transcriptional	O
25	activator	O
26	and	O
27	repressor	O
28	both	O
29	in	O
30	vitro	O
31	and	O
32	in	O
33	vivo	O
34	.	O

1	All	O
2	carcasses	O
3	resulted	O
4	in	O
5	contamination	O
6	with	O
7	aerobic	O
8	mesophilic	O
9	bacteria	O
10	in	O
11	the	O
12	range	O
13	from	O
14	6	O
15	x	O
16	10	O
17	(	O
18	3	O
19	)	O
20	to	O
21	1	O
22	.	O
23	2	O
24	x	O
25	10	O
26	(	O
27	6	O
28	)	O
29	CFU	O
30	/	O
31	ml	O
32	liquid	O
33	washed	O
34	,	O
35	and	O
36	94	O
37	%	O
38	them	O
39	with	O
40	sporulate	O
41	bacteria	O
42	,	O
43	the	O
44	threshold	O
45	being	O
46	under	O
47	100	O
48	CFU	O
49	/	O
50	ml	O
51	(	O
52	Figure	O
53	1	O
54	).	O

1	The	B
2	interferon	I
3	-	I
4	inducible	I
5	protein	I
6	kinase	I
7	PKR	O
8	modulates	O
9	the	O
10	transcriptional	O
11	activation	O
12	of	B
13	immunoglobulin	I
14	kappa	I
15	gene	I
16	.	I

1	Data	O
2	on	O
3	the	O
4	line	O
5	spread	O
6	function	O
7	(	O
8	LSF	O
9	)	O
10	were	O
11	obtained	O
12	from	O
13	the	O
14	image	O
15	of	O
16	a	O
17	0	O
18	.	O
19	2	O
20	mm	O
21	wide	O
22	slit	O
23	between	O
24	tungsten	O
25	blocks	O
26	that	O
27	were	O
28	positioned	O
29	at	O
30	the	O
31	isocentre	O
32	in	O
33	front	O
34	of	O
35	a	O
36	polystyrene	O
37	phantom	O
38	.	O

1	Consistent	O
2	with	O
3	the	O
4	protein	O
5	expression	O
6	data	O
7	,	B
8	V	I
9	beta	I
10	8	I
11	.	I
12	3	I
13	gene	I
14	transcripts	O
15	were	O
16	found	O
17	only	O
18	in	O
19	the	O
20	transgenic	O
21	lines	O
22	with	O
23	the	B
24	wild	I
25	-	I
26	type	I
27	promoter	I
28	.	I

1	The	O
2	pheromone	O
3	response	O
4	pathway	O
5	activates	O
6	transcription	O
7	of	O
8	Ty5	O
9	retrotransposons	O
10	located	O
11	within	O
12	silent	O
13	chromatin	O
14	of	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	In	O
2	contrast	O
3	,	O
4	a	B
5	Maf	I
6	-	I
7	related	I
8	protein	O
9	,	O
10	Nrl	O
11	,	O
12	completely	O
13	mimicked	B
14	c	I
15	-	I
16	Maf	I
17	actions	I
18	.	I

1	Oxidative	O
2	degradation	O
3	of	O
4	adrenaline	O
5	solutions	O
6	:	O
7	study	O
8	of	O
9	the	O
10	intermediate	O
11	stages	O
12	and	O
13	their	O
14	analytic	O
15	value	O
16	for	O
17	the	O
18	control	O
19	of	O
20	this	B
21	solute	B

1	Sequence	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	upstream	O
11	to	O
12	the	O
13	ATG	O
14	codon	O
15	did	O
16	not	O
17	contain	O
18	a	O
19	conventional	O
20	TATA	O
21	box	O
22	.	O

1	The	B
2	cdr1	O
3	sequence	O
4	includes	O
5	an	O
6	additional	O
7	237	O
8	amino	O
9	acids	O
10	of	O
11	the	O
12	contiguous	O
13	fragment	O
14	and	O
15	encodes	O
16	a	O
17	product	O
18	of	O
19	predicted	O
20	Mr	O
21	67	O
22	,	O
23	000	O
24	.	O

1	The	O
2	gene	O
3	is	O
4	separated	O
5	into	O
6	four	O
7	exons	O
8	by	O
9	three	O
10	short	O
11	introns	O
12	,	O
13	and	O
14	the	O
15	open	O
16	reading	O
17	frame	O
18	consists	O
19	of	O
20	6660	O
21	base	O
22	pairs	O
23	(	O
24	bp	O
25	)	O
26	capable	O
27	of	O
28	encoding	O
29	a	O
30	polypeptide	O
31	of	O
32	2220	O
33	amino	O
34	acid	O
35	residues	O
36	.	O

1	CONCLUSIONS	O
2	:	O
3	Physiologic	O
4	pacing	O
5	provides	O
6	little	O
7	benefit	O
8	over	O
9	ventricular	O
10	pacing	O
11	for	O
12	the	O
13	prevention	O
14	of	O
15	stroke	O
16	or	O
17	death	O
18	due	O
19	to	O
20	cardiovascular	O
21	causes	O
22	.	O

1	In	O
2	MCCP	O
3	functions	O
4	of	O
5	the	O
6	source	O
7	emission	O
8	,	O
9	surface	O
10	reflection	O
11	,	O
12	photoacceptor	O
13	sensitivity	O
14	are	O
15	approximated	O
16	by	O
17	the	O
18	normal	O
19	distribution	O
20	curves	O
21	.	O

1	Sequencing	O
2	of	O
3	the	O
4	three	B
5	pag	I
6	-	I
7	3	I
8	alleles	O
9	showed	O
10	that	O
11	two	O
12	apparent	O
13	null	O
14	alleles	O
15	encode	O
16	a	O
17	nonsense	O
18	mutation	O
19	before	O
20	the	O
21	zinc	O
22	fingers	O
23	and	O
24	a	O
25	missense	O
26	mutation	O
27	in	O
28	the	O
29	fourth	O
30	zinc	O
31	finger	O
32	that	O
33	changes	O
34	a	O
35	coordinating	O
36	histidine	O
37	to	O
38	a	O
39	tyrosine	O
40	.	O

1	Each	O
2	dietary	O
3	treatment	O
4	was	O
5	fed	O
6	to	O
7	six	O
8	pen	O
9	replicates	O
10	of	O
11	five	O
12	chicks	O
13	per	O
14	pen	O
15	for	O
16	21	O
17	d	O
18	.	O

1	Only	O
2	two	O
3	of	O
4	the	O
5	isoforms	O
6	possess	O
7	the	B
8	N	I
9	-	I
10	terminal	I
11	zinc	I
12	finger	I
13	domain	O
14	that	O
15	is	O
16	necessary	O
17	and	O
18	sufficient	O
19	for	B
20	TdT	I
21	promoter	I
22	binding	I
23	.	I

1	There	O
2	are	O
3	regions	O
4	with	O
5	long	O
6	runs	O
7	of	O
8	up	O
9	to	O
10	45	O
11	%	O
12	C	O
13	or	O
14	35	O
15	%	O
16	G	O
17	residues	O
18	.	O

1	Interestingly	O
2	,	O
3	although	O
4	E	O
5	domains	O
6	of	O
7	these	O
8	two	O
9	receptors	O
10	are	O
11	much	O
12	less	O
13	conserved	O
14	,	O
15	replacement	O
16	of	O
17	this	O
18	domain	O
19	in	O
20	rtER	O
21	by	O
22	its	O
23	human	O
24	counterpart	O
25	resulted	O
26	in	O
27	higher	O
28	estradiol	O
29	sensitivity	O
30	but	O
31	no	O
32	increase	O
33	in	O
34	the	O
35	magnitude	O
36	of	O
37	transactivation	O
38	.	O

1	Of	O
2	these	O
3	carriers	O
4	149	O
5	were	O
6	diagnosed	O
7	to	O
8	be	O
9	asymptomatic	O
10	clinically	O
11	,	O
12	biochemically	O
13	and	O
14	echographically	O
15	.	O

1	All	O
2	samples	O
3	exhibited	O
4	a	O
5	decline	O
6	in	O
7	ethanol	O
8	concentration	O
9	,	O
10	with	O
11	most	O
12	losses	O
13	falling	O
14	within	O
15	the	O
16	expected	O
17	20	O
18	to	O
19	40	O
20	mg	O
21	%	O
22	range	O
23	.	O

1	N	O
2	-	O
3	terminal	O
4	sequence	O
5	analysis	O
6	and	O
7	NMR	O
8	measurements	O
9	revealed	O
10	that	O
11	this	O
12	fragment	O
13	originates	O
14	from	O
15	the	O
16	C	O
17	-	O
18	terminal	O
19	80	O
20	residues	O
21	of	B
22	MBF1	O
23	and	O
24	form	O
25	a	O
26	well	O
27	structured	O
28	C	O
29	-	O
30	terminal	O
31	domain	O
32	of	B
33	MBF1	O
34	,	B
35	MBF1CTD	I
36	.	I

1	In	O
2	both	O
3	experiments	O
4	,	O
5	average	O
6	daily	O
7	gain	O
8	and	O
9	gain	O
10	-	O
11	to	O
12	-	O
13	feed	O
14	ratio	O
15	were	O
16	similar	O
17	for	O
18	TR	O
19	and	O
20	CR	O
21	.	O

1	In	O
2	humans	O
3	,	O
4	three	O
5	tissue	O
6	-	O
7	specific	O
8	plastin	O
9	isoforms	O
10	have	O
11	been	O
12	identified	O
13	.	O

1	The	O
2	former	O
3	procedure	O
4	is	O
5	economical	O
6	but	O
7	complicated	O
8	,	O
9	whereas	O
10	the	O
11	latter	O
12	is	O
13	simple	O
14	and	O
15	labour	O
16	-	O
17	saving	O
18	,	O
19	but	O
20	a	O
21	special	O
22	ultrafiltration	O
23	tube	O
24	is	O
25	required	O
26	.	O

1	There	O
2	were	O
3	122	O
4	cases	O
5	of	O
6	tuberculosis	O
7	over	O
8	an	O
9	average	O
10	10	O
11	.	O
12	3	O
13	yr	O
14	of	O
15	follow	O
16	-	O
17	up	O
18	(	O
19	crude	O
20	annual	O
21	incidence	O
22	,	O
23	76	O
24	.	O
25	2	O
26	/	O
27	100	O
28	,	O
29	000	O
30	).	O

1	It	O
2	can	O
3	be	O
4	concluded	O
5	that	O
6	in	O
7	normotensive	O
8	subjects	O
9	,	O
10	uric	O
11	acid	O
12	and	B
13	xanthine	I
14	oxidase	O
15	have	O
16	significant	O
17	association	O
18	with	O
19	blood	O
20	pressure	O
21	and	O
22	thus	O
23	are	O
24	one	O
25	of	O
26	the	O
27	many	O
28	factors	O
29	which	O
30	are	O
31	involved	O
32	in	O
33	the	O
34	cause	O
35	or	O
36	effect	O
37	of	O
38	hypertension	O
39	.	O

1	On	O
2	histologic	O
3	examination	O
4	the	O
5	cuboidal	O
6	epithelium	O
7	of	O
8	the	O
9	mucous	O
10	membrane	O
11	was	O
12	found	O
13	to	O
14	be	O
15	changed	O
16	into	O
17	columnar	O
18	epithelium	O
19	,	O
20	with	O
21	uneven	O
22	distribution	O
23	of	O
24	enlarged	O
25	nuclei	O
26	in	O
27	the	O
28	vacuolized	O
29	cytoplasm	O
30	.	O

1	T	O
2	antigen	O
3	contains	O
4	four	B
5	H	I
6	-	I
7	2Db	I
8	-	O
9	restricted	O
10	cytotoxic	O
11	T	O
12	lymphocyte	O
13	(	O
14	CTL	O
15	)	O
16	recognition	O
17	epitopes	O
18	that	O
19	are	O
20	targets	O
21	for	O
22	CTL	O
23	clones	O
24	Y	O
25	-	O
26	1	O
27	,	O
28	Y	O
29	-	O
30	2	O
31	,	O
32	Y	O
33	-	O
34	3	O
35	,	O
36	and	O
37	Y	O
38	-	O
39	5	O
40	.	O

1	To	O
2	further	O
3	investigate	O
4	the	O
5	nature	O
6	of	O
7	the	O
8	site	O
9	specificity	O
10	a	O
11	set	O
12	of	O
13	deletion	O
14	mutants	O
15	of	O
16	the	O
17	160	O
18	bp	O
19	sequence	O
20	were	O
21	analysed	O
22	.	O

1	The	O
2	variations	O
3	were	O
4	caused	O
5	by	O
6	opposite	O
7	shifts	O
8	in	O
9	TSH	O
10	frequency	O
11	distribution	O
12	in	O
13	mothers	O
14	and	O
15	neonates	O
16	.	O

1	A	O
2	cause	O
3	of	O
4	increase	O
5	of	B
6	alkaline	I
7	phosphatase	O
8	in	O
9	children	O

1	OBJECTIVES	O
2	:	O
3	To	O
4	measure	O
5	coagulation	O
6	factor	O
7	VIII	O
8	:	O
9	coagulant	O
10	(	O
11	F	O
12	.	O
13	VIII	O
14	:	O
15	C	O
16	)	O
17	and	B
18	C1	I
19	-	I
20	esterase	I
21	inhibitor	I
22	(	I
23	C1	I
24	-	O
25	INH	O
26	),	O
27	hemostasis	O
28	-	O
29	associated	O
30	acute	O
31	-	O
32	phase	O
33	reactant	O
34	proteins	O
35	and	O
36	coagulation	O
37	factors	O
38	VII	O
39	(	O
40	F	O
41	.	O
42	VII	O
43	),	O
44	IX	O
45	(	O
46	F	O
47	.	O
48	IX	O
49	),	O
50	and	O
51	X	O
52	(	O
53	F	O
54	.	O
55	X	O
56	),	O
57	hemostasis	O
58	proteins	O
59	not	O
60	associated	O
61	with	O
62	an	O
63	acute	O
64	-	O
65	phase	O
66	response	O
67	,	O
68	in	O
69	a	O
70	select	O
71	population	O
72	of	O
73	horses	O
74	with	O
75	colic	O
76	and	O
77	hemostasis	O
78	abnormalities	O
79	,	O
80	and	O
81	presumed	O
82	to	O
83	have	O
84	acute	O
85	-	O
86	phase	O
87	changes	O
88	.	O

1	Further	O
2	investigation	O
3	on	O
4	the	O
5	chemotactic	O
6	influence	O
7	of	O
8	thymic	O
9	hormone	O
10	on	O
11	lymphocytes	O

1	The	O
2	clinical	O
3	picture	O
4	of	O
5	the	O
6	disease	O
7	was	O
8	significantly	O
9	different	O
10	from	O
11	anthropogenic	O
12	cutaneous	O
13	leishmaniasis	O
14	caused	O
15	by	O
16	L	O
17	.	O
18	tropica	O
19	but	O
20	similar	O
21	to	O
22	cutaneous	O
23	patterns	O
24	caused	O
25	by	O
26	L	O
27	.	O
28	infantum	O
29	which	O
30	was	O
31	a	O
32	prevalent	O
33	pattern	O
34	in	O
35	the	O
36	southern	O
37	France	O
38	.	O

1	The	O
2	weak	O
3	base	O
4	ketoconazole	O
5	showed	O
6	complete	O
7	dissolution	O
8	from	O
9	a	O
10	tablet	O
11	formulation	O
12	in	O
13	Simulated	O
14	Gastric	O
15	Fluid	O
16	without	B
17	pepsin	O
18	(	B
19	SGFsp	O
20	)	O
21	within	O
22	30	O
23	minutes	O
24	,	O
25	70	O
26	%	O
27	dissolution	O
28	in	O
29	2	O
30	hours	O
31	under	O
32	fed	O
33	state	O
34	simulated	O
35	upper	O
36	jejunal	O
37	conditions	O
38	but	O
39	only	O
40	6	O
41	%	O
42	dissolution	O
43	in	O
44	2	O
45	hours	O
46	under	O
47	fasted	O
48	state	O
49	conditions	O
50	.	O

1	Cross	O
2	-	O
3	talking	O
4	among	B
5	Drosophila	I
6	nuclear	I
7	receptors	O
8	at	O
9	the	O
10	promiscuous	O
11	response	O
12	element	O
13	of	O
14	the	O
15	ng	O
16	-	O
17	1	O
18	and	O
19	ng	O
20	-	O
21	2	O
22	intermolt	O
23	genes	O
24	.	O

1	Similarity	O
2	of	O
3	DNA	O
4	binding	O
5	and	O
6	transcriptional	O
7	regulation	O
8	by	B
9	Caenorhabditis	I
10	elegans	I
11	MAB	I
12	-	I
13	3	O
14	and	O
15	Drosophila	O
16	melanogaster	O
17	DSX	O
18	suggests	O
19	conservation	O
20	of	O
21	sex	O
22	determining	O
23	mechanisms	O
24	.	O

1	Subjects	O
2	with	O
3	a	O
4	short	O
5	postexposure	O
6	time	O
7	and	O
8	a	O
9	dioxin	O
10	burden	O
11	>	O
12	0	O
13	.	O
14	6	O
15	pg	O
16	/	O
17	m3	O
18	had	O
19	a	O
20	significantly	O
21	higher	O
22	risk	O
23	of	O
24	hypoergy	O
25	than	O
26	unexposed	O
27	subjects	O
28	(	O
29	hypoergy	O
30	I	O
31	:	O
32	OR	O
33	=	O
34	9	O
35	.	O
36	51	O
37	,	O
38	95	O
39	%	O
40	CI	O
41	=	O
42	1	O
43	.	O
44	96	O
45	-	O
46	42	O
47	.	O
48	02	O
49	;	O
50	hypoergy	O
51	II	O
52	:	O
53	OR	O
54	=	O
55	2	O
56	.	O
57	92	O
58	,	O
59	95	O
60	%	O
61	CI	O
62	=	O
63	1	O
64	.	O
65	14	O
66	-	O
67	7	O
68	.	O
69	5	O
70	).	O

1	This	O
2	interaction	O
3	inhibits	O
4	the	O
5	histone	O
6	acetyltransferase	O
7	activity	O
8	of	O
9	p300	O
10	,	O
11	resulting	O
12	in	O
13	drastic	O
14	reduction	O
15	of	O
16	nucleosomal	O
17	histone	O
18	acetylation	O
19	and	O
20	alteration	O
21	of	O
22	chromatin	O
23	structure	O
24	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	functionally	O
6	characterized	O
7	the	O
8	mouse	O
9	gene	O
10	for	O
11	the	O
12	C2	O
13	subunit	O
14	of	O
15	the	O
16	20S	O
17	proteasome	O
18	.	O

1	These	O
2	discoloration	O
3	'	O
4	s	O
5	can	O
6	be	O
7	treated	O
8	in	O
9	several	O
10	ways	O
11	but	O
12	up	O
13	to	O
14	lately	O
15	tooth	O
16	structure	O
17	had	O
18	to	O
19	be	O
20	removed	O
21	in	O
22	an	O
23	irreversible	O
24	manner	O
25	in	O
26	order	O
27	to	O
28	provide	O
29	sufficient	O
30	bulk	O
31	for	O
32	the	O
33	new	O
34	restorative	O
35	material	O
36	.	O

1	Furthermore	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	transcription	O
7	from	O
8	the	O
9	MMTV	O
10	5	O
11	'	O
12	LTR	O
13	is	O
14	highly	O
15	active	O
16	in	O
17	the	O
18	absence	O
19	of	O
20	Stat5a	O
21	,	O
22	a	O
23	transcription	O
24	factor	O
25	that	O
26	had	O
27	been	O
28	shown	O
29	previously	O
30	to	O
31	be	O
32	required	O
33	for	O
34	transcription	O
35	from	O
36	the	O
37	MMTV	O
38	LTR	O
39	.	O

1	When	O
2	expressed	O
3	per	O
4	kilogram	O
5	body	O
6	weight	O
7	,	O
8	mean	O
9	GIT	O
10	increased	O
11	in	O
12	the	O
13	dF	O
14	group	O
15	from	O
16	0	O
17	.	O
18	14	O
19	%	O
20	to	O
21	0	O
22	.	O
23	16	O
24	%	O
25	above	O
26	RMR	O
27	,	O
28	with	O
29	a	O
30	significant	O
31	decrease	O
32	from	O
33	0	O
34	.	O
35	15	O
36	%	O
37	to	O
38	0	O
39	.	O
40	13	O
41	%	O
42	in	O
43	the	O
44	P	O
45	group	O
46	.	O

1	Sequencing	O
2	of	O
3	the	O
4	facB	O
5	gene	O
6	revealed	O
7	that	O
8	it	O
9	encodes	O
10	a	O
11	protein	O
12	that	O
13	contains	O
14	an	B
15	N	I
16	-	I
17	terminal	I
18	GAL4	I
19	-	I
20	like	I
21	Zn	I
22	(	I
23	II	I
24	)	I
25	2Cys6	I
26	(	I
27	or	I
28	C6	I
29	zinc	I
30	)	I
31	binuclear	I
32	cluster	O
33	for	O
34	DNA	O
35	binding	O
36	,	B
37	leucine	I
38	zipper	I
39	-	I
40	like	I
41	heptad	O
42	repeat	O
43	motifs	O
44	and	O
45	central	O
46	and	B
47	C	I
48	-	I
49	terminal	I
50	acidic	I
51	alpha	I
52	-	I
53	helical	O
54	regions	O
55	,	O
56	consistent	O
57	with	O
58	a	O
59	function	O
60	as	O
61	a	B
62	DNA	I
63	-	I
64	binding	I
65	transcriptional	I
66	activator	I
67	.	I

1	A	O
2	transgenic	O
3	complementation	O
4	assay	O
5	was	O
6	used	O
7	to	O
8	test	O
9	whether	O
10	NIa	O
11	supplied	O
12	in	O
13	trans	O
14	could	O
15	rescue	O
16	amplification	O
17	-	O
18	defective	O
19	viral	O
20	genomes	O
21	encoding	O
22	altered	O
23	NIa	O
24	proteins	O
25	.	O

1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	O
23	weight	O
24	protein	O
25	(	O
26	72K	O
27	protein	O
28	).	O

1	Martin	O
2	Luther	O
3	and	O
4	his	O
5	physicians	O
6	.	O

1	Generally	O
2	ILC	O
3	and	B
4	ILVF	O
5	values	O
6	decreased	O
7	with	O
8	increasing	O
9	exposure	O
10	time	O
11	with	O
12	rate	O
13	constants	O
14	ranging	O
15	from	O
16	0	O
17	.	O
18	03	O
19	to	O
20	0	O
21	.	O
22	33	O
23	day	O
24	-	O
25	1	O
26	(	O
27	wet	O
28	and	O
29	lipid	O
30	weight	O
31	)	O
32	for	O
33	ILC	O
34	and	O
35	0	O
36	.	O
37	03	O
38	to	O
39	0	O
40	.	O
41	31	O
42	day	O
43	-	O
44	1	O
45	for	B
46	ILVF	I
47	.	I

1	What	O
2	to	O
3	look	O
4	for	O
5	during	O
6	a	O
7	compliance	O
8	review	O
9	:	O
10	10	O
11	common	O
12	mistakes	O
13	made	O
14	by	B
15	SNFs	I
16	.	I

1	Delineating	O
2	the	O
3	molecular	O
4	basis	O
5	for	O
6	agonist	O
7	-	O
8	induced	O
9	destabilization	O
10	of	O
11	mRNA	O
12	of	B
13	G	I
14	-	I
15	protein	I
16	-	I
17	linked	I
18	receptors	O
19	that	O
20	contributes	O
21	to	O
22	receptor	O
23	down	O
24	-	O
25	regulation	O
26	is	O
27	fundamental	O
28	to	O
29	our	O
30	understanding	O
31	of	O
32	long	O
33	-	O
34	term	O
35	regulation	O
36	of	O
37	receptors	O
38	by	O
39	agonist	O
40	.	O

1	Prominent	I
2	protein	I
3	kinase	I
4	cascades	O
5	are	O
6	those	O
7	that	O
8	activate	B
9	mitogen	I
10	-	I
11	activated	I
12	protein	I
13	(	I
14	MAP	I
15	)	I
16	kinases	I
17	.	I

1	Beg2	O
2	and	O
3	Beg1	O
4	are	O
5	regulated	O
6	differently	O
7	which	O
8	may	O
9	indicate	O
10	variation	O
11	in	O
12	storage	O
13	or	O
14	utilization	O
15	properties	O
16	among	O
17	the	O
18	barley	I
19	globulins	I
20	.	I

1	Chronic	O
2	hepatitis	O
3	B	O
4	in	O
5	adopted	O
6	Romanian	O
7	children	O
8	.	O

1	After	O
2	surgery	O
3	,	O
4	patients	O
5	self	O
6	administered	O
7	one	O
8	of	O
9	three	O
10	possible	O
11	postsurgical	O
12	medications	O
13	,	O
14	which	O
15	included	O
16	placebo	O
17	,	O
18	codeine	O
19	60	O
20	mg	O
21	,	O
22	and	O
23	ibuprofen	O
24	400	O
25	mg	O
26	,	O
27	when	O
28	their	O
29	pain	O
30	reached	O
31	a	O
32	moderate	O
33	or	O
34	severe	O
35	intensity	O
36	.	O

1	The	O
2	frequency	O
3	of	O
4	PPNG	O
5	strains	O
6	increased	O
7	from	O
8	1	O
9	.	O
10	7	O
11	%	O
12	in	O
13	1981	O
14	to	O
15	6	O
16	.	O
17	7	O
18	%	O
19	in	O
20	1985	O
21	.	O

1	The	O
2	effect	O
3	of	O
4	smoking	O
5	was	O
6	not	O
7	examined	O
8	in	O
9	this	O
10	study	O
11	,	O
12	as	O
13	such	O
14	data	O
15	were	O
16	not	O
17	available	O
18	.	O

1	The	O
2	present	O
3	study	O
4	examined	O
5	the	O
6	effect	O
7	of	O
8	intensity	O
9	,	O
10	rate	O
11	,	O
12	and	O
13	polarity	O
14	on	O
15	the	O
16	spectral	O
17	content	O
18	of	O
19	ABRs	O
20	of	O
21	15	O
22	normal	O
23	-	O
24	hearing	O
25	subjects	O
26	.	O

1	Hypomagnesemia	O
2	was	O
3	due	O
4	to	O
5	magnesium	O
6	wasting	O
7	by	O
8	the	O
9	kidney	O
10	.	O

1	Demonstration	O
2	of	O
3	fine	O
4	structure	O
5	of	O
6	the	O
7	guinea	O
8	pig	O
9	organ	O
10	of	O
11	Corti	O
12	after	O
13	electron	O
14	microscopic	O
15	silver	O
16	staining	O

1	Sings	O
2	which	O
3	are	O
4	indicative	O
5	of	O
6	metaplastic	O
7	erythropoiesis	O
8	are	O
9	absent	O
10	.	O

1	A	O
2	correlation	O
3	coefficient	O
4	was	O
5	used	O
6	for	O
7	assessing	O
8	the	O
9	similarity	O
10	of	O
11	each	O
12	map	O
13	pattern	O
14	with	O
15	the	O
16	normal	O
17	mean	O
18	IQRST	O
19	map	O
20	.	O

1	The	O
2	B	O
3	.	O
4	germanica	O
5	cyclophilin	O
6	amino	O
7	acid	O
8	sequence	O
9	shares	O
10	83	O
11	%	O
12	identity	O
13	with	O
14	the	O
15	cytosolic	O
16	cyclophilin	O
17	isoform	O
18	from	B
19	Drosophila	I
20	melanogaster	I
21	(	I
22	Cyp	I
23	-	I
24	1	O
25	).	O

1	A	O
2	reduced	O
3	matrix	O
4	distribution	O
5	and	O
6	enhanced	O
7	cell	O
8	density	O
9	were	O
10	observed	O
11	as	O
12	the	O
13	biofilm	O
14	aged	O
15	.	O

1	Single	O
2	-	O
3	photon	O
4	emission	O
5	computed	O
6	tomography	O
7	(	O
8	SPECT	O
9	)	O
10	with	O
11	99mTc	O
12	-	O
13	hexamethylpropyleneamine	O
14	oxime	O
15	(	B
16	HMPAO	O
17	)	O
18	was	O
19	used	O
20	to	O
21	investigate	O
22	changes	O
23	in	O
24	cerebral	O
25	blood	O
26	flow	O
27	in	O
28	seven	O
29	patients	O
30	with	O
31	cortical	O
32	visual	O
33	impairment	O
34	.	O

1	Activation	O
2	of	O
3	PKA	O
4	by	O
5	8	O
6	-	O
7	bromo	O
8	-	O
9	cyclic	O
10	AMP	O
11	or	O
12	forskolin	O
13	,	O
14	and	O
15	inhibition	O
16	of	B
17	PKC	O
18	by	O
19	calphostin	O
20	C	O
21	,	O
22	resulted	O
23	in	O
24	a	O
25	significant	O
26	decrease	O
27	in	O
28	3TP	O
29	activity	O
30	as	O
31	well	O
32	as	O
33	in	O
34	vitro	B
35	ERK	I
36	kinase	O
37	activity	O
38	in	O
39	CRAC	O
40	.	O

1	Using	O
2	adenoviral	O
3	transfer	O
4	of	B
5	IkappaBalpha	I
6	(	I
7	IkappaBalpha	O
8	overexpression	O
9	),	O
10	the	O
11	production	O
12	of	B
13	TNF	I
14	-	I
15	alpha	O
16	induced	O
17	by	O
18	whole	O
19	GBS	O
20	was	O
21	inhibited	O
22	by	O
23	only	O
24	20	O
25	%.	O

1	At	O
2	different	O
3	times	O
4	of	O
5	the	O
6	surgical	O
7	procedures	O
8	(	O
9	thorax	O
10	opening	O
11	and	O
12	closure	O
13	,	O
14	period	O
15	of	O
16	cardiopulmonary	O
17	bypass	O
18	)	O
19	67	O
20	to	O
21	100	O
22	%	O
23	of	O
24	the	O
25	patients	O
26	in	O
27	group	O
28	1	O
29	had	O
30	vancomycin	O
31	concentrations	O
32	in	O
33	the	O
34	studied	O
35	tissues	O
36	above	O
37	the	O
38	MIC	O
39	90	O
40	for	O
41	Staphylococcus	O
42	aureus	O
43	(	O
44	1	O
45	microgram	O
46	/	O
47	g	O
48	)	O
49	and	O
50	Staphylococcus	O
51	epidermidis	O
52	(	O
53	2	O
54	micrograms	O
55	/	O
56	g	O
57	).	O

1	ID	O
2	-	O
3	PaGIA	O
4	diphtheria	O
5	toxin	O
6	polymer	O
7	particle	O
8	diagnostic	O
9	agent	O
10	manufactured	O
11	by	O
12	DiaMed	O
13	AG	O
14	,	O
15	Switzerland	O
16	,	O
17	was	O
18	tried	O
19	at	O
20	bacteriological	O
21	laboratory	O
22	of	O
23	Institute	O
24	of	O
25	Childhood	O
26	Infections	O
27	in	O
28	St	O
29	.	O

1	Derivatives	O
2	of	O
3	boswellic	O
4	acids	O
5	.	O

1	M	O
2	.	O
3	M	O
4	.	O
5	C	O
6	.	O
7	was	O
8	used	O
9	for	O
10	2	O
11	.	O
12	5	O
13	minutes	O
14	in	O
15	44	O
16	cases	O
17	(	O
18	20	O
19	HR	O
20	patients	O
21	,	O
22	24	O
23	LR	O
24	patients	O
25	),	O
26	and	O
27	for	O
28	5	O
29	minutes	O
30	in	O
31	66	O
32	cases	O
33	(	O
34	46	O
35	HR	O
36	patients	O
37	,	O
38	20	O
39	LR	O
40	patients	O
41	).	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	haloperidol	O
6	selectively	O
7	reduced	O
8	the	O
9	animal	O
10	'	O
11	s	O
12	capacity	O
13	to	O
14	'	O
15	programme	O
16	non	O
17	-	O
18	stimulus	O
19	directed	O
20	motor	O
21	behaviour	O
22	'.	O

1	Interestingly	O
2	,	O
3	highly	O
4	charged	O
5	residues	O
6	were	O
7	abundantly	O
8	possessed	O
9	in	O
10	the	O
11	carboxy	O
12	-	O
13	terminal	O
14	part	O
15	of	O
16	the	B
17	MDV2	B
18	UL10	I
19	protein	I
20	.	I

1	An	O
2	apparent	O
3	N	O
4	-	O
5	terminal	O
6	transit	O
7	peptide	O
8	in	O
9	the	O
10	coding	O
11	region	O
12	and	O
13	a	O
14	3	O
15	'	O
16	poly	O
17	(	O
18	A	O
19	)	O
20	tail	O
21	exist	O
22	in	O
23	the	O
24	cDNA	O
25	clone	O
26	indicated	O
27	that	O
28	this	O
29	chloroplast	O
30	protein	O
31	as	O
32	nuclear	O
33	encoded	O
34	.	O

1	An	O
2	analysis	O
3	of	O
4	synthetic	O
5	peptides	O
6	revealed	O
7	a	O
8	minimal	O
9	CTD	O
10	sequence	O
11	that	O
12	is	O
13	sufficient	O
14	to	O
15	bind	O
16	to	O
17	the	O
18	second	O
19	Rsp5	B
20	WW	I
21	domain	I
22	(	I
23	Rsp5	I
24	WW2	O
25	)	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	yeast	O
31	two	O
32	-	O
33	hybrid	O
34	assays	O
35	.	O

1	Twenty	O
2	eligible	O
3	patients	O
4	with	O
5	cirrhosis	O
6	were	O
7	randomized	O
8	into	O
9	two	O
10	groups	O
11	:	O
12	10	O
13	patients	O
14	treated	O
15	with	O
16	6	O
17	million	O
18	units	O
19	of	O
20	natural	B
21	IFN	I
22	-	I
23	beta	O
24	twice	O
25	a	O
26	week	O
27	for	O
28	36	O
29	months	O
30	and	O
31	10	O
32	patients	O
33	without	B
34	IFN	O
35	therapy	O
36	.	O

1	The	O
2	color	O
3	-	O
4	word	O
5	interference	O
6	effect	O
7	previously	O
8	reported	O
9	with	O
10	normal	O
11	populations	O
12	when	O
13	given	O
14	the	O
15	Stroop	O
16	test	O
17	was	O
18	demonstrated	O
19	for	O
20	this	O
21	retarded	O
22	sample	O
23	using	O
24	a	O
25	special	O
26	format	O
27	.	O

1	The	O
2	adeno	O
3	-	O
4	associated	O
5	virus	O
6	(	O
7	AAV	O
8	)	O
9	rep	O
10	gene	O
11	encodes	O
12	four	O
13	proteins	O
14	(	O
15	Rep78	O
16	,	O
17	Rep68	O
18	,	O
19	Rep52	O
20	,	O
21	and	O
22	Rep40	O
23	)	O
24	required	O
25	for	O
26	AAV	O
27	DNA	O
28	replication	O
29	and	O
30	AAV	O
31	gene	O
32	regulation	O
33	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	investigating	O
6	the	O
7	mechanisms	O
8	by	O
9	which	O
10	OF5	O
11	and	O
12	OF3	O
13	regulated	B
14	CYP11A1	I
15	transcription	O
16	,	O
17	we	O
18	found	O
19	that	O
20	OF5	O
21	and	O
22	OF3	O
23	bound	B
24	Sp1	O
25	and	O
26	Sp3	O
27	in	O
28	JEG	O
29	-	O
30	3	O
31	cells	O
32	.	O

1	Monkeys	O
2	were	O
3	evaluated	O
4	before	O
5	and	O
6	after	O
7	unilateral	O
8	and	O
9	serial	O
10	bilateral	O
11	removal	O
12	of	O
13	superior	O
14	temporal	O
15	cortex	O
16	.	O

1	Recombinant	B
2	human	B
3	erythropoietin	I
4	(	I
5	epoetin	O
6	)	O
7	is	O
8	approved	O
9	to	O
10	be	O
11	administered	O
12	by	O
13	the	O
14	intravenous	O
15	(	O
16	i	O
17	.	O
18	v	O
19	.)	O
20	or	O
21	subcutaneous	O
22	(	O
23	SC	O
24	)	O
25	route	O
26	.	O

1	Since	O
2	CENP	I
3	-	I
4	B	I
5	gene	O
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	I
13	-	I
14	B	I
15	boxes	O
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O

1	Cheung	O
2	and	O
3	S	O
4	.	O

1	In	O
2	contrast	O
3	to	B
4	full	I
5	-	I
6	length	I
7	E2F	I
8	-	I
9	3	O
10	,	O
11	which	O
12	is	O
13	expressed	O
14	only	O
15	at	O
16	the	O
17	G1	O
18	/	O
19	S	O
20	boundary	O
21	,	B
22	E2F	I
23	-	I
24	3B	O
25	is	O
26	detected	O
27	throughout	O
28	the	O
29	cell	O
30	cycle	O
31	with	O
32	peak	O
33	levels	O
34	in	O
35	GO	O
36	where	O
37	it	O
38	is	O
39	associated	O
40	with	O
41	Rb	O
42	.	O

1	Sci	O
2	.	O

1	Comparison	O
2	of	O
3	Tc	O
4	-	O
5	99m	O
6	sestamibi	O
7	perfusion	O
8	imaging	O
9	and	O
10	echocardiography	O
11	using	O
12	an	O
13	arbutamine	O
14	infusion	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	coronary	O
20	artery	O
21	disease	O
22	.	O

1	Nocodazole	O
2	arrest	O
3	of	O
4	DU249	O
5	cells	O
6	was	O
7	exploited	O
8	for	O
9	the	O
10	detection	O
11	of	O
12	an	B
13	M	I
14	-	I
15	phase	I
16	-	I
17	activated	I
18	MBP	I
19	kinase	O
20	that	O
21	was	O
22	resolved	O
23	from	B
24	p41	I
25	MAP	I
26	kinase	O
27	by	O
28	phenyl	O
29	-	O
30	Superose	O
31	chromatography	O
32	.	O

1	On	O
2	the	O
3	transport	O
4	of	O
5	mucus	O
6	and	O
7	its	O
8	rheologic	O
9	simulants	O
10	in	O
11	ciliated	O
12	systems	O
13	.	O

1	UPMC	O
2	is	O
3	not	O
4	the	O
5	only	O
6	organization	O
7	pursuing	O
8	controlled	O
9	NHBC	O
10	organ	O
11	procurement	O
12	,	O
13	however	O
14	.	O

1	These	O
2	studies	O
3	suggest	O
4	that	O
5	MAPK	O
6	acts	O
7	by	O
8	stimulating	B
9	AP	I
10	-	I
11	1	O
12	and	O
13	a	O
14	subsequent	O
15	physical	O
16	and	O
17	functional	O
18	interaction	O
19	of	B
20	AP	I
21	-	I
22	1	O
23	with	B
24	NF	I
25	-	I
26	kappaB	O
27	,	O
28	resulting	O
29	in	O
30	a	O
31	complex	O
32	that	O
33	synergistically	O
34	transactivates	O
35	the	B
36	HIV	I
37	-	I
38	1	I
39	LTR	I
40	.	I

1	According	O
2	to	O
3	their	O
4	staining	O
5	affinity	O
6	for	O
7	anti	O
8	-	O
9	T	O
10	antibodies	O
11	,	O
12	the	O
13	glandular	O
14	tissue	O
15	cells	O
16	were	O
17	classified	O
18	as	O
19	T	O
20	-,	O
21	T	O
22	+,	O
23	T	O
24	++,	O
25	and	O
26	T	O
27	and	O
28	the	O
29	annual	O
30	changes	O
31	in	O
32	the	O
33	numbers	O
34	of	O
35	these	O
36	cell	O
37	populations	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	volume	O
45	occupied	O
46	by	O
47	the	O
48	glandular	O
49	tissue	O
50	,	O
51	were	O
52	calculated	O
53	.	O

1	A	O
2	genetic	O
3	screen	O
4	applied	O
5	to	O
6	mutants	O
7	in	O
8	the	O
9	branch	O
10	site	O
11	region	O
12	shows	O
13	that	O
14	all	O
15	positions	O
16	in	O
17	the	O
18	conserved	B
19	TACTAAC	O
20	sequence	O
21	are	O
22	important	O
23	for	O
24	intron	O
25	recognition	O
26	.	O

1	RAS2val19	O
2	,	O
3	a	O
4	dominant	O
5	activated	O
6	form	O
7	of	B
8	Saccharomyces	I
9	cerevisiae	I
10	Ras2	O
11	,	O
12	stimulates	O
13	both	O
14	filamentous	O
15	growth	O
16	and	O
17	expression	O
18	of	O
19	a	O
20	transcriptional	O
21	reporter	O
22	FG	O
23	(	O
24	TyA	O
25	)::	B
26	lacZ	O
27	but	O
28	does	O
29	not	O
30	induce	O
31	the	O
32	mating	O
33	pathway	O
34	reporter	O
35	FUS1	O
36	::	B
37	lacZ	I
38	.	I

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	Hh	O
6	and	O
7	Patched	O
8	(	O
9	Ptc	O
10	)	O
11	act	O
12	through	O
13	those	O
14	Ci	O
15	binding	O
16	sites	O
17	to	O
18	modulate	O
19	the	O
20	level	O
21	of	O
22	Ci	O
23	-	O
24	dependent	O
25	transcriptional	O
26	activation	O
27	in	O
28	S2	O
29	cells	O
30	.	O

1	We	O
2	conclude	O
3	that	O
4	at	O
5	steady	O
6	state	O
7	the	O
8	timing	O
9	of	O
10	a	O
11	light	O
12	meal	O
13	is	O
14	unlikely	O
15	to	O
16	alter	O
17	in	O
18	any	O
19	clinically	O
20	important	O
21	manner	O
22	the	O
23	pharmacokinetics	O
24	of	O
25	nifedipine	I
26	released	O
27	from	O
28	'	O
29	biphasic	O
30	'	O
31	tablets	O
32	.	O

1	We	O
2	found	O
3	that	O
4	virulent	O
5	Ngo	O
6	strains	O
7	induce	O
8	phosphorylation	O
9	and	O
10	activation	O
11	of	B
12	JNK	O
13	but	O
14	not	O
15	of	B
16	p38	I
17	kinase	I
18	.	I

1	Consistent	O
2	with	O
3	its	O
4	role	O
5	in	B
6	p53	B
7	ubiquitination	O
8	,	O
9	mE6	O
10	-	O
11	AP	O
12	was	O
13	found	O
14	both	O
15	in	O
16	the	O
17	nucleus	O
18	and	O
19	cytosol	O
20	,	O
21	while	O
22	Nedd	O
23	-	O
24	4	O
25	was	O
26	found	O
27	only	O
28	in	O
29	the	O
30	cytosol	O
31	.	O

1	This	O
2	0	O
3	.	O
4	74	O
5	kb	O
6	cDNA	O
7	contains	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	of	O
16	477	O
17	bp	O
18	encoding	O
19	a	O
20	polypeptide	O
21	of	O
22	159	O
23	amino	O
24	acids	O
25	(	O
26	aa	O
27	)	O
28	which	O
29	differs	O
30	at	O
31	only	O
32	one	O
33	position	O
34	(	O
35	position	O
36	65	O
37	)	O
38	from	O
39	the	B
40	human	B
41	U1	I
42	-	I
43	C	I
44	protein	I
45	.	I

1	Rabbit	O
2	eyes	O
3	were	O
4	removed	O
5	and	O
6	held	O
7	in	O
8	temperature	O
9	-	O
10	regulated	O
11	chambers	O
12	and	O
13	irrigated	O
14	with	O
15	saline	O
16	.	O

1	Replacement	O
2	of	O
3	the	O
4	spacer	O
5	sequence	O
6	between	O
7	the	O
8	two	O
9	ARMs	O
10	with	O
11	a	O
12	shorter	O
13	stretch	O
14	of	O
15	sequence	O
16	also	O
17	reduced	O
18	RNA	O
19	binding	O
20	in	O
21	vitro	O
22	.	O

1	Furthermore	O
2	,	O
3	in	O
4	vivo	O
5	and	O
6	in	O
7	vitro	O
8	protein	O
9	-	O
10	protein	O
11	interaction	O
12	experiments	O
13	have	O
14	shown	O
15	that	O
16	SR33	O
17	protein	O
18	interacts	O
19	with	O
20	itself	O
21	and	O
22	with	B
23	SR45	I
24	protein	O
25	but	O
26	not	O
27	with	O
28	two	O
29	other	O
30	members	O
31	(	B
32	SRZ21	O
33	and	B
34	SRZ22	O
35	)	O
36	of	O
37	the	B
38	SR	I
39	family	O
40	that	O
41	are	O
42	known	O
43	to	O
44	interact	O
45	with	O
46	the	O
47	Arabidopsis	B
48	full	I
49	-	I
50	length	I
51	U	I
52	-	I
53	70K	O
54	only	O
55	.	O

1	The	O
2	oxygen	O
3	uptake	O
4	(	O
5	VO2	O
6	),	O
7	carbon	O
8	dioxide	O
9	output	O
10	(	O
11	VCO2	O
12	),	O
13	respiratory	O
14	rate	O
15	(	O
16	fR	O
17	),	O
18	minute	O
19	ventilation	O
20	(	O
21	VE	O
22	),	O
23	alveolar	O
24	ventilation	O
25	(	O
26	VA	O
27	),	O
28	alveolar	O
29	oxygen	O
30	pressure	O
31	(	O
32	PAO2	O
33	),	O
34	and	O
35	VE	O
36	/	O
37	VO2	O
38	ratio	O
39	were	O
40	higher	O
41	in	O
42	the	O
43	cows	O
44	,	O
45	while	O
46	the	O
47	tidal	O
48	volume	O
49	(	O
50	VT	O
51	)	O
52	and	O
53	physiological	O
54	dead	O
55	space	O
56	(	O
57	VD	O
58	)	O
59	were	O
60	larger	O
61	in	O
62	the	O
63	horses	O
64	.	O

1	The	O
2	interaction	O
3	of	O
4	radiation	O
5	and	O
6	hyperthermia	O
7	was	O
8	systematically	O
9	studied	O
10	in	O
11	the	O
12	Dunning	O
13	R3327G	O
14	prostatic	O
15	adenocarcinoma	O
16	,	O
17	the	O
18	preeminent	O
19	animal	O
20	model	O
21	for	O
22	human	O
23	prostatic	O
24	cancer	O
25	.	O

1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	the	O
7	simultaneous	O
8	determination	O
9	of	O
10	1	O
11	,	B
12	alpha	I
13	-	I
14	acetylmethadol	O
15	(	O
16	LAAM	O
17	)	O
18	and	O
19	five	O
20	active	O
21	metabolites	O
22	--	O
23	noracetylmethadol	O
24	,	O
25	dinoracetylmethadol	O
26	,	O
27	methadol	O
28	,	O
29	normethadol	O
30	,	O
31	and	O
32	dinormethadol	O
33	--	O
34	in	O
35	biofluids	O
36	by	O
37	high	O
38	-	O
39	performance	O
40	liquid	O
41	chromatography	O
42	using	O
43	a	O
44	normal	O
45	-	O
46	phase	O
47	column	O
48	and	O
49	a	O
50	UV	O
51	detector	O
52	at	O
53	218	O
54	nm	O
55	.	O

1	The	O
2	effect	O
3	of	O
4	ligustrazine	O
5	hydrochloride	O
6	(	O
7	LTH	O
8	)	O
9	on	O
10	depressing	O
11	pulmonary	O
12	artery	O
13	hypertension	O
14	has	O
15	been	O
16	proved	O
17	in	O
18	recent	O
19	studies	O
20	.	O

1	In	O
2	patients	O
3	in	O
4	group	O
5	A	O
6	("	O
7	normal	O
8	"	O
9	CI	O
10	),	O
11	the	O
12	CI	O
13	,	O
14	heart	O
15	rate	O
16	and	O
17	the	O
18	mean	O
19	circumferential	O
20	fiber	O
21	shortening	O
22	velocity	O
23	(	O
24	mVCF	O
25	)	O
26	were	O
27	normal	O
28	,	O
29	but	O
30	the	O
31	TPR	O
32	was	O
33	increased	O
34	significantly	O
35	.	O

1	The	O
2	T	O
3	-	O
4	box	O
5	motif	O
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O

1	When	O
2	the	O
3	l	O
4	-	O
5	methadone	O
6	-	O
7	sensitive	O
8	,	O
9	opioid	O
10	receptor	O
11	is	O
12	blocked	O
13	by	O
14	naloxone	O
15	or	O
16	tolerance	O
17	has	O
18	developed	O
19	,	O
20	than	O
21	l	O
22	-	O
23	methadone	O
24	can	O
25	produce	O
26	behavioral	O
27	effects	O
28	by	O
29	a	O
30	nonopioid	O
31	mechanism	O
32	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	IS2404	O
6	and	O
7	IS2606	O
8	:	O
9	two	O
10	distinct	O
11	repeated	O
12	sequences	O
13	for	O
14	detection	O
15	of	O
16	Mycobacterium	O
17	ulcerans	O
18	by	O
19	PCR	O
20	.	O

1	DNase	O
2	I	O
3	genomic	O
4	footprinting	O
5	revealed	O
6	that	O
7	the	B
8	c	I
9	-	I
10	Myb	I
11	site	O
12	is	O
13	occupied	O
14	in	O
15	a	O
16	tissue	O
17	-	O
18	specific	O
19	fashion	O
20	in	O
21	vivo	O
22	.	O

1	Transcriptional	O
2	regulation	O
3	of	B
4	fbp1	I
5	promoter	I
6	constructs	O
7	containing	O
8	only	O
9	UAS1	O
10	or	O
11	UAS2	O
12	confirms	O
13	that	O
14	the	O
15	PKA	O
16	and	O
17	MAPK	O
18	regulation	O
19	is	O
20	targeted	O
21	to	O
22	both	O
23	sites	O
24	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	SIMV	O
6	is	O
7	useful	O
8	in	O
9	weaning	O
10	neonates	O
11	from	O
12	the	O
13	ventilator	O
14	.	O

1	In	O
2	F42A	O
3	-	O
4	stimulated	O
5	internalization	O
6	assays	O
7	on	O
8	forskolin	I
9	-	I
10	induced	I
11	YT	I
12	-	I
13	1	O
14	cells	O
15	,	O
16	the	B
17	IL	I
18	-	I
19	2R	I
20	alpha	I
21	chain	O
22	is	O
23	consistently	O
24	endocytosed	O
25	together	O
26	with	O
27	the	B
28	IL	I
29	-	I
30	2R	I
31	beta	I
32	subunit	O
33	indicating	O
34	that	B
35	IL	I
36	-	I
37	2R	I
38	alpha	O
39	is	O
40	stably	O
41	associated	O
42	with	O
43	the	B
44	F42A	I
45	-	I
46	IL	I
47	-	I
48	2R	I
49	beta	I
50	complex	O
51	even	O
52	though	O
53	the	B
54	alpha	I
55	-	I
56	subunit	O
57	contributes	O
58	little	O
59	if	O
60	any	O
61	affinity	O
62	to	O
63	the	O
64	F42A	O
65	binding	O
66	reaction	O
67	.	O

1	Double	O
2	-	O
3	blind	O
4	,	O
5	placebo	O
6	-	O
7	controlled	O
8	trial	O
9	.	O

1	Synthesis	O
2	of	O
3	(+)-	O
4	lysergic	O
5	acid	O
6	diethylamide	O
7	tartrate	<s>

1	In	O
2	addition	O
3	,	O
4	this	O
5	kinase	O
6	is	O
7	well	O
8	conserved	O
9	evolutionarily	O
10	,	O
11	ubiquitously	O
12	expressed	O
13	,	O
14	and	O
15	its	O
16	genes	O
17	map	O
18	to	O
19	a	O
20	position	O
21	on	O
22	human	O
23	chromosome	O
24	1	O
25	frequently	O
26	deleted	O
27	in	O
28	the	O
29	late	O
30	stages	O
31	of	O
32	tumorigenesis	O
33	.	O

1	At	O
2	the	O
3	C	O
4	-	O
5	terminus	O
6	of	O
7	the	O
8	protein	O
9	is	O
10	a	O
11	domain	O
12	that	O
13	contains	O
14	sequences	O
15	very	O
16	similar	O
17	to	O
18	those	O
19	found	O
20	in	O
21	the	O
22	breakpoint	O
23	cluster	O
24	region	O
25	gene	O
26	product	O
27	,	O
28	n	O
29	-	O
30	chimerin	O
31	,	O
32	and	B
33	rho	B
34	GAP	O
35	,	O
36	all	O
37	of	O
38	which	O
39	have	O
40	been	O
41	shown	O
42	to	O
43	possess	O
44	intrinsic	O
45	GAP	O
46	activity	O
47	on	B
48	small	B
49	GTPases	I
50	.	I

1	With	O
2	a	O
3	sample	O
4	of	O
5	mothers	O
6	of	O
7	healthy	O
8	infants	O
9	,	O
10	all	O
11	three	O
12	subscales	O
13	of	O
14	the	O
15	revised	O
16	instrument	O
17	,	O
18	WPL	O
19	-	O
20	R	O
21	,	O
22	had	O
23	acceptable	O
24	levels	O
25	of	O
26	internal	O
27	consistency	O
28	at	O
29	7	O
30	,	O
31	30	O
32	,	O
33	and	O
34	90	O
35	days	O
36	postpartum	O
37	,	O
38	and	O
39	stability	O
40	across	O
41	administrations	O
42	.	O

1	A	O
2	limited	O
3	sampling	O
4	strategy	O
5	was	O
6	used	O
7	based	O
8	on	O
9	a	O
10	bayesian	O
11	parameter	O
12	estimation	O
13	algorithm	O
14	that	O
15	is	O
16	part	O
17	of	O
18	the	O
19	ADAPT	O
20	II	O
21	software	O
22	package	O
23	.	O

1	Bacteriologic	O
2	culture	O
3	of	O
4	pancreatic	O
5	tissue	O
6	was	O
7	positive	O
8	in	O
9	6	O
10	/	O
11	8	O
12	IB	O
13	and	O
14	3	O
15	/	O
16	17	O
17	NIB	O
18	rats	O
19	(	O
20	p	O
21	less	O
22	than	O
23	0	O
24	.	O
25	01	O
26	).	O

1	Here	O
2	we	O
3	present	O
4	evidence	O
5	that	O
6	major	B
7	IE	I
8	proteins	I
9	IE86	O
10	,	O
11	IE72	O
12	,	O
13	and	O
14	IE55	O
15	are	O
16	capable	O
17	of	O
18	trans	O
19	-	O
20	activating	O
21	the	O
22	HIV	O
23	LTR	O
24	in	O
25	a	O
26	T	O
27	-	O
28	cell	O
29	line	O
30	,	O
31	HUT	O
32	-	O
33	78	O
34	.	O

1	This	O
2	core	O
3	sequence	O
4	,	O
5	along	O
6	with	O
7	additional	O
8	nonspecific	O
9	downstream	O
10	nucleotides	O
11	,	O
12	is	O
13	sufficient	O
14	for	O
15	partial	O
16	suppression	O
17	of	O
18	spliceosome	O
19	assembly	O
20	and	O
21	splicing	O
22	of	B
23	BPV	I
24	-	I
25	1	I
26	pre	I
27	-	I
28	mRNAs	I
29	.	I

1	Derepression	O
2	of	O
3	gene	O
4	expression	O
5	mediated	O
6	by	O
7	the	O
8	5	O
9	'	O
10	upstream	O
11	region	O
12	of	O
13	the	O
14	isocitrate	I
15	lyase	I
16	gene	O
17	of	O
18	Candida	O
19	tropicalis	O
20	is	O
21	controlled	O
22	by	O
23	two	O
24	distinct	O
25	regulatory	O
26	pathways	O
27	in	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O

1	The	O
2	active	O
3	state	O
4	is	O
5	terminated	O
6	by	O
7	hydrolysis	O
8	of	O
9	bound	O
10	GTP	O
11	,	O
12	producing	O
13	inactive	B
14	ARF	I
15	-	I
16	GDP	I
17	.	I

1	Effects	O
2	of	O
3	Trypanosoma	O
4	vivax	O
5	on	O
6	pregnancy	O
7	of	O
8	Yankasa	O
9	sheep	O
10	and	O
11	the	O
12	results	O
13	of	O
14	homidum	O
15	chloride	O
16	chemotherapy	O
17	.	O

1	Consistent	O
2	with	O
3	our	O
4	model	O
5	,	O
6	CTCF	O
7	binding	O
8	is	O
9	abolished	O
10	by	O
11	DNA	O
12	methylation	O
13	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	of	O
5	a	O
6	3213	B
7	bp	B
8	BamHI	I
9	-	I
10	ClaI	I
11	fragment	O
12	revealed	O
13	that	O
14	three	O
15	open	O
16	reading	O
17	frames	O
18	(	O
19	ORFs	O
20	)	O
21	were	O
22	encoded	O
23	in	O
24	the	O
25	same	O
26	orientation	O
27	.	O

1	Eucaryotic	O
2	transcription	O
3	factors	O
4	that	O
5	stimulate	B
6	RNA	I
7	polymerase	I
8	II	O
9	by	O
10	increasing	O
11	the	O
12	efficiency	O
13	of	O
14	elongation	O
15	of	O
16	specifically	O
17	or	O
18	randomly	O
19	initiated	O
20	RNA	O
21	chains	O
22	have	O
23	been	O
24	isolated	O
25	and	O
26	characterized	O
27	.	O

1	This	O
2	article	O
3	reviews	O
4	recent	O
5	information	O
6	on	O
7	the	O
8	frequency	O
9	,	O
10	characteristics	O
11	,	O
12	and	O
13	possible	O
14	pathogenic	O
15	mechanisms	O
16	of	O
17	the	O
18	vasculitides	O
19	occurring	O
20	in	O
21	patients	O
22	with	O
23	the	O
24	main	O
25	connective	O
26	tissue	O
27	diseases	O
28	.	O

1	In	O
2	the	O
3	commercially	O
4	available	O
5	intravenous	O
6	formulation	O
7	of	O
8	Cyclosporin	O
9	A	O
10	(	O
11	Sandimmun	O
12	),	O
13	polyoxyethylated	O
14	castor	O
15	oil	O
16	(	O
17	Cremophor	O
18	EL	O
19	)	O
20	is	O
21	used	O
22	as	O
23	a	O
24	solubilizing	O
25	agent	O
26	.	O

1	Chicken	B
2	sterol	I
3	carrier	I
4	protein	I
5	2	I
6	/	I
7	sterol	I
8	carrier	I
9	protein	O
10	x	O
11	:	O
12	cDNA	O
13	cloning	O
14	reveals	O
15	evolutionary	O
16	conservation	O
17	of	O
18	structure	O
19	and	O
20	regulated	O
21	expression	O
22	.	O

1	The	O
2	spectrum	O
3	of	O
4	phenotypes	O
5	caused	O
6	by	O
7	these	O
8	mutations	O
9	was	O
10	strikingly	O
11	different	O
12	than	O
13	mutations	O
14	in	O
15	the	O
16	adaptor	O
17	for	O
18	the	O
19	VP16	O
20	activation	O
21	domain	O
22	.	O

1	All	O
2	9	O
3	untreated	O
4	patients	O
5	underwent	O
6	laparoscopy	O
7	,	O
8	which	O
9	identified	O
10	3	O
11	intra	O
12	-	O
13	abdominal	O
14	,	O
15	3	O
16	vanished	O
17	and	O
18	2	O
19	peeping	O
20	testes	O
21	,	O
22	and	O
23	1	O
24	atrophic	O
25	testis	O
26	in	O
27	the	O
28	inguinal	O
29	canal	O
30	.	O

1	CYC2	O
2	encodes	O
3	a	O
4	24	O
5	-	O
6	kDa	O
7	protein	O
8	that	O
9	has	O
10	sequence	O
11	identity	O
12	to	O
13	the	O
14	Neurospora	O
15	crassa	O
16	PREG1	O
17	and	O
18	the	O
19	S	O
20	.	O
21	cerevisiae	B
22	PHO80	B
23	cyclin	I
24	.	I

1	This	O
2	fragment	O
3	can	O
4	bind	O
5	several	O
6	trans	O
7	-	O
8	acting	O
9	factors	O
10	in	O
11	vitro	O
12	,	O
13	including	B
14	GATA	I
15	-	I
16	1	O
17	and	O
18	members	O
19	of	O
20	the	B
21	Ets	I
22	family	I
23	.	I

1	Selenium	O
2	,	O
3	as	O
4	a	O
5	constituent	O
6	of	B
7	glutathione	I
8	peroxidase	O
9	,	O
10	plays	O
11	a	O
12	role	O
13	in	O
14	the	O
15	antioxidant	O
16	defense	O
17	systems	O
18	of	O
19	the	O
20	body	O
21	,	O
22	but	O
23	other	O
24	metabolic	O
25	roles	O
26	for	O
27	selenium	O
28	may	O
29	yet	O
30	be	O
31	discovered	O
32	.	O

1	However	O
2	,	O
3	it	O
4	is	O
5	not	O
6	known	O
7	whether	O
8	the	O
9	recently	O
10	identified	O
11	isoforms	O
12	Vav2	O
13	and	O
14	Vav3	O
15	,	O
16	which	O
17	are	O
18	broadly	O
19	expressed	O
20	,	O
21	can	O
22	couple	O
23	with	O
24	similar	O
25	classes	O
26	of	O
27	receptors	O
28	,	O
29	nor	O
30	is	O
31	it	O
32	known	O
33	whether	O
34	all	O
35	Vav	O
36	isoforms	O
37	possess	O
38	identical	O
39	functional	O
40	activities	O
41	.	O

1	We	O
2	have	O
3	mutated	O
4	to	O
5	cysteine	O
6	,	O
7	one	O
8	at	O
9	a	O
10	time	O
11	,	O
12	21	O
13	consecutive	O
14	residues	O
15	in	O
16	the	O
17	fourth	O
18	TMS	O
19	(	O
20	TM4	O
21	).	O

1	Naloxone	O
2	(	O
3	2	O
4	mg	O
5	/	O
6	kg	O
7	bolus	O
8	+	O
9	2	O
10	mg	O
11	X	O
12	kg	O
13	-	B
14	1	B
15	X	B
16	h	I
17	-	I
18	1	O
19	)	O
20	was	O
21	given	O
22	with	O
23	one	O
24	of	O
25	the	O
26	two	O
27	doses	O
28	of	O
29	the	O
30	lipopolysaccharide	O
31	.	O

1	Blood	O
2	pressure	O
3	in	O
4	children	O
5	.	O

1	Cotransfection	O
2	with	O
3	the	B
4	ie1	I
5	gene	O
6	resulted	O
7	in	O
8	a	O
9	dramatic	O
10	increase	O
11	in	O
12	the	O
13	amount	O
14	of	O
15	the	O
16	two	O
17	enzymes	O
18	expressed	O
19	in	O
20	the	O
21	transfected	O
22	cells	O
23	.	O

1	Early	O
2	-	O
3	onset	O
4	scleral	O
5	necrosis	O
6	after	O
7	iodine	O
8	I	O
9	125	O
10	plaque	O
11	radiotherapy	O
12	for	O
13	ciliochoroidal	O
14	melanoma	O
15	.	O

1	Nuclear	O
2	spin	O
3	of	O
4	249Bk	O
5	from	O
6	the	O
7	hyperfine	O
8	structure	O
9	in	O
10	its	O
11	emission	O
12	spectrum	O
13	.	O

1	Our	O
2	data	O
3	show	O
4	that	O
5	multiple	O
6	MLSN1	I
7	transcripts	O
8	,	O
9	both	O
10	constitutively	O
11	expressed	O
12	and	O
13	inducible	O
14	,	O
15	are	O
16	present	O
17	in	O
18	cultured	O
19	pigmented	O
20	melanoma	O
21	cells	O
22	,	O
23	and	O
24	suggest	O
25	that	O
26	MLSN1	O
27	expression	O
28	can	O
29	be	O
30	regulated	O
31	at	O
32	the	O
33	level	O
34	of	O
35	both	O
36	transcription	O
37	and	O
38	mRNA	O
39	processing	O
40	.	O

1	Depth	O
2	-	O
3	controlled	O
4	grazing	O
5	-	O
6	incidence	O
7	diffraction	O
8	of	O
9	synchrotron	O
10	x	O
11	radiation	O
12	.	O

1	Complexes	O
2	of	B
3	qTBP42	O
4	with	O
5	each	O
6	complementary	O
7	strand	O
8	of	O
9	telomeric	O
10	DNA	O
11	and	O
12	with	O
13	quadruplex	O
14	forms	O
15	of	O
16	the	O
17	guanine	O
18	-	O
19	rich	O
20	strand	O
21	had	O
22	3	O
23	.	O
24	7	O
25	-	O
26	14	O
27	.	O
28	6	O
29	nM	O
30	dissociation	O
31	constants	O
32	,	O
33	Kd	O
34	,	O
35	whereas	O
36	complexes	O
37	with	O
38	double	O
39	-	O
40	stranded	O
41	telomeric	O
42	DNA	O
43	had	O
44	up	O
45	to	O
46	100	O
47	-	O
48	fold	O
49	higher	O
50	Kd	O
51	values	O
52	.	O

1	No	O
2	TATA	O
3	or	O
4	Inr	O
5	sequence	O
6	was	O
7	found	O
8	.	O

1	No	O
2	evidence	O
3	for	O
4	the	O
5	presence	O
6	of	O
7	introns	O
8	within	O
9	the	O
10	acvA	O
11	gene	O
12	has	O
13	been	O
14	found	O
15	.	O

1	The	O
2	antibodies	O
3	inhibited	O
4	specifically	O
5	the	O
6	transcription	O
7	of	B
8	DNA	I
9	polymerase	I
10	alpha	I
11	promoter	O
12	in	O
13	vitro	O
14	.	O

1	Genetic	O
2	and	O
3	phenotypic	O
4	analysis	O
5	indicates	O
6	that	B
7	NHP6A	O
8	and	B
9	NHP6B	O
10	function	O
11	downstream	O
12	of	O
13	SLT2	O
14	.	O

1	Moreover	O
2	,	O
3	expression	O
4	of	O
5	antisense	B
6	Ha	I
7	-	I
8	Ras	I
9	or	I
10	dominant	I
11	negative	I
12	Raf	I
13	-	I
14	1	I
15	abrogated	O
16	the	O
17	mitogenic	O
18	effect	O
19	of	B
20	TGF	I
21	-	I
22	beta1	I
23	in	I
24	TSU	I
25	-	I
26	Pr1	O
27	,	O
28	and	O
29	the	B
30	TGF	I
31	-	I
32	beta1	O
33	inhibition	O
34	of	O
35	DU145	O
36	was	O
37	switched	O
38	to	O
39	stimulation	O
40	by	B
41	V12Ha	I
42	-	I
43	Ras	O
44	transfection	O
45	.	O

1	Capsular	O
2	antigens	O
3	of	B
4	Staphylococcus	I
5	aureus	I

1	In	O
2	lean	O
3	mice	O
4	,	O
5	the	O
6	fat	O
7	/	O
8	water	O
9	intensity	O
10	ratio	O
11	was	O
12	about	O
13	1	O
14	:	O
15	4	O
16	,	O
17	about	O
18	half	O
19	that	O
20	in	O
21	normal	O
22	mice	O
23	.	O

1	Acute	O
2	decrease	O
3	in	O
4	body	O
5	temperature	O
6	(	O
7	TB	O
8	)	O
9	lowered	O
10	PaCO2	O
11	(	O
12	32	O
13	.	O
14	5	O
15	to	O
16	14	O
17	.	O
18	5	O
19	mmHg	O
20	)	O
21	and	O
22	[	O
23	HCO3	O
24	-]	O
25	a	O
26	(	O
27	24	O
28	.	O
29	20	O
30	mEq	O
31	/	O
32	L	O
33	to	O
34	17	O
35	.	O
36	56	O
37	mEq	O
38	/	O
39	L	O
40	),	O
41	increased	O
42	pHa	O
43	(	O
44	7	O
45	.	O
46	481	O
47	to	O
48	7	O
49	.	O
50	608	O
51	)	O
52	and	O
53	diminished	O
54	the	O
55	[	O
56	OH	O
57	-]/[	O
58	H	O
59	+]	O
60	ratio	O
61	,	O
62	but	O
63	had	O
64	no	O
65	significant	O
66	effect	O
67	on	O
68	[	O
69	SID	O
70	]	O
71	or	O
72	[	O
73	Atot	O
74	],	O
75	although	O
76	both	O
77	total	O
78	phosphorus	O
79	[	O
80	PT	O
81	]	O
82	and	O
83	inorganic	O
84	phosphate	O
85	[	O
86	Pi	O
87	]	O
88	increased	O
89	.	O

1	The	O
2	mean	O
3	values	O
4	of	O
5	the	O
6	first	O
7	three	O
8	components	O
9	were	O
10	not	O
11	significantly	O
12	different	O
13	in	O
14	ARVD	O
15	patients	O
16	and	O
17	control	O
18	subjects	O
19	.	O

1	These	O
2	viruses	O
3	depend	O
4	on	O
5	the	O
6	host	O
7	cell	O
8	machinery	O
9	for	O
10	their	O
11	existence	O
12	,	O
13	and	O
14	interference	O
15	with	O
16	these	O
17	processes	O
18	typically	O
19	interferes	O
20	with	O
21	other	O
22	important	O
23	host	O
24	physiology	O
25	.	O

1	The	O
2	receptor	O
3	for	O
4	hyaluronan	O
5	mediated	O
6	motility	O
7	(	O
8	RHAMM	O
9	)	O
10	gene	O
11	expression	O
12	is	O
13	markedly	O
14	elevated	O
15	in	O
16	fibrosarcomas	O
17	exposed	O
18	to	O
19	transforming	B
20	growth	I
21	factor	I
22	-	I
23	beta1	I
24	(	I
25	TGF	I
26	-	I
27	beta1	O
28	).	O

1	In	O
2	the	O
3	studies	O
4	described	O
5	in	O
6	this	O
7	report	O
8	,	O
9	we	O
10	have	O
11	investigated	O
12	the	O
13	signaling	O
14	pathway	O
15	(	O
16	s	O
17	)	O
18	that	O
19	are	O
20	responsible	O
21	for	B
22	CREB	O
23	activation	O
24	in	O
25	normal	O
26	T	O
27	cells	O
28	.	O

1	Solution	O
2	structure	O
3	and	O
4	mechanism	O
5	of	O
6	the	B
7	MutT	I
8	pyrophosphohydrolase	I
9	.	I

1	To	O
2	map	O
3	this	O
4	regulatory	O
5	serine	O
6	phosphorylation	O
7	site	O
8	we	O
9	developed	O
10	a	O
11	baculovirus	O
12	-	O
13	mediated	O
14	expression	O
15	system	O
16	for	B
17	wild	I
18	-	I
19	type	I
20	annexin	I
21	II	O
22	and	O
23	for	O
24	a	O
25	series	O
26	of	B
27	annexin	I
28	II	I
29	mutants	O
30	which	O
31	contained	O
32	substitutions	O
33	in	O
34	one	O
35	or	O
36	more	O
37	serine	O
38	residues	O
39	present	O
40	in	O
41	the	B
42	N	I
43	-	I
44	terminal	I
45	domain	I
46	.	I

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	function	O
7	of	O
8	the	O
9	DS2	O
10	may	O
11	be	O
12	the	O
13	protection	O
14	of	O
15	the	O
16	nuclear	O
17	DNA	O
18	from	O
19	desiccation	O
20	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	these	O
6	unique	O
7	properties	O
8	,	O
9	the	O
10	newly	O
11	characterized	B
12	hemagglutinin	O
13	has	O
14	been	O
15	termed	O
16	Limulus	O
17	18K	O
18	agglutination	O
19	-	O
20	aggregation	O
21	factor	O
22	(	O
23	18K	O
24	-	O
25	LAF	O
26	).	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	myocardial	O
5	uptake	O
6	of	O
7	99mTc	O
8	sestamibi	O
9	in	O
10	normal	O
11	subjects	O
12	and	O
13	patients	O
14	with	O
15	coronary	O
16	artery	O
17	disease	O
18	is	O
19	comparable	O
20	after	O
21	exercise	O
22	,	O
23	dipyridamole	O
24	,	O
25	and	O
26	adenosine	O
27	stress	O
28	.	O

1	Ligand	O
2	-	O
3	independent	O
4	activation	O
5	of	B
6	platelet	I
7	-	I
8	derived	I
9	growth	I
10	factor	I
11	receptor	O
12	is	O
13	a	O
14	necessary	O
15	intermediate	O
16	in	O
17	lysophosphatidic	O
18	,	O
19	acid	O
20	-	O
21	stimulated	O
22	mitogenic	O
23	activity	O
24	in	O
25	L	O
26	cells	O
27	.	O

1	In	O
2	the	O
3	presence	O
4	of	O
5	the	O
6	in	O
7	vivo	O
8	reducing	O
9	system	O
10	(	O
11	thioredoxin	O
12	,	B
13	thioredoxin	I
14	reductase	O
15	,	O
16	and	O
17	NADPH	O
18	),	O
19	however	O
20	,	O
21	each	O
22	of	O
23	these	O
24	mutants	O
25	catalyzed	O
26	the	O
27	formation	O
28	of	O
29	only	O
30	0	O
31	.	O
32	6	O
33	-	O
34	0	O
35	.	O
36	8	O
37	dCTPs	O
38	per	O
39	mole	O
40	of	O
41	enzyme	O
42	.	O

1	Increased	B
2	granulocyte	I
3	-	I
4	colony	I
5	stimulating	I
6	factor	I
7	(	I
8	G	I
9	-	I
10	CSF	O
11	)	O
12	levels	O
13	in	O
14	neonates	O
15	with	O
16	perinatal	O
17	complications	O
18	.	O

1	These	O
2	results	O
3	suggested	O
4	that	O
5	BACH1t	O
6	recruits	O
7	BACH1	O
8	to	O
9	the	O
10	nucleus	O
11	through	B
12	BTB	I
13	domain	I
14	-	O
15	mediated	O
16	interaction	O
17	.	O

1	Among	O
2	unusual	O
3	features	O
4	,	O
5	we	O
6	report	O
7	numerous	O
8	large	O
9	G	O
10	+	O
11	C	O
12	-	O
13	rich	O
14	conserved	O
15	sequences	O
16	located	O
17	in	O
18	the	O
19	first	O
20	intron	O
21	.	O

1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	B
13	collagen	I
14	type	I
15	IV	O
16	than	O
17	similarly	O
18	sized	O
19	vessels	O
20	in	O
21	the	O
22	submucosa	O
23	,	O
24	and	O
25	perforating	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	O
40	mucosae	O
41	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	new	B
6	human	I
7	RING	I
8	-	I
9	finger	I
10	gene	I
11	(	I
12	RNF4	O
13	)	O
14	that	O
15	encodes	O
16	a	O
17	190	I
18	-	I
19	amino	I
20	-	I
21	acid	I
22	protein	I
23	.	I

1	The	O
2	development	O
3	and	O
4	distribution	O
5	of	O
6	Trypanosoma	O
7	congolense	O
8	,	O
9	T	O
10	vivax	O
11	and	O
12	T	O
13	brucei	O
14	in	O
15	the	O
16	skin	O
17	of	O
18	goats	O
19	was	O
20	examined	O
21	after	O
22	the	O
23	animals	O
24	were	O
25	bitten	O
26	by	O
27	infected	O
28	Glossina	O
29	morsitans	O
30	centralis	O
31	.	O

1	G	O
2	.,	O
3	and	O
4	Hyde	O
5	,	O
6	C	O
7	.	O

1	A	O
2	beta2	O
3	RARE	O
4	reporter	O
5	construct	O
6	in	O
7	which	O
8	the	O
9	methylation	O
10	-	O
11	susceptible	O
12	cytosines	O
13	in	O
14	the	O
15	sense	O
16	strand	O
17	were	O
18	replaced	O
19	by	O
20	thymine	O
21	displayed	O
22	marked	O
23	loss	O
24	of	O
25	activity	O
26	in	O
27	a	O
28	replicated	O
29	chromatin	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	DDP1	O
2	also	O
3	localizes	O
4	to	O
5	heterochromatin	O
6	in	O
7	interphase	O
8	nuclei	O
9	of	O
10	larval	O
11	neuroblasts	O
12	.	O

1	Thus	O
2	,	B
3	TRAF2	B
4	initiates	B
5	SAPK	O
6	and	O
7	p38	O
8	activation	O
9	by	O
10	binding	O
11	two	O
12	proximal	O
13	protein	O
14	kinases	O
15	:	O
16	GCK	O
17	and	O
18	RIP	O
19	.	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	seizure	O
7	,	O
8	the	O
9	patient	O
10	was	O
11	asked	O
12	to	O
13	read	O
14	a	O
15	test	O
16	phrase	O
17	aloud	O
18	until	O
19	it	O
20	was	O
21	read	O
22	correctly	O
23	and	O
24	clearly	O
25	.	O

1	A	O
2	single	O
3	rectal	O
4	dose	O
5	of	O
6	25	O
7	mg	O
8	/	O
9	kg	O
10	will	O
11	obtain	O
12	this	O
13	lower	O
14	concentration	O
15	within	O
16	1	O
17	h	O
18	of	O
19	administration	O
20	and	O
21	maintain	O
22	it	O
23	for	O
24	up	O
25	to	O
26	6	O
27	h	O
28	.	O

1	Gene	O
2	constructs	O
3	consisting	O
4	of	B
5	human	I
6	growth	I
7	hormone	O
8	(	O
9	hGH	O
10	)	O
11	gene	O
12	driven	O
13	by	O
14	promoter	O
15	/	O
16	regulatory	O
17	sequence	O
18	of	B
19	mouse	B
20	metallothionein	O
21	(	O
22	mMT	O
23	),	B
24	viral	B
25	thymidine	I
26	kinase	I
27	(	I
28	vTK	O
29	),	O
30	rat	O
31	cholecystokinin	O
32	(	O
33	rCCK	O
34	),	O
35	or	B
36	chicken	I
37	beta	I
38	-	I
39	actin	I
40	(	I
41	cBA	I
42	)	I
43	gene	O
44	were	O
45	injected	O
46	into	O
47	the	O
48	cytoplasm	O
49	of	O
50	fertilized	O
51	medaka	O
52	eggs	O
53	via	O
54	the	O
55	micropyle	O
56	.	O

1	This	O
2	shows	O
3	that	O
4	the	O
5	characteristically	O
6	diffuse	O
7	banding	O
8	pattern	O
9	of	O
10	plant	O
11	nuclear	O
12	proteins	O
13	interacting	O
14	with	O
15	the	O
16	G	O
17	-	O
18	box	O
19	is	O
20	also	O
21	observed	O
22	in	O
23	a	O
24	binding	O
25	assay	O
26	using	O
27	only	O
28	one	O
29	recombinant	O
30	GBF	O
31	.	O

1	In	O
2	ischemic	O
3	and	O
4	hypoxic	O
5	hypoxia	O
6	,	O
7	a	O
8	strong	O
9	correlation	O
10	was	O
11	found	O
12	between	O
13	cyt	O
14	a	O
15	,	O
16	a3	O
17	oxidation	O
18	level	O
19	and	O
20	VO2	O
21	in	O
22	both	O
23	ischemic	O
24	and	O
25	hypoxic	O
26	hypoxia	O
27	(	O
28	r2	O
29	=.	O
30	90	O
31	and	O
32	.	O
33	87	O
34	,	O
35	respectively	O
36	).	O

1	The	O
2	method	O
3	is	O
4	applied	O
5	to	O
6	determine	O
7	aberration	O
8	constants	O
9	of	O
10	a	O
11	CM300	O
12	FEG	O
13	/	O
14	UT	O
15	microscope	O
16	with	O
17	correction	O
18	of	O
19	the	O
20	three	O
21	-	O
22	fold	O
23	astigmatism	O
24	.	O

1	The	B
2	small	B
3	GTPase	B
4	Rho	O
5	is	O
6	implicated	O
7	in	O
8	physiological	O
9	functions	O
10	associated	O
11	with	B
12	actin	I
13	-	I
14	myosin	O
15	filaments	O
16	such	O
17	as	O
18	cytokinesis	O
19	,	O
20	cell	O
21	motility	O
22	,	O
23	and	O
24	smooth	O
25	muscle	O
26	contraction	O
27	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	have	O
7	investigated	O
8	the	O
9	regulatory	O
10	mechanism	O
11	for	O
12	CD95L	O
13	expression	O
14	.	O

1	Mammalian	B
2	M	I
3	-	I
4	Ras	O
5	and	O
6	a	O
7	Caenorhabditis	O
8	elegans	O
9	orthologue	O
10	exhibit	O
11	conserved	O
12	structural	O
13	features	O
14	,	O
15	and	O
16	these	O
17	are	O
18	likely	O
19	to	O
20	mediate	O
21	activation	O
22	of	O
23	distinctive	O
24	signaling	O
25	paths	O
26	that	O
27	function	O
28	in	O
29	parallel	O
30	to	O
31	those	O
32	downstream	O
33	of	B
34	p21	B
35	Ras	I
36	.	I

1	AgMNPV	O
2	and	O
3	Orgyia	O
4	pseudotsugata	O
5	MNPV	O
6	(	O
7	OpMNPV	O
8	)	O
9	are	O
10	similar	O
11	in	O
12	terms	O
13	of	O
14	promoter	O
15	structure	O
16	and	O
17	polyhedrin	O
18	primary	O
19	sequence	O
20	,	O
21	and	O
22	the	O
23	polyhedrin	O
24	gene	O
25	of	O
26	both	O
27	viruses	O
28	is	O
29	transcribed	O
30	in	O
31	the	O
32	anti	O
33	-	O
34	clockwise	O
35	direction	O
36	in	O
37	relation	O
38	to	O
39	their	O
40	physical	O
41	maps	O
42	.	O

1	RESULTS	O
2	:	O
3	The	O
4	overall	B
5	FNF	O
6	for	O
7	1992	O
8	was	O
9	12	O
10	.	O
11	3	O
12	%	O
13	and	O
14	was	O
15	19	O
16	.	O
17	1	O
18	%,	O
19	22	O
20	.	O
21	2	O
22	%,	O
23	3	O
24	.	O
25	8	O
26	%	O
27	and	O
28	6	O
29	.	O
30	1	O
31	%	O
32	per	O
33	successive	O
34	quarters	O
35	in	O
36	1992	O
37	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	identify	B
6	ERK2	O
7	as	O
8	a	O
9	specific	O
10	and	O
11	direct	O
12	target	O
13	of	O
14	HePTP	O
15	and	O
16	are	O
17	consistent	O
18	with	O
19	a	O
20	model	O
21	in	O
22	which	O
23	HePTP	O
24	negatively	O
25	regulates	B
26	ERK2	O
27	activity	O
28	as	O
29	part	O
30	of	O
31	a	O
32	feedback	O
33	mechanism	O
34	.	O

1	The	O
2	electrocardiogram	O
3	.	O

1	The	O
2	potential	O
3	impact	O
4	of	O
5	using	O
6	a	O
7	rapid	O
8	diagnostic	O
9	test	O
10	(	O
11	Strep	O
12	A	O
13	OIA	O
14	)	O
15	on	O
16	detection	O
17	and	O
18	treatment	O
19	of	O
20	group	O
21	A	O
22	beta	O
23	-	O
24	hemolytic	O
25	streptococcal	O
26	(	O
27	GABHS	O
28	)	O
29	pharyngitis	O
30	in	O
31	a	O
32	large	O
33	-	O
34	volume	O
35	pediatric	O
36	and	O
37	adolescent	O
38	clinic	O
39	was	O
40	examined	O
41	.	O

1	This	O
2	combined	O
3	intravenous	O
4	anaesthetic	O
5	regimen	O
6	gave	O
7	good	O
8	anaesthesia	O
9	and	O
10	analgesia	O
11	to	O
12	pigs	O
13	for	O
14	up	O
15	to	O
16	2	O
17	h	O
18	as	O
19	monitored	O
20	by	O
21	clinical	O
22	signs	O
23	.	O

1	Interleukin	O
2	-	O
3	12	O
4	(	B
5	IL	I
6	-	O
7	12	O
8	)	O
9	is	O
10	a	O
11	cytokine	O
12	produced	O
13	by	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	(	O
19	PBMC	O
20	)	O
21	that	O
22	causes	B
23	interferon	I
24	-	I
25	gamma	I
26	(	I
27	IFN	I
28	-	I
29	gamma	O
30	)	O
31	production	O
32	and	O
33	enhancement	O
34	of	O
35	cell	O
36	-	O
37	mediated	O
38	cytotoxicity	O
39	.	O

1	The	O
2	FMN	O
3	moiety	O
4	but	O
5	not	O
6	the	O
7	[	O
8	3Fe	O
9	-	O
10	4S	O
11	]	O
12	cluster	O
13	of	O
14	the	O
15	subunit	O
16	appears	O
17	to	O
18	participate	O
19	in	O
20	this	O
21	reaction	O
22	.	O

1	The	O
2	MXR	O
3	gene	O
4	encodes	O
5	a	O
6	half	O
7	-	O
8	transporter	O
9	and	O
10	the	O
11	absence	O
12	of	O
13	cytogenetic	O
14	evidence	O
15	of	O
16	coamplification	O
17	of	O
18	other	O
19	regions	O
20	suggests	O
21	that	O
22	a	O
23	partner	O
24	may	O
25	not	O
26	be	O
27	overexpressed	O
28	,	O
29	and	O
30	instead	O
31	the	O
32	MXR	I
33	half	I
34	-	I
35	transporter	I
36	homodimerizes	O
37	to	O
38	mediate	O
39	drug	O
40	transport	O
41	.	O

1	In	O
2	another	O
3	study	O
4	,	O
5	intravenous	O
6	administration	O
7	of	O
8	devazepide	O
9	,	O
10	a	O
11	specific	O
12	cholecystokinin	I
13	-	I
14	A	I
15	receptor	O
16	antagonist	O
17	,	O
18	at	O
19	a	O
20	dose	O
21	of	O
22	0	O
23	.	O
24	1	O
25	mg	O
26	/	O
27	kg	O
28	/	O
29	hr	O
30	was	O
31	begun	O
32	15	O
33	min	O
34	before	O
35	postprandial	O
36	saline	O
37	intake	O
38	and	O
39	continued	O
40	for	O
41	1	O
42	hr	O
43	.	O

1	Addition	O
2	of	O
3	sucralfate	O
4	or	O
5	De	O
6	-	O
7	Nol	O
8	resulted	O
9	in	O
10	increments	O
11	of	O
12	gastric	O
13	HCO3	O
14	secretion	O
15	,	O
16	reaching	O
17	about	O
18	45	O
19	%	O
20	and	O
21	59	O
22	%,	O
23	respectively	O
24	,	O
25	of	O
26	the	O
27	maximal	O
28	HCO3	O
29	response	O
30	to	O
31	16	O
32	,	O
33	16	O
34	-	O
35	dimethyl	O
36	PGE2	O
37	(	O
38	dmPGE2	O
39	).	O

1	Mutation	O
2	of	O
3	nucleotides	O
4	adjacent	O
5	to	O
6	the	B
7	AP	I
8	-	I
9	1	I
10	cis	I
11	-	O
12	response	O
13	elements	O
14	had	O
15	no	O
16	effect	O
17	on	O
18	trans	O
19	-	O
20	activation	O
21	.	O

1	Canine	O
2	reproduction	O
3	:	O
4	effects	O
5	of	O
6	a	O
7	single	O
8	injection	O
9	of	O
10	medroxyprogesterone	O
11	acetate	O
12	on	O
13	the	O
14	reproductive	O
15	organs	O
16	of	O
17	the	O
18	bitch	O
19	.	O

1	A	O
2	comparative	O
3	analysis	O
4	of	O
5	the	O
6	reported	O
7	MOCT	O
8	-	O
9	associated	O
10	malignant	O
11	melanomas	O
12	emphasizes	O
13	the	O
14	singularity	O
15	of	O
16	our	O
17	case	O
18	in	O
19	the	O
20	amelanotic	O
21	character	O
22	of	O
23	the	O
24	melanoma	O
25	,	O
26	its	O
27	lymphotropism	O
28	and	O
29	the	O
30	coexistence	O
31	of	O
32	invasive	O
33	squamous	O
34	cell	O
35	carcinoma	O
36	.	O

1	Automatic	O
2	view	O
3	box	O
4	.	O

1	Regulation	O
2	of	O
3	irgA	O
4	by	O
5	iron	O
6	in	O
7	V	O
8	.	O
9	cholerae	O
10	occurs	O
11	at	O
12	the	O
13	transcriptional	O
14	level	O
15	,	O
16	and	O
17	there	O
18	is	O
19	an	O
20	interrupted	O
21	dyad	O
22	symmetric	O
23	sequence	O
24	in	O
25	the	O
26	vicinity	O
27	of	O
28	the	O
29	promoter	O
30	that	O
31	is	O
32	homologous	O
33	to	O
34	Fur	O
35	binding	O
36	sites	O
37	of	O
38	E	O
39	.	O
40	coli	O
41	.	O

1	When	O
2	the	O
3	blood	O
4	pressure	O
5	increase	O
6	in	O
7	response	O
8	to	O
9	smoking	O
10	was	O
11	blunted	O
12	by	O
13	nitroprusside	O
14	infusion	O
15	,	O
16	there	O
17	was	O
18	a	O
19	striking	O
20	increase	O
21	in	O
22	muscle	O
23	SNA	O
24	.	O

1	We	O
2	further	O
3	show	O
4	that	O
5	proteolytic	O
6	targeting	O
7	by	O
8	calpain	O
9	II	O
10	and	O
11	the	O
12	proteasome	O
13	involves	O
14	different	O
15	structural	O
16	elements	O
17	of	O
18	YY1	O
19	.	O

1	The	O
2	cloned	O
3	HindIII	O
4	fragment	O
5	,	O
6	which	O
7	was	O
8	shown	O
9	by	O
10	DNA	O
11	sequence	O
12	analysis	O
13	to	O
14	encode	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	half	O
20	of	O
21	the	O
22	B	O
23	.	O
24	subtilis	O
25	IF2	O
26	protein	O
27	and	O
28	0	O
29	.	O
30	2	O
31	kb	O
32	of	O
33	upstream	O
34	flanking	O
35	sequence	O
36	,	O
37	was	O
38	utilized	O
39	as	O
40	a	O
41	homologous	O
42	probe	O
43	to	O
44	clone	O
45	an	O
46	overlapping	O
47	2	O
48	.	O
49	76	O
50	-	O
51	kb	O
52	ClaI	O
53	chromosomal	O
54	fragment	O
55	containing	O
56	the	O
57	entire	O
58	IF2	O
59	structural	O
60	gene	O
61	.	O

1	We	O
2	also	O
3	identify	O
4	several	O
5	regulatory	O
6	domain	O
7	mutants	O
8	in	O
9	which	O
10	Cd	O
11	(	O
12	2	O
13	+)	O
14	tolerance	O
15	of	O
16	the	O
17	mutant	O
18	strain	O
19	and	O
20	transport	O
21	activity	O
22	of	O
23	the	O
24	protein	O
25	are	O
26	dissociated	O
27	.	O

1	The	O
2	potency	O
3	of	O
4	the	O
5	effect	O
6	of	O
7	Nim	O
8	(	O
9	0	O
10	.	O
11	5	O
12	mg	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	i	O
18	.	O
19	p	O
20	.)	O
21	was	O
22	similar	O
23	to	O
24	that	O
25	of	O
26	NBP	O
27	(	O
28	10	O
29	mg	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	i	O
35	.	O
36	p	O
37	.).	O

1	It	O
2	corresponds	O
3	to	O
4	the	O
5	complete	O
6	mitochondrial	O
7	presequence	O
8	and	O
9	the	O
10	lipoyl	O
11	-	O
12	bearing	O
13	domain	O
14	that	O
15	are	O
16	encoded	O
17	by	O
18	exons	O
19	I	O
20	through	O
21	IV	O
22	of	O
23	the	O
24	functional	B
25	E2	I
26	gene	I
27	.	I

1	In	O
2	addition	O
3	,	O
4	depletion	O
5	of	B
6	Oct	I
7	-	I
8	1	O
9	from	O
10	the	O
11	nuclear	O
12	extract	O
13	by	O
14	using	B
15	Oct	I
16	-	I
17	1	I
18	-	I
19	specific	O
20	antiserum	O
21	or	O
22	a	O
23	sequence	O
24	-	O
25	specific	O
26	DNA	O
27	affinity	O
28	resin	O
29	decreased	O
30	in	O
31	vitro	O
32	transcription	O
33	from	O
34	the	O
35	wild	O
36	-	O
37	type	O
38	MMTV	O
39	promoter	O
40	to	O
41	a	O
42	level	O
43	identical	O
44	to	O
45	that	O
46	obtained	O
47	from	O
48	a	O
49	promoter	O
50	in	O
51	which	O
52	all	O
53	three	O
54	octamer	O
55	-	O
56	related	O
57	sequences	O
58	were	O
59	mutated	O
60	.	O

1	Analyses	O
2	of	O
3	additional	O
4	tumors	O
5	induced	O
6	in	O
7	mice	O
8	from	O
9	two	O
10	reciprocal	O
11	crosses	O
12	,	O
13	A	O
14	/	O
15	J	O
16	x	O
17	C3H	O
18	/	O
19	HeJ	O
20	F1	O
21	(	O
22	hereafter	O
23	called	B
24	AC3F1	O
25	)	O
26	and	O
27	C3H	O
28	/	O
29	HeJ	O
30	x	O
31	A	O
32	/	O
33	J	O
34	F1	O
35	(	O
36	hereafter	O
37	called	B
38	C3AF1	O
39	),	O
40	provided	O
41	evidence	O
42	for	O
43	the	O
44	inactivation	O
45	of	O
46	one	O
47	allele	O
48	of	O
49	the	O
50	putative	O
51	chromosome	B
52	4	B
53	tumor	I
54	suppressor	I
55	gene	O
56	by	O
57	parental	O
58	imprinting	O
59	.	O

1	The	O
2	subgroup	O
3	innervating	O
4	the	O
5	medial	O
6	rectus	O
7	lies	O
8	exclusively	O
9	along	O
10	the	O
11	medial	O
12	face	O
13	of	O
14	the	O
15	oculomotor	O
16	nucleus	O
17	,	O
18	with	O
19	no	O
20	aberrant	O
21	neurons	O
22	in	O
23	the	O
24	medial	O
25	longitudinal	O
26	fasciculus	O
27	,	O
28	as	O
29	have	O
30	been	O
31	found	O
32	in	O
33	other	O
34	mammals	O
35	.	O

1	These	O
2	two	O
3	contigs	O
4	contain	O
5	a	O
6	total	O
7	of	O
8	163	O
9	open	O
10	reading	O
11	frames	O
12	(	O
13	ORFs	O
14	)	O
15	in	O
16	26	O
17	-	O
18	29	O
19	putative	O
20	operons	O
21	;	O
22	56	O
23	ORFs	O
24	could	O
25	be	O
26	identified	O
27	with	O
28	reasonable	O
29	certainty	O
30	.	O

1	PCR	O
2	/	O
3	Southern	O
4	blot	O
5	analysis	O
6	of	O
7	human	O
8	kidney	O
9	cDNA	O
10	using	O
11	primers	O
12	flanking	O
13	the	O
14	hKID	O
15	coding	O
16	sequence	O
17	revealed	O
18	expression	O
19	of	O
20	a	B
21	full	I
22	-	I
23	length	I
24	mRNA	O
25	and	O
26	short	O
27	transcripts	O
28	with	O
29	partial	O
30	exon	O
31	1	O
32	and	O
33	partial	O
34	exon	O
35	4	O
36	deletions	O
37	.	O

1	DESIGN	O
2	:	O
3	Comparison	O
4	of	O
5	number	O
6	of	O
7	women	O
8	with	B
9	PKU	O
10	aged	O
11	15	O
12	-	O
13	44	O
14	years	O
15	on	O
16	the	B
17	NSW	B
18	PKU	O
19	database	O
20	(	O
21	observed	O
22	number	O
23	)	O
24	with	O
25	expected	O
26	number	O
27	derived	O
28	from	O
29	population	O
30	data	O
31	.	O

1	Protein	O
2	sequence	O
3	analysis	O
4	reveals	O
5	that	O
6	MAN1	O
7	shares	O
8	a	O
9	conserved	O
10	globular	O
11	domain	O
12	of	O
13	approximately	O
14	40	O
15	amino	O
16	acids	O
17	,	O
18	which	O
19	we	O
20	term	O
21	the	O
22	LEM	O
23	module	O
24	,	O
25	with	O
26	inner	B
27	nuclear	I
28	membrane	I
29	proteins	I
30	lamina	I
31	-	I
32	associated	I
33	polypeptide	I
34	2	O
35	and	O
36	emerin	O
37	.	O

1	Identification	O
2	of	B
3	Ets	I
4	-	O
5	and	O
6	notch	I
7	-	I
8	related	I
9	subunits	I
10	in	I
11	GA	I
12	binding	I
13	protein	I
14	.	I

1	VEGF	I
2	promoter	O
3	activity	O
4	in	O
5	transient	O
6	transfections	O
7	was	O
8	decreased	O
9	by	O
10	either	O
11	pharmacological	O
12	or	O
13	genetic	O
14	inhibition	O
15	of	B
16	EGFR	O
17	,	O
18	Ras	O
19	,	O
20	or	B
21	phosphatidylinositol	I
22	3	I
23	'-	I
24	kinase	I
25	[	I
26	PI	I
27	(	I
28	3	I
29	)	I
30	kinase	I
31	].	I

1	Sex	O
2	of	O
3	calf	O
4	(	O
5	variate	O
6	2	O
7	)	O
8	was	O
9	associated	O
10	most	O
11	closely	O
12	with	O
13	width	O
14	of	B
15	muzzle	O
16	and	O
17	head	O
18	.	O

1	Thyroid	O
2	lymphoma	O
3	and	O
4	its	O
5	management	O
6	.	O

1	The	O
2	second	O
3	class	O
4	of	O
5	cDNA	O
6	hybridized	O
7	to	O
8	a	O
9	13	O
10	kb	O
11	transcript	O
12	,	O
13	which	O
14	was	O
15	approximately	O
16	twice	O
17	as	O
18	large	O
19	as	O
20	the	B
21	mammalian	I
22	lactase	I
23	mRNA	I
24	.	I

1	Expression	O
2	of	O
3	this	O
4	protein	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	demonstrated	O
10	that	O
11	tyrosine	O
12	was	O
13	incorporated	O
14	during	O
15	suppression	O
16	and	O
17	that	O
18	yeast	O
19	cytoplasmic	O
20	TyrRS	O
21	activity	O
22	was	O
23	produced	O
24	.	O

1	Among	O
2	the	O
3	patients	O
4	grades	B
5	1	I
6	-	I
7	2	I
8	-	I
9	3	O
10	,	O
11	81	O
12	%	O
13	had	O
14	a	O
15	good	O
16	out	O
17	come	O
18	without	O
19	any	O
20	neurological	O
21	abnormality	O
22	,	O
23	among	O
24	the	O
25	patients	O
26	graded	O
27	4	O
28	-	O
29	5	O
30	,	O
31	only	O
32	27	O
33	%	O
34	had	O
35	a	O
36	fair	O
37	out	O
38	come	O
39	.	O

1	Most	O
2	of	O
3	them	O
4	were	O
5	situated	O
6	at	O
7	Sylvius	O
8	fissure	O
9	(	O
10	13	O
11	cases	O
12	).	O

1	Problems	O
2	common	O
3	to	O
4	pediatrics	O
5	and	O
6	anesthesiology	B

1	The	O
2	interaction	O
3	between	O
4	U	O
5	(	O
6	L	O
7	)	O
8	3	O
9	.	O

1	Marker	O
2	rescue	O
3	analysis	O
4	has	O
5	localized	O
6	ts8	O
7	to	O
8	a	O
9	910	O
10	-	O
11	bp	O
12	internal	O
13	segment	O
14	of	O
15	rpoB	O
16	that	O
17	encodes	O
18	the	O
19	Rif	O
20	domain	O
21	.	O

1	C	O
2	-	O
3	SP	O
4	duration	O
5	was	O
6	significantly	O
7	reduced	O
8	in	O
9	ALS	O
10	patients	O
11	compared	O
12	to	O
13	controls	O
14	at	O
15	low	O
16	stimulation	O
17	intensity	O
18	corresponding	O
19	to	O
20	an	O
21	MEP	O
22	threshold	O
23	increased	O
24	by	O
25	15	O
26	%.	O

1	Cryopreservation	O
2	straws	O
3	filled	O
4	with	O
5	media	O
6	plus	O
7	additive	O
8	are	O
9	emersed	O
10	below	O
11	the	O
12	surface	O
13	of	O
14	an	O
15	unprocessed	O
16	donor	O
17	ejaculate	O
18	.	O

1	Cat	O
2	proteins	O
3	are	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	when	O
8	co	O
9	-	O
10	expressed	O
11	in	O
12	cells	O
13	with	O
14	the	O
15	focal	I
16	adhesion	I
17	kinase	I
18	Fak	I
19	and	I
20	Src	I
21	.	I

1	After	O
2	recovery	O
3	,	O
4	a	O
5	hypertonic	O
6	saline	O
7	challenge	O
8	was	O
9	performed	O
10	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	inhibition	O
6	of	B
7	Jun	I
8	kinase	O
9	activation	O
10	was	O
11	sufficient	O
12	to	O
13	inhibit	O
14	Ras	O
15	transformation	O
16	even	O
17	in	O
18	the	O
19	presence	O
20	of	O
21	activated	B
22	Erk	I
23	-	I
24	2	I
25	.	I

1	The	O
2	interaction	O
3	of	O
4	caffeine	O
5	,	O
6	theophylline	O
7	and	O
8	theobromine	O
9	with	O
10	monoamine	I
11	oxidase	I
12	inhibitors	I
13	.	I

1	The	O
2	author	O
3	provides	O
4	a	O
5	rationale	O
6	for	O
7	an	O
8	interactional	O
9	view	O
10	and	O
11	presents	O
12	a	O
13	case	O
14	in	O
15	which	O
16	post	O
17	-	O
18	surgical	O
19	hiccups	O
20	were	O
21	successfully	O
22	treated	O
23	,	O
24	using	O
25	principles	O
26	developed	O
27	by	O
28	the	O
29	Mental	O
30	Research	O
31	Institute	O
32	.	O

1	In	O
2	the	O
3	premating	O
4	period	O
5	male	O
6	rate	O
7	of	O
8	aggression	O
9	was	O
10	not	O
11	significantly	O
12	correlated	O
13	with	O
14	testosterone	O
15	level	O
16	.	O

1	This	O
2	report	O
3	expands	O
4	on	O
5	previous	O
6	work	O
7	with	B
8	interferon	B
9	alfa	I
10	-	I
11	2b	O
12	(	O
13	Intron	O
14	A	O
15	;	O
16	Schering	O
17	-	O
18	Plough	O
19	)	O
20	in	O
21	the	O
22	treatment	O
23	of	O
24	hairy	O
25	cell	O
26	leukemia	O
27	(	O
28	HCL	O
29	).	O

1	The	O
2	Ng	O
3	/	O
4	RC3	O
5	and	B
6	PKC	I
7	-	I
8	gamma	I
9	genes	O
10	have	O
11	a	O
12	similar	O
13	expression	O
14	pattern	O
15	in	O
16	the	O
17	brain	O
18	during	O
19	development	O
20	.	O

1	Agranulocytosis	O
2	treatment	O
3	with	B
4	rhGM	I
5	-	I
6	CSF	I

1	A	O
2	striking	O
3	finding	O
4	in	O
5	all	O
6	of	O
7	the	O
8	studies	O
9	was	O
10	a	O
11	positive	O
12	correlation	O
13	between	O
14	PI	O
15	ACTH	O
16	and	O
17	MSH	O
18	contents	O
19	.	O

1	The	O
2	Euglena	I
3	ribosomal	I
4	protein	I
5	gene	I
6	cluster	O
7	resembles	O
8	the	O
9	S	O
10	-	O
11	10	B
12	ribosomal	I
13	protein	I
14	operon	O
15	of	O
16	Escherichia	O
17	coli	O
18	in	O
19	gene	O
20	organization	O
21	and	O
22	follows	O
23	the	O
24	exact	O
25	linear	O
26	order	O
27	of	O
28	the	O
29	analogous	O
30	genes	O
31	in	O
32	the	O
33	tobacco	O
34	and	O
35	liverwort	O
36	chloroplast	O
37	genomes	O
38	.	O

1	The	O
2	human	O
3	cDNA	O
4	clone	B
5	NFBD1	O
6	(	O
7	previously	O
8	designated	O
9	KIAA0170	O
10	)	O
11	encodes	O
12	a	O
13	novel	O
14	protein	O
15	(	O
16	2089	O
17	amino	O
18	acids	O
19	in	O
20	length	O
21	;	O
22	calculated	O
23	molecular	O
24	mass	O
25	226	O
26	,	O
27	440	O
28	D	O
29	)	O
30	with	O
31	possible	O
32	BRCT	O
33	domains	O
34	at	O
35	its	O
36	carboxy	O
37	terminus	O
38	(	O
39	amino	O
40	acid	O
41	residues	O
42	1894	O
43	-	O
44	2089	O
45	).	O

1	Respiratory	O
2	chain	O
3	enzyme	O
4	activity	O
5	was	O
6	normal	O
7	.	O

1	Overexpression	O
2	of	B
3	Trdpm1	B
4	in	B
5	a	B
6	dpm1	I
7	(+)::	O
8	his7	O
9	/	B
10	dpm1	I
11	(+)	O
12	S	O
13	.	O
14	pombe	O
15	diploid	O
16	resulted	O
17	in	O
18	a	O
19	4	O
20	-	O
21	fold	O
22	increase	O
23	in	O
24	specific	B
25	DPM	I
26	synthase	O
27	activity	O
28	.	O

1	To	O
2	date	O
3	,	O
4	two	O
5	such	O
6	proteins	O
7	,	B
8	PLZF	I
9	and	I
10	LAZ	I
11	-	I
12	3	I
13	/	I
14	BCL	I
15	-	I
16	6	O
17	,	O
18	have	O
19	been	O
20	implicated	O
21	in	O
22	oncogenesis	O
23	.	O

1	We	O
2	show	O
3	that	O
4	LexA	O
5	-	O
6	GAL4	O
7	and	O
8	LexA	O
9	-	O
10	Bicoid	O
11	fusion	O
12	proteins	O
13	are	O
14	both	O
15	dependent	O
16	on	O
17	SNF2	O
18	,	O
19	SNF5	O
20	,	O
21	and	O
22	SNF6	O
23	for	O
24	activation	O
25	of	O
26	target	O
27	genes	O
28	containing	O
29	one	O
30	or	O
31	multiple	O
32	lexA	O
33	operators	O
34	.	O

1	SNAC	O
2	or	O
3	PBS	O
4	was	O
5	infused	O
6	for	O
7	6	O
8	.	O
9	5	O
10	h	O
11	,	O
12	beginning	O
13	30	O
14	min	O
15	before	O
16	ischemia	O
17	and	O
18	continuing	O
19	throughout	O
20	the	O
21	duration	O
22	of	O
23	reperfusion	O
24	.	O

1	Light	O
2	regulatory	O
3	unit	O
4	1	O
5	(	B
6	LRU1	O
7	)	O
8	is	O
9	necessary	O
10	for	O
11	and	O
12	sufficient	O
13	to	O
14	mediate	O
15	light	O
16	-	O
17	dependent	O
18	activation	O
19	of	O
20	the	B
21	chalcone	I
22	synthase	O
23	(	O
24	CHS	O
25	)	O
26	minimal	O
27	promoter	O
28	in	O
29	Petroselinum	O
30	crispum	O
31	.	O

1	The	O
2	LAMMER	I
3	protein	I
4	kinase	O
5	encoded	O
6	by	O
7	the	O
8	Doa	O
9	locus	O
10	of	O
11	Drosophila	O
12	is	O
13	required	O
14	in	O
15	both	O
16	somatic	O
17	and	O
18	germline	O
19	cells	O
20	and	O
21	is	O
22	expressed	O
23	as	O
24	both	O
25	nuclear	O
26	and	O
27	cytoplasmic	O
28	isoforms	O
29	throughout	O
30	development	O
31	.	O

1	Recessive	O
2	lethal	O
3	mutations	O
4	were	O
5	isolated	O
6	based	O
7	upon	O
8	failure	O
9	to	O
10	complement	O
11	the	O
12	recessive	O
13	lethality	O
14	of	O
15	Df	O
16	(	O
17	3L	O
18	)	O
19	RR2	O
20	,	O
21	a	O
22	deletion	O
23	of	O
24	the	O
25	DRE	O
26	region	O
27	that	O
28	removes	O
29	16	O
30	-	O
31	18	O
32	polytene	O
33	chromosome	O
34	bands	O
35	.	O

1	The	O
2	effects	O
3	of	O
4	tap	O
5	(	O
6	TW	O
7	)	O
8	or	O
9	carbonated	O
10	(	O
11	CW	O
12	)	O
13	water	O
14	on	O
15	arterial	O
16	pH	O
17	,	O
18	partial	O
19	pressure	O
20	of	O
21	carbon	O
22	dioxide	O
23	(	O
24	PCO2	O
25	)	O
26	and	O
27	plasma	O
28	lactate	O
29	were	O
30	determined	O
31	in	O
32	heat	O
33	-	O
34	stressed	O
35	broilers	O
36	.	O

1	The	O
2	following	O
3	aspects	O
4	were	O
5	assessed	O
6	:	O
7	(	O
8	1	O
9	)	O
10	The	O
11	effect	O
12	on	O
13	the	O
14	cardiovascular	O
15	system	O
16	in	O
17	terms	O
18	of	O
19	brachial	O
20	arterial	O
21	pressure	O
22	,	O
23	pulse	O
24	rate	O
25	,	O
26	and	O
27	oxygen	O
28	consumption	O
29	(	O
30	VO2	O
31	)	O
32	during	O
33	exercise	O
34	in	O
35	5	O
36	health	O
37	volunteers	O
38	;	O
39	(	O
40	2	O
41	)	O
42	emg	O
43	activity	O
44	of	O
45	the	O
46	tibialis	O
47	anterior	O
48	and	O
49	gastrocnemius	O
50	muscles	O
51	during	O
52	exercise	O
53	in	O
54	the	O
55	same	O
56	5	O
57	volunteers	O
58	;	O
59	and	O
60	(	O
61	3	O
62	)	O
63	postexercise	O
64	ankle	O
65	pressure	O
66	changes	O
67	in	O
68	10	O
69	subjects	O
70	with	O
71	angiographically	O
72	proven	O
73	occlusive	O
74	arterial	O
75	diseases	O
76	of	O
77	the	O
78	lower	O
79	extremities	O
80	.	O

1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	(	O
7	EMSA	O
8	),	O
9	this	B
10	GLUT4	I
11	repressor	I
12	element	O
13	(	O
14	G4RE	O
15	)	O
16	generated	O
17	specific	O
18	bands	O
19	with	O
20	nuclear	O
21	extracts	O
22	from	O
23	preadipocytes	O
24	,	O
25	but	O
26	not	O
27	from	O
28	adipocytes	O
29	.	O

1	SETTING	O
2	:	O
3	A	O
4	division	O
5	of	O
6	a	O
7	large	O
8	tea	O
9	plantation	O
10	in	O
11	Kandy	O
12	.	O

1	In	O
2	a	O
3	retrospective	O
4	analysis	O
5	of	O
6	first	O
7	-	O
8	time	O
9	total	O
10	colonoscopies	O
11	in	O
12	685	O
13	patients	O
14	,	O
15	we	O
16	investigated	O
17	the	O
18	relationship	O
19	between	O
20	hyperplastic	O
21	and	O
22	adenomatous	O
23	polyps	O
24	.	O

1	New	O
2	diagnostic	O
3	strategies	O
4	for	O
5	lupus	O
6	anticoagulants	O
7	and	O
8	antiphospholipid	O
9	antibodies	O
10	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	primary	O
7	visual	O
8	cortex	O
9	of	O
10	the	O
11	rat	O
12	is	O
13	asymmetrical	O
14	in	O
15	volume	O
16	,	O
17	and	O
18	that	O
19	the	O
20	asymmetry	O
21	reflects	O
22	side	O
23	differences	O
24	in	O
25	the	O
26	number	O
27	of	O
28	neurons	O
29	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	Jkappa	I
2	DNA	I
3	-	I
4	binding	I
5	sites	O
6	were	O
7	not	O
8	required	O
9	for	O
10	this	O
11	activation	O
12	,	O
13	and	O
14	a	O
15	mutant	B
16	EBNA	I
17	-	I
18	3C	I
19	protein	O
20	unable	O
21	to	O
22	bind	O
23	Jkappa	O
24	activated	O
25	transcription	O
26	as	O
27	efficiently	O
28	as	B
29	wild	I
30	-	I
31	type	I
32	EBNA	I
33	-	I
34	3C	O
35	,	O
36	indicating	O
37	that	B
38	EBNA	I
39	-	I
40	3C	O
41	can	O
42	regulate	O
43	transcription	O
44	through	O
45	a	O
46	mechanism	O
47	that	O
48	is	O
49	independent	O
50	of	O
51	Jkappa	O
52	.	O

1	The	O
2	mEmBP	I
3	-	I
4	1	I
5	protein	O
6	can	O
7	activate	O
8	transcription	O
9	from	O
10	a	O
11	truncated	O
12	promoter	O
13	containing	O
14	a	O
15	pentamer	O
16	of	O
17	the	O
18	O2	O
19	site	O
20	in	O
21	yeast	O
22	cells	O
23	;	O
24	however	O
25	,	O
26	it	O
27	inhibited	O
28	regulated	O
29	transcription	O
30	of	O
31	a	O
32	22	O
33	kDa	O
34	zein	O
35	promoter	O
36	in	O
37	a	O
38	transient	O
39	expression	O
40	assay	O
41	using	O
42	cultured	O
43	maize	O
44	endosperm	O
45	cells	O
46	.	O

1	This	O
2	study	O
3	allows	O
4	us	O
5	to	O
6	draw	O
7	conclusions	O
8	about	O
9	the	O
10	identity	O
11	of	O
12	proteins	O
13	required	O
14	for	O
15	the	O
16	development	O
17	of	O
18	the	O
19	nervous	O
20	system	O
21	in	O
22	Drosophila	O
23	and	O
24	provides	O
25	an	O
26	example	O
27	of	O
28	a	O
29	molecular	O
30	approach	O
31	to	O
32	characterize	O
33	en	O
34	masse	O
35	transposon	O
36	-	O
37	tagged	O
38	mutations	O
39	identified	O
40	in	O
41	genetic	O
42	screens	O
43	.	O

1	Despite	O
2	the	O
3	small	O
4	number	O
5	of	O
6	patients	O
7	,	O
8	on	O
9	the	O
10	basis	O
11	of	O
12	this	O
13	report	O
14	,	O
15	we	O
16	can	O
17	confirm	O
18	that	O
19	1	O
20	.	O
21	5	O
22	MU	O
23	/	O
24	day	O
25	of	B
26	alpha	I
27	-	I
28	IFN	O
29	is	O
30	an	O
31	adequate	O
32	treatment	O
33	for	O
34	patients	O
35	with	O
36	hairy	O
37	cell	O
38	leukemia	O
39	.	O

1	Therefore	O
2	the	O
3	procedure	O
4	of	O
5	Lich	O
6	-	O
7	Gregoir	O
8	is	O
9	not	O
10	to	O
11	be	O
12	recommended	O
13	in	O
14	adults	O
15	.	O

1	The	B
2	alpha	B
3	T3	I
4	-	I
5	1	O
6	cell	O
7	line	O
8	,	O
9	a	B
10	GnRH	I
11	-	I
12	responsive	I
13	gonadotroph	O
14	cell	O
15	line	O
16	developed	O
17	by	O
18	targeted	O
19	oncogenesis	O
20	in	O
21	transgenic	O
22	mice	O
23	,	O
24	was	O
25	used	O
26	to	O
27	study	O
28	regulation	O
29	of	O
30	the	B
31	glycoprotein	I
32	hormone	I
33	alpha	I
34	-	I
35	subunit	O
36	by	B
37	activin	I
38	.	I

1	Lesions	O
2	were	O
3	made	O
4	by	O
5	pressure	O
6	injection	O
7	of	O
8	kainic	O
9	acid	O
10	into	O
11	the	O
12	SOC	O
13	through	O
14	a	O
15	stereotaxically	O
16	positioned	O
17	glass	O
18	micropipette	O
19	.	O

1	Experimental	O
2	reproduction	O
3	of	O
4	malignant	O
5	catarrhal	O
6	fever	O
7	in	O
8	Bali	O
9	cattle	O

1	These	O
2	articles	O
3	both	O
4	report	O
5	the	O
6	results	O
7	of	O
8	multi	O
9	-	O
10	institutional	O
11	,	O
12	randomized	O
13	,	O
14	phase	O
15	3	O
16	trials	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	patients	O
22	with	O
23	localized	O
24	(	B
25	T1	I
26	-	I
27	3	I
28	N0	I
29	-	I
30	1	O
31	M0	O
32	)	O
33	esophageal	O
34	squamous	O
35	cell	O
36	carcinoma	O
37	(	O
38	SCC	O
39	)	O
40	or	O
41	esophageal	O
42	adenocarcinoma	O
43	.	O

1	Using	O
2	lectin	O
3	-	O
4	affinity	O
5	chromatography	O
6	,	O
7	discordance	O
8	between	O
9	the	O
10	pattern	O
11	of	O
12	O	O
13	-	O
14	glycosylation	O
15	of	O
16	SSBP	O
17	and	O
18	DSBP	O
19	was	O
20	demonstrated	O
21	.	O

1	Induction	O
2	of	O
3	Fas	O
4	ligand	O
5	expression	O
6	by	O
7	HIV	O
8	involves	O
9	the	O
10	interaction	O
11	of	O
12	Nef	O
13	with	O
14	the	B
15	T	I
16	cell	I
17	receptor	I
18	zeta	I
19	chain	I
20	.	I

1	We	O
2	linked	O
3	hypersensitivity	O
4	site	O
5	2	O
6	(	O
7	HS2	O
8	)	O
9	from	O
10	the	O
11	locus	O
12	control	O
13	region	O
14	(	O
15	LCR	O
16	)	O
17	to	O
18	a	O
19	A	B
20	gamma	I
21	-	I
22	globin	I
23	gene	I
24	(	I
25	A	I
26	gamma	I
27	*)	O
28	mutationally	O
29	marked	O
30	to	O
31	allow	O
32	its	O
33	transcript	O
34	to	O
35	be	O
36	distinguished	O
37	from	B
38	endogenous	I
39	gamma	I
40	-	I
41	globin	I
42	mRNA	I
43	.	I

1	To	O
2	study	O
3	the	O
4	sensitivity	O
5	of	O
6	some	O
7	central	O
8	brain	O
9	structures	O
10	to	O
11	the	O
12	action	O
13	of	O
14	an	O
15	electromagnetic	O
16	field	O
17	of	O
18	decimeter	O
19	waves	O
20	(	O
21	EMF	O
22	of	O
23	DW	O
24	)	O
25	a	O
26	dynamic	O
27	investigation	O
28	of	O
29	single	O
30	unit	O
31	activity	O
32	was	O
33	undertaken	O
34	.	O

1	OBJECTIVES	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	the	O
7	study	O
8	was	O
9	to	O
10	analyze	O
11	the	O
12	clinical	O
13	characteristics	O
14	,	O
15	treatment	O
16	and	O
17	outcome	O
18	of	O
19	310	O
20	patients	O
21	with	O
22	hydatidiform	O
23	mole	O
24	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	Flavobacterium	O
6	glycosylasparaginase	O
7	with	O
8	a	B
9	mammalian	I
10	glycosylasparaginase	O
11	revealed	O
12	30	O
13	%	O
14	structural	O
15	identity	O
16	and	O
17	60	O
18	%	O
19	overall	O
20	similarity	O
21	between	O
22	the	O
23	prokaryotic	O
24	and	O
25	eukaryotic	O
26	forms	O
27	of	O
28	the	O
29	enzyme	O
30	.	O

1	Neurofibromatosis	O
2	of	O
3	the	O
4	breast	O
5	in	O
6	a	O
7	patient	O
8	with	O
9	Morbus	O
10	von	O
11	Recklinghausen	B

1	NIK	O
2	-	O
3	244	O
4	suppressed	O
5	coronary	O
6	ligation	O
7	-	O
8	and	O
9	digitalis	O
10	-	O
11	induced	O
12	arrhythmias	O
13	,	O
14	and	O
15	the	O
16	minimum	O
17	effective	O
18	plasma	O
19	concentrations	O
20	for	O
21	arrhythmias	O
22	induced	O
23	by	O
24	24	O
25	-	O
26	h	O
27	and	O
28	48	O
29	-	O
30	h	O
31	coronary	O
32	ligation	O
33	and	O
34	digitalis	O
35	were	O
36	0	O
37	.	O
38	41	O
39	+/-	O
40	0	O
41	.	O
42	10	O
43	(	O
44	by	O
45	1	O
46	mg	O
47	/	O
48	kg	O
49	i	O
50	.	O
51	v	O
52	.),	O
53	0	O
54	.	O
55	70	O
56	+/-	O
57	0	O
58	.	O
59	13	O
60	(	O
61	by	O
62	1	O
63	mg	O
64	/	O
65	kg	O
66	i	O
67	.	O
68	v	O
69	.),	O
70	and	O
71	0	O
72	.	O
73	21	O
74	+/-	O
75	0	O
76	.	O
77	08	O
78	(	O
79	by	O
80	0	O
81	.	O
82	5	O
83	mg	O
84	/	O
85	kg	O
86	i	O
87	.	O
88	v	O
89	.)	O
90	microgram	O
91	/	O
92	ml	O
93	,	O
94	respectively	O
95	(	O
96	mean	O
97	+/-	O
98	SD	O
99	of	O
100	the	O
101	mean	O
102	,	O
103	n	O
104	=	O
105	6	O
106	).	O

1	Elementary	O
2	visual	O
3	hallucinations	O
4	in	O
5	migraine	O
6	and	O
7	epilepsy	O
8	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	isolation	O
6	of	O
7	a	O
8	full	O
9	-	O
10	length	O
11	cDNA	O
12	clone	O
13	coding	O
14	for	O
15	a	O
16	hitherto	O
17	undiscovered	O
18	isoform	O
19	of	O
20	the	B
21	bovine	B
22	C	I
23	-	I
24	subunit	I
25	.	I

1	Extramedullary	O
2	plasmacytoma	O
3	of	O
4	the	O
5	parotid	O
6	gland	O

1	Results	O
2	of	O
3	a	O
4	controlled	O
5	study	O

1	Finally	O
2	,	O
3	some	O
4	point	O
5	mutations	O
6	in	O
7	the	B
8	Gag	I
9	-	I
10	Pol	I
11	PR	I
12	domain	O
13	inhibited	O
14	activation	O
15	of	O
16	RT	O
17	in	O
18	trans	O
19	by	O
20	a	B
21	wild	I
22	-	I
23	type	I
24	PR	O
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	correct	O
30	conformation	O
31	of	O
32	the	B
33	PR	I
34	domain	I
35	in	I
36	Gag	I
37	-	I
38	Pol	O
39	is	O
40	prerequisite	O
41	for	O
42	activation	O
43	of	O
44	RT	O
45	.	O

1	CPAP	O
2	reduced	O
3	isotime	O
4	(	O
5	defined	O
6	as	O
7	the	O
8	last	O
9	common	O
10	minute	O
11	of	O
12	exercise	O
13	)	O
14	VO2	O
15	and	O
16	dyspnea	O
17	in	O
18	those	O
19	patients	O
20	with	O
21	more	O
22	severe	O
23	lung	O
24	disease	O
25	,	O
26	but	O
27	these	O
28	values	O
29	tended	O
30	to	O
31	increase	O
32	slightly	O
33	in	O
34	the	O
35	patients	O
36	with	O
37	only	O
38	mild	O
39	lung	O
40	disease	O
41	.	O

1	Artificial	O
2	ventilation	O
3	was	O
4	conducted	O
5	using	O
6	a	O
7	tidal	O
8	volume	O
9	of	O
10	10	O
11	ml	O
12	X	O
13	kg	O
14	-	O
15	1	O
16	and	O
17	a	O
18	rate	O
19	of	O
20	10	O
21	to	O
22	12	O
23	c	O
24	X	O
25	min	O
26	-	O
27	1	O
28	.	O

1	CONCLUSION	O
2	(	O
3	S	O
4	):	O
5	Measuring	O
6	urinary	O
7	LH	O
8	levels	O
9	is	O
10	an	O
11	excellent	O
12	method	O
13	for	O
14	determining	O
15	ovulation	O
16	.	O

1	Recombinant	O
2	soluble	O
3	pMCP	O
4	that	O
5	lacked	O
6	transmembrane	O
7	and	O
8	cytoplasmic	O
9	domains	O
10	had	O
11	factor	O
12	I	O
13	cofactor	O
14	activity	O
15	in	O
16	C3b	O
17	cleavage	O
18	,	O
19	indicating	O
20	that	O
21	it	O
22	is	O
23	functionally	O
24	,	O
25	as	O
26	well	O
27	as	O
28	structurally	O
29	homologous	O
30	to	O
31	MCP	O
32	.	O

1	Information	O
2	on	O
3	conserved	O
4	noncoding	O
5	sequences	O
6	will	O
7	help	O
8	in	O
9	studies	O
10	on	O
11	the	O
12	regulation	O
13	of	O
14	the	B
15	pro	I
16	alpha	I
17	1	I
18	(	I
19	II	I
20	)	I
21	collagen	I
22	gene	I
23	.	I

1	Nuclear	O
2	hormone	O
3	receptors	O
4	(	O
5	NRs	O
6	)	O
7	are	O
8	ligand	O
9	-	O
10	inducible	O
11	transcription	O
12	factors	O
13	that	O
14	mediate	O
15	critical	O
16	functions	O
17	in	O
18	many	O
19	species	O
20	.	O

1	Beta	O
2	blocking	O
3	agents	O
4	.	O

1	Calcium	O
2	and	O
3	phosphorus	O
4	metabolism	O
5	in	O
6	chronic	O
7	uremia	O
8	.	O

1	When	O
2	the	O
3	entire	O
4	diet	O
5	consisted	O
6	of	O
7	SBF	O
8	,	O
9	voluntary	O
10	feed	O
11	intake	O
12	was	O
13	reduced	O
14	,	O
15	indicating	O
16	that	O
17	SBF	O
18	should	O
19	not	O
20	be	O
21	fed	O
22	to	O
23	ponies	O
24	as	O
25	the	O
26	sole	O
27	dietary	O
28	ingredient	O
29	.	O

1	The	O
2	Mauriceville	O
3	and	O
4	Varkud	O
5	mitochondrial	O
6	plasmids	O
7	are	O
8	closely	O
9	related	O
10	,	O
11	closed	O
12	-	O
13	circular	O
14	DNAs	O
15	(	O
16	3	O
17	.	O
18	6	O
19	and	O
20	3	O
21	.	O
22	7	O
23	kb	O
24	,	O
25	respectively	O
26	)	O
27	that	O
28	have	O
29	characteristics	O
30	of	O
31	mtDNA	O
32	introns	O
33	and	O
34	retroid	O
35	elements	O
36	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	i	O
6	)	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	candidate	O
12	latency	O
13	genes	O
14	of	B
15	murine	B
16	gammaHV68	O
17	,	O
18	(	O
19	ii	O
20	)	O
21	expression	O
22	of	O
23	genes	O
24	during	O
25	latency	O
26	may	O
27	be	O
28	different	O
29	in	O
30	different	O
31	organs	O
32	,	O
33	consistent	O
34	with	O
35	multiple	O
36	latency	O
37	programs	O
38	and	O
39	/	O
40	or	O
41	multiple	O
42	cellular	O
43	sites	O
44	of	O
45	latency	O
46	,	O
47	and	O
48	(	O
49	iii	O
50	)	O
51	regions	O
52	of	O
53	the	O
54	viral	O
55	genome	O
56	(	B
57	v	I
58	-	I
59	bcl	I
60	-	I
61	2	I
62	gene	O
63	,	O
64	v	O
65	-	B
66	GCR	I
67	gene	O
68	,	O
69	and	O
70	gene	O
71	73	O
72	)	O
73	are	O
74	transcribed	O
75	during	O
76	latency	O
77	with	O
78	both	B
79	gammaHV68	O
80	and	O
81	primate	O
82	gammaherpesviruses	O
83	.	O

1	Insulin	O
2	-	O
3	stimulated	O
4	glucose	O
5	transport	O
6	in	O
7	adipocytes	O
8	is	O
9	mediated	O
10	by	O
11	the	B
12	insulin	I
13	receptor	I
14	.	I

1	Anastrozole	O
2	is	O
3	the	O
4	first	B
5	aromatase	I
6	inhibitor	O
7	to	O
8	show	O
9	a	O
10	significant	O
11	survival	O
12	advantage	O
13	over	O
14	megestrol	O
15	acetate	O
16	in	O
17	post	O
18	-	O
19	menopausal	O
20	women	O
21	with	O
22	advanced	O
23	breast	O
24	cancer	O
25	.	O

1	The	O
2	results	O
3	from	O
4	the	O
5	first	O
6	five	O
7	years	O
8	of	O
9	follow	O
10	up	O
11	in	O
12	1972	O
13	showed	O
14	a	O
15	4	O
16	.	O
17	7	O
18	-	O
19	fold	O
20	excess	O
21	mortality	O
22	for	O
23	ischaemic	O
24	and	O
25	other	O
26	heart	O
27	diseases	O
28	(	O
29	ICD	O
30	A83	O
31	-	O
32	A84	O
33	)	O
34	compared	O
35	with	O
36	a	O
37	comparable	O
38	reference	O
39	cohort	O
40	of	O
41	paper	O
42	mill	O
43	workers	O
44	.	O

1	Limited	O
2	role	O
3	for	O
4	PCR	O
5	-	O
6	based	O
7	diagnosis	O
8	of	O
9	Whipple	O
10	'	O
11	s	O
12	disease	O
13	from	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	.	O

1	In	O
2	fact	O
3	,	O
4	SPT	O
5	activity	O
6	in	O
7	the	O
8	fly	O
9	expressing	O
10	epitope	O
11	-	O
12	tagged	O
13	Lace	O
14	was	O
15	absorbed	O
16	by	O
17	epitope	O
18	-	O
19	specific	O
20	antibody	O
21	.	O

1	The	O
2	two	O
3	main	O
4	experimental	O
5	variables	O
6	were	O
7	the	O
8	attended	O
9	hemifield	O
10	(	O
11	left	O
12	or	O
13	right	O
14	)	O
15	and	O
16	the	O
17	proportion	O
18	of	O
19	trials	O
20	requiring	O
21	a	O
22	shift	O
23	within	O
24	that	O
25	hemifield	O
26	(	O
27	20	O
28	%	O
29	or	O
30	80	O
31	%).	O

1	The	O
2	population	O
3	of	O
4	between	O
5	75	O
6	,	O
7	000	O
8	and	O
9	100	O
10	,	O
11	000	O
12	was	O
13	largely	O
14	unstable	O
15	,	O
16	and	O
17	cost	O
18	per	O
19	capita	O
20	was	O
21	$	O
22	0	O
23	.	O
24	95	O
25	to	O
26	$	O
27	1	O
28	.	O
29	21	O
30	.	O

1	All	O
2	mutant	O
3	JCV	O
4	T	O
5	antigens	O
6	bound	O
7	to	O
8	JCV	O
9	and	O
10	SV40	O
11	origins	O
12	of	O
13	DNA	O
14	replication	O
15	.	O

1	The	O
2	authors	O
3	have	O
4	tested	O
5	the	O
6	interference	O
7	of	O
8	the	B
9	hemoglobin	O
10	by	O
11	two	O
12	routine	O
13	methods	O
14	(	O
15	Berthelot	O
16	classic	O
17	and	O
18	Berthelot	O
19	modified	O
20	)	O
21	for	O
22	the	O
23	determination	O
24	of	O
25	plasmatic	O
26	urea	O
27	.	O

1	We	O
2	show	O
3	,	O
4	by	O
5	injection	O
6	of	O
7	synthetic	O
8	mRNAs	O
9	,	O
10	that	O
11	the	O
12	cis	O
13	-	O
14	acting	O
15	sequences	O
16	responsible	O
17	for	O
18	repression	O
19	of	B
20	cyclin	B
21	B1	I
22	mRNA	O
23	reside	O
24	within	O
25	its	O
26	3	O
27	'	O
28	UTR	O
29	.	O

1	The	O
2	role	O
3	of	O
4	HIV	O
5	tat	O
6	,	O
7	which	O
8	is	O
9	the	O
10	main	O
11	enhancing	O
12	factor	O
13	for	O
14	viral	O
15	LTR	O
16	,	O
17	in	O
18	the	O
19	regulation	O
20	of	B
21	IL	I
22	-	I
23	2	I
24	gene	I
25	transcription	O
26	has	O
27	been	O
28	studied	O
29	following	O
30	transient	O
31	expression	O
32	of	O
33	the	B
34	tat	I
35	gene	O
36	in	O
37	phorbol	O
38	ester	O
39	and	O
40	calcium	O
41	ionophore	O
42	-	O
43	activated	O
44	Jurkat	O
45	cells	O
46	transfected	O
47	with	B
48	IL	I
49	-	I
50	2	I
51	promoter	I
52	-	I
53	chloramphenicol	I
54	acetyltransferase	I
55	reporter	I
56	constructs	I
57	.	I

1	Regulation	O
2	of	O
3	mitochondrial	O
4	single	O
5	-	O
6	stranded	B
7	DNA	I
8	-	I
9	binding	I
10	protein	I
11	gene	O
12	expression	O
13	links	O
14	nuclear	O
15	and	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	in	O
20	drosophila	O
21	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	PTH	O
6	and	O
7	cAMP	O
8	can	O
9	repress	B
10	collagen	I
11	promoter	O
12	activity	O
13	in	O
14	calvariae	O
15	from	O
16	transgenic	O
17	mice	O
18	,	O
19	suggesting	O
20	that	O
21	the	B
22	alpha	I
23	1	I
24	(	I
25	I	I
26	)	I
27	collagen	I
28	promoter	O
29	may	O
30	contain	O
31	cis	O
32	elements	O
33	down	O
34	-	O
35	stream	O
36	of	O
37	-	O
38	2	O
39	.	O
40	3	O
41	kilobases	O
42	that	O
43	mediate	O
44	PTH	O
45	and	O
46	cAMP	O
47	repression	O
48	of	B
49	collagen	I
50	gene	O
51	expression	O
52	in	O
53	bone	O
54	.	O

1	Thiopentone	O
2	sodium	O
3	administered	O
4	at	O
5	30	O
6	and	O
7	10	O
8	min	O
9	before	O
10	or	O
11	5	O
12	,	O
13	10	O
14	and	O
15	15	O
16	min	O
17	after	O
18	exposure	O
19	to	O
20	NOC	O
21	-	O
22	5	O
23	,	O
24	but	O
25	not	O
26	thereafter	O
27	,	O
28	significantly	O
29	attenuated	O
30	NO	O
31	-	O
32	induced	O
33	neurotoxicity	O
34	compared	O
35	with	O
36	controls	O
37	.	O

1	These	O
2	results	O
3	demonstrate	O
4	the	O
5	existence	O
6	of	O
7	different	B
8	PI	I
9	3	I
10	-	I
11	kinase	I
12	isoforms	O
13	and	O
14	define	O
15	a	O
16	family	O
17	of	O
18	genes	O
19	encoding	O
20	distinct	B
21	PI	I
22	3	I
23	-	I
24	kinase	I
25	catalytic	I
26	subunits	O
27	that	O
28	can	O
29	associate	O
30	with	O
31	p85	O
32	.	O

1	A	O
2	stable	O
3	heterologous	O
4	cell	O
5	line	O
6	containing	O
7	the	B
8	mouse	B
9	TRH	I
10	receptor	O
11	was	O
12	constructed	O
13	by	O
14	transfection	O
15	of	O
16	nonexcitable	O
17	293	O
18	cells	O
19	,	O
20	which	O
21	lack	O
22	L	O
23	channel	O
24	activity	O
25	.	O

1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	I
8	-	I
9	threonine	I
10	-	I
11	rich	I
12	peptides	I
13	.	I

1	Technetium	O
2	-	O
3	99m	O
4	stannous	O
5	pyrophosphate	O
6	myocardial	O
7	scintigrams	O
8	were	O
9	obtained	O
10	in	O
11	138	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	260	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O

1	Movement	O
2	time	O
3	and	O
4	kinematic	O
5	characteristics	O
6	were	O
7	analyzed	O
8	together	O
9	with	O
10	the	O
11	magnitude	O
12	of	O
13	cerebral	O
14	blood	O
15	flow	O
16	to	O
17	identify	O
18	areas	O
19	of	O
20	brain	O
21	activity	O
22	proportionate	O
23	to	O
24	task	O
25	and	O
26	movement	O
27	variables	O
28	.	O

1	Elevated	O
2	IOP	O
3	developed	O
4	in	O
5	35	O
6	patients	O
7	(	O
8	44	O
9	eyes	O
10	)	O
11	during	O
12	the	O
13	study	O
14	.	O

1	Interdigitated	O
2	residues	O
3	within	O
4	a	O
5	small	O
6	region	O
7	of	O
8	VP16	O
9	interact	O
10	with	B
11	Oct	I
12	-	I
13	1	O
14	,	O
15	HCF	O
16	,	O
17	and	O
18	DNA	O
19	.	O

1	In	O
2	conclusion	O
3	,	O
4	these	O
5	studies	O
6	indicate	O
7	that	O
8	LiCl	O
9	(	O
10	1	O
11	)	O
12	decreases	O
13	histamine	O
14	-	O
15	stimulated	O
16	gastric	O
17	acid	O
18	secretion	O
19	,	O
20	and	O
21	(	O
22	2	O
23	)	O
24	diminishes	O
25	bile	O
26	-	O
27	induced	O
28	disruption	O
29	of	O
30	the	O
31	gastric	O
32	mucosal	O
33	barrier	O
34	in	O
35	the	O
36	canine	O
37	Heidenhain	O
38	pouch	O
39	.	O

1	Role	O
2	of	B
3	c	I
4	-	I
5	myc	O
6	in	O
7	simian	O
8	virus	O
9	40	O
10	large	B
11	tumor	I
12	antigen	I
13	-	O
14	induced	O
15	DNA	O
16	synthesis	O
17	in	O
18	quiescent	O
19	3T3	O
20	-	O
21	L1	O
22	mouse	O
23	fibroblasts	O
24	.	O

1	A	O
2	22K	O
3	polypeptide	O
4	was	O
5	detected	O
6	as	O
7	a	O
8	translation	O
9	product	O
10	of	O
11	late	O
12	RNA	O
13	that	O
14	hybridized	O
15	to	O
16	this	O
17	DNA	O
18	fragment	O
19	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	DNA	O
6	-	O
7	binding	O
8	experiments	O
9	show	O
10	that	O
11	either	O
12	one	O
13	of	O
14	the	O
15	two	O
16	MADS	O
17	domains	O
18	of	O
19	a	O
20	dimer	O
21	can	O
22	be	O
23	sufficient	O
24	to	O
25	confer	O
26	a	O
27	particular	O
28	DNA	O
29	-	O
30	binding	O
31	specificity	O
32	to	O
33	the	O
34	complex	O
35	and	O
36	that	O
37	sequences	O
38	outside	O
39	the	O
40	amino	O
41	-	O
42	terminal	O
43	basic	O
44	region	O
45	of	O
46	the	O
47	MADS	O
48	domain	O
49	can	O
50	,	O
51	in	O
52	some	O
53	cases	O
54	,	O
55	contribute	O
56	to	O
57	the	O
58	DNA	O
59	-	O
60	binding	O
61	specificity	O
62	of	O
63	the	O
64	proteins	O
65	.	O

1	Our	O
2	results	O
3	showed	O
4	that	O
5	compared	O
6	to	O
7	the	O
8	primary	O
9	photon	O
10	fluence	O
11	,	O
12	the	O
13	extra	O
14	-	O
15	focal	O
16	photon	O
17	fluence	O
18	from	O
19	the	O
20	primary	O
21	collimator	O
22	and	O
23	the	O
24	flattening	O
25	filter	O
26	was	O
27	11	O
28	%-	O
29	16	O
30	%	O
31	at	O
32	the	O
33	isocenter	O
34	,	O
35	among	O
36	which	O
37	70	O
38	%	O
39	was	O
40	contributed	O
41	by	O
42	the	O
43	flattening	O
44	filter	O
45	.	O

1	The	O
2	size	O
3	discrepancy	O
4	is	O
5	not	O
6	due	O
7	to	O
8	glycosylation	O
9	or	O
10	phosphorylation	O
11	of	O
12	Ag35	O
13	but	O
14	may	O
15	result	O
16	from	O
17	a	O
18	proline	O
19	-	O
20	rich	O
21	sequence	O
22	which	O
23	occurs	O
24	in	O
25	this	O
26	polypeptide	O
27	.	O

1	From	O
2	sequence	O
3	alignments	O
4	with	O
5	phylogenetically	O
6	related	O
7	viruses	O
8	,	O
9	including	O
10	tymoviruses	O
11	,	O
12	we	O
13	predicted	O
14	that	O
15	p223	O
16	contained	O
17	a	O
18	papain	I
19	-	I
20	like	I
21	proteinase	I
22	domain	O
23	with	O
24	a	O
25	putative	O
26	catalytic	O
27	cysteine994	O
28	and	O
29	histidine1075	O
30	.	O

1	A	O
2	--	O
3	A	O
4	natural	O
5	hydrostatic	O
6	phenomenon	O
7	,	O
8	at	O
9	the	O
10	level	O
11	of	O
12	the	O
13	ends	O
14	of	O
15	the	O
16	plantar	O
17	arcs	O
18	,	O
19	diffuses	O
20	body	O
21	weight	O
22	,	O
23	as	O
24	PAIN	O
25	plays	O
26	the	O
27	role	O
28	of	O
29	outsentry	O
30	(	O
31	fig	O
32	.--	O
33	1	O
34	)	O
35	(	O
36	5	O
37	);	O
38	B	O
39	--	O
40	Plantar	O
41	perforating	O
42	ulceration	O
43	(	O
44	PPU	O
45	)	O
46	is	O
47	caused	O
48	by	O
49	a	O
50	combination	O
51	of	O
52	INSENSITIVITY	O
53	and	O
54	TRAUMATIS	O
55	(	O
56	1	O
57	);	O
58	C	O
59	--	O
60	The	O
61	patient	O
62	reposing	O
63	,	O
64	as	O
65	body	O
66	weight	O
67	(	O
68	traumatism	O
69	)	O
70	effects	O
71	disappear	O
72	,	O
73	cicatrization	O
74	process	O
75	can	O
76	be	O
77	easily	O
78	observed	O
79	;	O
80	D	O
81	--	O
82	PNEUMATIC	O
83	INSOLE	O
84	,	O
85	being	O
86	elastic	O
87	,	O
88	diffuses	O
89	localized	O
90	compression	O
91	at	O
92	the	O
93	ends	O
94	of	O
95	the	O
96	plantar	O
97	arcs	O
98	,	O
99	reduces	O
100	attrition	O
101	,	O
102	makes	O
103	easier	O
104	blood	O
105	circulation	O
106	,	O
107	as	O
108	well	O
109	as	O
110	cure	O
111	and	O
112	prophylaxis	O
113	of	O
114	PPU	O
115	(	O
116	fig	O
117	.--	O
118	6	O
119	)	O
120	(	O
121	3	O
122	).	O

1	Further	O
2	investigations	O
3	are	O
4	necessary	O
5	to	O
6	elucidate	O
7	the	O
8	biochemical	O
9	and	O
10	physiological	O
11	properties	O
12	of	O
13	DLIS	O
14	.	O

1	Franz	O
2	Schubert	O
3	--	O
4	his	O
5	life	O
6	,	O
7	music	O
8	and	O
9	diseases	O

1	We	O
2	show	O
3	that	B
4	IL	I
5	-	I
6	6	O
7	activates	O
8	JRE	O
9	-	O
10	IL6	O
11	through	O
12	an	O
13	H7	O
14	-	O
15	sensitive	O
16	pathway	O
17	that	O
18	does	O
19	not	B
20	involve	I
21	protein	I
22	kinase	I
23	C	I
24	,	I
25	cyclic	I
26	AMP	I
27	-	I
28	dependent	I
29	kinase	O
30	,	O
31	Ca	O
32	(	O
33	2	O
34	+)-	O
35	or	O
36	calmodulin	I
37	-	I
38	dependent	I
39	kinases	I
40	,	I
41	Ras	I
42	,	I
43	Raf	I
44	-	I
45	1	O
46	,	O
47	or	B
48	NF	I
49	-	I
50	IL6	I
51	(	I
52	C	I
53	/	I
54	EBP	I
55	beta	O
56	).	O

1	The	O
2	sign	O
3	of	O
4	Leser	O
5	-	O
6	Trelat	O
7	:	O
8	does	O
9	it	O
10	exist	O
11	?	O
12	The	O
13	sign	O
14	of	O
15	Leser	O
16	-	O
17	Trelat	O
18	is	O
19	usually	O
20	regarded	O
21	as	O
22	a	O
23	reliable	O
24	cutaneous	O
25	marker	O
26	of	O
27	internal	O
28	malignancy	O
29	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	determine	O
9	the	O
10	risk	O
11	factors	O
12	for	O
13	background	O
14	diabetic	O
15	retinopathy	O
16	(	O
17	BDR	O
18	)	O
19	and	O
20	PDR	O
21	by	O
22	following	O
23	394	O
24	Japanese	O
25	patients	O
26	with	O
27	early	O
28	-	O
29	onset	O
30	type	O
31	2	O
32	diabetes	O
33	diagnosed	O
34	before	O
35	30	O
36	years	O
37	of	O
38	age	O
39	(	O
40	mean	O
41	age	O
42	27	O
43	,	O
44	mean	O
45	blood	O
46	pressure	O
47	at	O
48	entry	O
49	116	O
50	/	O
51	73	O
52	mm	O
53	Hg	O
54	).	O

1	Keeping	O
2	in	O
3	mind	O
4	the	O
5	limited	O
6	range	O
7	of	O
8	age	O
9	and	O
10	dosages	O
11	,	O
12	advantages	O
13	and	O
14	disadvantages	O
15	of	O
16	the	O
17	drug	O
18	are	O
19	discussed	O
20	,	O
21	comparing	O
22	the	O
23	experimental	O
24	results	O
25	with	O
26	those	O
27	derived	O
28	from	O
29	the	O
30	literature	O
31	.	O

1	Paralemmin	O
2	is	O
3	also	O
4	phosphorylated	O
5	,	O
6	and	O
7	its	O
8	mRNA	O
9	is	O
10	differentially	O
11	spliced	O
12	in	O
13	a	O
14	tissue	O
15	-	O
16	specific	O
17	and	O
18	developmentally	O
19	regulated	O
20	manner	O
21	.	O

1	We	O
2	found	O
3	14	O
4	protein	O
5	binding	O
6	sites	O
7	that	O
8	were	O
9	occupied	O
10	in	O
11	vivo	O
12	.	O

1	Animals	O
2	were	O
3	put	O
4	to	O
5	death	O
6	8	O
7	weeks	O
8	later	O
9	and	O
10	the	O
11	grafts	O
12	were	O
13	sterilely	O
14	explanted	O
15	and	O
16	analyzed	O
17	via	O
18	microbiologic	O
19	culture	O
20	and	O
21	standard	O
22	histologic	O
23	procedures	O
24	for	O
25	evidence	O
26	of	O
27	infection	O
28	.	O

1	To	O
2	establish	O
3	a	O
4	possible	O
5	association	O
6	between	O
7	familial	O
8	dysfibrinogenemia	O
9	and	O
10	thrombophilia	O
11	,	O
12	data	O
13	on	O
14	cases	O
15	with	O
16	both	O
17	affections	O
18	were	O
19	collected	O
20	in	O
21	a	O
22	study	O
23	within	O
24	the	O
25	framework	O
26	of	O
27	the	O
28	SSC	O
29	Subcommittee	O
30	on	B
31	Fibrinogen	O
32	of	O
33	the	O
34	International	O
35	Society	O
36	on	O
37	Thrombosis	O
38	and	O
39	Haemostasis	O
40	.	O

1	Invertases	O
2	are	O
3	responsible	O
4	for	O
5	the	O
6	breakdown	O
7	of	O
8	sucrose	O
9	to	O
10	fructose	O
11	and	O
12	glucose	O
13	.	O

1	Fas	O
2	-	O
3	resistant	O
4	DT	O
5	-	O
6	40	O
7	lymphoma	O
8	B	O
9	-	O
10	cells	O
11	rendered	B
12	BTK	I
13	-	O
14	deficient	O
15	through	O
16	targeted	O
17	disruption	O
18	of	O
19	the	B
20	btk	I
21	gene	O
22	by	O
23	homologous	O
24	recombination	O
25	knockout	O
26	underwent	O
27	apoptosis	O
28	after	O
29	Fas	O
30	ligation	O
31	,	O
32	but	O
33	wild	O
34	-	O
35	type	O
36	DT	O
37	-	O
38	40	O
39	cells	O
40	or	B
41	BTK	I
42	-	O
43	deficient	O
44	DT	O
45	-	O
46	40	O
47	cells	O
48	reconstituted	O
49	with	O
50	wild	O
51	-	O
52	type	B
53	human	B
54	btk	I
55	gene	O
56	did	O
57	not	O
58	.	O

1	Although	O
2	the	O
3	consumption	O
4	of	B
5	myoglobin	I
6	-	O
7	bound	O
8	O2	O
9	(	O
10	MbO2	O
11	)	O
12	stores	O
13	in	O
14	seal	O
15	muscles	O
16	has	O
17	been	O
18	demonstrated	O
19	in	O
20	seal	O
21	muscles	O
22	during	O
23	laboratory	O
24	simulations	O
25	of	O
26	diving	O
27	,	O
28	this	O
29	may	O
30	not	O
31	be	O
32	a	O
33	feature	O
34	of	O
35	normal	O
36	field	O
37	diving	O
38	in	O
39	which	O
40	measurements	O
41	of	O
42	heart	O
43	rate	O
44	and	O
45	lactate	O
46	production	O
47	show	O
48	marked	O
49	differences	O
50	from	O
51	the	O
52	profound	O
53	diving	O
54	response	O
55	induced	O
56	by	O
57	forced	O
58	immersion	O
59	.	O

1	These	O
2	data	O
3	will	O
4	help	O
5	us	O
6	to	O
7	better	O
8	detail	O
9	the	O
10	CXCR4	O
11	structural	O
12	requirements	O
13	exhibited	O
14	by	O
15	different	O
16	HIV	O
17	-	O
18	1	O
19	strains	O
20	and	O
21	will	O
22	direct	O
23	further	O
24	mutagenesis	O
25	efforts	O
26	aimed	O
27	at	O
28	better	O
29	defining	O
30	the	O
31	domains	O
32	in	O
33	CXCR4	O
34	involved	O
35	in	O
36	the	B
37	HIV	I
38	-	I
39	1	I
40	Env	I
41	-	O
42	mediated	O
43	fusion	O
44	process	O
45	.	O

1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O

1	Regulation	O
2	of	B
3	pituitary	I
4	vasopressin	I
5	V1b	I
6	receptors	O
7	plays	O
8	a	O
9	critical	O
10	role	O
11	in	O
12	regulating	B
13	pituitary	I
14	adrenocorticotropic	I
15	hormone	O
16	(	O
17	ACTH	O
18	)	O
19	secretion	O
20	during	O
21	adaptation	O
22	to	O
23	stress	O
24	.	O

1	Five	O
2	additional	O
3	copies	O
4	of	O
5	Lian	O
6	elements	O
7	were	O
8	isolated	O
9	,	O
10	mapped	O
11	by	O
12	restriction	O
13	digestion	O
14	,	O
15	and	O
16	partially	O
17	sequenced	O
18	.	O

1	Human	O
2	LTBP	O
3	-	O
4	1	O
5	is	O
6	known	O
7	to	O
8	exist	O
9	in	O
10	different	O
11	forms	O
12	.	O

1	Baseline	O
2	data	O
3	were	O
4	obtained	O
5	from	O
6	10	O
7	adults	O
8	.	O

1	This	O
2	study	O
3	compared	O
4	the	O
5	gross	O
6	and	O
7	fine	O
8	motor	O
9	performance	O
10	of	O
11	14	O
12	traumatically	O
13	brain	O
14	-	O
15	injured	O
16	children	O
17	(	O
18	five	O
19	to	O
20	15	O
21	years	O
22	old	O
23	,	O
24	with	O
25	loss	O
26	of	O
27	consciousness	O
28	for	O
29	at	O
30	least	O
31	24	O
32	hours	O
33	)	O
34	to	O
35	14	O
36	normal	O
37	children	O
38	group	O
39	matched	O
40	for	O
41	age	O
42	and	O
43	sex	O
44	.	O

1	In	O
2	ICE	O
3	gamma	O
4	,	O
5	most	O
6	of	O
7	the	O
8	propeptide	O
9	(	O
10	amino	O
11	acids	O
12	20	O
13	-	O
14	112	O
15	)	O
16	is	O
17	deleted	O
18	,	O
19	which	O
20	suggests	O
21	that	O
22	it	O
23	may	O
24	function	O
25	as	O
26	a	O
27	catalyst	O
28	for	O
29	ICE	O
30	autoprocessing	O
31	in	O
32	vivo	O
33	.	O

1	According	O
2	to	O
3	Sugiura	O
4	'	O
5	s	O
6	classification	O
7	,	O
8	they	O
9	consisted	O
10	of	O
11	Type	O
12	Ia	O
13	in	O
14	63	O
15	%,	O
16	Type	O
17	Ib	O
18	in	O
19	11	O
20	%,	O
21	Type	O
22	II	O
23	in	O
24	11	O
25	%,	O
26	and	O
27	Type	O
28	III	O
29	in	O
30	16	O
31	%.	O

1	Relapse	O
2	of	O
3	leukemia	O
4	after	O
5	prolonged	O
6	remission	O
7	.	O

1	The	O
2	second	O
3	part	O
4	of	O
5	this	O
6	paper	O
7	shows	O
8	some	O
9	medical	O
10	applications	O
11	of	O
12	these	O
13	two	O
14	aspects	O
15	of	O
16	NMR	O
17	,	O
18	with	O
19	help	O
20	of	O
21	some	O
22	examples	O
23	,	O
24	taken	O
25	from	O
26	the	O
27	literature	O
28	,	O
29	according	O
30	to	O
31	what	O
32	is	O
33	concerned	O
34	with	O
35	endocrinology	O
36	.	O

1	Neither	O
2	the	O
3	reaction	O
4	of	O
5	monosaccharides	O
6	nor	O
7	the	O
8	disaccharides	O
9	with	O
10	beta	O
11	-	O
12	alanine	O
13	resulted	O
14	in	O
15	the	O
16	formation	O
17	of	O
18	maltol	O
19	.	O

1	Thus	O
2	,	O
3	the	O
4	active	O
5	-	O
6	site	O
7	mutation	O
8	prevents	O
9	the	O
10	wild	O
11	-	O
12	type	O
13	processing	O
14	of	O
15	the	O
16	N	O
17	-	O
18	glycosylated	O
19	73	O
20	-	O
21	kDa	O
22	precursor	O
23	of	O
24	PrB	O
25	to	O
26	the	O
27	41	O
28	.	O
29	5	O
30	kDa	O
31	pro	O
32	-	O
33	PrB	O
34	in	O
35	the	O
36	endoplasmic	O
37	reticulum	O
38	.	O

1	Regulation	O
2	of	O
3	ASN1	O
4	and	O
5	ASN2	O
6	expression	O
7	was	O
8	studied	O
9	using	B
10	lacZ	I
11	fusions	O
12	and	O
13	both	O
14	genes	O
15	were	O
16	found	O
17	to	O
18	be	O
19	several	O
20	times	O
21	less	O
22	expressed	O
23	in	O
24	the	O
25	absence	O
26	of	O
27	the	O
28	transcription	B
29	activator	B
30	Gcn4p	I
31	.	I

1	The	O
2	statistical	O
3	analysis	O
4	consist	O
5	of	O
6	the	O
7	F	O
8	test	O
9	followed	O
10	by	O
11	Snedecor	O
12	'	O
13	s	O
14	contrast	O
15	test	O
16	.	O

1	Overexpression	O
2	of	O
3	ICBP90	O
4	in	O
5	COS	O
6	-	O
7	1	O
8	-	O
9	transfected	O
10	cells	O
11	induced	O
12	an	O
13	enhanced	O
14	expression	O
15	of	B
16	endogenous	I
17	topoisomerase	I
18	IIalpha	I
19	.	I

1	The	O
2	obvious	O
3	functional	O
4	necessity	O
5	for	O
6	editing	O
7	in	O
8	kinetoplastid	O
9	mitochondria	O
10	is	O
11	the	O
12	formation	O
13	of	O
14	translatable	O
15	mRNAs	O
16	.	O

1	Both	O
2	methods	O
3	were	O
4	employed	O
5	for	O
6	various	O
7	focal	O
8	-	O
9	film	O
10	distances	O
11	,	O
12	image	O
13	intensifier	O
14	tube	O
15	modes	O
16	and	O
17	laser	O
18	printer	O
19	formats	O
20	.	O

1	Therefore	O
2	,	O
3	homozygous	O
4	co	O
5	-	O
6	deletions	O
7	of	B
8	CDKN2A	O
9	and	B
10	CDKN2B	O
11	rather	O
12	than	O
13	mutations	O
14	targeting	O
15	individual	O
16	transcripts	O
17	are	O
18	frequently	O
19	selected	O
20	for	O
21	in	O
22	these	O
23	tumors	O
24	.	O

1	Examination	O
2	of	O
3	the	O
4	MMP	I
5	-	I
6	2	I
7	RE1	O
8	sequence	O
9	revealed	O
10	an	O
11	incomplete	O
12	Y	O
13	-	O
14	box	O
15	sequence	O
16	(	B
17	CTGCTGGGCAAG	O
18	),	O
19	which	O
20	specifically	O
21	interacted	O
22	with	B
23	recombinant	B
24	YB	I
25	-	I
26	1	O
27	on	O
28	DMS	O
29	protection	O
30	footprinting	O
31	analysis	O
32	.	O

1	Phenobarbital	O
2	-	O
3	induced	O
4	alterations	O
5	in	O
6	the	O
7	metabolism	O
8	of	O
9	[	O
10	3H	O
11	]	O
12	vitamin	O
13	D3	O
14	by	O
15	the	O
16	perfused	O
17	rachitic	O
18	rat	O
19	liver	O
20	in	O
21	vitro	O
22	.	O

1	In	O
2	E	O
3	.	O
4	coli	O
5	,	O
6	CheW	O
7	mediates	O
8	the	O
9	physical	O
10	coupling	O
11	of	O
12	the	O
13	receptors	O
14	to	O
15	the	O
16	kinase	O
17	CheA	O
18	.	O

1	An	O
2	unusual	O
3	complication	O
4	in	O
5	an	O
6	unsuitable	O
7	patient	O
8	.	O

1	Whereas	O
2	a	B
3	PR55	I
4	beta	I
5	transcript	O
6	of	O
7	about	O
8	2	O
9	.	O
10	3	O
11	kb	O
12	was	O
13	detected	O
14	at	O
15	high	O
16	levels	O
17	in	O
18	the	O
19	neuroblastoma	O
20	derived	O
21	cell	O
22	line	B
23	LA	I
24	-	I
25	N	I
26	-	I
27	1	O
28	,	O
29	the	O
30	level	O
31	of	O
32	the	O
33	mRNA	O
34	was	O
35	very	O
36	low	O
37	in	O
38	the	O
39	other	O
40	human	O
41	cell	O
42	lines	O
43	analyzed	O
44	.	O

1	Use	O
2	of	O
3	prostaglandin	B
4	F2	I
5	alpha	O
6	(	B
7	PGF2	I
8	alpha	O
9	)	O
10	in	O
11	cattle	O
12	breeding	O
13	.	O

1	The	O
2	time	O
3	course	O
4	of	O
5	RNA1	O
6	replication	O
7	and	O
8	RNA3	O
9	synthesis	O
10	in	O
11	induced	O
12	yeast	O
13	paralleled	O
14	that	O
15	in	O
16	yeast	O
17	transfected	O
18	with	O
19	natural	O
20	FHV	O
21	virion	O
22	RNA	O
23	.	O

1	Both	O
2	proprioceptive	O
3	and	O
4	electroreceptive	O
5	units	O
6	showed	O
7	a	O
8	progression	O
9	of	O
10	receptive	O
11	fields	O
12	from	O
13	anterior	O
14	to	O
15	posterior	O
16	body	O
17	in	O
18	the	O
19	rostral	O
20	to	O
21	caudal	O
22	direction	O
23	along	O
24	the	O
25	length	O
26	of	O
27	DGR	O
28	.	O

1	Four	O
2	forms	O
3	of	O
4	salmonellosis	O
5	were	O
6	recognised	O
7	in	O
8	feedlots	O
9	and	O
10	during	O
11	transport	O
12	by	O
13	sea	O
14	:	O
15	septicaemic	O
16	,	O
17	and	O
18	acute	O
19	,	O
20	subacute	O
21	and	O
22	chronic	O
23	enteric	O
24	.	O

1	This	B
2	Tbx6	I
3	-	I
4	subfamily	I
5	gene	O
6	is	O
7	likely	O
8	to	O
9	participate	O
10	in	O
11	paraxial	O
12	mesoderm	O
13	formation	O
14	and	O
15	somitogenesis	O
16	in	O
17	human	O
18	embryo	O
19	.	O

1	Chimaeric	B
2	VP16	I
3	-	I
4	E2	I
5	molecules	O
6	suggest	O
7	that	O
8	the	O
9	epithelial	O
10	specific	O
11	transcriptional	O
12	activation	O
13	of	O
14	the	B
15	BPV	I
16	-	I
17	4	I
18	LCR	I
19	promoter	O
20	is	O
21	mediated	O
22	by	O
23	the	O
24	E2	O
25	transactivation	O
26	domain	O
27	.	O

1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	B
31	alpha	I
32	-	I
33	and	I
34	beta	I
35	-	I
36	adrenoceptors	I
37	.	I

1	As	O
2	no	O
3	complete	B
4	PPARgamma	O
5	antagonists	O
6	have	O
7	been	O
8	described	O
9	hitherto	O
10	,	O
11	we	O
12	have	O
13	constructed	O
14	a	B
15	dominant	I
16	-	I
17	negative	I
18	mutant	I
19	receptor	O
20	to	O
21	inhibit	B
22	wild	I
23	-	I
24	type	I
25	PPARgamma	O
26	action	O
27	.	O

1	A	O
2	study	O
3	of	O
4	human	O
5	genes	O
6	coding	O
7	for	O
8	U4	O
9	small	O
10	nuclear	O
11	RNA	O
12	is	O
13	presented	O
14	.	O

1	Drug	O
2	and	O
3	personnel	O
4	costs	O
5	were	O
6	reduced	O
7	when	O
8	batch	O
9	manufacturing	O
10	with	O
11	40	O
12	-	O
13	mL	O
14	multidose	O
15	vials	O
16	was	O
17	compared	O
18	with	O
19	extemporaneous	O
20	compounding	O
21	with	O
22	unit	O
23	-	O
24	dose	O
25	vials	O
26	.	O

1	Thus	O
2	,	O
3	the	O
4	P	O
5	.	O
6	aeruginosa	O
7	orfX	O
8	and	O
9	vfr	O
10	promoters	O
11	are	O
12	arranged	O
13	in	O
14	a	O
15	back	O
16	-	O
17	to	O
18	-	O
19	back	O
20	orientation	O
21	rather	O
22	than	O
23	the	O
24	face	O
25	-	O
26	to	O
27	-	O
28	face	O
29	orientation	O
30	of	O
31	the	O
32	dorf	O
33	and	B
34	crp	I
35	promoters	I
36	.	I

1	In	O
2	addition	O
3	,	O
4	the	O
5	affinities	O
6	of	O
7	CBF2	O
8	for	O
9	binding	O
10	to	O
11	the	B
12	LMP	I
13	-	I
14	1	O
15	,	B
16	LMP	I
17	-	I
18	2	O
19	,	O
20	and	O
21	CD23	O
22	promoters	O
23	were	O
24	also	O
25	measured	O
26	.	O

1	Utero	O
2	-	O
3	placental	O
4	blood	O
5	flow	O
6	and	O
7	the	O
8	effect	O
9	of	B
10	beta	I
11	2	I
12	-	I
13	adrenoceptor	I
14	stimulating	O
15	drugs	O
16	.	O

1	After	O
2	profound	O
3	normovolemic	O
4	hemodilution	O
5	(	O
6	Hct	O
7	9	O
8	%)	O
9	superiority	O
10	of	O
11	LV	O
12	MC	O
13	and	O
14	LV	O
15	diastolic	O
16	properties	O
17	was	O
18	found	O
19	,	O
20	when	O
21	myocardial	O
22	oxygenation	O
23	was	O
24	supported	O
25	by	O
26	i	O
27	.	O
28	v	O
29	.	O
30	perflubron	O
31	emulsion	O
32	,	O
33	a	O
34	temporary	O
35	O2	O
36	carrier	O
37	.	O

1	Three	O
2	different	O
3	techniques	O
4	of	O
5	EA	O
6	analysis	O
7	were	O
8	used	O
9	in	O
10	the	O
11	study	O
12	:	O
13	1	O
14	)	O
15	fast	O
16	Fourier	O
17	transformation	O
18	(	O
19	FFT	O
20	)	O
21	of	O
22	EA	O
23	in	O
24	a	O
25	broad	O
26	band	O
27	,	O
28	2	O
29	)	O
30	developed	O
31	by	O
32	us	O
33	alternative	O
34	method	O
35	of	O
36	non	O
37	-	O
38	harmonic	O
39	expansion	O
40	of	O
41	the	O
42	EEG	O
43	curves	O
44	taking	O
45	into	O
46	account	O
47	their	O
48	shape	O
49	,	O
50	3	O
51	)	O
52	factor	O
53	analysis	O
54	of	O
55	the	O
56	EA	O
57	spectral	O
58	densities	O
59	.	O

1	272	O
2	,	O
3	1904	O
4	].	O

1	Thus	O
2	,	O
3	patients	O
4	with	O
5	metastatic	O
6	melanoma	O
7	are	O
8	not	O
9	tolerant	O
10	to	O
11	gp100	O
12	Ag	O
13	based	O
14	on	O
15	the	O
16	detection	O
17	of	O
18	CD8	O
19	+	O
20	T	O
21	cells	O
22	specific	O
23	for	O
24	multiple	B
25	HLA	I
26	-	O
27	A	O
28	*	O
29	0201	O
30	-	O
31	restricted	O
32	,	O
33	gp100	O
34	-	O
35	derived	O
36	epitopes	O
37	.	O

1	The	O
2	present	O
3	studies	O
4	compare	O
5	the	O
6	biochemical	O
7	characteristics	O
8	,	O
9	Kanagawa	O
10	hemolysin	O
11	reactions	O
12	,	O
13	and	O
14	plasmid	O
15	profiles	O
16	of	O
17	13	O
18	patient	O
19	and	O
20	221	O
21	environmental	O
22	isolates	O
23	of	O
24	the	O
25	organism	O
26	.	O

1	Histological	O
2	examination	O
3	revealed	O
4	a	O
5	small	O
6	simple	O
7	renal	O
8	cyst	O
9	associated	O
10	with	O
11	renal	O
12	cell	O
13	carcinoma	O
14	.	O

1	Its	O
2	C	O
3	-	O
4	terminal	O
5	catalytic	O
6	domain	O
7	was	O
8	found	O
9	to	O
10	be	O
11	highly	O
12	conserved	O
13	in	O
14	the	O
15	homologues	B
16	p140	I
17	(	I
18	ras	I
19	-	I
20	GRF	O
21	)	O
22	and	O
23	Sos	O
24	.	O

1	All	O
2	three	B
3	NR	I
4	isoforms	O
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O

1	Antibiotic	O
2	effect	O
3	of	O
4	the	O
5	mud	O
6	from	O
7	heviz	B

1	DNA	O
2	from	O
3	PCR	O
4	was	O
5	labeled	O
6	and	O
7	used	O
8	to	O
9	isolate	O
10	several	O
11	lambda	O
12	gt11	O
13	cDNA	O
14	clones	O
15	,	O
16	including	O
17	one	O
18	full	O
19	-	O
20	length	O
21	one	O
22	(	B
23	Dd	I
24	kinase	I
25	-	I
26	2	O
27	).	O

1	Cholangiography	O
2	was	O
3	performed	O
4	in	O
5	all	O
6	cases	O
7	and	O
8	classified	O
9	by	O
10	a	O
11	scoring	O
12	system	O
13	specifically	O
14	developed	O
15	for	O
16	pediatric	O
17	patients	O
18	.	O

1	Reporter	O
2	gene	O
3	expression	O
4	analyses	O
5	indicate	O
6	that	O
7	both	O
8	WASP	O
9	promoters	O
10	show	O
11	high	O
12	levels	O
13	of	O
14	expression	O
15	in	O
16	different	O
17	hematopoietic	O
18	cell	O
19	lines	O
20	.	O

1	Because	O
2	the	B
3	Pit	I
4	-	I
5	1	I
6	sites	O
7	in	O
8	the	B
9	hGH	I
10	-	I
11	N	I
12	gene	I
13	promoter	O
14	are	O
15	insufficient	O
16	for	O
17	such	O
18	gene	O
19	activation	O
20	in	O
21	vivo	O
22	,	O
23	these	O
24	data	O
25	suggested	O
26	a	O
27	unique	O
28	chromatin	O
29	-	O
30	mediated	O
31	developmental	O
32	role	O
33	for	O
34	Pit	O
35	-	O
36	1	O
37	in	O
38	the	B
39	hGH	B
40	LCR	I
41	.	I

1	However	O
2	,	O
3	a	O
4	specific	O
5	ICE	O
6	/	B
7	caspase	I
8	-	I
9	1	I
10	inhibitor	O
11	called	O
12	N1445	O
13	completely	O
14	abolished	O
15	the	O
16	CK	O
17	-	O
18	induced	O
19	apoptosis	O
20	by	O
21	reactivating	B
22	PKB	O
23	,	O
24	but	O
25	without	O
26	affecting	O
27	the	O
28	CK	O
29	-	O
30	induced	O
31	suppression	O
32	of	O
33	Ras	O
34	transformation	O
35	.	O

1	Laboratory	O
2	studies	O
3	using	O
4	Ca45	O
5	labeled	O
6	teeth	O
7	and	O
8	biologically	O
9	stained	O
10	teeth	O
11	confirmed	O
12	that	O
13	the	O
14	dentifrice	O
15	did	O
16	not	O
17	decalcify	O
18	enamel	O
19	or	O
20	bleach	O
21	teeth	O
22	.	O

1	Viruses	O
2	were	O
3	isolated	O
4	from	O
5	9	O
6	lungs	O
7	:	O
8	7	O
9	with	O
10	PI	O
11	-	O
12	3V	O
13	,	O
14	1	O
15	with	B
16	NCP	I
17	BVDV	I
18	type	I
19	1	O
20	,	O
21	and	O
22	1	O
23	with	O
24	both	B
25	BVHV	I
26	-	I
27	1	I
28	and	I
29	BVDV	I
30	.	I

1	Pathogenetic	O
2	relationships	O
3	between	O
4	renal	O
5	tubular	O
6	acidosis	O
7	and	O
8	sodium	O
9	metabolism	O
10	alterations	O
11	in	O
12	liver	O
13	cirrhosis	O
14	.	O

1	The	O
2	transcript	O
3	was	O
4	initially	O
5	identified	O
6	as	O
7	a	O
8	partial	O
9	cDNA	O
10	sequence	O
11	in	O
12	the	O
13	course	O
14	of	O
15	constructing	O
16	a	O
17	transcript	O
18	map	O
19	of	O
20	the	O
21	region	O
22	between	O
23	markers	B
24	D11S1765	I
25	and	I
26	uteroglobin	O
27	known	O
28	to	O
29	encompass	O
30	the	O
31	gene	O
32	causing	O
33	Best	O
34	disease	O
35	.	O

1	A	O
2	brief	O
3	discussion	O
4	of	O
5	color	O
6	deficiencies	O
7	.	O

1	In	O
2	Experiments	O
3	1	O
4	and	O
5	2	O
6	,	O
7	infants	O
8	,	O
9	like	O
10	adults	O
11	,	O
12	initially	O
13	categorized	O
14	novel	O
15	objects	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	physical	O
21	appearance	O
22	,	O
23	but	O
24	only	O
25	if	O
26	trained	O
27	with	O
28	multiple	O
29	exemplars	O
30	,	O
31	after	O
32	delays	O
33	of	O
34	1	O
35	and	O
36	7	O
37	days	O
38	.	O

1	The	B
2	Cdk2	I
3	-	I
4	cyclin	I
5	-	I
6	D1	I
7	complex	O
8	did	O
9	not	O
10	phosphorylate	O
11	any	O
12	tested	O
13	substrates	O
14	,	O
15	such	O
16	as	O
17	H1	O
18	histone	O
19	,	O
20	pRB	O
21	,	O
22	SV40	O
23	large	O
24	T	O
25	antigen	O
26	,	B
27	p53	O
28	,	B
29	E2F	I
30	-	I
31	1	O
32	or	O
33	a	O
34	preparation	O
35	of	O
36	nuclear	O
37	proteins	O
38	from	O
39	HeLa	O
40	cells	O
41	;	O
42	in	O
43	contrast	O
44	,	B
45	Cdk2	I
46	-	I
47	cyclin	I
48	-	I
49	E	O
50	and	B
51	Cdk2	I
52	-	I
53	cyclin	I
54	-	O
55	A	O
56	phosphorylated	O
57	these	O
58	proteins	O
59	.	O

